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1. Introduction to the family of myosins 
Myosins are cellular proteins that act as motors which consume fuel in the form of adenosine 
triphosphate (ATP). More specifically, they are ATP-hydrolyzing enzymes (Scheme 1) that 
convert the chemical energy stored in ATP into mechanical force and movement. Within 
cells, these proteins use actin as a track for transport, or to produce tension. As such, 
myosins participate in many biological processes, of which muscle-based movement is the 
most striking one.1-3 
 
Scheme 1. Hydrolysis of adenosine triphosphate (ATP) to inorganic phosphate (Pi) and adenosine 
diphosphate (ADP).  
Conventionally, the myosin superfamily is divided into different classes, based on sequence 
homology. The class II myosins were the first to be discovered and form the largest 
subfamily. They are generally referred to as conventional myosins. In addition to the class II 
myosins, at least 34 classes of so-called unconventional myosins are known. These were 
assigned a class number in the order of discovery of the first class member, with the 
exception that class II myosins were discovered long before class I myosins. It should be 
noted that not all myosin classes are present in all phyla. For instance, no class II myosins 
have been identified in plants, while several myosin classes are exclusive to plants (VIII, XI 
and XIII). To date, 12 myosin classes have been discovered in humans (I–III, V–VII, IX, X, 
XV, XVI, XVIII and XIX), of which myosin II is the most abundant.1-7 
2. Myosin II 
2.1. Structural properties 
Myosin II is composed of six non-covalently associated polypeptides, consisting of two heavy 
chains with a molecular weight of 171–244 kDa, two 17-kDa essential light chains and two 
20-kDa regulatory light chains (Figure 1A). The essential light chains stabilize the heavy 
chains, whereas the regulatory light chains regulate the heavy-chain enzymatic activity in a 
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phosphorylation-dependent manner. The myosin II heavy chains, essential light chains and 
regulatory light chains are encoded by three different genes.1,7-12 
regulatory light chains
essential light chains












Figure 1. A. Structure of the myosin II complex, consisting of two heavy chains, two essential light chains 
and two regulatory light chains. B. Association of myosin II into filaments and crosslinking of actin filaments. 
Each heavy chain is further built up of three different domains (Figure 1A): (i) the N-terminal 
head domain, which is also referred to as the motor domain, because it contains the actin 
and ATP binding sites required for motor activity, (ii) the neck domain or lever arm that binds 
the essential and regulatory light chains and amplifies structural changes (induced by ATP 
binding and hydrolysis) in the motor domain and (iii) the tail domain, which mediates heavy-
chain homodimerization via an α-helical-coiled coil and ends with a C-terminal non-helical 
tailpiece. The tail domain determines the cellular localization and is responsible for cargo 
binding and filament assembly (Figure 1B). The latter anti-parallel association into filaments 
allows myosin II to crosslink actin filaments and contract them during the ATPase cycle (vide 
infra).1,7-11,13-17  
The head domain essentially consists of a seven-stranded β-sheet and α-helices that form a 
deep cleft (i.e. the 50-kDa cleft) (Figure 2). Four subdomains can be distinguished. The 
N-terminal subdomain is connected to the upper 50-kDa subdomain via loop 1, whereas the 
upper and lower 50-kDa subdomains are separated by the large 50-kDa cleft. The lower 
50-kDa subdomain is linked via the relay helix to the converter subdomain, which, in its turn, 
is joined to the N-terminal subdomain through the SH1-helix.1,3,13  










































Figure 2. Detail of the myosin II head domain, which ends in the lever arm. A. Ribbon diagram. 
B. Schematic diagram. Adapted from Sweeney et al.
3
   
The ATP binding site is situated close to the apex of the 50-kDa cleft, at the boundary of the 
N-terminal and upper 50-kDa subdomains, and consists of the P-loop and switch I. The actin 
binding site spans the upper and lower 50-kDa subdomains. Coupling between the actin 
binding interface and ATP binding site is mediated via the large 50-kDa cleft through 
switch II. Cleft opening and closing are influenced by ATP binding and hydrolysis, and tight 
actin binding requires the 50-kDa cleft to be closed. Finally, the converter subdomain is able 
to amplify relatively small conformational changes of the head domain. Through a 60° 
INTRODUCTION AND GOALS 
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rotation in response to ATP binding and products (i.e. ADP and Pi) release, it can transmit 
these conformational changes to the neck domain or lever arm of the heavy chain. In 
conclusion, internally coupled rearrangements of the head subdomains allow direct 
communication between the ATP binding site, the actin binding interface and the lever 
arm.1,3,7,13,15,16,18-21  
2.2. Biochemical properties: the ATPase cycle 
Movement of myosin along the actin filament requires energy which is provided by ATP 
hydrolysis in the head domain during an ATPase cycle (Figure 3). This cycle starts with 
myosin tightly bound to actin. Next, a sequence of conformational changes is triggered in the 
myosin head domain by contact of the γ-phosphate group of an ATP molecule with the 
P-loop of the ATP binding site. Both the P-loop and switch I move to enclose the ATP 
molecule through a network of hydrogen bonds (for more details, see Figure 4). Additionally, 
these movements induce twisting of the seven-stranded β-sheet which causes cleft opening 
in the actin binding site. This results in a largely decreased actin affinity and hence actin 






















myosin head domain 
and lever arm (M)
actin (A)
 
Figure 3. Schematic representation of the ATPase cycle. Adapted from Winkelmann et al.
25
 
In order for ATP hydrolysis to occur, switch II closes to form the enzymatically active site (for 
more details, see Figure 4). This movement is coupled to bending of the relay helix, rotation 
of the converter subdomain through 60° and priming of the lever arm (step b). ATP is then 
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hydrolyzed into ADP and inorganic phosphate (Pi) (step c). At this stage, the hydrolysis 
products remain bound to the myosin head, forming a myosin·ADP·Pi complex that has a 
















Figure 4. Enzymatically active conformation of the ATP binding site in the myosin II head domain (left) and 
details of ATP hydrolysis (right) (cfr. step c in Figure 3). ATP has been modeled into the crystal structure of 
Dictyostelium discoideum myosin II complexed with Mg
2+
·ADP·vanadate (PDB: 1VOM). Only the 
triphosphate moiety (α, β, γ) of ATP is depicted. Legend: red (oxygen); gold (phosphorus); white 
(hydrogen); blue (nitrogen); green, orange, cyan (carbon); thin dotted lines (hydrogen bonds); thick grey 
D 
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Figure 4. (continued) lines (Mg
2+
 coordination sphere). Simultaneous coordination of Mg
2+
 to two oxygen 
atoms of the γ-phosphate and β-phosphate groups of ATP, and the Ser237 and Thr186 residues hold the 
ATP molecule in the vicinity of an attacking water molecule (Wa). A1,A2. In the enzymatically active 
conformation, the triphosphate group of ATP is enclosed by switch I, switch II and the P-loop, where switch 
I and switch II are linked by a salt bridge between Arg238 and Glu459. The P-loop favors and stabilizes a 
shift of the negative charge on the γ-phosphate toward the β-phosphate by placing six backbone NH groups 
(residues Gly182, Ala183, Gly184, Lys185, Thr186 and Glu187) and the Lys185 side chain around the α- 





, which is a better target for the subsequent attack by a hydroxy anion due to its planar 
geometry and single negative charge. Switch I promotes the formation of a hydrate complex between PγO3
−
 
and an attacking water molecule (Wa) by polarizing the latter with a hydrogen bond to the backbone 
carbonyl of Ser237. Switch II then activates a helping water molecule (Wh) through complexation with the 




 and proton transfer along the 
Pγ-Ser181-Wh-Wa chain takes place, which results in the formation of H2PγO4
−
. D1,D2. The Ser181 side 
chain breaks its hydrogen bond with Wh and rotates to donate a hydrogen bond to the γ-phosphate, which 
itself now donates a hydrogen bond to the β-phosphate. The latter event keeps these two phosphate groups 
in close contact, even though the covalent bond between them is broken after hydrolysis. Upon release of 
inorganic phosphate, it is believed that one proton is transferred from the γ-phosphate to the β-phosphate, 
resulting in HPγO4
2−
 (Pi) and HADP
2− 
(ADP). Adapted from Kiani and Fischer.
27,28
  
Next, the myosin head rebinds at a new position on the actin filament which is accompanied 
by Pi release and cleft closure (step d), yet the temporal ordering and structural basis of 
these events is still under debate. The lever arm then returns to its initial orientation and this 
results in the so-called power stroke, in which the myosin head pulls the actin filament over a 
distance of approximately 10 nm (step e). At the end of the power stroke, ADP is released 
(step f) which allows the start of a new cycle.7,13,18,21-24,26 
2.3. Myosin II isoforms 
Class II myosins can be subdivided into four groups on the basis of sequence analysis of the 
head domain: (i) the sarcomeric myosins from striated and cardiac muscle, (ii) the vertebrate 
smooth-muscle myosins and non-muscle myosins, (iii) the myosins from lower eukaryotic 
species such as Acanthamoeba and Dictyostelium, and (iv) the myosins from fungi.1 In 
humans, the myosin II subfamily only comprises skeletal-, cardiac- and smooth-muscle 
myosins, as well as non-muscle myosin II. Skeletal-muscle myosin II is the motor of skeletal-
muscle contraction and is responsible for posture and all voluntary movements, whereas 
cardiac-muscle myosin II drives contraction of the heart. Smooth-muscle myosin II is 
responsible for involuntary contractions of hollow organs, except the heart, such as the 
stomach, intestine, uterus and blood vessels.1,16,22,29  
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Non-muscle myosin II (NM II) is a collective term covering three distinct isoforms, i.e. NM IIA, 
NM IIB and NM IIC. Although the name is intended to differentiate it from the muscle 
myosins, non-muscle myosin II is also present in skeletal-, cardiac- and smooth-muscle cells, 
yet in smaller quantities than the respective muscle myosins.1,8,16,22,29 It plays an important 
role in embryonic development and in the normal functioning of the adult organism. These 
roles include cytokinesis, cell-cell adhesion and cell migration.8,9,30 However, overactivity of 
non-muscle myosin II’s ATPase is associated with a range of human diseases, such as viral 
infections,31-35 liver fibrosis and portal hypertension,36 arthrofibrosis,37 glaucoma,38 
methamphetamine use relapse,39,40 and cancer metastasis.41-46 Therefore, inhibitors of non-
muscle myosin II ATPase activity are valuable tools for dissecting its exact role in 
physiological functions or for developing targeted treatments against diseases involving non-
muscle myosin II ATPase overactivity. 
3. (S)-Blebbistatin and goals of this doctoral research 
The central role of non-muscle myosin II in the aforementioned biological processes and 
diseases has in part been revealed with the aid of (S)-blebbistatin (S)-4 (Figure 5). This 
molecule has been discovered in 200147 as a micromolar inhibitor of the protein’s ATPase 
activity (for more details on (S)-blebbistatin (S)-4, consult the Literature overview of this 
manuscript). Its cell membrane permeability and rapid inhibitory effects have made it an 
important tool for research on cellular processes and diseases involving non-muscle 
myosin II function. Furthermore, the reversible nature of its inhibitory effects further 
underlines the usefulness of (S)-blebbistatin (S)-4 in characterizing precise non-muscle 
myosin II-driven cellular events.  
 
Figure 5. Structure of (S)-blebbistatin (S)-4 and goals of this doctoral research. 
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Unfortunately, the affinity of (S)-blebbistatin (S)-4 is not limited to non-muscle myosin II, but 
also covers the other myosin II isoforms, i.e. cardiac-, skeletal- and smooth-muscle 
myosin II.48-56 This feature and its low potency (IC50 values in the micromolar range) render it 
unusable as a starting point for the development of non-muscle myosin II-targeted 
therapeutic tools. (S)-Blebbistatin (S)-4 also has several physicochemical liabilities that 
hamper its application as a research tool. For example, it displays poor water solubility and 
its (fluorescent) precipitates interfere in (fluorescence) read-outs.52-54,57-60 Additionally, it has 
cytotoxic side effects in certain contexts and is light sensitive and phototoxic.50,52,61-66  
Due to these deficiencies, a demand for improved inhibitors of non-muscle myosin II, and 
thus for novel blebbistatin derivatives, exists. Such molecules have the potential to become 
highly valuable research tools in cell biology studies or serve as a starting point for the 
development of non-muscle myosin II-targeted therapeutic tools. 
Chapter 1 of this PhD thesis will focus on the search for (S)- and (R)-blebbistatin analogs 
with improved physicochemical properties through modification of ring D (molecules (S)-5 
and (R)-5, Figure 5). D-ring modification will also be explored to gain insight into the 
structure-activity relationship (SAR) landscape. Inhibition constants for myosin II ATPase 
activity will be determined via an in-house-developed biochemical ATPase assay. The newly 
synthesized compounds will be compared to (S)-blebbistatin derivatives developed 
simultaneously by other groups. 
In chapter 2, the quest for improved myosin II inhibitory potency will center on the synthesis 
of a new series of (S)-blebbistatin analogs with a modified A-ring (compounds (S)-6, 
Figure 5). In order to obtain insight into the influence of structural modifications (in this part of 
the scaffold) on myosin II ATPase inhibitory potency, the compounds will also be evaluated 
in an ATPase assay.   
Finally, potency enhancement will be pursued via C-ring modification in chapter 3 (analogs 
(±)-7, Figure 5). Again, an ATPase assay will be used to assess the influence of chemical 
changes on myosin II ATPase inhibitory potency. 
The synthesis of the blebbistatin analogs will follow the general route depicted in Scheme 2. 
First, rings D and C, via compounds 8 and 9, respectively, will be coupled through Goldberg- 
or Chan-Lam-type N-arylations (step a). Ring A will be introduced by condensation of 
amines 11 and amides 10 (step b). Next, ring B will be created via intramolecular ring closure 
upon deprotonation with lithium hexamethyldisilazide (LiHMDS) (step c). Lastly, asymmetric 
α-hydroxylation of quinolinones 13 will be achieved via oxaziridine 14 or 15, where the former 
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will result in (S)-blebbistatin derivatives (S)-16 and the latter will yield (R)-blebbistatin 
analogs (R)-16 (step d). 
 












This literature overview will focus on the discovery of (S)-blebbistatin (S)-4 as an inhibitor of 
(non-muscle) myosin II ATPase activity. The synthesis of (S)-blebbistatin (S)-4 will be 
discussed, as well as its mechanism of action and molecular targets. Furthermore, attention 
will be given to its strengths and deficiencies as a therapeutic tool and research tool. Finally, 
an overview of all blebbistatin derivatives developed up to 2013 (i.e. the start of this PhD 
research) will be presented. It should be noted that literature analogs prepared during this 
PhD research (i.e. 2014–2017), will be discussed in chapter 1 of the Results and discussion 
section for clarity and ease of comparison. 
1. (S)-Blebbistatin 
1.1. Discovery 
In search of inhibitors of non-muscle myosin IIA ATPase activity, Cheung et al. performed a 
high-throughput screening (HTS) in 2001 using a commercial small-molecule library 
(DIVERSet E, Chembridge Inc.).47,67 From the 16,300 compounds they screened, only two 
positive hits were identified that also inhibited non-muscle myosin IIA-dependent processes 
in cells (Figure 6, presumed to be compounds 17 and 18). 
 
Figure 6. Discovery of (±)-blebbistatin (±)-4 as an oxidation product of compound 17.  
However, by that time, the library had been subjected to many freeze-thaw cycles and upon 
retesting a freshly dissolved dimethyl sulfoxide (DMSO) sample of compound 17, this 
molecule was shown to have no influence on non-muscle myosin IIA ATPase activity. 
Intriguingly, this new DMSO solution of component 17 converted from colorless to bright 
yellow on standing in air with a concomitant gain in non-muscle myosin IIA ATPase inhibition 
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after a day or two. This suggested degradation of molecule 17. Upon further investigation, 
(±)-blebbistatin (±)-4, an oxidation product of component 17, turned out to be the active 
compound in the degraded solution. Separation via chiral HPLC and testing of both 
enantiomers revealed (−)-blebbistatin (−)-4 (which later turned out to be the (S)-enantiomer, 
vide infra) as the active species. (+)-Blebbistatin (+)-4 was inactive.47,48,67-70 The inhibitor was 
named after its ability to block the cell blebbing that often accompanies cytokinesis, a 
process which requires non-muscle myosin IIA ATPase activity.68 
1.2. Synthesis 
The synthesis of (S)-blebbistatin (S)-4 has been reported by the group of Westwood.50,70 In 
the sequence, rings A and CD of the scaffold were connected via condensation of amine 20 
with amide 19, respectively. Microwave irradiation of a mixture of these two substrates did 
not result in any reaction, even in the presence of a dehydrating agent. Prior amide activation 
with POCl3, though, afforded amidine 21 in moderate yield (Scheme 3, step a, 41%). 
Formation of amide dimer 22 was also observed. Attempts to further optimize this reaction by 
the addition of base or by the use of other activating agents (i.e. SOCl2, MeOTf, PCl5) proved 
unsuccessful. Next, intramolecular cyclization of amidine 21 using excess LiHMDS resulted 
in quinolinone 23 (step b, 90%). This intermediate was found to be stable for extended 
periods of time in the absence of air and light. However, it decomposed to (±)-blebbistatin 
(±)-4 when dissolved in DMSO and exposed to direct sunlight for 40 days in the presence of 
air, or when supported on silica and irradiated with 365-nm light.  
 
Scheme 3. Synthesis of amidine 21 and quinolinone 23.
50,70
 Reagents and conditions: a. 1) 1.1 equiv amide 
19, 1 equiv POCl3, dry CH2Cl2, rt, 3 h; 2) 1 equiv amine 20, dry CH2Cl2, reflux, 16 h. b. 3 equiv LiHMDS, dry 
THF, −78 °C to 0 °C, 3 h. 
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The key step in this synthesis was the asymmetric α-hydroxylation of quinolinone 23 using 
Davis’ oxaziridine methodology.71 Various oxaziridines, bases and temperatures were 
evaluated (Table 1). Reactions performed with LiHMDS at −78 °C, using either oxaziridine 24 
or 14, were unsuccessful (entries 1 and 4). Treatment with LiHMDS (entry 2) or lithium 
diisopropylamide (LDA) (entry 3) and oxaziridine 24 at higher temperatures gave high yields 
of blebbistatin 4 (70–90%), but low enantioselectivities (ee 31–42%). The use of LiHMDS 
and oxaziridine 14 resulted in the production of (−)-blebbistatin (−)-4 in both a high yield and 
high enantiomeric excess (entry 5, 82%, ee 86%). A final attempt with NaHMDS and 
oxaziridine 14 at −78 °C gave no significant improvement (entry 6, 69%, ee 90%). A single 
recrystallization from CH3CN of the crude obtained in entry 5 resulted in (−)-blebbistatin (−)-4 
in >99% enantiomeric excess.  
Table 1. Asymmetric α-hydroxylation of quinolinone 23.
50,70,a 
 








1 24 LiHMDS −78 16 0 / / 
2 24 LiHMDS −10 16 70 42 −104 
3 24 LDA 0 16 90 31 / 
4 14 LiHMDS −78 16 0 / / 




6 14 NaHMDS −78 72 69 90 −403 
a
 Reagents and conditions: 1) 1.2 equiv base, dry THF, −78 °C, 30 min; 2) 2.4 equiv oxaziridine, dry THF, 
temperature, time. 
b
 Determination of enantiomeric excess via chiral-HPLC analysis. 
c
 Upon recrystallization 
from CH3CN; the corresponding yield was not reported.  
At that time, X-ray crystallographic analysis of the obtained (−)-blebbistatin (−)-4 crystals was 
unable to provide sufficiently high-quality data for an absolute stereochemistry determination. 
In analogy to literature asymmetric α-hydroxylations of cyclic enolates by oxaziridine 14,71 the 
(−)-enantiomer was believed to possess the (S)-configuration. Later, this absolute 
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stereochemistry was confirmed after synthesis and X-ray crystallographic analysis of a 
heavy-atom-bearing analog (vide infra).50 
1.3. Mechanism and structural basis of (non-muscle) myosin II ATPase 
inhibition 
In order to understand the mechanism via which (S)-blebbistatin (S)-4 inhibits (non-muscle) 
myosin II ATPase activity, the overall scheme of the ATPase cycle must be revisited 
(Figure 7). This cycle can be divided into six different events: ATP binding and actin 
dissociation (step a), lever arm priming (step b), ATP hydrolysis and formation of a 
myosin·ADP·Pi complex (step c), actin binding and Pi release (step d), force generation 
during the power stroke (step e) and ADP release (step f). (S)-Blebbistatin (S)-4 does not 
affect ATP binding or ATP hydrolysis (steps a–c). Structural studies on Dictyostelium 
discoideum myosin II and kinetic analysis have shown that it binds to the myosin·ADP·Pi 
complex in the 50-kDa cleft between the ATP binding site and actin binding interface. This 
leads to a stabilized, long-lived (S)-blebbistatin·myosin·ADP·Pi complex, in which the 50-kDa 
cleft is kept partially open (Figure 8). As a result, (S)-blebbistatin (S)-4 traps myosin in a state 
with low actin affinity and inhibits the release of Pi after ATP hydrolysis (step d). In this way, it 
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Figure 7. (Non-muscle) myosin II ATPase inhibition mechanism of (S)-blebbistatin (S)-4. During the 
ATPase cycle, (S)-blebbistatin (S)-4 binds to the myosin·ADP·Pi complex and forms a long-lived, stable 
(S)-blebbistatin·myosin·ADP·Pi complex with a weak actin affinity. This prevents Pi release and force 






head domain of Dictyostelium discoideum myosin II
 
Figure 8. Co-crystal structure of (S)-blebbistatin (S)-4 bound to the head domain of the Dictyostelium 
discoideum myosin II·ADP·vanadate complex (PDB: 1YV3).
73
 Heteroatoms are colored as follows: nitrogen: 
dark blue; oxygen: red; phosphorus: green; vanadium: purple.  
The co-crystal structure of (S)-blebbistatin (S)-4 bound to the Dictyostelium discoideum 
myosin II·ADP·vanadate complex (PDB: 1YV3)73 has also revealed that the selective activity 
of (S)-blebbistatin (S)-4 over its (R)-enantiomer (R)-4 stems from hydrogen bonds between 
the chiral hydroxyl group of (S)-blebbistatin (S)-4, and the amide hydrogen of Gly240 and 
carboxylate oxygen of Leu262 (Figure 9). These bonds ensure a correct orientation of the 
scaffold in the binding pocket. However, most of the binding strength originates from 
hydrophobic interactions. For example, rings AB are enclosed by Tyr261, Thr474, Tyr634, 
Gln637 and Leu641, ring C interacts with Ile455, Ser456 and Ile471, whereas the side chains 


















Figure 9. Detail of the (S)-blebbistatin (S)-4 binding site in Dictyostelium discoideum myosin II (PDB: 
1YV3).
73
 Legend: grey (carbon, amino acid residues); blue (nitrogen); red (oxygen); yellow (sulfur); orange 
(carbon, (S)-blebbistatin (S)-4); red dashed line (hydrogen bond).  
1.4. Molecular targets of (S)-blebbistatin 
Multiple groups have examined the ATPase inhibitory potency of blebbistatin 4 (in racemic 
form or as (S)-enantiomer) against diverse members of the myosin superfamily through in 
vitro ATPase assays (Table 2).48-57,74,75 In such an assay, ATP consumption, Pi production or 
ADP generation is quantified as a measure of ATPase activity. These studies have shown 
that (S)-blebbistatin (S)-4 inhibits the ATPase activity of most myosin II class members, with 
half-maximum inhibitory concentrations (IC50) in the micromolar range. An exception is 
Drosophila melanogaster non-muscle myosin II, which is uniquely insensitive toward 
(±)-blebbistatin (±)-4 at concentrations up to 200 µM. Interestingly, (±)-blebbistatin (±)-4 does 
not inhibit the ATPase activity of unconventional myosins from classes I, V, X and XV, even 
at 150 µM. These data indicate that (±)-blebbistatin (±)-4, and hence (S)-blebbistatin (S)-4, is 
selective for myosin II, but possesses low selectivity within this class. 
These observations are supported by comparison of the residues interacting with 
(S)-blebbistatin in the Dictyostelium discoideum myosin II co-crystal structure (PDB: 1YV3),73 
to the homologous residues among the different myosins. All myosins listed in Table 2 
possess the Gly240 and Leu262 residues required for orientation control. The insensitivity of 
myosins I, V, X and XV can be explained by the substitution of residue Ser456 by residues 
bearing large, aromatic side chains (i.e. Tyr or Phe) that prevent (S)-blebbistatin (S)-4 from 
binding.73 Further, in silico modeling and kinetic studies have provided an explanation for the 
lack of inhibition of Drosophila melanogaster non-muscle myosin II ATPase activity. In this 
LITERATURE OVERVIEW 
21 
organism, Ile455 is substituted by a Met residue which sterically hinders (S)-blebbistatin 
(S)-4 binding.75 
Table 2. Half-maximum inhibitory concentration (IC50) of (±)-blebbistatin (±)-4 for the ATPase activity of 
diverse myosins and sequence comparison with selected blebbistatin contact residues in Dictyostelium 
discoideum myosin II.  
Species Myosin isoform IC50 (µM) 
Selected blebbistatin contact 
residues
a Reference 
D. discoideum II 4.9–13
b 
Gly240 Leu262 Ser456 Ile455 49,52-54,57,74 
Acanthamoeba II 83 Gly Leu Ser Ile 49 
H. sapiens Non-muscle IIA 4–14
b 
Gly Leu Ala Ile 48-50 
G. gallus Non-muscle IIB 1.8 Gly Leu Ala Ile 49 
G. gallus Smooth-muscle II
c 
5.5–23.5 Gly Leu Ala Ile 56 
A. irradians Striated-muscle II 2.3 Gly Leu Ala Ile 49 
O. cuniculus Skeletal-muscle II 0.22–1.6
b 
Gly Leu Ala Ile 49,51-54 
S. scrofa β-Cardiac-muscle II 1.2 Gly Leu Ala Ile 49 
D. melanogaster Non-muscle II >200
d 
Gly Leu Ala Met 75 
R. norvegicus Ib >150
d 
Gly Leu Tyr Ile 49 
Acanthamoeba Ic >150
d 
Gly Leu Tyr Ile 49 
M. musculus Va >150
d 
Gly Leu Tyr Ile 49 
B. taurus X >150
d 
Gly Leu Phe Ile 49 
H. sapiens XV >100
d 
Gly Leu Tyr Ile 49 
a
 Sequence alignments were performed on the UniProt website (accession numbers are P08799, P05659, 





 Data obtained with (S)-blebbistatin (S)-4 were recalculated to mixtures 
containing 50% (S)-blebbistatin (S)-4 and 50% (R)-blebbistatin (R)-4, assuming that (R)-blebbistatin (R)-4 
would not contribute to inhibition. 
c
 The IC50 value for M. gallopavo
49
 and B. taurus
55
 smooth-muscle 
myosin II ATPase inhibition are 80 µM and 4.3–11 µM, respectively; these data are not included in the table, 
since no sequence information is available for these myosins. 
d
 No inhibition was observed at the highest 
concentration evaluated. 
1.5. Strengths and deficiencies 
Since its discovery as a selective myosin II inhibitor, (S)-blebbistatin (S)-4 has rapidly been 
embraced as a research tool to investigate myosin II-dependent processes in different 
species and cell types. Its main advantages are that it is cell membrane permeable and its 
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effects are rapid (i.e. minutes) and reversible. As such, it has played a significant role in the 
understanding of the function of non-muscle myosin II in cellular events, including 
cytokinesis, cell-cell adhesion and cell migration.8,9,30,48 Moreover, in cardiac-muscle 
research, (S)-blebbistatin (S)-4 serves as a valuable tool for excitation-contraction 
uncoupling in electrophysiological studies.77,78 Finally, it has provided insight into the cellular 
and molecular events that drive a range of non-muscle myosin II-related diseases, such as 
viral infections,31-35 liver fibrosis and portal hypertension,36 arthrofibrosis,37 glaucoma,38 
methamphetamine use relapse,39,40 and cancer metastasis.41-46 
Unfortunately, (S)-blebbistatin (S)-4 also bears deficiencies that encumber or prohibit its use 
as a therapeutic tool or research tool. These include low potency, lack of discrimination 
between myosin II isoforms, fluorescence, poor water solubility, possible cytotoxic side 
effects, light sensitivity and phototoxicity. These properties will be discussed in more detail 
below. 
1.5.1. Potency and selectivity 
Table 2 has shown that (S)-blebbistatin (S)-4 inhibits non-muscle myosin II ATPase activity 
at micromolar concentrations and also inhibits other myosin II isoforms. Its low potency and 
poor selectivity between myosin II isoforms present two disadvantages which render it 
unusable as a starting point for the development of a non-muscle myosin II-targeted 
therapeutic tool. In this context, IC50 values in the nanomolar range and selectivity for non-
muscle myosin II would provide a more relevant therapeutic tool. 
1.5.2. Fluorescence and solubility 
A common approach to study protein distribution (and thus function) within a cell is via green-
fluorescent protein-labeling (GFP) and ensuing fluorescence microscopy imaging. In these 
settings, visualization is achieved after excitation with 420–490-nm light and collection of the 
subsequently emitted light in the 520–570-nm range.79 A second application that uses 
fluorescence as a read-out, is cardiac optical mapping. Here, electrical activity and calcium 
concentrations on the heart’s surface are recorded with the aid of voltage-sensitive dyes and 
fluorescent Ca2+ indicators, which exhibit an increase in fluorescence (488–494-nm 
excitation, 502–526-nm emission) upon Ca2+ binding. Heart contraction, though, causes 
motion artifacts by continuously changing the relative position of the heart tissue to the 
sensor. This evidently distorts optical recordings and, therefore, (S)-blebbistatin (S)-4 is often 
used as a tool to inhibit contraction.77,78,80 However, for both applications, (S)-blebbistatin 
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(S)-4 has been found to interfere with the acquisition of the fluorescence signal and this limits 
its use as a research tool in these types of experiments.52,58,59  
Although it has originally been assumed that the fluorescence of (S)-blebbistatin (S)-4 is 
significant enough to cause this interference,50,52 Swift et al. have shown that (S)-blebbistatin 
(S)-4 solutions exhibit negligible fluorescence in the 500–600-nm emission range. 
Conversely, when it forms precipitates in aqueous solutions, its fluorescence signal 
increases substantially.60  
The steady-state solubility of (S)-blebbistatin (S)-4 in aqueous buffers at 25 °C is 7–11 µM at 
0.1% (v/v) DMSO and it increases quasi-linearly with the DMSO concentration to 80 µM at 
10% (v/v) DMSO.54,57 This molecule is usually applied at concentrations of 50–100 µM to fully 
inhibit cellular processes driven by myosin II.49 Initially, (S)-blebbistatin (S)-4 concentrations 
can indeed reach 50 µM. Thereafter, however, the compound precipitates to equilibrium 
concentrations over a timescale of 90 minutes.53,54 
Apart from causing fluorescence interference, the application of (S)-blebbistatin (S)-4 at 
concentrations exceeding its steady-state solubility also has other unwanted consequences, 
which complicate its use as a research tool. First, experiments carried out in oversaturated 
solutions create uncertainty about actual assay concentrations, because these will depend 
on the time between treatment and measurement. This can affect reproducibility. Second, 
the aggregates redissolve very slowly and have the tendency to attach to the bottom of a well 
or petri dish. This compromises the reversibility of the inhibition on supposed wash-out in 
commonly used experimental set-ups. Third, the precipitates perturb light scattering-based 
measurements. Finally, crystals may interrupt normal vascular flow in cardiac optical-
mapping experiments.54,60 
1.5.3. Cytotoxicity 
Another disadvantageous feature that might impair the use of (S)-blebbistatin (S)-4 as a 
research tool, is the potential for cytotoxic effects in long-term experiments (Table 3). 
Mikulich et al. showed that 200 µM of (S)-blebbistatin (S)-4 induced 65–100% cell death in 
human U87 glioblastoma cells (entry 1), human prostate Du145 and LNCaP adenocarcinoma 
cells (entries 3 and 5), F11-hTERT immortalized human fibroblast cells (entry 7) and human 
melanoma FEMX-1 cells (entry 9) after an incubation period of 24 h. This effect was much 
less pronounced in short-term experiments (3-h incubation, entries 2, 4, 6, 8 and 10).61 
Further, Képiró et al. reported that (S)-blebbistatin (S)-4 caused 90% cell death in HeLa cells 
at 20 µM after 3 days of incubation (entry 11), whereas no cytotoxic effects were observed 
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on Dictyostelium discoideum cells under the same conditions (entry 12). Pancreatic-
adenocarcinoma cell viability was only impaired at very high concentrations of 
(S)-blebbistatin (S)-4. For instance, cytotoxicity for MIAPaCa2 (entry 13), BxPC3 (entry 14) 
and Capan2 (entry 15) cells exposed to 400 µM of (S)-blebbistatin (S)-4 for 24 h was 20–
45%, while no cytotoxic effects on PANC1 cells were observed at this concentration (entry 
16).41 Finally, zebrafish embryos treated with 10 µM of (S)-blebbistatin (S)-4 all died after 
36 h (entry 17).52  
Table 3. Cytotoxicity of (S)-blebbistatin (S)-4 depends on cell type, inhibitor concentration and incubation 
time. 
Entry Cell type Concentration (µM) Incubation time Cytotoxicity (%) Reference 
1 U87 200 24 h 65 61 
2 U87 200 3 h 40 61 
3 Du145 200 24 h 90 61 
4 Du145 200 3 h 30 61 
5 LNCaP 200 24 h 96 61 
6 LNCaP 200 3 h 10 61 
7 F11-hTERT 200 24 h 85 61 
8 F11-hTERT 200 3 h 30 61 
9 FEMX-1 200 24 h 100 61 
10 FEMX-1 200 3 h 30 61 
11 HeLa 20 3 days 90 52 
12 D. discoideum 20 3 days 0 52 
13 MIAPaCa2 400 24 h 20 41 
14 BxPC3 400 24 h 25 41 
15 Capan2 400 24 h 45 41 
16 PANC1 400 24 h 0 41 
17 Zebrafish embryo 10 36 h 100 52 
 
In sum, the sensitivity to cytotoxic effects caused by (S)-blebbistatin (S)-4 strongly depends 
on the species under investigation and the incubation time. These effects need to be 
accounted for when using (S)-blebbistatin (S)-4 as a myosin II research tool, since the 
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phenotype caused by cytotoxicity may be falsely attributed to the inhibition of myosin II 
function.  
1.5.4. Light sensitivity and phototoxicity 
As mentioned above, fluorescence imaging with 420–490-nm excitation is often used in 
cardiac optical mapping or to study protein distribution. In addition, other fluorescence 
techniques have contributed to the understanding of the ATPase mechanism of myosins. For 
example, ATP binding and hydrolysis can be identified by measuring the fluorescent signal of 
the nucleotide upon 295-nm or 365-nm excitation, whereas Pi release and ADP release are 
monitored after 425-nm and 365-nm excitation, respectively.62 
Unfortunately, these studies have identified a further limitation of (S)-blebbistatin (S)-4 
(Table 4). It was observed that exposure to light with wavelengths of 295 nm (entry 1), 
351 nm (entry 2), 425 nm (entry 5), 458 nm (entry 8) and 488 nm (entry 10) rapidly 
eliminated the inhibitory action of (S)-blebbistatin (S)-4 on myosin II, whereas virtually no 
inactivation occurred at 543-nm excitation (entry 11).62,63,65  
Table 4. Light sensitivity of (S)-blebbistatin (S)-4 at various wavelengths. 
Entry Wavelength (nm) Observed effect on (S)-blebbistatin (S)-4 Reference 
1 295 Loss of inhibitory action on ATPase activity 62 
2 351 Loss of inhibitory action on actin filament movement 65 
3 365 Change in absorption spectrum 64 
4 390–470 Change in absorption and emission spectrum 61 
5 425 Loss of inhibitory action on Pi release 62 
6 436 + 510 Change in absorption spectrum 50 
7 450–490 Change in absorption and emission spectrum 64,66 
8 458 Loss of inhibitory action on actin filament movement 65 
9 480 Change in absorption spectrum 52 
10 488 
Loss of inhibitory action on actin filament movement and 
cytokinetic-ring contraction 
63,65 
11 543 None 65 
 
Numerous groups investigated the effect of blue-light irradiation on (S)-blebbistatin (S)-4 
degradation in more detail. They mainly based their reports on the effects on the molecule’s 
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absorption and emission spectrum. Kolega identified that illumination with 365 nm (entry 3) 
and 450–490 nm (entry 7) changed the absorption and emission spectrum, and that the 
photoproduct of 365-nm irradiation was spectrally distinct from that obtained after 450–490-
nm illumination.64 In analogous experiments performed by Lucas-Lopez et al.,50 Képiró et 
al.,52 and Bzymek et al.,66 a change in absorption spectrum of (S)-blebbistatin (S)-4 was 
observed after exposure to 436-nm and 510-nm-filtered light (entry 6), 480-nm illumination 
(entry 9) and 450–490-nm irradiation (entry 7), respectively. Lastly, Mikulich et al. evaluated 
the photostability and photosensitizing properties of (S)-blebbistatin (S)-4 upon 390–470-nm 
illumination (entry 4). During irradiation, its absorption spectrum altered and the compound 
oxidized dihydrorhodamine 123 (a probe for peroxynitrite anions, nitroso radicals, nitro 
radicals, hydroxyl radicals and superoxide anions), but not singlet oxygen sensor green (a 
probe for singlet oxygen).61 This suggests that peroxynitrite anions, nitroso radicals, nitro 
radicals, hydroxyl radicals or superoxide anions, but not singlet oxygen, might be formed 
during the photochemical reaction. 
Importantly, the destruction of (S)-blebbistatin (S)-4 by blue light entails toxic effects in cells, 
which are distinct from the cytotoxic effects mentioned above. In multiple cases, cell death 
was observed after illumination in the presence of (S)-blebbistatin (S)-4, even when provided 
with fresh medium afterwards (e.g. HeLa, FEMX-1, LNCaP, Du145, U87, F11-hTERT, bovine 
aortic endothelial cells, human blood monocytes, rat cardiac myocytes).52,54,61,64-66,81 Since 
the photoproduct itself was not found to be toxic, it was suggested that the cells were 
irreversibly damaged by a short-lived product formed during the photochemical reaction.64 
However, the exact mechanism of phototoxicity has not been clarified yet. 
From these results, it may be clear that the sensitivity of (S)-blebbistatin (S)-4 to wavelengths 
below 500 nm can have a strong and negative impact on its use as a research tool in 
applications that require fluorescence as a read-out. Moreover, the phototoxicity limits its use 
in live cell-imaging experiments. 
2. Blebbistatin derivatives 
In this section, an overview of all blebbistatin derivatives developed up to 2013 (i.e. the start 
of this PhD research) will be presented. However, the discovery of (±)-6-bromo-4’-ethoxy-
blebbistatin (±)-25 (see Figure 10 for numbering within the blebbistatin scaffold) should be 
mentioned first. This analog was discovered by Cheung et al. in the same high-throughput 
screen as (±)-blebbistatin (±)-4 and was also found to be an oxidation product of a compound 
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(i.e. molecule 18) present in the commercial small-molecule library (DIVERSet E, 
Chembridge Inc.).47,48,67  
 
Figure 10. Numbering within the blebbistatin scaffold and discovery of (±)-6-bromo-4’-ethoxyblebbistatin 
(±)-25 as an oxidation product of compound 18.
47,48,67
 
The other blebbistatin derivatives will be discussed below. They are classified according to 
the application for which they were developed. 
2.1. Determination of the absolute stereochemistry of (−)-blebbistatin 
(−)-4 
As mentioned above, Lucas-Lopez et al. were initially unable to determine the absolute 
stereochemistry of (−)-blebbistatin (−)-4, since X-ray crystallographic analysis did not provide 
sufficiently high-quality data. Therefore, they decided to prepare a heavy-atom (bromine)-
containing analog, which might give way to better-quality crystals.50  
First, they tried to prepare (−)-4’-bromoblebbistatin (−)-26 via direct bromination of 
(−)-blebbistatin (−)-4 with N-bromosuccinimide (NBS), but purification of the resulting 
products proved difficult (Scheme 4, step a). This was also the case for bromination of 
intermediates en route to (−)-blebbistatin (−)-4. Thus, the synthesis of (−)-6-bromo-
blebbistatin (−)-30 from brominated building block 27 was envisioned. This approach was 
also unsuccessful due to the low yield of amidine 28 (step b).  
In a third attempt, the authors successfully prepared (−)-O-(3-bromobenzoyl)blebbistatin 
(−)-33 and (−)-O-(4-bromobenzoyl)blebbistatin (−)-34 through acylation of the chiral alcohol 
in (−)-blebbistatin (−)-4 with bromobenzoyl chlorides 31 and 32, respectively (Scheme 5, 
97%–quant). Unfortunately, recrystallization of the obtained products from EtOAc/hexane did 




Scheme 4. Failed attempts to prepare brominated (−)-blebbistatin analogs (−)-26 and (−)-30.
50
 Reagents 
and conditions: a. 1 equiv NBS, dry DMF, rt, 24 h. b. 1) 1.1 equiv amide 19, 1 equiv POCl3, dry CH2Cl2, rt; 
2) 1 equiv amine 27, dry CH2Cl2, reflux (the time and yield were not reported). 
 
Scheme 5. Synthesis of (−)-O-(3-bromobenzoyl)blebbistatin (−)-33 and (−)-O-(4-bromobenzoyl)blebbistatin 
(−)-34.
50
 Reagents and conditions: 0.5 equiv DMAP, 4 equiv dry pyridine, 10 equiv 3-bromobenzoyl chloride 
(31) or 4-bromobenzoyl chloride (32), dry CH2Cl2, rt, 24 h. The enantiomeric excess was not reported, but 
[α]
D
26 was −568 and −607 after recrystallization of (−)-33 and (−)-34, respectively, from EtOAc/hexane. 
Finally, (−)-4’-bromoblebbistatin (−)-26 was synthesized from amide 19 (Scheme 6). 
Bromination of the latter compound with NBS resulted in amide 35 in moderate yield (step a, 
50%). The preparation of amidine 36 proved troublesome (step b, 26%). Next, intramolecular 
cyclization, using excess LiHMDS, resulted in quinolinone 37 (step c, 60%) that was further 
α-hydroxylated with oxaziridine 14 to afford (−)-4’-bromoblebbistatin (−)-26 in good yield and 
high enantiomeric excess (step d, 68%, ee 88%). An enantiopure sample was obtained after 
recrystallization from CH3CN, for which the absolute stereochemistry could be determined via 
X-ray crystallographic analysis.  
Via this work, it was proven that (−)-4’-bromoblebbistatin (−)-26 possessed the 
(S)-configuration. Further, using H2 and 1% (m/m) palladium on carbon in the presence of 
Et3N, enantiopure (S)-4’-bromoblebbistatin (S)-26 was reduced to (S)-blebbistatin (S)-4 
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(step e, 99%, ee >99%). Lastly, chiral-HPLC, 1H-NMR and MS analysis showed that (S)-
blebbistatin (S)-4 was identical to (−)-blebbistatin (−)-4, which finally confirmed its absolute 
stereochemistry. 
 
Scheme 6. Synthesis of enantiopure (−)-4’-bromoblebbistatin (−)-26 and (−)-blebbistatin (−)-4, and 
confirmation of the (S)-configuration of (−)-4’-bromoblebbistatin (−)-26 by X-ray crystallographic analysis.
50
 
Reagents and conditions: a. 1 equiv NBS, dry DMF, rt, 2 days. b. 1) 1 equiv POCl3, dry CH2Cl2, rt, 3 h; 2) 
1.1 equiv amine 20, dry CH2Cl2, reflux, 16 h. c. 3 equiv LiHMDS, dry THF, −78 °C to 0 °C, 3 h. d. 1) 
1.2 equiv LiHMDS, dry THF, −78 °C, 30 min; 2) 2.4 equiv oxaziridine 14, dry THF, −10 °C, 16 h. e. 3.7 equiv 
Et3N, 1% (m/m) Pd/C, H2, MeOH/DMF (1:1), rt, 24 h. 
a
 Determination of enantiomeric excess via chiral-
HPLC analysis. 
b




 = −526. 
2.2. Late-stage incorporation of (hetero)aromatic D-rings in the 
blebbistatin scaffold 
In the synthesis of (S)-blebbistatin (S)-4 as reported by Lucas-Lopez et al., the scaffold is 
constructed from A- and CD-ring-containing building blocks.50 This approach does not allow 
for a highly divergent synthesis of analogs with varying (hetero)aromatic D-rings. Therefore, 
Lawson et al. investigated the potential of a late-stage incorporation of (hetero)aromatic 
D-rings into a priorly formed ABC-tricyclic scaffold.82  
This was attempted via the synthesis of racemic precursor (±)-47 which was prepared from 
aryl iodide 38 in seven steps (Scheme 7). The latter compound was used to introduce an 
amide protecting para-methoxyphenyl (PMP) group via N-arylation of pyrrolidin-2-one (39) 
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(step a, 88%). The synthesis of amidine 41 and preparation of quinolinone 42 proceeded 
smoothly (steps b–c, 89–91%). Key steps in the synthesis pathway were the racemic 
α-chlorination of quinolinone 42 with sodium dichloroisocyanurate (43) and subsequent 
nucleophilic substitution in alkaline aqueous medium (steps d and e, 91% and 52%, 
respectively). The authors did not comment on their choice to prepare (±)-4’-methoxy-
blebbistatin (±)-45 via the α-chlorinated intermediate (±)-44. Based on the preceeding work 
on blebbistatin, the direct conversion of quinolinone 42 with Davis’ oxaziridine methodology 
also seems plausible. This would have shortened the sequence with one step and may have 
resulted in a higher yield of (±)-4’-methoxyblebbistatin (±)-45. Before removing the PMP 
group, the chiral hydroxyl group was protected with triisopropylsilyl trifluoromethanesulfonate 
(TIPSOTf) (step f, 80%). Afterwards, PMP deprotection of compound (±)-46 with cerium 
ammonium nitrate (CAN) yielded racemic precursor (±)-47 (step g, 50%). 
 
Scheme 7. Synthesis of racemic precursor (±)-47.
82
 Reagents and conditions: a. 1.1 equiv aryl iodide 38, 
1 equiv pyrrolidin-2-one (39), 0.1 equiv CuI, 0.2 equiv N,N’-dimethylethylenediamine (DMEDA), 3 equiv 
K3PO4, molecular sieves (4 Å), dry toluene, reflux, 18 h. b. 1) 1.2 equiv amide 40, 1.2 equiv POCl3, dry 
CH2Cl2, rt, 3 h; 2) 1 equiv amine 20, dry CH2Cl2, reflux, 18 h. c. 2.5 equiv LiHMDS, dry THF, −78 °C to 0 °C, 
3 h. d. 0.5 equiv sodium dichloroisocyanurate (43), THF/H2O (1:1), rt, 4 h. e. 1.85 equiv NaOH, H2O/THF 
(9:4), rt, 18 h. f. 4 equiv DIPEA, 3 equiv TIPSOTf, dry CH2Cl2, reflux, 6 h. g. 4.5 equiv CAN, CH3CN/H2O 
(1:1), 0 °C, 8 h.  
Having precursor (±)-47 in hand, the authors next sought suitable conditions for its 
CuI-catalyzed N-arylation with iodobenzene (Table 5). Of the six ligands screened, the amino 
acid-based ligands 61 and 62 (entries 1 and 2, respectively) and the β-diketone ligand 63 
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(entry 3) did not result in any reaction. In the diamine ligand series 64–66 (entries 4–6), the 
best results were obtained with (±)-trans-N,N’-1,2-dimethyldiaminocyclohexane ((±)-66) 
(entry 6, 80%). Lowering the loading of both the catalyst and ligand (±)-66 caused a 
significant drop in the yield of compound (±)-48 (entry 7, 47%). 
Table 5. Synthesis of (±)-blebbistatin analogs (±)-55–60 via introduction of (hetero)aromatic D-rings in 









1 (±)-48 / Ph 0.1 61 0.2 0
b 
2 (±)-48 / Ph 0.1 62 0.2 0
b
 
3 (±)-48 / Ph 0.1 63 0.2 0
b
 
4 (±)-48 / Ph 0.1 64 0.2 7
b
 
5 (±)-48 / Ph 0.1 (±)-65 0.2 25
b
 
6 (±)-48 / Ph 0.1 (±)-66 0.2 80
b
 
7 (±)-48 / Ph 0.05 (±)-66 0.1 47
b
 
8 (±)-49 (±)-55 2-Thienyl 0.1 (±)-66 0.2 53
c 
9 (±)-50 (±)-56 4-CH3C6H4 0.1 (±)-66 0.2 63
c 
10 (±)-51 (±)-57 4-ClC6H4 0.1 (±)-66 0.2 66
c 
11 (±)-52 (±)-58 4-Pyridyl 0.1 (±)-66 0.2 71
c 
12 (±)-53 (±)-59 3-CF3C6H4 0.05 (±)-66 0.1 19
c 
13 (±)-54 (±)-60 4-Biphenyl 0.05 (±)-66 0.1 34
c 
a
 Reagents and conditions: a. 3 equiv Cs2CO3, 1.2 equiv ArI, CuI, ligand, molecular sieves (4 Å), dry 
toluene, 120 °C, 24 h. b. 3 equiv TBAF, THF, rt, 2 h. 
b
 Yield of intermediate (±)-48 (step a). 
c
 Combined 
yield of steps a and b; intermediates (±)-49–54 were not purified. 
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The best conditions (entry 6) were subsequently used in the preparation of products (±)-49–
52. Direct desilylation (without intermediate purification) with tetra-n-butylammonium fluoride 
(TBAF) yielded (±)-blebbistatin derivatives (±)-55–58 (entries 8–11, 53–71%). However, for 
reasons unknown, TIPS protected (±)-blebbistatin analogs (±)-53–54 were prepared from 
precursor (±)-47 using the low catalyst and ligand loading of entry 7. This resulted in a low 
yield of (±)-blebbistatin analogs (±)-59–60 after deprotection (entries 12–13, 19–34%). 
Finally, and unfortunately, the myosin II ATPase inhibitory potency of the newly synthesized 
(±)-blebbistatin analogs (±)-45 and (±)-55–60 was never reported. 
In conclusion, due to the numerous steps required for the preparation of racemic precursor 
(±)-47, the late-stage incorporation of (hetero)aromatic D-rings via this route is not attractive 
when only a small number (i.e. 1–3) of D-ring-modified blebbistatin analogs is envisioned. 
However, after optimization, this pathway could be useful for the preparation of more 
elaborate libraries. 
2.3. Structure-activity relationship of A-ring-modified blebbistatin 
analogs 
The need for more potent (S)-blebbistatin analogs prompted Lucas-Lopez et al. to investigate 
the impact of A-ring modification on biological activity.83 In this light, the influence of the 
methyl position was evaluated. 
(S)-blebbistatin derivatives (S)-75–78 were obtained via the same route as developed for 
(S)-blebbistatin (S)-4 and started with the preparation of amidines 71–74 from amide 19 and 
amines 67–70 (Scheme 8, step a). This transformation proceeded in rather low yields (24–
28%), except for amidine 74 which was isolated in 52% yield after a highly increased reaction 
time. Amidines 71–73 easily underwent intramolecular cyclization upon deprotonation with 
LiHMDS, but a higher reaction temperature and longer reaction time were required for 
amidine 74. A possible explanation for this decreased reaction rate is the steric clash 
between the 3-methyl substituent and the nitrogen-coordinated lithium cation that needs to 
be tolerated upon ring closure. Quinolinones 75–78 were all synthesized in excellent yield 




Scheme 8. Synthesis of amidines 21,71–74 and quinolinones 23,75–78.
83
 Reagents and conditions: a. 1) 
1.1 equiv amide 19, 1 equiv POCl3, dry CH2Cl2, rt, 3 h; 2) 1 equiv amine 20,67–70, dry CH2Cl2, reflux, 16 h 
or 72 h (for 74). b. 3 equiv LiHMDS, dry THF, −78 °C to 0 °C or −78 °C to rt (for 78), 3 h or 12 h (for 78). 
a




A variation in the enantioselectivity of the quinolinone α-hydroxylation with oxaziridine 14 was 
observed (Table 6). More specifically, (S)-blebbistatin analogs (S)-79 and (S)-81–82 were 
prepared in high enantiomeric excess (ee 86–90%), while quinolinone 76 was α-hydroxylated 
in a significantly lower enantiomeric excess (ee 64%). Using 7Li-NMR analysis, the authors 
prudently suggested that the steric clash with the 5-methyl substituent might disfavor 
coordination of the lithium cation with the enolate oxygen, resulting in a decreased 
asymmetric induction. Finally, highly optically enriched samples of analogs (S)-79–82 were 
obtained upon recrystallization from CH3CN. 
The latter samples, together with (S)-blebbistatin (S)-4, were then used to assess their 
inhibition of the ATPase activity of two myosin II isoforms (i.e. Dictyostelium discoideum 
myosin II and rabbit skeletal-muscle myosin II) (Table 6). Analogs bearing a methyl 
substituent on C5 ((S)-80), C6 ((S)-4) or C7 ((S)-81) of ring A, or having no substituent at all 
((S)-79), almost completely inhibited the ATPase activity of Dictyostelium discoideum 
myosin II at a concentration of 50 µM. In contrast, a reduced potency was obtained when the 
methyl substituent was present on C8 ((S)-82). The same trend was observed in ATPase 
assays conducted against rabbit skeletal-muscle myosin II and compound concentrations of 
50 µM or 5 µM, with the differences being more pronounced at 5 µM. Furthermore, co-
crystallization experiments of each of the molecules (S)-4,79–82 with Dictyostelium 
discoideum myosin II suggested that the steric hindrance between the 8-methyl substituent 




Table 6. Synthesis of (S)-blebbistatin (S)-4
a
 and its analogs (S)-79–82 from quinolinones 23,75–78,
b
 and 
overview of the inhibition percentage of the ATPase activity of Dictyostelium discoideum myosin II and 
rabbit skeletal-muscle myosin II at the indicated concentrations.
83
 The co-crystal structure of (S)-blebbistatin 
(S)-4 in the head domain of Dictyostelium discoideum myosin II (PDB: 1YV3)
73




          
Product R Yield (%) Ee
d
 (%) 
D. discoideum myosin II Skeletal-muscle myosin II
e
  
50 µM (%) 50 µM (%) 5 µM (%) 
(S)-4
 
6-Me 82 86 / >99
f
 92 97 ± 2 93 ± 1 
(S)-79 H 78 86 / >99
f 
88 95 ± 1 84 ± 1 
(S)-80 5-Me 87 64 / 99
f 
88 95 ± 1 86 ± 1 
(S)-81 7-Me 83 90 / >99
f 
90 94 ± 1 86 ± 1 
(S)-82 8-Me 63 86 / >99
f 
35 72 ± 2 31 ± 9 
a




 Reagents and conditions: 1) 1.2 equiv 
LiHMDS, dry THF, −78 °C, 30 min; 2) 2.4 equiv oxaziridine 14, dry THF, −10 °C, 16 h. 
c
 Legend: orange 
(carbon), red (oxygen), blue (nitrogen), grey (carbon). 
d
 Determination of enantiomeric excess via chiral-
HPLC analysis. 
e
 The data represent the mean ± s.d. of 3 samples.
 f
 Upon recrystallization from CH3CN; the 
corresponding yield was not reported.  
In conclusion, the experimental results of the ATPase assays with Dictyostelium discoideum 
myosin II and rabbit skeletal-muscle myosin II indicate that small substituents can be 
tolerated on C5, C6 or C7, but not on C8. Because of the poor asymmetric induction observed 
in the presence of C5 substitution, the authors suggested that incorporation of substituents is 
best directed at C6 and C7 in the future design of A-ring-modified (S)-blebbistatin analogs. 
2.4. Development of a photoreactive covalent myosin II inhibitor 
The low water solubility of (S)-blebbistatin (S)-4 prevents inhibition at high concentrations in 
aqueous media. This limits the complete inhibition of myosin II-driven cellular processes49 
and complicates the identification of low-affinity cellular targets. Therefore, Képiró et al. 
envisioned an azidated (S)-blebbistatin derivative that would induce an irreversible (i.e. 
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covalent) crosslink with its cellular targets upon UV irradiation. For this application, 
(S)-4’-azidoblebbistatin (S)-84 was thought to be fit for purpose.53,57 
Képiró et al. developed a small-scale synthesis strategy of the latter analog that was based 
on the aromatic iodination of 5 mg of (S)-blebbistatin (S)-4 using N-iodosuccinimide (NIS) in 
the presence of BF3·2H2O (Scheme 9, step a).
57 During this reaction, two products were 
formed, of which the main one was (S)-4’-iodoblebbistatin (S)-83. The side product was not 
characterized, and the yield and enantiomeric excess were not determined. It seems that 
direct iodination of (S)-blebbistatin (S)-4 was not feasible on a larger scale, as larger 
amounts of (S)-4’-iodoblebbistatin (S)-83 were obtained in an alternative manner (Scheme 
10).53 More specifically, iodination of amide 19 (step a) and subsequent amidine 86 synthesis 
(step b), quinolinone 87 preparation (step c) and asymmetric α-hydroxylation (step d) 
afforded (S)-4’-iodoblebbistatin (S)-83 in large quantities. Unfortunately, little information is 
available on these transformations, as yields and enantiomeric excesses were not reported. 
 
Scheme 9. Small-scale preparation of (S)-4’-iodoblebbistatin (S)-83 and (S)-4’-azidoblebbistatin (S)-84 from 
5 mg of (S)-blebbistatin (S)-4.
57
 Reagents and conditions: a. 1.5 equiv NIS, BF3·2H2O/MeOH (7:3), 50 °C, 
microwave, 30 min. b. NaN3, CuI, sodium ascorbate, DMEDA, DMSO/H2O (5:1), rt, 30 min. 
a
 The yield and 
enantiomeric excess were not reported. 
b
 The reagent stoichiometry was not reported.  
(S)-4’-Iodoblebbistatin (S)-83 was subsequently converted into (S)-4’-azidoblebbistatin (S)-84 
via a CuI-catalyzed halogen-azide exchange with sodium azide on both small (Scheme 9, 
step b) and large scale (Scheme 10, step e). In both cases, the yield and enantiomeric 
excess were not reported.  
Next, the myosin II ATPase inhibitory potency of (S)-4’-azidoblebbistatin (S)-84 was 
evaluated in an ATPase assay against Dictyostelium discoideum myosin II. Without UV 
irradiation, it acted as a reversible inhibitor with an IC50 value of 5.2 ± 0.3 µM, which was 
similar to that of (S)-blebbistatin (S)-4 (i.e. 6.4 ± 0.9 µM). Its water solubility was also 




Scheme 10. Large-scale preparation of (S)-4’-iodoblebbistatin (S)-83 and (S)-4’-azidoblebbistatin (S)-84.
53
 
Reagents and conditions: a. NIS, BF3·2H2O/MeOH, 80 °C, microwave, 60 min. b. POCl3, amine 20, dry 
CH2Cl2, 50 °C, 18 h. c. LiHMDS, −78 °C to 0 °C, 3 h. d. oxaziridine 14, −10 °C, 16 h; e. CuI, DMEDA, 
sodium ascorbate, DMSO/H2O (5:1), rt, 1 h. 
a
 The reagent stoichiometry and yield were not reported. 
b
 The 
enantiomeric excess was not reported. 
The authors confirmed the potential use of (S)-4’-azidoblebbistatin (S)-84 as a covalent 
inhibitor. For example, Dictyostelium discoideum myosin II could be completely and 
covalently bound by (S)-4’-azidoblebbistatin (S)-84 using multiple cycles of inhibitor addition 
in low concentrations (e.g. 10 µM) and UV irradiation at a wavelength of 310 nm. Importantly, 
the residual activity of the unbound inhibitor molecules was eliminated after 310-nm 
irradiation. Furthermore, the use of (S)-4’-azidoblebbistatin (S)-84 for the identification of 
weak-binding partners in cellular extracts was demonstrated. As such, previously unknown 
low-affinity (i.e. EC50 value of more than 50 µM) targets of (S)-4’-azidoblebbistatin (S)-84 
(and likely (S)-blebbistatin (S)-4) could be identified in the cellular extracts of Dictyostelium 
discoideum.  
2.5. Modification of the physicochemical properties 
As mentioned above, the interference of (S)-blebbistatin (S)-4 during fluorescence imaging 
upon 420–490-nm excitation and its degradation at wavelengths below 500 nm limit its use 
as a research tool in applications that require fluorescence as a read-out. To meet the need 
for (S)-blebbistatin derivatives that eliminate these defiencies, Lucas-Lopez et al. proposed 
the introduction of an electron-withdrawing nitro group on the scaffold.50,70  
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Since their research on A-ring-modified (S)-blebbistatin analogs had demonstrated that C7 
substitution is tolerated from a biological-activity point of view,83 (S)-7-nitro-6-norblebbistatin 
(S)-91 was prepared (Scheme 11).50,70 The synthesis followed the same route as for the 
preparation of (S)-blebbistatin (S)-4 (Scheme 3 and Table 1),50 but lower yields were 
obtained in all steps. It started with the condensation of amide 19 and amine 88 upon amide 
activation by POCl3 (step a, 22%), whereafter intramolecular ring closure of amidine 89 
afforded quinolinone 90 (step b, 44%). Asymmetric α-hydroxylation with oxaziridine 14 
subsequently yielded (S)-7-nitro-6-norblebbistatin (S)-91 (step c, 31%, ee 76%). 
 
Scheme 11. Synthesis of (S)-7-nitro-6-norblebbistatin (S)-91. Reagents and conditions: a. 1) 1.1 equiv 
amide 19, 1 equiv POCl3, dry CH2Cl2, rt, 3 h; 2) 1 equiv amine 88, dry CH2Cl2, reflux, 72 h. 
b. 1+0.5+0.5+0.5 equiv LiHMDS, dry THF, 0 °C, 4× 24 h. c. 1) 1.2 equiv LiHMDS, dry THF, −78 °C, 30 min; 
2) 3.1 equiv oxaziridine 14, dry THF, −10 °C, 32 h. 
At that time, it was still assumed that the fluorescence of (S)-blebbistatin (S)-4 is significant 
enough to cause interference upon 488-nm excitation. Therefore, the emission spectrum of 
(S)-blebbistatin (S)-4 and (S)-7-nitro-6-norblebbistatin (S)-91 following 488-nm excitation 
were analyzed. The authors presented that (S)-7-nitro-6-norblebbistatin (S)-91 showed a 
significantly reduced fluorescence as compared to (S)-blebbistatin (S)-4, but actually both 
were negligible. To further investigate whether this analog retained its biological activity, 
Lucas-Lopez et al. evaluated the inhibition of non-muscle myosin IIA ATPase. The IC50 value 
lay in the same order of magnitude as that of (S)-blebbistatin (S)-4 (28 ± 3 µM and 
7.1 ± 0.4 µM, respectively). Finally, comparison of the absorption spectrum of (S)-blebbistatin 
(S)-4 and (S)-7-nitro-6-norblebbistatin (S)-91 upon exposure to 436-nm and 510-nm-filtered 
light indicated that compound (S)-91 was stable under these conditions, while molecule (S)-4 
decomposed. This observation suggests that (S)-7-nitro-6-norblebbistatin (S)-91 could be a 
LITERATURE OVERVIEW 
38 
viable alternative to (S)-blebbistatin (S)-4 for fluorescence-imaging experiments. On the 
contrary, its reduced potency may also raise concerns in the light of low aqueous solubility. 
Solubility data were, however, not provided by the authors. 
3. Conclusion 
(S)-blebbistatin (S)-4 has been discovered together with (±)-6-bromo-4’-ethoxyblebbistatin 
(±)-25 as a degradation product during a high-throughput screening for inhibitors of non-
muscle myosin IIA ATPase activity (Figure 11). It is a micromolar, uncompetitive inhibitor that 
stabilizes the myosin·ADP·Pi complex of the ATPase cycle. The chiral hydroxyl group is 
crucial for the selective activity of the (S)-enantiomer.  
Its cell membrane permeability, rapid inhibition and reversible effects have established 
(S)-blebbistatin (S)-4 as an important research tool in the understanding of the function of 
non-muscle myosin II in both normal and aberrant biological processes. Unfortunately, its 
inhibition is not limited to non-muscle myosin II, but also covers other myosin II isoforms, 
such as cardiac-, skeletal- and smooth-muscle myosin II. This feature and its low potency are 
the key factors that render it unusable as a starting point for the development as a non-
muscle myosin II-targeted therapeutic tool. Furthermore, it possesses other deficiencies that 
encumber its application as a research tool, which include fluorescence interference, poor 
water solubility, cytotoxicity, blue-light sensitivity and phototoxicity.  
The synthesis of (S)-blebbistatin (S)-4 has been developed by the group of Westwood and 
comprises three main steps, i.e. amidine synthesis, quinolinone formation and asymmetric 
α-hydroxylation.50,70 This pathway has been applied in the development of several analogs 
(Figure 11). The confirmation of the absolute stereochemistry of (S)-blebbistatin (S)-4 has 
been achieved with the aid of X-ray crystallographic analysis of the heavy-atom-bearing 
analog (S)-4’-bromoblebbistatin (S)-26.50 The potential of a late-stage incorporation of 
(hetero)aromatic D-rings has been investigated for racemic analogs (±)-55–60.82 Due to the 
numerous reaction steps, this route is only attractive for the preparation of four or more 
derivatives. Some pitfalls in the synthesis pathway of the (S)-blebbistatin scaffold have also 
been revealed. The formation of amidines is the most problematic step in the sequence and 
the presence of para-substituted (i.e. relative to the nucleophilic moiety) electron-withdrawing 
groups on rings A and D further complicates this reaction. On the other hand, this 
transformation benefits from para-substituted electron-donating groups on ring D. Lastly, 




Figure 11. Overview of blebbistatin analogs developed up to 2013.
48,50,53,57,70,82,83
 All were discussed in this 
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A brief SAR study on A-ring-modified derivatives (S)-79–82 has identified that small-sized 
substituents are of little influence at the C5, C6 and C7 positions, but are undesired at the C8 
position (Figure 11).83 A photoreactive analog, (S)-4’-azido-blebbistatin (S)-84, has been 
developed as a covalent inhibitor upon 310-nm irradiation.53,57 Finally, (S)-7-nitro-6-nor-
blebbistatin (S)-91 presents a derivative with improved photostability.50,70  
In conclusion, most of (S)-blebbistatin’s research tool liabilities (e.g. poor water solubility, 
ensuing interference of precipitates in (fluorescence) read-outs, and phototoxicity) were 
unresolved at the start of this PhD research and none of the literature analogs showed an 
improved myosin II ATPase inhibitory potency. Hence, a need for superior research and 
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1. Introduction 
As mentioned in the Literature overview, (S)-blebbistatin (S)-4 has two main disadvantages 
which limit its application as a research tool in cell biology: (i) low water solubility (and 
ensuing interference of (fluorescent) precipitates during (fluorescence) read-outs) and (ii) 
degradation upon exposure to wavelengths below 500 nm (and associated phototoxicity). At 
the start of this PhD research, preliminary work that tackled the light sensitivity had been 
performed by Lucas-Lopez et al.50 However, (S)-blebbistatin derivatives with a highly 
increased water solubility were lacking. We thus focused on the development of polar 
(S)-blebbistatin analogs and used D-ring modification to enable this. The (R)-enantiomers 
were also synthesized in order to use them as negative controls. 
Furthermore, the low myosin II ATPase inhibitory potency of (S)-blebbistatin (S)-4 presents a 
major limitation that prohibits its application as a starting point for the development of non-
muscle myosin II-targeted therapeutic tools. Hence, D-ring modification was also used to 
explore the possibilities of potency enhancement. In this context, the parallel development of 
D-ring-modified analogs in literature will be discussed in this chapter as well. 
The newly synthesized compounds were compared to (S)-blebbistatin derivatives developed 
by other groups and (S)-blebbistatin (S)-4 was used as a benchmark in all our studies. 
Therefore, its preparation (and that of (R)-blebbistatin (R)-4) was optimized and this will be 
discussed first. 
2. Synthesis of (S)-blebbistatin (S)-4 and (R)-blebbistatin (R)-4 
The general pathway for the synthesis of the blebbistatin scaffold is depicted in Scheme 12. 
In our hands, a Goldberg-type N-arylation of pyrrolidin-2-one (39) with iodobenzene (92) 
afforded amide 19 in very good yield (step a, 89%).84 The synthesis of amidine 21 from 
amide 19 and amine 20 was performed in the presence of POCl3 via a modified procedure of 
Lucas-Lopez et al. (step b).50 The amount of phosphorus oxychloride was doubled and the 
reaction time for the formation of the chloroiminium intermediate was increased from 3 h 
to 24 h. In this way, a conversion of 95% was obtained.  
However, isolation of the amidine from the crude reaction mixture via acid-base extraction, 
as described by Lucas-Lopez et al.,50 proved difficult and afforded amidine 21 in only 2% 
yield. Moreover, on a number of occasions, hydrolysis of the amidine functionality was 
observed upon neutralization during aqueous work-up. Therefore, a purification strategy 
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using automated flash chromatography and gradient elution was developed. This required 
laborious optimization, since this technique was not generally used and well-known in the lab 
at that time. Both normal-phase and reversed-phase conditions were tested, and 
reproducibility and scale-up were evaluated. Finally, amidine 21 was isolated in 78% yield on 
a multigram scale by reversed-phase automated flash chromatography. This procedure 
afforded amidine 21 in a much higher yield than the previously reported strategy (41%).50 
 
Scheme 12. Synthesis of (S)-blebbistatin (S)-4 and (R)-blebbistatin (R)-4. Reagents and conditions: 
a. 0.05 equiv CuI, 0.05 equiv tris(3,5-dimethyl-1H-pyrazol-1-yl)methane (TPM),
85
 1.2 equiv pyrrolidin-2-one 
(39), 2 equiv K3PO4, dry 1,4-dioxane, reflux, 24 h. b. 1) 2 equiv POCl3, dry CH2Cl2, rt, 24 h; 2) 1.05 equiv 
amine 20, dry CH2Cl2, 35 °C, 24 h. c. 2.5 equiv LiHMDS, dry THF, 0 °C, 1 h. d. 1) 1.2 equiv LiHMDS, dry 
THF, −78 °C, 30 min; 2) 2.4 equiv oxaziridine 14 (for (S)-4) or oxaziridine 15 (for (R)-4), dry THF, −15 °C, 
16 h. 
a
 Previously prepared by Lucas-Lopez et al. in 41% yield: 1) 1.1 equiv amide 19, 1 equiv POCl3, dry 




 Determination of enantiomeric excess via chiral-HPLC analysis. 
c
 After recrystallization from CH3CN.  
Intramolecular cyclization gave quinolinone 23 in excellent yield (step c, 98%). The ensuing 
asymmetric α-hydroxylation was carried out using Davis’ oxaziridine methodology (step d, 
63–85%, ee 75%).71 Quinolinone 23 was completely converted to α-hydroxy ketones (S)-4 
and (R)-4, yet isolated yields varied. A single recrystallization from CH3CN resulted in highly 
optically enriched (S)-blebbistatin (S)-1 (ee >99%) and (R)-blebbistatin (R)-1 (ee 99%). 
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3. Development of polar (S)-blebbistatin analogs with improved 
research tool properties 
The main focus in this part is on the development of (S)-blebbistatin analogs with enhanced 
water solubility. We hypothesized that this would be attainable via the introduction of polar 
functionalities on its scaffold (Figure 12). In addition, the increased aqueous solubility would 
eliminate interference of (fluorescent) precipitates during (fluorescence) read-outs. 
Therefore, the novel analogs (S)-3’-cyanoblebbistatin (S)-93, (S)-3’-hydroxyblebbistatin 
(S)-94, (S)-3’-aminoblebbistatin (S)-95, (S)-3’-carbamoylblebbistatin (S)-96 and 
(S)-3’-carboxyblebbistatin (S)-97, and the (R)-enantiomers (negative controls),48 were 
synthesized. The myosin II ATPase inhibitory potency of these compounds was evaluated in 
a biochemical assay (i.e. an ATPase assay). Furthermore, some key physicochemical 
properties of these molecules were determined, including solubility and fluorescence data.  
 
Figure 12. Overview of proposed polar (S)-blebbistatin derivatives. 
3.1. Synthesis of both enantiomers of compounds 93–97 
3.1.1. Selection of protecting groups and N-arylation 
The key step in the synthesis of blebbistatin derivatives 93–97 was the selection of a suitable 
masked polar group which (i) would withstand the acidic conditions generated during amidine 
synthesis, (ii) would be stable under the alkaline conditions of quinolinone formation and (iii) 
could be cleaved off without affecting the blebbistatin scaffold. Bearing these criteria in mind, 
the allyl protecting group and cyano function were selected for the preparation of blebbistatin 
analogs 94–95 and 93,96,97, respectively (Scheme 13).  
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Scheme 13. Introduction of protecting groups and N-arylation. Reagents and conditions: a. 0.015 equiv 
TBAB, 1.05 equiv allyl bromide, 25% (m/v) aq NaOH/2-mTHF (3:2), reflux, 2 h. b. 1.25+1.25+0.5 equiv 
LiHMDS, 4 equiv allyl bromide, dry THF, reflux, 2+1+1 h. c. 0.05 equiv CuI (3× for 105), 0.05 equiv TPM (3× 
for 105), 1.2 equiv pyrrolidin-2-one (39), 2 equiv K3PO4, dry 1,4-dioxane, reflux, 24 h (3× for 105). 
a
 Prior to 
aqueous work-up, 94% and 6% of 3-iodoaniline (99) were converted to diallylamine 101 and 
monoallylamine, respectively.  
Aryl iodide 100 was prepared from 3-iodophenol (98) and allyl bromide in a similar way as 
reported by Brown Ripin and Vetelino86 (step a, quant), while aryl iodide 101 was obtained 
through a selective diallylation of 3-iodoaniline (99) described by Vandekerckhove et al.87 
(step b, 75%). In the latter reaction, small amounts of side product 102 were formed which 
could be distilled off easily. These aryl iodides and commercially available 3-iodobenzonitrile 
(103) were used for the N-arylation of pyrrolidin-2-one (39), which afforded amides 104–106 
in a high yield (step c, 75–88%). 
3.1.2. Amidine synthesis 
Amidine 109 (Table 7) was synthesized according to the optimized synthesis and purification 
protocol of amidine 21 (Scheme 12, step b). However, the presence of an electron-
withdrawing group in amide 106 hampered the nucleophilic character of the aryl amide, 
leading to rather high amounts of unreacted starting material (entry 1, 37% conversion). 
Attempts were undertaken to improve this transformation using an alternative activating 
agent or starting material (i.e. Mukaiyama’s reagent 10888 and thioamide 107, respectively) 
and/or by the addition of base.  
This required the prior preparation of thioamide 107 which was synthesized from amide 106 
with Lawesson’s reagent 11089 (Scheme 14, 79%). When excess Lawesson’s reagent 110 
(more than 0.5 equivalents) and/or prolonged reaction times (more than 30 minutes) were 
used at elevated temperatures (70 °C), thionation of the nitrile functionality in thioamide 107 
also occurred. Further, it should be noted that it was crucial to dissolve the crude product in 
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toluene during silica coating prior to flash chromatography. From an extensive series of 
solvents (ethyl acetate, acetone, tetrahydrofuran, dichloromethane, chloroform, acetonitrile, 
methanol, toluene), toluene was the only solvent able to yield a free-flowing, well-coated 
silica mixture which was required for a good separation between thioamide 107, Lawesson’s 
reagent byproduct 111 and thiobenzamide 112 during flash chromatography.  
Table 7. Attempts to optimize the synthesis of amidine 109.  
 




1) 2 equiv POCl3, rt, 24 h 





1) 2 equiv Et3N, 1.2 equiv 108, rt, 5 min 





1) 2 equiv Et3N, 1.2 equiv 108, rt, 5 min 





1) 2 equiv Et3N, 2 equiv 108, rt, 5 min 





1) 2 equiv Et3N, 2 equiv POCl3, rt, 5 min 




1) 2 equiv Et3N, 2 equiv POCl3, rt, 24 h 




1) 2 equiv POCl3, rt, 5 min 





1) 2 equiv POCl3, rt, 24 h 





 Not determined.  
Unfortunately, this synthesis and purification effort turned out to be in vain, as all subsequent 
attempts to improve the preparation of amidine 109 were unsuccessful (Table 7). 
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Scheme 14. Synthesis of thioamide 107 from amide 106 and Lawesson’s reagent 110. Reagents and 
conditions: 0.5 equiv Lawesson’s reagent 110, dry THF, reflux, 30 min. 
After these failed attempts, we returned to the initial reaction conditions for the preparation of 
amidines 113–114 (Scheme 15, 26–50%). Again, the presence of an electron-withdrawing 
group (i.e. a protonated amino group formed under the acidic conditions generated) resulted 
in a moderate conversion of amide 104. Moreover, during aqueous work-up, part of the 
amidine 114 was converted into hydrolysis product 115. Attempts to purify this amidine 
resulted in a low yield, while removal of the side product was not complete.   
 
Scheme 15. Synthesis of amidines 113–114 from amides 104–105. Reagents and conditions: 1) 2 equiv 
POCl3, dry CH2Cl2, rt, 24 h; 2) 1.05 equiv amine 20, dry CH2Cl2, 35 °C, 24 h. 
a
 Prior to aqueous work-up, the 
reaction mixture consisted of 38 mol% of amide 104 and 62 mol% of amidine 113. 
b
 Prior to aqueous work-
up, the reaction mixture consisted of 46 mol% of amide 105 and 54 mol% of amidine 114. 
c
 86% (m/m) 
purity: contained 115 as impurity, which later led to the presence of impurity 116 in quinolinone 119 
(Scheme 16). 
3.1.3. Quinolinone synthesis and enantioselective α-hydroxylation 
Intramolecular cyclization of amidines 109,113–114 upon treatment with LiHMDS resulted in 
the formation of quinolinones 117–119 (Scheme 16, step a, 66–86%). Quinolinone 119 was 
contaminated with compound 116 (Scheme 15) which was formed by ring closure of impurity 
115 present in amidine 114. Efforts to remove this contamination during flash 
chromatography, were unsuccessful and resulted in a decreased yield. 
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Scheme 16. Synthesis of quinolinones 117–119 from amidines 109,113–114 and asymmetric 
α-hydroxylation. Reagents and conditions: a. 2.5 equiv LiHMDS, dry THF, 0 °C, 1 h. b. 1) 1.2 equiv 
LiHMDS, −78 °C, 30 min; 2) 2.4 equiv oxaziridine 14 (for (S)-93,120–121) or 15 (for (R)-93,120–121), 
dry THF, −15 °C, 16 h. 
a
 91% (m/m) purity: contained 116 as impurity (Scheme 15). 
b
 Determination of 
enantiomeric excess via chiral-HPLC analysis. 
c
 After recrystallization from CH3CN. 
d
 After 
recrystallization from EtOH. 
Next, asymmetric α-hydroxylation was carried out using Davis’ oxaziridine methodology.71 In 
this way, quinolinones 117–119 were completely converted to α-hydroxy ketones (S)- and 
(R)-93,120–121, but isolated yields varied (step b, 68–97%, ee 74–84%). Enantiopure 
compounds were pursued by recrystallization. Recrystallization parameters (solvent volume 
and time) appeared to be crucial in yielding crystals containing only one enantiomer. A single 
recrystallization from CH3CN or EtOH resulted in highly optically enriched α-hydroxy ketones 
(S)- and (R)-120 (ee >99%) and (S)- and (R)-121 (ee 98%–quant), respectively. 
Unfortunately, both solvents were ineffective in producing enantiopure (S)-3’-cyano-
blebbistatin (S)-93 and (R)-3’-cyanoblebbistatin (R)-93. 
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3.1.4. Deprotection and further derivatization 
Several allyl deprotection strategies were investigated for intermediate 120, which are 
summarized in Table 8. Isomerization of the allyl group via ruthenium(IV) catalysis and 
subsequent hydrolysis90 failed (entry 1). Half of the starting material was hydrolyzed to side 
product 123 under these conditions. Next, a DMSO-I2-mediated deprotection
91 attempt 
resulted in complete decomposition of substrate 120 into a complex mixture (entry 2), while a 
base-catalyzed isomerization gave moderate amounts of isomer 124 together with 
elimination product 125 (entry 3). No reaction occurred when Pd(PPh3)4 in MeOH was used 
at room temperature (entry 4).92 This was mainly due to the poor solubility of the starting 
material in the reaction solvent, since a temperature increase resulted in complete 
solubilization and conversion of 3’-allyloxyblebbistatin 120 to 3’-hydroxyblebbistatin 94 
(entry 5).  
Table 8. Attempted allyl deprotection strategies for compound 120. 
 
Entry Reaction conditions Result (%) 
1 0.017 equiv Ru-catalyst 122, H2O/THF (5:2), reflux, 24 h 120/94/123 (50:0:50) 
2 1.1 equiv I2, dry DMSO, 130 °C, 24 h complex mixture 
3 0.1 equiv KO
t
Bu, dry DMSO, 120 °C, 3 h 120/124/125 (45:30:25) 
4 0.05 equiv Pd(PPh3)4, 6 equiv K2CO3, dry MeOH, rt, 3 h 120 (quant) 
5 0.05 equiv Pd(PPh3)4, 6 equiv K2CO3, dry MeOH, 50 °C, 1 h 94 (quant) 
 
When these conditions were applied to the deprotection of 3’-(diallylamino)blebbistatin 121, 
no trace of 3’-aminoblebbistatin 95 was detected. Yet, the use of N,N’-dimethylbarbituric acid 
(126) instead of K2CO3 resulted in a full conversion. Ensuing purification of both 
3’-hydroxyblebbistatin 94 and 3’-aminoblebbistatin 95 via base-acid and acid-base extraction, 
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respectively, yielded substantial amidine hydrolysis. On the other hand, automated flash 
chromatography proved troublesome because of the low solubility of the desired products in 
organic solvents such as hexane, ethyl acetate, dichloromethane and acetone. This 
hampered coating onto silica and caused large tailing during chromatography. Moreover, low 
sample loadings (i.e. 1–2% (m/m) instead of the usual 20% (m/m)) were required to avoid the 
product from precipitating in the valves and onto the column during chromatography. Taking 
the above into account, (S)-3’-hydroxyblebbistatin (S)-94, (R)-3’-hydroxyblebbistatin (R)-94, 
(S)-3’-aminoblebbistatin (S)-95 and (R)-3’-aminoblebbistatin (R)-95 were isolated in a high 
yield (Scheme 17, 72–79%, ee 95%–quant). Finally, the absolute configuration of analogs 
(S)-94 and (R)-94 was determined by X-ray analysis (Figure 13). This confirmed the 
formation of (S)- and (R)-α-hydroxy ketones from quinolinones using Davis’ oxaziridines 14 
and 15, respectively (Scheme 16).  
 
Scheme 17. Allyl deprotection of compounds 120–121: synthesis of (S)-3’-hydroxyblebbistatin (S)-94, 
(R)-3’-hydroxyblebbistatin (R)-94, (S)-3’-aminoblebbistatin (S)-95 and (R)-3’-aminoblebbistatin (R)-95. 
Reagents and conditions: a. 0.05 equiv Pd(PPh3)4, 6 equiv K2CO3, dry MeOH, 50 °C, 1 h. b. 6 equiv 
N,N’-dimethylbarbituric acid (126), 0.1 equiv Pd(PPh3)4, dry CH2Cl2, reflux, 1 h. 
a
 Determination of 
enantiomeric excess via chiral-HPLC analysis. 
 
Figure 13. X-ray structure of (S)-3’-hydroxyblebbistatin (S)-94 and (R)-3’-hydroxyblebbistatin (R)-94. 
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Nitriles (S)- and (R)-93 (ee 83–84%) were selectively hydrolyzed to amides (S)- and (R)-96 
with diethylhydroxylamine93 (Scheme 18, step a, 90–91%, ee 86%) and subsequently 
optically enriched by recrystallization from EtOH (ee 97–98%). The outcome of the latter 
procedure was quite unpredictable. For example, 5 equal portions of amide (S)-96 (ee 86%) 
were simultaneously recrystallized in the same amount of solvent, resulting in a mother liquor 
that was optically enriched in one case, while the crystals yielded an enantiomeric excess of 
98% in another case. The three other recrystallizations resulted in scalemic mixtures in both 
the crops and the mother liquors. A similar observation was made during recrystallization of 
amide (R)-96.  
 
Scheme 18. Synthesis of (S)-3’-carbamoylblebbistatin (S)-96, (R)-3’-carbamoylblebbistatin (R)-96, 
(S)-3’-carboxyblebbistatin (S)-97 and (R)-3’-carboxyblebbistatin (R)-97. Reagents and conditions: 
a. 2× 4 equiv Et2NOH, dry CH2Cl2, reflux, 2× 24 h. b. 30 equiv H2SO4, H2O, 70 °C, 14 h. 
a
 Determination of 
enantiomeric excess via chiral-HPLC analysis. 
b
 After recrystallization from EtOH. 
c
 Determination of 
enantiomeric excess via chiral-HPLC analysis of the corresponding methyl ester. 
Afterwards, these optically enriched amides were further converted into carboxylic acids 
(S)-and (R)-97 (step b, 22–75%, ee 91–96%). Isolation of the acids from the crude reaction 
mixture proved tedious due to their polar and zwitterionic nature. Compound (S)-97 was only 
recovered in low yield (22%) by preparative TLC. Conversely, work-up of the crude mixture 
afforded carboxylic acid (R)-97 in good yield (75%) and similar purity as obtained for 
molecule (S)-97 after preparative TLC.  
Finally, in order to determine the enantiomeric excess of the carboxylic acids (and to 
overcome the separation difficulties associated with their chiral-HPLC analysis), an analytical 
sample of each was converted into the corresponding methyl esters by treatment with 
diazomethane at room temperature for 45 minutes. 
3.1.5. Conclusion 
The crucial steps in the synthesis of 3’-cyanoblebbistatin 93, 3’-hydroxyblebbistatin 94, 
3’-aminoblebbistatin 95, 3’-carbamoylblebbistatin 96 and 3’-carboxyblebbistatin 97 were the 
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successful introduction and removal of a suitable masked polar group. The allyl protecting 
group and cyano function proved appropriate for the preparation of blebbistatin analogs 94–
95 and 93,96–97, respectively. Finally, the enantiopurity of both enantiomers of all newly 
synthesized blebbistatin derivatives 93–97 and 120–121 was determined via chiral-HPLC 
analysis. Unfortunately, this feature is often neglected in literature.54,57 Knowledge of the 
enantiopurity of (S)-blebbistatin or its derivatives is highly important when these molecules 
are used to modulate (non-muscle) myosin II function in biochemical or biological 
experiments, as the (R)-enantiomers display no affinity for myosin II (vide infra). 
3.2. Evaluation of the research tool properties 
3.2.1. Biochemical evaluation 
The myosine II ATPase inhibitory potency of both enantiomers of blebbistatin 4, 3’-cyano-
blebbistatin 93, 3’-hydroxyblebbistatin 94, 3’-aminoblebbistatin 95, 3’-carbamoylblebbistatin 
96 and 3’-carboxyblebbistatin 97 was evaluated in vitro in a steady-state ATPase assay. At 
the time, this was not a routinely performed assay in our lab, so a suitable experimental set-
up needed to be developed first. Since purified or recombinantly expressed non-muscle 
myosin II is not easily accessible and its production costs are exceptionally high,* rabbit 
skeletal-muscle myosin II was used as a model for non-muscle myosin II. As the binding 
pocket of (S)-blebbistatin (S)-4 is conserved over species and isoforms, the relative inhibitory 
potency (as compared to (S)-blebbistatin (S)-4) against rabbit skeletal-muscle myosin II 
ATPase was expected to be comparable against non-muscle myosin II.  
ATP hydrolysis (and thus ATPase activity) was determined through a colorimetric reaction of 
Pi with malachite green. The resulting color change from yellow to green was quantified via 
absorbance reading at 650 nm. In this way, dose-response curves were generated for both 
enantiomers of compounds 93–97 (Figures 14 and 15) and the corresponding half-maximum 
inhibitory concentrations (IC50) were determined via 4-parameter logistic curve fitting 
(Table 9).  
                                               
*
 0.1 mg of recombinant protein costs $4000 and with this amount only one compound can be evaluated in 
twofold.  






























































































Figure 14. Myosin II ATPase inhibitory potency of both enantiomers of blebbistatin 4, 3’-cyanoblebbistatin 
93 and 3’-hydroxyblebbistatin 94, evaluated in a steady-state ATPase assay against rabbit skeletal-muscle 
myosin II. Example of a dose-response curve and 4-parameter logistic curve fitting obtained for A. (S)-4 and 
(R)-4, B. (S)-93 and (R)-93 and C. (S)-94 and (R)-94. The data points represent the mean ± s.d. of at least 
three samples (N = 1). (S)-Blebbistatin (S)-4 is shown as a benchmark. Concentrations exceeding 40 µM 
caused (S)-3’-cyanoblebbistatin (S)-93 to precipitate in the assay buffer. As an approximation, the relative 
ATPase activity obtained for (S)-blebbistatin (S)-4 at a concentration of 32.5 µM was used to set the lower 
asymptote of the fitted curve for this compound. 
































































































Figure 15. Myosin II ATPase inhibitory potency of both enantiomers of 3’-aminoblebbistatin 95, 
3’-carbamoylblebbistatin 96 and 3’-carboxyblebbistatin 97, evaluated in a steady-state ATPase assay 
against rabbit skeletal-muscle myosin II. Example of a dose-response curve and 4-parameter logistic curve 
fitting obtained for A. (S)-95 and (R)-95, B. (S)-96 and (R)-96 and C. (S)-97 and (R)-97. The data points 
represent the mean ± s.d. of at least three samples (N = 1). (S)-Blebbistatin (S)-4 is shown as a benchmark.  
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Table 9. Biochemical and preliminary physicochemical evaluation of compounds (S)- and (R)-4,93–97: half-
maximum inhibitory concentration (IC50) for the steady-state ATPase activity of rabbit skeletal-muscle 






 (µM) Compound R IC50
c
 (µM) 
(S)-4 H 2.16 ± 0.14 6.18 ± 0.08 (R)-4 H >100
d
* 
(S)-93 CN 48.5 ± 0.1* N.D.
e
 (R)-93 CN >40
f
* 
(S)-94 OH 19.3 ± 0.5* 193 ± 1 (R)-94 OH >300
g
* 
















 The data represent the mean ± s.d. of two independent experiments (1.6% (v/v) DMSO). 
b
 The data 
represent the mean ± s.d. of two independent experiments (2% (v/v) DMSO). 
c
 The data represent two 
independent experiments (1.6% (v/v) DMSO). 
d,f–h
 The highest concentration evaluated was 100, 40, 300 
and 200 µM, respectively. 
e
 Not determined. 
f
 Concentrations exceeding 40 µM resulted in compound 
precipitation in the assay buffer. * P < 0.01 versus (S)-blebbistatin (S)-4. 
The half-maximum inhibitory concentration of (S)-3’-hydroxyblebbistatin (S)-94 and 
(S)-3’-aminoblebbistatin (S)-95 in the ATPase assay lie somewhat higher, but still in the 
same order of magnitude as that of parent compound (S)-4. (S)-3’-Cyanoblebbistatin (S)-93 
proves less potent. The maximal extent of inhibition is the same for all four compounds at 
high concentrations (50–100 µM). (S)-3’-Carbamoylblebbistatin (S)-96 and (S)-3’-carboxy-
blebbistatin (S)-97, on the other hand, are ineffective at concentrations up to 100 µM. As 
expected,48 all (R)-enantiomers lack efficacy.  
The data generated from the ATPase assay yield useful SAR information. They highlight that 
the (S)-configuration is essential for activity, confirming a similar binding mode for 
(S)-3’-hydroxyblebbistatin (S)-94, (S)-3’-aminoblebbistatin (S)-95 and (S)-3’-cyano-
blebbistatin (S)-93 as for (S)-blebbistatin (S)-4. The data also reveal that small hydrophilic 
groups can be introduced in the 3’-position of ring D without influencing the myosin II ATPase 
inhibitory potency in an appreciable manner. Large polar groups are not well tolerated.  
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3.2.2. Preliminary physicochemical evaluation 
As discussed in the Literature overview, a major liability of (S)-blebbistatin (S)-4 is its limited 
solubility in aqueous media. In general, in vitro biochemical or biological experiments are 
carried out with pre-dissolved (e.g. a DMSO solution) compounds which are transferred into 
the aqueous medium used in the assay. In this context, the compound’s solubility is referred 
to as kinetic solubility. This is in contrast to thermodynamic solubility, where compounds are 
introduced in an aqueous medium as a solid compound. Since precipitation is not an 
instantaneous process, a sufficiently long time period is furthermore required to allow for 
precipitation to stabilize and to obtain reproducible results. This we term the steady-state 
solubility. We found that the steady-state solubility of (S)-blebbistatin (S)-4 in PBS pH 7.4 
buffer (Table 9) was 6.18 ± 0.08 µM at 2% (v/v) DMSO. As anticipated, the solubility of the 
newly synthesized alcohol, amine, amide and carboxylic acid derivatives proved significantly 
higher under the same conditions. (S)-3’-Cyanoblebbistatin (S)-93 was not evaluated, since 
precipitation had been noticed above 40 µM in the ATPase assay. Most importantly, the 
solubility of the most potent derivatives, (S)-3’-hydroxyblebbistatin (S)-94 and (S)-3’-amino-
blebbistatin (S)-95, is over 30 times higher than that of (S)-blebbistatin (S)-4. In order to 
successfully and fully inhibit cellular processes driven by myosin II, we strive for our research 
tool compounds to possess a steady-state solubility that exceeds the IC50 value by at least a 
factor of 10. This criterion is met for both (S)-3’-hydroxyblebbistatin (S)-94 and (S)-3’-amino-
blebbistatin (S)-95. 
A second severe limitation of (S)-blebbistatin (S)-4 is its interference when using 
fluorescence (420–490-nm excitation, 520–570-nm emission) as a read-out. Although Swift 
et al. had shown that (S)-blebbistatin (S)-4 solutions exhibit negligible fluorescence in the 
500–600-nm emission range,60 it was still postulated that (S)-blebbistatin (S)-4 solutions are 
highly fluorescent and thereby cause this interference.52,54 In this work, the hypothesis was 
therefore tested that (S)-blebbistatin (S)-4 crystals, rather than (S)-blebbistatin (S)-4 in 
solution, are the actual cause of fluorescence interference. If true, then the use of more water 
soluble blebbistatin analogs would eliminate this interference. Hence, aqueous solutions with 
a low or high concentration of (S)-blebbistatin (S)-4 were imaged after 24 h of incubation 
(Figure 16). At low (S)-blebbistatin (S)-4 concentrations (Figure 16A), no fluorescence upon 
488-nm excitation was observed. Conversely, at high (S)-blebbistatin (S)-4 concentrations 
(Figure 16B), fluorescent precipitates were clearly visible. When repeating the experiment 
with the most potent polar derivatives, (S)-3’-hydroxyblebbistatin (S)-94 (Figure 16C) and 
(S)-3’-aminoblebbistatin (S)-95 (Figure 16D), no fluorescence was detected.  






Figure 16. Low aqueous solubility of (S)-blebbistatin (S)-4 results in precipitates that interfere during 
fluorescence (488-nm excitation) imaging when applied at high concentrations in aqueous medium 
(DMEM/Ham’s F-12 (1:1) supplemented with 10% (v/v) fetal bovine serum). A. 5 µM of (S)-blebbistatin 
(S)-4 (0.1% (v/v) DMSO). B. 50 µM of (S)-blebbistatin (S)-4 (0.1% (v/v) DMSO). C. 50 µM of (S)-3’-hydroxy-
blebbistatin (S)-94 (0.1% (v/v) DMSO). D. 50 µM of (S)-3’-aminoblebbistatin (S)-95 (0.1% (v/v) DMSO). 













































Figure 17. Emission spectrum of (S)-blebbistatin (S)-4, (S)-3’-hydroxyblebbistatin (S)-94 and 
(S)-3’-aminoblebbistatin (S)-95 upon 488-nm excitation. Compounds were evaluated as 20-µM solutions in 
PBS pH 7.4 buffer (2.67% (v/v) MeOH). 
CHAPTER 1   RESULTS AND DISCUSSION 
61 
As (S)-blebbistatin (S)-4, (S)-3’-hydroxyblebbistatin (S)-94 and (S)-3’-aminoblebbistatin 
(S)-95 show a similar weak fluorescence upon 488-nm excitation (Figure 17), these 
observations confirm that the fluorescence interference of (S)-blebbistatin (S)-4 are due to its 
low aqueous solubility and the resulting formation of precipitates. 
3.2.3. Conclusion 
The biochemical and preliminary physicochemical evaluation demonstrate that both 
(S)-3’-hydroxyblebbistatin (S)-94 and (S)-3’-aminoblebbistatin (S)-95 combine a good 
myosin II ATPase inhibitory potency with a 30-times higher aqueous solubility than 
(S)-blebbistatin (S)-4. These polar analogs moreover do not show interference in 
fluorescence read-outs. Given these virtues, (S)-3’-hydroxyblebbistatin (S)-94 and 
(S)-3’-aminoblebbistatin (S)-95 can be considered superior research tool molecules for the 
study of myosin II. 
4. Extending the library of D-ring-modified (S)-blebbistatin 
analogs 
4.1. Synthesis of (S)-4’-chloroblebbistatin (S)-57 and (S)-4’-nitro-
blebbistatin (S)-130 by Képiró et al.52,53 
As discussed in the Literature overview, Lucas-Lopez et al.50 had previously reported that 
introduction of an electron-withdrawing group in (S)-7-nitro-6-norblebbistatin (S)-91 increased 
the photostability as compared to (S)-blebbistatin (S)-4. However, at the same time, the non-
muscle myosin IIA ATPase inhibitory potency decreased 4-fold. These observations and the 
fact that 4’-substitution had not resulted in a negative impact on the potency of (S)-4’-azido-
blebbistatin (S)-84,57 inspired Képiró et al. to further explore the possibilities of obtaining a 
photostable and non-phototoxic (S)-blebbistatin analog via electron-withdrawing groups on 
the 4’-position. In June 2014, they reported their work on (S)-4’-chloroblebbistatin (S)-57 and 
(S)-4’-nitroblebbistatin (S)-130.52,53  
(S)-4’-Chloroblebbistatin (S)-57 was synthesized via chlorination of (S)-blebbistatin (S)-4 with 
N-chlorosuccinimide (NCS) in a moderate yield (Scheme 19, 40%), yet the enantiomeric 
excess was not reported.  
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Scheme 19. Synthesis of (S)-4’-chloroblebbistatin (S)-57 reported by Képiró et al.
52
 Reagents and 
conditions: 2.5 equiv NCS, BF3·2H2O/MeOH (7:2), 100 °C, microwave, 30 min. 
a
 The enantiomeric excess 
was not reported. 
The preparation of (S)-4’-nitroblebbistatin (S)-130 started with nitration of amide 19 
(Scheme 20, step a, 90%). Subsequent formation of amidine 128 and quinolinone 129 both 
proved difficult (steps b and c, 10% and 20%, respectively). Finally, asymmetric 
hydroxylation with oxaziridine 14 afforded (S)-4’-nitroblebbistatin (S)-130 (step d, 54%, 
ee 80%) which was further purified via preparative chiral HPLC (ee >99%).  
 
Scheme 20. Synthesis of (S)-4’-nitroblebbistatin (S)-130 reported by Képiró et al.
52
 Reagents and 
conditions: a. 6 equiv H2SO4, 1.1 equiv HNO3, 0 °C, 15 min. b. 1) 1.1 equiv amide 127, 1.2 equiv POCl3, dry 
CH2Cl2, rt, 3 h; 2) 1 equiv amine 20, dry CH2Cl2, reflux, 18 h. c. 4 equiv LiHMDS, dry THF, −78 °C to 0 °C, 
3 h. d. 1) 1.3 equiv LiHMDS, dry THF, −78 °C, 30 min; 2) 2.5 equiv oxaziridine 14, dry THF, −10 °C, 16 h. 
a
 Determination of enantiomeric excess via chiral-HPLC analysis. 
b
 After purification via preparative chiral 
HPLC; the corresponding yield was not reported. 
Next, the biochemical and physicochemical properties of (S)-4’-chloroblebbistatin (S)-57 and 
(S)-4’-nitroblebbistatin (S)-130 were compared to those of (S)-blebbistatin (S)-4 (Table 10). 
ATPase assays against Dictyostelium discoideum myosin II (and rabbit skeletal-muscle 
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myosin II) showed that both analogs inhibit the ATPase activity to the same extent as 
(S)-blebbistatin (S)-4. The photostability of both analogs was determined by comparison of 
the absorption spectrum recorded before and after 480-nm irradiation. The absorption 
spectrum of (S)-4’-chloroblebbistatin (S)-57 and (S)-4’-nitroblebbistatin (S)-130 remained 
essentially unaffected, whereas that of (S)-blebbistatin (S)-4 changed markedly. The 
photostability of the analogs is thus largely superior.  
Képiró et al. also investigated whether the improved photostability was accompanied by a 
reduced phototoxicity. Therefore, HeLa cells were treated with the three compounds and 
irradiated with 480-nm light for 15 minutes. (S)-Blebbistatin (S)-4 and (S)-4’-chloro-
blebbistatin (S)-57 treatments caused extensive cell death, while no difference in toxicity was 
observed between the control group and (S)-4’-nitroblebbistatin (S)-130-treated cells. Based 
on these results, the authors concluded that improved photostability (of 
(S)-4’-chloroblebbistatin (S)-57) is not necessarily accompanied by a reduced phototoxicity. 
However, this statement should be interpreted with caution, because their method of 
photostability determination (of (S)-4’-chloroblebbistatin (S)-57) was not quantitative, as will 
be further discussed below.  
Table 10. Biochemical and physicochemical evaluation of (S)-blebbistatin (S)-4, (S)-4’-chloroblebbistatin 


















(S)-4 H 3.0 ± 0.5 0.41 ± 0.03 No Yes 11 ± 1 




(S)-130 NO2 2.3 ± 0.1 0.40 ± 0.05 Yes No 3.3 ± 0.1 
a
 The data represent the mean ± s.d. of two independent experiments. 
b
 Determined in qualitative manner 
by overlay of the absorption spectrum of a 5-µM solution in aqueous medium (40 mM NaCl, 4 mM MgCl2, 
20 mM HEPES pH 7.3) recorded before and after 15 min of 480-nm irradiation. 
c
 HeLa cells and 15 min of 
480-nm illumination. 
d
 Steady-state solubility of a 0.1% (v/v) DMSO solution in aqueous buffer (40 mM 
NaCl, 4 mM MgCl2, 20 mM HEPES pH 7.3). 
e
 Not determined. 
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Finally, the steady-state solubility of (S)-4’-nitroblebbistatin (S)-130 was shown to be similar 
to that of (S)-blebbistatin (S)-4. This still poses a limitation on the broad-scope applicability of 
(S)-4’-nitroblebbistatin (S)-130. 
4.2. Improved synthesis of (S)-blebbistatin (S)-4 
(S)-Blebbistatin (S)-4 and all (S)-blebbistatin derivatives discussed in the Literature overview 
(i.e. compounds 26,45,79–83,91) and this chapter up to now (i.e. analogs 93,120,121,130) 
were synthesized via isolation of a quinolinone intermediate.  
In the work discussed below, the synthesis pathway was shortened via the development of a 
more convenient one-pot synthesis of α-hydroxy ketones from amidines, without isolation of 
the intermediate quinolinones (Scheme 21). Amidine 21 was converted to α-hydroxy ketone 
(S)-4 (step c) in a higher yield (quant vs 83%) and enantiomeric excess (86% vs 75%) than 
the two-pot procedure (steps a and b). This important enhancement in the synthesis of the 
blebbistatin scaffold was applied in the following work from here on. 
 
Scheme 21. One-pot synthesis of α-hydroxy ketones from amidines. Reagents and conditions: a. 2.5 equiv 
LiHMDS, dry THF, 0 °C, 1 h. b. 1) 1.2 equiv LiHMDS, dry THF, −78 °C, 30 min; 2) 2.4 equiv oxaziridine 14, 
dry THF, −15 °C, 16 h. c. 1) 2.1 equiv LiHMDS, dry THF, 0 °C, 1 h; 2) 2.4 equiv oxaziridine 14, dry THF, 
−15 °C, 16 h. 
a
 Determination of enantiomeric excess via chiral-HPLC analysis. 
4.3. Investigating the space for extra substituents on ring D 
Identification of (S)-blebbistatin analogs with significantly enhanced myosin II ATPase 
inhibitory potency could deliver a starting point for the development of targeted therapeutic 
tools. This, however, requires a profound insight into the structure-activity relationship of the 
(S)-blebbistatin scaffold. Therefore, new D-ring-modified (S)-blebbistatin derivatives were 
prepared to extend the existing small library of analogs. 
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Analysis of the co-crystal structure of (S)-blebbistatin (S)-4 bound to Dictyostelium 
discoideum myosin II (PDB: 1YV3) indicated that space for extra (hydrophobic) substituents 
is present in the binding pocket surrounding ring D, in particular near the 3’- and 4’-positions 




Figure 18. A. Binding mode of (S)-blebbistatin (S)-4 (orange) with Dictyostelium discoideum myosin II (PDB 
structure: 1YV3).
73
 B. Predicted binding poses of (S)-3’-acrylamidoblebbistatin (S)-133 (cyan), (S)-3’-(diallyl-
amino)blebbistatin (S)-121 (yellow) and (S)-(1H)-pyrrolo[2,3-c’]blebbistatin (S)-138 (fuchsia). C. Predicted 
binding poses of (S)-benzo[c’]blebbistatin (S)-136 (white), (S)-4’-allyloxyblebbistatin (S)-141 (cyan) and 
(S)-4’-benzyloxyblebbistatin (S)-142 (yellow). The figures were generated using the molecular modelling 
software Molecular Operating Environment (MOE).
94
 Interaction surfaces (onset of Van der Waals clash) 
are shown: pink indicates polar areas on the receptor surface, green indicates hydrophobic areas.  
Using the molecular modelling software Molecular Operating Environment (MOE),94 we 
investigated the tolerance of: (i) substituents of increasing size in the 3’-position, ranging 
from allyloxy in analog (S)-120 to diallylamino in compound (S)-121, (ii) ring fusion at the 
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3’,4’-position, with a conformationally restrained monofunctionalized 3’-amino group in 
indoline (S)-135, a lipophilic naphthyl group incorporated in structure (S)-136 and a more 
polar isoquinoline or indole moiety in analogs (S)-137–138 and (iii) functional groups of 
increasing size in the 4’-position, i.e. hydroxy, amino, allyloxy, benzyloxy and diallylamino 
(derivatives (S)-139–143) (Figure 19). These compounds all seemed to fit into the binding 
pocket and were therefore synthesized. 
 
Figure 19. Overview of proposed D-ring-modified (S)-blebbistatin derivatives (S)-120–121 and (S)-131–
143. 
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4.3.1. Synthesis of (S)-3’-allyloxyblebbistatin (S)-120, (S)-3’-(diallylamino)blebbistatin 
(S)-121, (S)-3’-acryloxyblebbistatin (S)-131, (S)-3’-propionyloxyblebbistatin (S)-132, 
(S)-3’-acrylamidoblebbistatin (S)-133 and (S)-propionylamidoblebbistatin (S)-134 
(S)-3’-Allyloxyblebbistatin (S)-120 and (S)-3’-(diallylamino)blebbistatin (S)-121 were readily 
available as intermediates in the preparation of (S)-3’-hydroxyblebbistatin (S)-94 and 
(S)-3’-aminoblebbistatin (S)-95, respectively (Scheme 16). The latter molecules were used 
as starting points for the synthesis of derivatives (S)-131–134 (Scheme 22). Selective 
esterification of phenol (S)-94 (step a) was achieved with stoichiometric amounts of Cs2CO3 
and a small excess of acryloyl chloride or propionyl chloride, resulting in (S)-3’-acryloxy-
blebbistatin (S)-131 (61%, ee >99%) and (S)-3’-propionyloxyblebbistatin (S)-132 (99%, ee 
99%), respectively. (S)-3’-Acrylamidoblebbistatin (S)-133 (73%, ee 99%) and 
(S)-3’-propionylamidoblebbistatin (S)-134 (91%, ee >99%) were prepared through a 
procedure adopted from Jahani et al.95 Selective monoamidation of aniline (S)-95 (step b) 
was achieved using stoichiometric amounts of acrylic anhydride96 or propionic anhydride and 
guanidine hydrochloride. In both sequences, reactions conducted with acryloyl reagents 
required chromatographic purification, thereby lowering the isolated yields. Finally, 
determination of the enantiomeric excess via chiral-HPLC analysis was performed after the 
synthesis of analytical amounts of the (R)-enantiomers (i.e. (R)-131–134) from molecules 
(R)-94–95. 
 
Scheme 22. Synthesis of (S)-3’-acryloxyblebbistatin (S)-131, (S)-3’-propionyloxyblebbistatin (S)-132, 
(S)-3’-acrylamidoblebbistatin (S)-133 and (S)-3’-propionylamidoblebbistatin (S)-134 via selective 
esterification of phenol (S)-94 and selective monoamidation of aniline (S)-95, respectively. Reagents and 
conditions: a. 1.05 equiv Cs2CO3, 0.2 equiv DMAP, 1.3 equiv acryloyl chloride (for (S)-131) or 1.4 equiv 
propionyl chloride (for (S)-132), dry CH3CN, rt, 30 min. b. 0.15 equiv guanidine hydrochloride, 1.01 equiv 
acrylic anhydride (for (S)-133) or propionic anhydride (for (S)-134), EtOH, 40 °C, 30 min. 
a
 Determination of 
enantiomeric excess via chiral-HPLC analysis. 
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4.3.2. Synthesis of (S)-benzo[c’]blebbistatin (S)-136 
The synthesis of (S)-benzo[c’]blebbistatin (S)-136 was performed using 2-bromonaphthalene 
(144) as starting material (Scheme 23). CuI-catalyzed N-arylation of pyrrolidin-2-one (39) 
with TPM and K2CO3
97,† as a ligand and a base, respectively, only gave trace amounts of 
amide 145. In contrast, the use of DMEDA and K2CO3 provided amide 145 in excellent yield 
(step a, 98%). Amidine 146 was obtained in moderate yield (step b, 48%) and was 
completely converted into α-hydroxy ketone (S)-136 through the improved two-step one-pot 
procedure (step c, 50%, ee 72%). Isolation of compound (S)-136 by acid-base extraction 
proved more difficult than for (S)-4 due to the more hydrophobic nature of the former, 
resulting in a moderate yield. Recrystallization from CH3CN afforded enantiopure 
(S)-benzo[c’]blebbistatin (S)-136 (ee >99%). 
 
Scheme 23. Synthesis of (S)-benzo[c’]blebbistatin (S)-136. Reagents and conditions: a. 2× 0.05 equiv CuI, 
2× 0.1 equiv DMEDA, 1.2 equiv pyrrolidin-2-one (39), 2 equiv K2CO3, dry 1,4-dioxane, reflux, 23+8 h. 
b. 1) 2 equiv POCl3, dry CH2Cl2, rt, 24 h; 2) 1.05 equiv amine 20, dry CH2Cl2, 35 °C, 24 h. c. 1) 2.1 equiv 
LiHMDS, dry THF, 0 °C, 1.5 h; 2) 2.4 equiv oxaziridine 14, dry THF, −15 °C, 15 h. 
a
 Prior to aqueous work-
up, the reaction mixture consisted of 36 mol% of amide 145 and 64 mol% of amidine 146. 
b
 Determination 
of enantiomeric excess via chiral-HPLC analysis. 
c
 After recrystallization from CH3CN. 
4.3.3. Attempted synthesis of (S)-pyrido[4,3-c’]blebbistatin (S)-137 
We attempted to synthesize (S)-pyrido[4,3-c’]blebbistatin (S)-137 starting from 6-bromo-
isoquinoline (147) (Scheme 24). The latter compound was successfully used in the 
N-arylation of pyrrolidin-2-one (39), yielding amide 148 (step a, 90%). Unfortunately, 
                                               
†
In general, amidation reactions of aryl bromides often fail in the presence of K3PO4. In those cases, K3PO4 
is generally replaced with K2CO3.  
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subsequent synthesis of amidine 149 failed, presumably because of the strong electron-
withdrawing nature of the protonated isoquinoline moiety. The synthesis of (S)-pyrido-
[4,3-c’]blebbistatin (S)-137 was hence abandoned. Instead, focus was shifted to the 
synthesis of (S)-(2,3-dihydro-1H)-pyrrolo[2,3-c’]blebbistatin (S)-135 and (S)-(1H)-pyrrolo-
[2,3-c’]blebbistatin (S)-138. 
 
Scheme 24. Synthesis of amide 148 and amidine 149. Reagents and conditions: a. 2× 0.05 equiv CuI, 
2× 0.1 equiv DMEDA, 1.2 equiv pyrrolidin-2-one (39), 2 equiv K2CO3, dry 1,4-dioxane, reflux, 22+6 h. 
b. 1) 2 equiv POCl3, dry CH2Cl2, rt, 24 h; 2) 1.05 equiv amine 20, dry CH2Cl2, 35 °C, 24 h. 
4.3.4. Synthesis of (S)-(2,3-dihydro-1H)-pyrrolo[2,3-c’]blebbistatin (S)-135 and 
(S)-(1H)-pyrrolo[2,3-c’]blebbistatin (S)-138 
Preparation of (S)-(2,3-dihydro-1H)-pyrrolo[2,3-c’]blebbistatin (S)-135 and (S)-(1H)-pyrrolo-
[2,3-c’]blebbistatin (S)-138 started from 6-bromoindole (150) (Scheme 25) which was 
selectively protected to yield allylated indole 151 (step a, 99%). The feasibility to remove the 
allyl protecting group from the indole moiety was tested using a first generation Grubbs’ 
carbene catalyst,98 but this attempt failed. As successful allyl deprotection of aliphatic amines 
was obtained before, the choice was made to reduce allylated indole 151 to indoline 152 
(step b, 80%) and reoxidize it further down the line.  
Amide 153 was synthesized from indoline 152 via a CuI-catalyzed arylation with DMEDA and 
K2CO3 (step c, 99%). Next, the synthesis of amidine 154 proved difficult (step d, 42%) due to 
the electron-withdrawing protonated amino group (formed under the reaction conditions 
used) present on the aryl amide. Subsequent one-pot intramolecular ring closure and 
enantioselective α-hydroxylation (step e, 51%, ee 80%) afforded a mixture containing 86% 
(m/m) of compound (S)-155 and 14% (m/m) of oxidation product (S)-156, which was not the 
result of oxidized impurities present in the starting material. The moderate yield was caused 
by the cumbersome isolation via acid-base extraction. Recrystallization from CH3CN resulted 
in an enantiopure mixture (ee >99%) containing 91% (m/m) of (S)-155 and 9% (m/m) of 
(S)-156.  
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Scheme 25. Synthesis of (S)-(2,3-dihydro-1H)-pyrrolo[2,3-c’]blebbistatin (S)-135 and (S)-(1H)-pyrrolo-
[2,3-c’]blebbistatin (S)-138. Reagents and conditions: a. 1) 1.05 equiv NaH, dry DMF, 0 °C, 30 min; 
2) 1 equiv allyl bromide, dry DMF, rt, 30 min. b. 1.05 equiv NaCNBH3, glacial acetic acid, rt, 4.5 h. 
c. 2× 0.05 equiv CuI, 2× 0.1 equiv DMEDA, 1.2 equiv pyrrolidin-2-one (39), 2 equiv K2CO3, dry 1,4-dioxane, 
reflux, 19+8 h. d. 1) 2 equiv POCl3, dry CH2Cl2, rt, 24 h; 2) 1.05 equiv amine 20, dry CH2Cl2, 35 °C, 48 h. 
e. 1) 2.1 equiv LiHMDS, dry THF, 0 °C, 2 h; 2) 2.4 equiv oxaziridine 14, dry THF, −15 °C, 15 h. f. 6 equiv 
N,N’-dimethylbarbituric acid (126), 0.1 equiv Pd(PPh3)4, dry CH2Cl2, reflux, 1 h. g. 10 equiv MnO2, CHCl3, rt, 
3 h. 
a
 Prior to aqueous work-up, the reaction mixture consisted of 37 mol% of amide 153 and 63 mol% of 
amidine 154. 
b
 Determination of enantiomeric excess via chiral-HPLC analysis. 
c
 After recrystallization from 
CH3CN. 
Selective deprotection of the more basic amine (S)-155 in the presence of allylated indole 
(S)-156 afforded (S)-(2,3-dihydro-1H)-pyrrolo[2,3-c’]blebbistatin (S)-135 (step f, 73%, 
ee >99%) which was separated from the unreacted (S)-156 via chromatography. Afterwards, 
oxidation of intermediate (S)-135 with MnO2 yielded (S)-(1H)-pyrrolo[2,3-c’]blebbistatin 
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(S)-138 (step g, 70%, ee >99%). Finally, during recrystallization of (S)-155 (ee 80%), the 
mother liquor was enriched in (R)-155 (i.e. ee 72% for (S)-155). This fraction was used to 
subsequently prepare analytical amounts of analogs enriched in (R)-135 and (R)-138. In this 
way, the enantiomeric excess of compounds (S)-135 and (S)-138 was determined after 
selection of a fit analysis method. 
4.3.5. (Attempted) synthesis of (S)-4’-allyloxyblebbistatin (S)-141, (S)-4’-(diallylamino)-
blebbistatin (S)-143, (S)-4’-hydroxyblebbistatin (S)-139, (S)-4’-aminoblebbistatin 
(S)-140 and (S)-4’-benzyloxyblebbistatin (S)-142 
The synthesis of (S)-4’-allyloxyblebbistatin (S)-141 and (S)-4’-(diallylamino)blebbistatin 
(S)-143 (Scheme 26) was envisioned to commence in an analogous way as that of 
(S)-3’-allyloxyblebbistatin (S)-120 and (S)-3’-(diallylamino)blebbistatin (S)-121 (Scheme 13 
and 15).  
 
Scheme 26. Attempted synthesis of amidines 163 and 164. Reagents and conditions: a. 0.015 equiv TBAB, 
1.05 equiv allyl bromide, 25% (m/v) aq NaOH/2-mTHF (3:2), reflux, 30 min. b. 2× 1.25 equiv LiHMDS, 
4 equiv allyl bromide, dry THF, reflux, 1+0.5 h. c. 0.05 equiv CuI (3× for 162), 0.05 equiv TPM (3× for 162), 
1.2 equiv pyrrolidin-2-one (39), 2 equiv K3PO4, dry 1,4-dioxane, reflux, 19 h (3× 24 h for 162). d. 1) 2 equiv 
POCl3, dry CH2Cl2, rt, 24 h; 2) 1.05 equiv amine 20, dry CH2Cl2, 35 °C, 24 h. 
Aryl iodide 159 and 160 were prepared from 4-iodophenol (157) and 4-iodoaniline (158) by 
allyl protection (steps a and b, quant). In the latter reaction, side product 102 was formed 
which could be distilled off easily. Subsequent N-arylation of pyrrolidin-2-one (39) was 
successful for both aryl iodides (step c, 75%), but the amidine synthesis could only be 
accomplished from amide 161 (step d, 78%). At that time, the synthesis of 
(S)-4’-(diallylamino)blebbistatin (S)-143 and (S)-4’-aminoblebbistatin (S)-140 was 
deprioritized and focus was shifted to finishing the preparation of (S)-4’-allyloxyblebbistatin 
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(S)-141, (S)-4’-hydroxy-blebbistatin (S)-139 and (S)-4’-benzyloxyblebbistatin (S)-142 
(Scheme 27).  
 
Scheme 27. Synthesis of (S)-4’-allyloxyblebbistatin (S)-141, (S)-4’-hydroxyblebbistatin (S)-139 and 
(S)-4’-benzyloxyblebbistatin (S)-142. Reagents and conditions: a. 1) 2.1 equiv LiHMDS, dry THF, 0 °C, 1 h; 
2) 2.4 equiv oxaziridine 14, dry THF, −15 °C, 16 h. b. 0.05 equiv Pd(PPh3)4, 6 equiv K2CO3, dry MeOH, 
50 °C, 1.5 h. c. 0.1 equiv NaI, 1.05 equiv Cs2CO3, 1.05 equiv benzyl bromide, dry CH3CN, 50 °C, 1 h. 
a
 Determination of enantiomeric excess via chiral-HPLC analysis. 
b
 After recrystallization from CH3CN. 
c
 Enantiomeric excess derived from enantiomeric excess of (S)-142. 
d
 Compound (S)-139 was converted 
into (S)-142 (94 mol%) and dibenzylated product (6 mol%) prior to aqueous work-up. 
Amidine 163 was completely converted to α-hydroxy ketone (S)-141 using the improved two-
step one-pot procedure, but was isolated in a moderate yield (Scheme 27, step a, 43%, 
ee 82%). A single recrystallization from CH3CN afforded enantiopure (S)-4’-allyloxy-
blebbistatin (S)-141 (ee >99%). Subsequent allyl deprotection yielded (S)-4’-hydroxy-
blebbistatin (S)-139 (step b, 77%, ee >99%). The latter was further modified with benzyl 
bromide, delivering (S)-4’-benzyloxyblebbistatin (S)-142 (step c, 62%, ee >99%). 
Noteworthy, during recrystallization of (S)-141 (ee 82%), the mother liquor was enriched in 
(R)-141 (i.e. ee 58% for (S)-141). This fraction was subsequently used to prepare analytical 
amounts of analogs enriched in (R)-139 and (R)-142. In this way, the enantiomeric excess of 
compound (S)-142 was determined after identification of a proper analysis method. However, 
for analog (S)-139, no such method was found on the available chiral HPLC column (Daicel 
Chiralpak IA). The enantiomeric excess of the latter compound was therefore derived from 
that of molecule (S)-142. 
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4.3.6. Development of (S)-4’-aminoblebbistatin (S)-140 by Várkuti et al.54 
Where our initial attempt to synthesize (S)-4’-aminoblebbistatin (S)-140 via (S)-4’-(diallyl-
amino)blebbistatin (S)-143 (Scheme 26) had proven unsuccessful in October 2015, Várkuti 
et al.54 succeeded in obtaining small amounts of the same molecule by the end of May 2016 
(Scheme 28). More specifically, 3.6 mg of (S)-4’-nitroblebbistatin (S)-130 (Scheme 20) was 
reduced by ammonium formate and the resulting reaction mixture was purified via 
preparative HPLC. Unfortunately, no information on the yield and enantiomeric excess is 
available. 
 
Scheme 28. Synthesis of (S)-4’-aminoblebbistatin (S)-140 as reported by Várkuti et al.
54
 Reagents and 
conditions: 1.04 equiv HCOONH4, Pd/C, rt, 18 h. 
a
 The yield and enantiomeric excess were not reported. 
Várkuti et al. developed this analog under the premise that the amino group (protonated at 
physiological pH) would both increase the aqueous solubility and provide an electron-
withdrawing substituent required for improved photostability. Indeed, the steady-state 
aqueous solubility of (S)-4’-aminoblebbistatin (S)-140 turned out to be 30 times higher than 
that of (S)-blebbistatin (S)-4 (298 ± 3 µM and 11 ± 1 µM, respectively, at 0.1% (v/v) DMSO). 
Moreover, comparison of the absorption spectrum recorded before and after 15 minutes of 
480-nm irradiation in aqueous medium (40 mM NaCl, 4 mM MgCl2, 20 mM HEPES pH 7.3) 
suggested‡ that the compound is highly photostable. In addition, the IC50 value for ATPase 
inhibition of Dictyostelium discoideum myosin II and rabbit skeletal-muscle myosin II were 
6.6 ± 2 µM and 1.3 ± 0.1 µM, respectively, which were slightly higher than those of 
(S)-blebbistatin (S)-4 (4.4 ± 0.3 µM and 0.3 ± 0.1 µM, respectively). 
In order to compare the newly synthesized (S)-blebbistatin derivatives (S)-120,121,131–
136,138,139,141,142 of this chapter with the literature compounds (S)-4’-nitroblebbistatin 
(S)-130 and (S)-4’-aminoblebbistatin (S)-140, the synthesis of the latter molecules was also 
pursued in this work.  
                                               
‡
 This will be further discussed in section 5.2. of this chapter. 
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4.3.7. Synthesis of (S)-4’-nitroblebbistatin (S)-130 and (S)-4’-aminoblebbistatin (S)-140 
Since preparation of (S)-4’-nitroblebbistatin (S)-130 via direct nitration of (S)-blebbistatin 
(S)-4 resulted in a complex mixture (Scheme 29, step a), we opted to prepare it starting from 
amide 127, as reported by Képiró et al.52 In our hands, the synthesis of the latter compound 
by nitration of amide 19 was not selective: a mixture of 70 mol% of 4’-nitrated (127), 10 mol% 
of 2’-nitrated (165) and 20 mol% of 2’,4’-dinitrated (166) material was obtained which proved 
difficult to separate (step b). However, amide 127 was synthesized from 1-bromo-4-nitro-
benzene (167) and pyrrolidin-2-one (39) in excellent yield (Scheme 30, step a, 95%). 
 
Scheme 29. Nitration of (S)-blebbistatin (S)-4 and amide 19. Reagents and conditions: a. 160 equiv H2SO4, 
1.1 equiv HNO3, 0 °C, 30 min. b. 6 equiv H2SO4, 1.1 equiv HNO3, 0 °C, 5 min. 
a
 Conversion (not isolated). 
As observed by Képiró et al.,52 formation of amidine 128 was difficult due to the highly 
electron-withdrawing nitro group (step b, 20%). Intramolecular ring closure upon treatment 
with LiHMDS was accompanied by the production of dimer 168 (step c 1)), a side reaction 
which was not observed for any other analog in this work. Nevertheless, we were able to 
increase the yield of (S)-4’-nitroblebbistatin (S)-130 from previously reported 11%52 to 38% 
via the improved one-pot intramolecular ring closure and enantioselective α-hydroxylation 
(step c, 38%, ee 82%). Enantiopure (S)-4’-nitroblebbistatin (S)-130 was obtained after 
recrystallization from CH3CN (ee >99%).  
Reduction of the nitro group in the latter compound was attempted as reported by Várkuti et 
al.,54 but turned out to be rather unreproducible (Table 11). The use of 1.05 equivalents of 
ammonium formate did not result in any conversion, neither at room temperature (entry 1), 
nor at 55 °C (entry 2). In a further attempt, 10 equivalents of ammonium formate partially 
resulted in double hydrogenation with formation of side product 169 (entry 3). In a final trial, 
identical conditions on the same scale gave incomplete conversion of (S)-4’-nitroblebbistatin 
(S)-130 (entry 4). (S)-4’-Aminoblebbistatin (S)-140 was finally isolated from the latter attempt 
in 31% yield. 
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Scheme 30. Synthesis of (S)-4’-nitroblebbistatin (S)-130. Reagents and conditions: a. 2× 0.05 equiv CuI, 2× 
0.1 equiv DMEDA, 1.2 equiv pyrrolidin-2-one (39), 2 equiv K2CO3, dry 1,4-dioxane, reflux, 4+14 h. b. 1) 
2 equiv POCl3, dry CH2Cl2, rt, 24 h; 2) 1.05 equiv amine 20, dry CH2Cl2, 35 °C, 4 days. c. 1) 2.1 equiv 
LiHMDS, dry THF, 0 °C, 1 h; 2) 2.4 equiv oxaziridine 14, dry THF, −15 °C, 15 h. 
a
 Prior to aqueous work-up, 
the reaction mixture consisted of 80 mol% of amide 127 and 20 mol% of amidine 128. 
b
 41% and 59% of 
amidine 128 were converted to compound (S)-130 and side product 168, respectively. 
c
 Determination of 
enantiomeric excess via chiral-HPLC analysis. 
d
 After recrystallization from CH3CN. 
Table 11. Synthesis of (S)-4’-aminoblebbistatin (S)-140 via reduction of (S)-4’-nitroblebbistatin (S)-130.
a 
 
Entry HCOONH4 (equiv) Temperature Time Result (%) Yield (%) 
1 1.05 rt 24 h 130 (quant) / 
2 1.05 55 °C 24 h 130 (quant) / 
3 10 rt 15 min 140/169 (34:66)  / 
4 10 rt 15 min 130/140 (50:50) 31 
a
 Reagents and conditions: HCOONH4, 10% (m/m) Pd/C, MeOH, temperature, time. 
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4.3.8. Conclusion 
Novel D-ring-modified (S)-blebbistatin analogs were prepared using a shorter and higher 
yielding synthesis of the blebbistatin scaffold. This was accomplished by conducting the 
intramolecular ring closure of amidines and subsequent α-hydroxylation of the intermediate 
quinolinones in a two-step one-pot procedure. In this way, together with existing literature 
compounds, a more complete library of D-ring-modified (S)-blebbistatin derivatives was 
obtained, enabling a thorough structure-activity and structure-property analysis which will be 
discussed in the next sections.  
4.4. Biochemical evaluation  
The myosin II ATPase inhibitory potency of the newly synthesized (S)-blebbistatin derivatives 
(S)-120,121,131–136,138,139,141,142 and literature analogs (S)-130 and (S)-140 (Table 12) 
was evaluated in the previously developed steady-state ATPase assay against rabbit 
skeletal-muscle myosin II. In these studies, (S)-blebbistatin (S)-4 was used as a benchmark. 
Dose-response curves are presented in Figure 20 and 21. The half-maximum inhibitory 
concentrations (IC50) and relative potencies, expressed as the ratio of the IC50 of (S)-4 to the 
compound IC50, are summarized in Table 12.  
Table 12. Evaluation of the myosin II ATPase inhibitory potency of compounds (S)-4,120,121,130–
136,138–142: half-maximum inhibitory concentration (IC50) for the steady-state ATPase activity of rabbit 





Compound R IC50 (µM) Relative potency 
(S)-4 H 2.16 ± 0.14 1.0 ± 0.1 
(S)-120 3’-OAllyl 9.41 ± 1.83 0.23 ± 0.05 
(S)-131 3’-OAcryl 57.6 ± 7.8 0.04 ± 0.01 
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Table 12. (continued) 
Compound R IC50 (µM) Relative potency 
(S)-4 H 0.873 ± 0.114 1.0 ± 0.2 
(S)-135 / 7.70 ± 0.19*
 




(S)-138 / 7.20 ± 0.59
 
0.12 ± 0.02 
(S)-139 4’-OH 5.47 ± 1.32
 
0.16 ± 0.04 
(S)-141 4’-OAllyl 0.380 ± 0.003
 




(S)-4 H 1.02 ± 0.05 1.0 ± 0.1 
(S)-130 4’-NO2 0.403 ± 0.030*
 
2.5 ± 0.2 
(S)-140 4’-NH2 5.38 ± 0.25
 
0.19 ± 0.01 
a
 Compounds (S)-120,131–134,121, (S)-135–139,141,142 and (S)-130,140 were evaluated with a different 
batch of rabbit skeletal-muscle myosin II, resulting in a marginally different protein activity.
 
In all series, this 
deviation was accounted for by expressing the IC50 of each compound relative to the respective IC50 of 
(S)-4. 
b
 The data represent the mean ± s.d. of two independent experiments (1.6% (v/v) DMSO). 
c–e
 The 
highest concentration used was 100, 10.8 and 40 µM, respectively. 
d
 Concentrations exceeding 10.8 µM 
resulted in compound precipitation in the assay buffer. * P < 0.01 versus (S)-blebbistatin (S)-4. 






































































































Figure 20. Myosin II ATPase inhibitory potency of compounds (S)-120,121,131–136,138, evaluated in a 
steady-state ATPase assay against rabbit skeletal-muscle myosin II. Example of a dose-response curve 
and 4-parameter logistic curve fitting obtained for A. (S)-120, (S)-131 and (S)-132, B. (S)-133, (S)-134 and 
(S)-121 and C. (S)-135, (S)-136 and (S)-138. The data points represent the mean ± s.d. of at least three 
samples (N = 1). (S)-Blebbistatin (S)-4 is shown as a benchmark. Concentrations exceeding 10.8, 100 and 
50 µM resulted in precipitation of (S)-120, (S)-131 and (S)-132, respectively, in the assay buffer. As an 
approximation, the relative ATPase activity obtained for (S)-blebbistatin (S)-4 at a concentration of 32.5 µM 
was used to set the lower asymptote of the fitted curve for these compounds.  



































































Figure 21. Myosin II ATPase inhibitory potency of compounds (S)-130,139–142, evaluated in a steady-
state ATPase assay against rabbit skeletal-muscle myosin II. Example of a dose-response curve and 
4-parameter logistic curve fitting obtained for A. (S)-139, (S)-141 and (S)-142 and B. (S)-130 and (S)-140. 
The data points represent the mean ± s.d. of at least three samples (N = 1). (S)-Blebbistatin (S)-4 is shown 
as a benchmark.  
5. Comparative analysis of the new and existing D-ring-
modified (S)-blebbistatin analogs 
5.1. Biochemical evaluation 
From the data presented in Table 9 and Table 12 some patterns can be recognized 
regarding the influence of D-ring substitution on myosin II ATPase inhibitory potency 
(presented as relative potency in Table 13). First, small groups are equally well tolerated in 
the 4’-position as in the 3’-position ((S)-139 and (S)-140 vs (S)-94 and (S)-95, respectively). 
However, for medium-sized groups, 4’-substitution of ring D is preferred over 3’-substitution 
((S)-141 vs (S)-120). Finally, large substituents ((S)-97, (S)-96, (S)-136, (S)-133, (S)-134 and 
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(S)-142) are not compatible with the binding pocket at either position. The kinetics of the 
chemomechanical cycle of myosin, which was not accounted for in generating Figure 18, 
may plan an important role in the observed ligand discrimination. Steric and temporal 
restrictions imposed by the path leading toward the binding site may be a possible reason 
behind this observation.  
Table 13. Summary of the relative potency of all known D-ring-modified (S)-blebbistatin analogs evaluated 
in a steady-state ATPase assay against rabbit skeletal-muscle myosin II.
a,b
 The data are expressed as the 














0.16 ± 0.04 
 
0.11 ± 0.01 
 
0.19 ± 0.01 
 







2.5 ± 0.2 
 
0.12 ± 0.02 
 
0.11 ± 0.02 
 
2.3 ± 0.3 
 
0.23 ± 0.05 
CHAPTER 1   RESULTS AND DISCUSSION 
81 














0.04 ± 0.01 
 








 (S)-3’-(Diallylamino)blebbistatin (S)-121 is not included, since precipitation occurred at concentrations 
exceeding 10.8 µM. (S)-4’-Chloroblebbistatin (S)-57 and (S)-4’-azidoblebbistatin (S)-84 are not included, 





 The data represent the mean ± s.d. of two independent experiments. 
c
 The data 
represent the mean ± s.d. of three independent experiments. 
d
 Enantiomeric excess of 84%.  
In all, these structure-activity relationships indicate that D-ring substitution does not lead to 
significant potency enhancement. However, this part of the (S)-blebbistatin scaffold can be 
used to fine-tune the physicochemical profile of the molecule, without affecting its myosin II 
ATPase inhibitory potency in an appreciable manner. Thus, disadvantages that encumber 
the use of (S)-blebbistatin (S)-4 as a research tool (e.g. light sensitivity and low aqueous 
solubility) can be eliminated through D-ring modification. This has been exemplified in the 
beginning of this chapter and by the group of Málnási-Csizmadia.52,54 Yet, a more general 
overview will be produced in the following section. As such, the photostability, water solubility 
and cell permeability of (S)-blebbistatin (S)-4 and the most potent analogs from Table 13 (i.e. 
(S)-3’-hydroxyblebbistatin (S)-94, (S)-3’-aminoblebbistatin (S)-95, (S)-3’-allyloxyblebbistatin 
(S)-120, (S)-4’-nitroblebbistatin (S)-130, (S)-4’-hydroxyblebbistatin (S)-139, (S)-4’-amino-
blebbistatin (S)-140 and (S)-4’-allyloxyblebbistatin (S)-141) were evaluated. 
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5.2. Photostability 
A large body of qualitative data was available in literature showing that (S)-blebbistatin (S)-4 
is sensitive to blue-light irradiation (400–500 nm), while (S)-4’-nitroblebbistatin (S)-130 and 
(S)-4’-aminoblebbistatin (S)-140 are not.50,52,54,61,64,66 However, quantification of this behavior 
was still lacking. A suitable experimental set-up to generate half-life curves was therefore 
developed.  
Using a fluorescence spectrometer (F900, Edingburgh Instruments) equipped with a 450-W 
Xenon Lamp, Képiró et al. had observed changes in the absorption spectrum of 
(S)-blebbistatin (S)-4 after 5 minutes of irradiation at 480 ± 10 nm in aqueous medium 
(40 mM NaCl, 4 mM MgCl2, 20 mM HEPES pH 7.3).
52,54 Therefore, this light source was 
initially used to examine the time-dependent effect of blue-light irradiation on the degradation 
of the latter compound. However, irradiating 20-µM samples of (S)-blebbistatin (S)-4 in PBS 
(containing 2.67% (v/v) MeOH) for 30 minutes at 488 nm did not induce changes in the 
absorption spectrum in our hands (Figure 22). Different instrument settings, solvent and/or 











































Figure 22. Effect of 488-nm irradiation on the absorbance spectrum of 20 µM of (S)-blebbistatin (S)-4 in 
PBS/MeOH (97.3:2.7) at the indicated times.  
Therefore, the set-up was changed to one reported by Mikulich et al.61 Solutions of 
(S)-blebbistatin (S)-4 in DMSO and DMSO/H2O (1:1), with concentrations ranging from 
100 µM to 600 µM, were irradiated with two parallel tube lamps emitting light in the 390–
470-nm range with a maximum at 420 nm (Figure 23). Decomposition of (S)-blebbistatin 
(S)-4 was followed up in time by HPLC (Figure 24A) and the DT50 value (half-maximum 
degradation time) was determined using 4-parameter logistic curve fitting.  
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Figure 23. Experimental set-up for the investigation of photostability using two parallel tube lamps emitting 
390–470-nm light (maximum at 420 nm). 
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Figure 24. Investigation of the photostability of (S)-blebbistatin (S)-4 after 390–470-nm (maximum at 
420 nm) irradiation. A. Degradation of 100 µM of (S)-4 in DMSO or DMSO/H2O (1:1) and 4-parameter 
logistic curve fitting for the latter (DT50 is 41 min in DMSO/H2O (1:1)). B. Linear increase of DT50 of (S)-4 in 
DMSO/H2O (1:1) in function of compound concentration. C. Degradation of 100 µM (S)-4 in a 1:1 mixture of 
DMSO and DMEM supplemented with 20% (v/v) fetal calf serum and 4-parameter logistic curve fitting (DT50 
is 14 min). The data points represent one measurement for each irradiation time. 
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As depicted by Figure 24A, degradation required the presence of water: at all concentrations 
evaluated, hardly any decomposition was observed when 100% DMSO was used as solvent. 
Figure 24B shows the dependence of (S)-blebbistatin’s DT50 on concentration which follows 
a linear pattern. Illumination times exceeding two hours resulted in substantial evaporation of 
solvent, making quantification of degradation impossible. In order to obtain sufficient 
degradation within 90 minutes of irradiation, a concentration of 100 µM was therefore used in 
further experiments.  
Finally, the light sensitivity of (S)-blebbistatin (S)-4 was studied in an aqueous medium that is 
more representative for the conditions of cell experiments, i.e. a mixture of Dulbecco’s 
modified eagle medium (DMEM) supplemented with 20% (v/v) fetal calf serum and DMSO 
(Figure 24C). The observed reduction in half-life (Figure 24C vs Figure 24A) indicated that 
observations made in simple aqueous solutions cannot be extrapolated to complex biological 
media. The stability of the (S)-blebbistatin derivatives was therefore assessed in a 1:1 
mixture of DMSO and DMEM supplemented with 20% (v/v) fetal calf serum. 
Figure 25 illustrates the decomposition of (S)-3’-hydroxyblebbistatin (S)-94, (S)-3’-amino-
blebbistatin (S)-95, (S)-3’-allyloxyblebbistatin (S)-120, (S)-4’-nitroblebbistatin (S)-130, 
(S)-4’-hydroxyblebbistatin (S)-139, (S)-4’-aminoblebbistatin (S)-140 and (S)-4’-allyloxy-
blebbistatin (S)-141 in function of time. The DT50 of these compounds was determined using 













































Figure 25. Investigation of the photostability of (S)-3’-hydroxyblebbistatin (S)-94, (S)-3’-aminoblebbistatin 
(S)-95, (S)-3’-allyloxyblebbistatin (S)-120, (S)-4’-nitroblebbistatin (S)-130, (S)-4’-hydroxyblebbistatin 
(S)-139, (S)-4’-aminoblebbistatin (S)-140 and (S)-4’-allyloxyblebbistatin (S)-141 toward 390–470-nm 
(maximum at 420 nm) irradiation. (S)-Blebbistatin (S)-4 is shown as a benchmark and 4-parameter logistic 
curve fitting was performed for all compounds except (S)-130. Compounds were evaluated as 100-µM 
solutions in a 1:1 mixture of DMSO and DMEM supplemented with 20% (v/v) fetal calf serum. The data 
points represent one measurement for each irradiation time. 
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Table 14. Overview of the key tool properties of (S)-blebbistatin (S)-4 and analogs (S)-3’-hydroxy-
blebbistatin (S)-94, (S)-3’-aminoblebbistatin (S)-95, (S)-3’-allyloxyblebbistatin (S)-120, (S)-4’-nitro-
blebbistatin (S)-130, (S)-4’-hydroxyblebbistatin (S)-139, (S)-4’-aminoblebbistatin (S)-140 and 
(S)-4’-allyloxyblebbistatin (S)-141: myosin II ATPase inhibitory potency (expressed as relative potency, i.e. 
the ratio of the IC50 of (S)-4 to the compound IC50), photostability (expressed as DT50), steady-state 
aqueous solubility and Caco-2 apical-to-basolateral (A-B) and basolateral-to-apical (B-A) cell permeability 

























A-B B-A A-B B-A 
(S)-4 H 1.0 ± 0.2 14 6.18 ± 0.08 60.5 ± 1.8 19.2 ± 0.3 66 ± 1 66 ± 4 
(S)-94 3’-OH 0.11 ± 0.01 12 193 ± 1
 
28.5 ± 0.3 17.2 ± 0.1 49 ± 1 70 ± 1 
(S)-95 3’-NH2 0.15 ± 0.01 14 186 ± 9 62.7 ± 3.1 26.2 ± 0.1 79 ± 1 74 ± 4 








(S)-130 4’-NO2 2.5 ± 0.2 >90
f 
31.7 ± 1.6 32.5 ± 1.0 2.23 ± 0.02 34 ± 1 72 ± 1 
(S)-139 4’-OH 0.16 ± 0.04 4.7
 








(S)-140 4’-NH2 0.19 ± 0.01 46 >200
g 
69.4 ± 3.0 31.1 ± 3.5 85 ± 1 82 ± 1 
(S)-141 4’-OAllyl 2.3 ± 0.3 9.2 2.75 ± 0.05 29.7 ± 0.6 7.58 ± 0.05 32 ± 1 65 ± 1 
a
 The data represent the mean ± s.d. of two independent experiments. 
b
 Compounds were evaluated as a 
100-µM solution in a 1:1 mixture of DMSO and DMEM supplemented with 20% (v/v) fetal calf serum.
 
c
 Steady-state solubility in PBS pH 7.4 buffer (2% (v/v) DMSO). 
d
 Caco-2 A-B (pH 7.4/7.4) and B-A (pH 
7.4/7.4) permeability; compound concentration was 10 µM (1% (v/v) DMSO). 
e
 Not determined. 
f
 The 
sample collected after 90 min showed 33% degradation. 
g
 Highest compound concentration used was 
200 µM.  
Consistent with the observations of Képiró et al.,52 (S)-4’-nitroblebbistatin (S)-130 was found 
to possess the highest stability. More specifically, its DT50 value was 10-fold higher than the 
one of (S)-blebbistatin (S)-4. (S)-4’-Aminoblebbistatin (S)-140 concentration, however, 
started to decline significantly after 10 minutes, while this analog was expected to be equally 
stable as (S)-4’-nitroblebbistatin (S)-130.54,§ This observation underlines the importance of a 
                                               
§
 See section 4.3.6. of this chapter. 
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quantitative instead of a qualitative determination of light sensitivity when comparing 
(S)-blebbistatin analogs. Nonetheless, the latter compound still has a higher DT50 value than 
(S)-blebbistatin (S)-4. On the contrary, (S)-3’-allyloxyblebbistatin (S)-120, (S)-3’-amino-
blebbistatin (S)-95, (S)-3’-hydroxyblebbistatin (S)-94 and (S)-4’-allyloxyblebbistatin (S)-141 
displayed a similar susceptibility to photodegradation as (S)-blebbistatin (S)-4. 
(S)-4’-Hydroxyblebbistatin (S)-139 possessed the lowest stability. 
5.3. Water solubility and cell permeability 
As proven earlier, the low aqueous solubility of (S)-blebbistatin (S)-4 and its ensuing 
precipitates pose a problem for read-outs in cell-based experiments. In these settings, the 
ideal tool compound should combine a good cell permeability with a high aqueous solubility. 
The steady-state solubility of (S)-3’-allyloxyblebbistatin (S)-120, (S)-4’-nitroblebbistatin (S)-
130, (S)-4’-hydroxyblebbistatin (S)-139, (S)-4’-aminoblebbistatin (S)-140 and (S)-4’-
allyloxyblebbistatin (S)-141 was determined in PBS pH 7.4 buffer (2% (v/v) DMSO) and was 
compared with our previously reported data on (S)-blebbistatin (S)-4, (S)-3’-
hydroxyblebbistatin (S)-94 and (S)-3’-aminoblebbistatin (S)-95 (Table 14). As expected,54 
(S)-3’-hydroxyblebbistatin (S)-94, (S)-3’-aminoblebbistatin (S)-95 and (S)-4’-amino-
blebbistatin (S)-140 showed the highest water solubility, while (S)-4’-hydroxyblebbistatin 
(S)-139 was surprisingly significantly less soluble.  
The two most common in vitro cell permeability assays are the parallel artificial membrane 
permeability assay (PAMPA) and Caco-2 cell monolayers. The PAMPA model consists of a 
hydrophobic filter coated with a mixture of lecithin/phospholipids dissolved in an inert organic 
solvent such as dodecane, thus creating an artificial lipid membrane. This model is much 
less labor intensive than cell culture methods, but underestimates cell permeability of 
compounds that are taken up by active transport.99 Caco-2 cells are human colorectal 
carcinoma cells, characterized by morphological and functional similarities to the small 
intestinal epithelium cells. A porous membrane is used to support the growth of a Caco-2 cell 
monolayer. Unlike PAMPAs, more than just passive diffusion can be involved in transport 
through Caco-2 cells, i.e. active transport through the cell or efflux back out of the cells can 
also take place.100 Since Caco-2 assays constitute a more composite system than the 
relatively pure passive diffusion that PAMPAs reflect, Caco-2 apical-to-basolateral (A-B) and 
basolateral-to-apical (B-A) cell permeation data were collected. All compounds evaluated 
showed high A-B permeability (Papp >20×10
-6 cm s-1). Further, the high ratio of A-B to B-A 
permeability suggested that none of the compounds are substrates for efflux transporters. 
Compound concentrations in both donor and acceptor compartments were analyzed to 
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identify potential underestimation of permeability. The low A-B recovery of (S)-3’-hydroxy-
blebbistatin (S)-94, (S)-4’-nitroblebbistatin (S)-130 and (S)-4’-allyloxyblebbistatin (S)-141 may 
be due to retention in the cell monolayer, nonspecific binding onto plastic, compound 
precipitation or degradation during assay incubation. As B-A recovery was significantly 
higher for these molecules, the low A-B recovery is likely attributable to retention. 
Interestingly, a comparison between (S)-blebbistatin (S)-4 and the highly water soluble 
analogs (S)-94, (S)-95 and (S)-140 revealed that the increase in aqueous solubility is not 
accompanied by a loss in cell membrane permeability. In cell-based screenings requiring 
high inhibitor concentrations (and where precipitates might interfere with read-outs), these 
molecules are thus ideal substitutes for (S)-blebbistatin (S)-4. 
6. Conclusion 
In this chapter, D-ring-modified analogs of (S)-blebbistatin (S)-4 were prepared in order to 
gain insight into the structure-activity and structure-property relationships for this part of the 
scaffold. The myosin II ATPase inhibitory potency of the new analogs and literature 
derivatives was evaluated in an in-house-developed ATPase assay against rabbit skeletal-
muscle myosin II. The latter myosin II isoform was used as a model for non-muscle myosin II, 
since purified or recombinantly expressed non-muscle myosin II is not easily accessible and 
its production costs are exceptionally high. The thus obtained SAR information has revealed 
that large groups in the 3’- and/or 4’-position present potential bottlenecks for inhibitor 
design. In all, D-ring substitution does not lead to significant potency enhancement, but is 
useful to fine-tune the physicochemical profile of (S)-blebbistatin (S)-4.  
The blue-light sensitivity of (S)-blebbistatin (S)-4 was quantified for the first time. The 
obtained data confirmed that research applications requiring blue-light irradiation are best 
conducted with (S)-4’-nitroblebbistatin (S)-130. On the other hand, when solubility issues of 
(S)-blebbistatin (S)-4 pose a problem for read-outs in cell-based experiments, (S)-3’-hydroxy-
blebbistatin (S)-94, (S)-3’-aminoblebbistatin (S)-95 or (S)-4’-aminoblebbistatin (S)-140 should 
be used as alternatives. These compounds combine a 30-fold higher aqueous solubility with 
conservation of cell membrane permeability. From an economical point of view, 
(S)-3’-hydroxyblebbistatin (S)-94 is the optimal compound for these applications, as it is the 
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1. Introduction 
In chapter 1, we reported on the feasibility of improving (S)-blebbistatin’s myosin II ATPase 
inhibitory potency and physicochemical properties. These studies have shown that D-ring 
modification enables fine-tuning of (S)-blebbistatin’s physicochemical properties, but potency 
enhancement cannot be pursued in this manner. In this chapter, our search for improved 
potency through structural changes in ring A will be discussed.  
Analysis of the co-crystal structure of (S)-blebbistatin (S)-4 bound to Dictyostelium 
discoideum myosin II (PDB: 1YV3)73 showed that the residues in closest proximity to rings 
AB are Tyr261, Thr474, Tyr634, Gln637 and Leu641 (Figure 26). Extending the (aromatic) 
ring system in this part of the molecule therefore had the potential to improve binding affinity 
through additional hydrophobic interactions and π-π stacking with Tyr261. Lucas-Lopez et al. 
had previously reported that small-sized substituents are of little influence at the C5, C6 and 
C7 positions, but are undesired at the C8 position.83 We therefore incorporated larger cyclic 
substituents fused at positions C6 and C7. Analog (S)-170 was envisioned to generate π-π 
stacking with Tyr261. To overcome potential solubility issues associated with the latter 
compound, a more polar analog (S)-171 was also prepared. Indoline (S)-172 and an N-allyl 
protected synthetic intermediate (S)-173 were included as aliphatic counterparts. 
 
Figure 26. The co-crystal structure of (S)-blebbistatin (S)-4 bound to Dictyostelium discoideum myosin II 
(PDB: 1YV3)
73
 indicated the possibility for additional π-π stacking interactions with Tyr261 through 
extension of the aromatic system in ring A of the scaffold. Legend: orange (carbon), red (oxygen), blue 
(nitrogen), grey (carbon). 
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2. Synthesis of A-ring-modified (S)-blebbistatin analogs 
The synthesis of (S)-benzo[h]blebbistatin (S)-170 started from commercially available 
3-amino-2-naphthoic acid (174) (Scheme 31) which was converted to methyl ester 175 upon 
treatment with sulfuric acid in MeOH (step a, 96%). Reaction of amide 19 with POCl3 and 
amine 175 resulted in a 75% conversion to amidine 176 and isolated yield of 65% (step b). 
One-pot intramolecular ring closure and asymmetric α-hydroxylation of the latter compound 
yielded analog (S)-170 (step c, 76%, ee 72%). A single recrystallization from CH3CN 
afforded enantiopure (S)-benzo[h]blebbistatin (S)-170 (ee >99%).  
 
Scheme 31. Synthesis of (S)-benzo[h]blebbistatin (S)-170. Reagents and conditions: a. 2× 3 equiv H2SO4, 
MeOH, reflux, 2× 24 h. b. 1) 1 equiv amide 19, 2 equiv POCl3, dry CH2Cl2, rt, 24 h; 2) 1.05 equiv amine 175, 
dry CH2Cl2, 35 °C, 48 h. c. 1) 2.1 equiv LiHMDS, dry THF, 0 °C, 1.5 h; 2) 2.4 equiv oxaziridine 14, dry THF, 
−15 °C, 16 h. 
a
 Prior to aqueous work-up, the reaction mixture consisted of 25 mol% of amide 19 and 
75 mol% of amidine 176. 
b
 Determination of enantiomeric excess via chiral-HPLC analysis. 
c
 After 
recrystallization from CH3CN. 
The synthesis of (S)-(N-allyl-2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-173, (S)-(2,3-di-
hydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-172 and (S)-(1H)-pyrrolo[3,2-h]blebbistatin (S)-171 
required the preparation of precursor 181 which was synthesized via the Leimgruber-Batcho 
indole synthesis method in an analogous way as described by Showalter et al. 
(Scheme 32).101 In short, nitration of methyl 3-methyl-4-nitro-benzoate (177) resulted in a 
85:15 mixture of methyl 5-methyl-2,4-dinitrobenzoate (178) and isomeric methyl 3-methyl-
2,4-dinitrobenzoate. Isolation of compound 178 from this mixture proved difficult. Efforts to 
purify it via normal-phase and reversed-phase automated flash chromatography both failed 
and initial recrystallization attempts in 2-propanol were not successful either. However, the 
use of the same solvent and judiciously chosen recrystallization parameters (solvent volume, 
timing) eventually afforded methyl 5-methyl-2,4-dinitrobenzoate (178) in 55% yield (step a). 
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Scheme 32. Synthesis of (S)-(N-allyl-2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-173, (S)-(2,3-dihydro-
1H)-pyrrolo[3,2-h]blebbistatin (S)-172 and (S)-(1H)-pyrrolo[3,2-h]blebbistatin (S)-171. Reagents and 
conditions: a. 17 equiv H2SO4, 4 equiv HNO3, −20 °C, 20 h. b. 1.2+0.3 equiv reagent 179, dry 1,4-dioxane, 
reflux, 4+16 h. c. 10% (m/m) Pd/C, H2 (1 bar), 1,4-dioxane/MeOH (5:2), rt, 16 h. d. 1) 1.05 equiv NaH, dry 
DMF, 0 °C, 30 min; 2) 1 equiv allyl bromide, dry DMF, 0 °C, 30 min. e. 1.05 equiv NaCNBH3, glacial acetic 
acid, rt, 4 h. f. 1) 1 equiv amide 19, 2 equiv POCl3, dry CH2Cl2, rt, 24 h; 2) 1.05 equiv amine 183, dry 
CH2Cl2, 35 °C, 3 days. g. 1) 2.1 equiv LiHMDS, dry THF, 0 °C, 1.5 h; 2) 2.4 equiv oxaziridine 14, dry THF, 
−15 °C, 16 h. h. 6 equiv N,N’-dimethylbarbituric acid (126), 4× 0.1 equiv Pd(PPh3)4, dry CH2Cl2, reflux, 4× 
1.5 h. i. 5× 10 equiv MnO2, DMF, rt, 5× 5 min. 
a
 Prior to aqueous work-up, the reaction mixture consisted of 
44 mol% of amide 183 and 56 mol% of amidine 184. 
b
 Determination of enantiomeric excess via chiral-
HPLC analysis. 
c
 After recrystallization from CH3CN. 
Condensation with reagent 179 gave enamine 180 (step b) which was reductively cyclized to 
precursor 181 (step c, 81%) without intermediate isolation. Subsequent protection with allyl 
bromide yielded a crude mixture of unreacted starting material and mono- and diallylated 
regioisomers, from which indole 182 was isolated via reversed-phase automated flash 
chromatography (step d, 71%). Reduction with NaCNBH3 in glacial acetic acid yielded 
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indoline 183 (step e, 92%). The synthesis of amidine 184 proved difficult due to the rather 
low nucleophilic propensity of aniline 183 (step f, 48%).  
One-pot intramolecular cyclization and enantioselective α-hydroxylation (step g, 73%, 
ee 92%) afforded highly optically enriched (S)-(N-allyl-2,3-dihydro-1H)-pyrrolo[3,2-h]-
blebbistatin (S)-173 upon recrystallization from CH3CN (ee 96%). (S)-(2,3-Dihydro-1H)-
pyrrolo[3,2-h]blebbistatin (S)-172 was obtained after successful allyl deprotection (step h, 
95%). The oxidation of indoline (S)-172 to indole (S)-171 by MnO2 was initially performed 
according to the procedure used in Scheme 25 of chapter 1. However, as indoline (S)-172 
proved completely insoluble in chloroform, the solvent was changed to DMF. Since the latter 
solvent can have a deactivating effect by adsorption on the MnO2 surface,
102 multiple 
portions of MnO2 were added. In this way, (S)-(1H)-pyrrolo[3,2-h]blebbistatin (S)-171 was 
prepared in excellent yield (step i, 96%). 
Finally, the enantiomeric excess of compounds (S)-171–173 was determined via chiral-HPLC 
analysis after the synthesis of analytical amounts of the (R)-enantiomer (R)-173 from amidine 
184. Compound (R)-173 was subsequently converted to molecules (R)-172 and (R)-171. 
Unfortunately, a proper analysis method for (S)-(1H)-pyrrolo[3,2-h]blebbistatin (S)-171 was 
not found on the available chiral HPLC column (Daicel Chiralpak IA). 
3. Evaluation of the myosin II ATPase inhibitory potency 
The myosin II ATPase inhibitory potency of (S)-blebbistatin derivatives (S)-170–173 was 
evaluated with the in-house-developed steady-state ATPase assay against rabbit skeletal-
muscle myosin II. Again, the latter myosin II isoform was used as a model for non-muscle 
myosin II and (S)-blebbistatin (S)-4 was included as a benchmark. Dose-response curves are 
presented in Figure 27 and half-maximum inhibitory concentrations (IC50) are provided in 
Figure 28.  
Extending the aromatic system of ring A of the blebbistatin scaffold ((S)-170 and (S)-171) did 
not result in improved binding affinity. The aliphatic ring systems of analogs (S)-172 and 
(S)-173 had a negative impact on myosin II ATPase inhibitory potency as well. These data 
indicate that there is little tolerance toward linear extension of the blebbistatin scaffold at the 
side of ring A. In addition, Lucas-Lopez et al. observed that moving the small methyl group to 
C8 resulted in a reduced potency.83 Thus, other modifications of ring A are also unlikely to 
result in improved potency. This SAR investigation, focused on ring A, complements earlier 
CHAPTER 2   RESULTS AND DISCUSSION 
95 
data on ring D.52,54,57,103,104 Taken together, when maintaining the same core framework, little 
































































Figure 27. Overview of the myosin II ATPase inhibitory potency of compounds (S)-170–173 evaluated in a 
steady-state ATPase assay against rabbit skeletal-muscle myosin II. Example of a dose-response curve 
and 4-parameter logistic curve fitting obtained for A. (S)-benzo[h]blebbistatin (S)-170 and (S)-(1H)-
pyrrolo[3,2-h]blebbistatin (S)-171 and B. (S)-(2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-172 and 
(S)-(N-allyl-2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-173. The data points represent the mean ± s.d. of 
at least three samples (N = 1). (S)-Blebbistatin (S)-4 is shown as a benchmark. Concentrations exceeding 
10, 40 and 20 µM caused precipitation of compounds (S)-170, (S)-172 and (S)-173, respectively, in the 
assay buffer. As an approximation, the relative ATPase activity obtained for (S)-blebbistatin (S)-4 at a 
concentration of 32.5 µM was used to set the lower asymptote of the fitted curve for these compounds. 
Since precipitation of the most potent derivatives in this series ((S)-170 and (S)-173) had 
been noticed in the ATPase assay at an even lower concentration (i.e. above 10 µM and 
20 µM, respectively) than for (S)-blebbistatin (S)-4 (i.e. above 50 µM), the physicochemical 
properties of these analogs deemed even poorer than those of the parent compound. The 
choice was therefore made to not evaluate these compounds any further. 
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Figure 28. Evaluation of the myosin II ATPase inhibitory potency of compounds (S)-170–173: half-
maximum inhibitory concentration (IC50) for the steady-state ATPase activity of rabbit skeletal-muscle 
myosin II. The data represent the mean ± s.d. of two independent experiments. 
a
 Highest compound 
concentration used was 20 µM, as concentrations exceeding 20 µM resulted in compound precipitation in 
the assay buffer. * P < 0.01 versus (S)-blebbistatin (S)-4. 
4. Conclusion 
A new series of (S)-blebbistatin derivatives with a modified A-ring was developed in this 
chapter, comprising (S)-benzo[h]blebbistatin (S)-170, (S)-(1H)-pyrrolo[3,2-h]blebbistatin 
(S)-171, (S)-(2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-172 and (S)-(N-allyl-2,3-dihydro-
1H)-pyrrolo[3,2-h]blebbistatin (S)-173. The myosin II ATPase inhibitory potency of these 
molecules was evaluated in an ATPase assay against rabbit skeletal-muscle myosin II. 
These analogs proved less potent than the parent compound (S)-blebbistatin (S)-4. 
Therefore, potency enhancement via modification of ring A of the blebbistatin scaffold 
seemed unattainable. Further attempts to improve the myosin II ATPase inhibitory potency of 
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1. Introduction 
In continuation of our search for blebbistatin derivatives with improved potency, we wanted to 
assess the influence of small chemical modifications on ring C, which had not been explored 
in literature before. Again, the co-crystal structure of (S)-blebbistatin (S)-4 bound to 
Dictyostelium discoideum myosin II (PDB: 1YV3) was used as a guide in our quest.73 
Looking at Figure 29, cis-oriented hydrophilic moieties (e.g. hydroxymethyl, carboxyl or 
carbamoyl) on C2 of the blebbistatin scaffold might form a hydrogen bond with the 
carboxylate oxygen of the neighboring Arg238 residue, while this additional bonding 
possibility would be absent in the trans-oriented diastereoisomers. Further, both cis- and 
trans-oriented larger functionalities (e.g. allyloxymethyl or allyloxycarbonyl) might optimize 
filling of the binding pocket. For these reasons, the development of both diastereoisomers of 
analogs 185–189 (Figure 30) was envisioned. Due to time constraints, the syntheses were 





Figure 29. The co-crystal structure of (S)-blebbistatin (S)-4 bound to Dictyostelium discoideum myosin II 
(PDB: 1YV3)
73
 suggested possible hydrogen bonding between cis-oriented hydrophilic moieties (e.g. 
hydroxymethyl, carboxyl, carbamoyl) at C
2
 and the carboxylate oxygen of Arg238. Legend: orange (carbon), 
red (oxygen), blue (nitrogen), grey (carbon).  
 
Figure 30. Overview of the suggested blebbistatin derivatives (±)-185–189 with a modified C-ring, all 
accessible via proposed key intermediate quinolinone 190. 
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2. Synthesis of C-ring-modified (±)-blebbistatin analogs 
The precursor (±)-pyroglutamic acid (191) was chosen as an ideal starting point for the 
synthesis of all proposed C-ring-modified blebbistatin analogs (±)-185–189. This strategy 
required the preparation of a key intermediate quinolinone 190 (Scheme 33). The pathway 
commenced with the synthesis of amide 193 which could be accessed via two separate 
routes. In a first method, allyl protection of the carboxyl group of (±)-pyroglutamic acid (191) 
(step a, 97%) preceded Goldberg-type N-arylation of compound 192 with iodobenzene 
(92).84 The rather low conversion of the latter step (step b, 25%) prompted us to use an 
alternative method for the preparation of amide 193. In this approach, Chan-Lam-type 
N-arylation of the unprotected (±)-pyroglutamic acid (191) was performed with phenylboronic 
acid (194) (step c, 85%).105 Subsequent allyl protection of the carboxyl group of compound 
195 afforded amide 193 (step d, 93%) in a much higher yield than via the first method.  
 
Scheme 33. Attempted synthesis of quinolinone 190. Reagents and conditions: a. 1.2 equiv SOCl2, allyl 
alcohol, rt, 17 h. b. 3× 0.1 equiv CuI, 3× 0.1 equiv TPM, 1.2 equiv iodobenzene (92), 2 equiv K3PO4, dry 
1,4-dioxane, reflux, 5+16+48 h. c. 2 equiv DBU, 0.15 equiv CuTMEDA, 1.5 equiv phenylboronic acid (194), 
dry CH3CN, rt, 48 h. d. 2× 1.2 equiv SOCl2, allyl alcohol, rt, 9+15 h. e. 1) 2 equiv POCl3, dry CH2Cl2, rt, 24 h; 
2) 1.05 equiv amine 20, dry CH2Cl2, 35 °C, 48 h. f. 2.1 equiv LiHMDS, dry THF, 0 °C, 2 h. 
a
 Conversion (not 
isolated). 
b
 Prior to aqueous work-up, the reaction mixture consisted of 55 mol% of amide 193 and 45 mol% 
of amidine 196. 
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The latter product reacted with POCl3 and amine 20 to furnish amidine 196 (step e, 21%) 
which was subsequently treated with LiHMDS to induce intramolecular cyclization. However, 
this resulted in a complex mixture, containing only trace amounts of quinolinone 190 (step f). 
As we presumed these side reactions were due to the presence of an acidic hydrogen in 
α-position of the allyl ester, we opted to reduce this functionality (Scheme 34).  
 
Scheme 34. Synthesis of (±)-2-(allyloxymethyl)blebbistatin (±)-188, (±)-trans-2-(hydroxymethyl)blebbistatin 
(±)-trans-185 and (±)-cis-2-(hydroxymethyl)blebbistatin (±)-cis-185. Reagents and conditions: a. 0.1 equiv 
InBr3, 10 equiv Et3SiH, dry CHCl3, 60 °C, 1 h. b. 3× 1.2 equiv NaBH4, EtOH, rt, 4+4+2 h. c. 1) 1.5 equiv 
NaH, dry THF/DMF (2:1), 0 °C, 30 min; 2) 2 equiv allyl bromide, dry THF/DMF (2:1), rt, 1 h. d. 1) 2 equiv 
POCl3, dry CH2Cl2, rt, 24 h; 2) 1.05 equiv amine 20, dry CH2Cl2, 35 °C, 24 h. e. 1) 2.1 equiv LiHMDS, dry 
THF, 0 °C, 1.5 h; 2) 1.2 equiv oxaziridine 14, 1.2 equiv oxaziridine 15, dry THF, −15 °C, 15 h. f. 0.05 equiv 
Pd(PPh3)4, 6 equiv K2CO3, dry MeOH, reflux, 10 h. 
a
 Conversion (not isolated). 
b
 Prior to aqueous work-up, 
the reaction mixture consisted of 23 mol% of amide 198 and 77 mol% of amidine 200. 
c
 The relative 
configuration was determined via 1D-NOESY experiments with the major and minor diastereoisomer of 
compound (±)-185 (Figure 31). 
d
 50% conversion of (±)-trans-188 to (±)-trans-185. 
e
 50% conversion of 
(±)-cis-188 to (±)-cis-185.  
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Sakai et al. had reported on the direct and selective reduction of esters to the corresponding 
ethers in the presence of secondary amides with Et3SiH and catalytic amounts of InBr3.
106 
We applied these conditions in an attempt to selectively convert the allyl ester in amide 193 
to an allyl ether which would furnish amide 198 (Scheme 34, step a). A clean conversion to a 
sole product was obtained. Unfortunately, reduction of the tertiary amide, rather than the 
ester, occurred affording allyl ester 197. No trace of amide 198 was observed. Therefore, a 
detour was made by first completely reducing the allyl ester in amide 193 to primary alcohol 
199 (step b, 93%), after which the latter was allyl protected to yield amide 198 (step c, 92%).  
Preparation of amidine 200 was achieved by treatment with POCl3 and amine 20 (step d, 
52%). This time, deprotonation with LiHMDS resulted in a clean intramolecular ring closure 
(step e). Subsequent α-hydroxylation, using an equimolar mixture of oxaziridines 14 and 15, 
gave formation of (±)-2-(allyloxymethyl)blebbistatin (±)-188 in a diastereoisomeric ratio of 
84:16 (step e, 90%). This mixture of diastereoisomers was allyl deprotected with Pd(PPh3)4 
and K2CO3, but only a 50% conversion toward (±)-2-(hydroxymethyl)blebbistatin (±)-185 was 
obtained for each diastereoisomer (step f, 30–36%). Likely, a higher conversion could have 
been achieved by adding multiple portions of Pd(PPh3)4. By chance, we observed that a 
yellow precipitate persisted when trying to dissolve the crude reaction mixture in THF. This 
precipitate was isolated and identified as the minor diastereoisomer of compound (±)-185 in 
pure form. The remaining major diastereoisomer was subsequently purified via automated 
flash chromatography.  
The relative stereochemistry of both the major and minor diastereoisomer of (±)-2-(hydroxy-
methyl)blebbistatin (±)-185 (and thus (±)-2-(allyloxymethyl)blebbistatin (±)-188) was 
determined with 1D-NOESY experiments (Figure 31), as crystallization efforts failed. These 
experiments revealed an interaction between H2 and the hydroxyl hydrogen on C3a in the 
major diastereoisomer. This NOE was absent in the minor diastereoisomer. These results 
suggest a trans- and cis-configuration for the major and minor diastereoisomer, respectively. 
 
Figure 31. 1D-NOESY experiments of the major and minor diastereoisomer of (±)-2-(hydroxymethyl)-
blebbistatin (±)-185 suggest a trans- and cis-configuration, respectively. 
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At this point, the myosin II ATPase inhibitory potency of the already obtained blebbistatin 
derivatives (±)-trans-2-(hydroxymethyl)blebbistatin (±)-trans-185, (±)-cis-2-(hydroxymethyl)-
blebbistatin (±)-cis-185 and (±)-2-(allyloxymethyl)blebbistatin (±)-188 was evaluated before 
attempting to make analogs with larger substituents (i.e. (±)-trans-2-carboxyblebbistatin 
(±)-trans-186, (±)-cis-2-carboxyblebbistatin (±)-cis-186, (±)-trans-2-carbamoylblebbistatin 
(±)-trans-187, (±)-cis-2-carbamoylblebbistatin (±)-cis-187, (±)-trans-2-(allyloxycarbonyl)-
blebbistatin (±)-trans-189 and (±)-cis-2-(allyloxycarbonyl)blebbistatin (±)-cis-189) from these 
molecules. In this way, a possible low potency would be detected early on and further 
unnecessary synthesis efforts would be avoided. 
3. Evaluation of the myosin II inhibitory potency 
A preliminary screen was performed to assess the myosin II ATPase inhibitory potency of 
(±)-trans-2-(hydroxymethyl)blebbistatin (±)-trans-185, (±)-cis-2-(hydroxymethyl)blebbistatin 
(±)-cis-185 and 2-(allyloxymethyl)blebbistatin (±)-188 (the latter containing an 84:16 mixture 
of the trans- and cis-diastereoisomer). To this extend, the in-house-developed steady-state 
ATPase assay against rabbit skeletal-muscle myosin II was applied. (S)-Blebbistatin (S)-4 
was used as a benchmark (Figure 32). Contrary to what was expected based on the 
observation made in Figure 29, (±)-cis-2-(hydroxymethyl)blebbistatin (±)-cis-185 displayed no 
inhibition at a concentration as high as 100 µM, while (±)-trans-2-(hydroxymethyl)blebbistatin 
(±)-trans-185 possessed an IC50 value of ~75 µM (vs 0.95 µM for (S)-blebbistatin (S)-4). 
Further, an 84:16 mixture of (±)-trans- and -cis-2-(allyloxymethyl)blebbistatin (±)-trans- 
and -cis-188 showed no inhibition of the ATPase activity at 100 µM. These data revealed that 
a small modification of ring C has a large negative impact on the myosin II ATPase inhibitory 
potency. As the results of this screen were rather disappointing and suggested that there is 
little room for potency enhancement via C-ring substitution, we decided to end our quest for 
C-ring-modified blebbistatin analogs at this stage. Since the derivatives in this series 
displayed no or very poor activity, their physicochemical properties were not further 
investigated either.  
 



































Figure 32. Overview of the myosin II ATPase inhibitory potency of (±)-trans-2-(hydroxymethyl)blebbistatin 
(±)-trans-185, (±)-cis-2-(hydroxymethyl)blebbistatin (±)-cis-185 and (±)-2-(allyloxymethyl)blebbistatin (±)-188 
(the latter containing an 84:16 mixture of the (±)-trans- and (±)-cis-diastereoisomer), evaluated in a steady-
state ATPase assay against rabbit skeletal-muscle myosin II. The data points represent the mean ± s.d. of 
at least three samples (N = 1). Concentrations exceeding 100 µM were not evaluated in this screen. As an 
approximation, the relative ATPase activity obtained for (S)-blebbistatin (S)-4 at a concentration of 32.5 µM 
was used to set the lower asymptote of the 4-parameter logistic curve fitted to (±)-trans-
2-(hydroxymethyl)blebbistatin (±)-trans-185. 
4. Conclusion 
The synthesis of a small library of blebbistatin derivatives with C-ring modifications at C2 was 
attempted in order to (i) enable the formation of an additional hydrogen bond with the 
neighboring Arg238 residue in the binding pocket via cis-substituted hydrophilic moieties 
(e.g. hydroxymethyl, carboxyl or carbamoyl) and (ii) optimize filling of the binding pocket 
through both cis- and trans-oriented larger functionalities (e.g. allyloxymethyl or 
allyloxycarbonyl). Difficulties in the preparation of the intermediate quinolinone 190 arose, but 
a selection of the initially proposed blebbistatin analogs was prepared nonetheless. 
Moreover, it was demonstrated via 1D-NOESY experiments that α-hydroxylation of racemic 
amidine 200 with racemic mixtures of oxaziridines 14 and 15 was diastereoselective, 
producing an 84:16 mixture of the trans- and cis-diastereoisomer. Finally, the myosin II 
ATPase inhibitory potency of (±)-trans-2-(hydroxymethyl)blebbistatin (±)-trans-185, 
(±)-cis-2-(hydroxymethyl)blebbistatin (±)-cis-185 and (±)-2-(allyloxymethyl)blebbistatin 
(±)-188 (the latter containing an 84:16 mixture of the trans- and cis-diastereoisomer) was 
evaluated in a steady-state ATPase assay against rabbit skeletal-muscle myosin II. This test 
revealed that a small modification on ring C already induced a large negative impact on 
myosin II ATPase inhibitory potency. These preliminary results suggest that there is little 









In chapter 1, it was shown that D-ring modification of the (S)-blebbistatin scaffold is 
accessible to fine-tune the physicochemical profile of the parent compound. In this way, 
deficiencies that encumber the use of (S)-blebbistatin (S)-4 as a research tool can be 
eliminated. However, some pitfalls were encountered in the applied synthesis strategy, 
where ring D was introduced at the start of the sequence (Scheme 35A).  
 
Scheme 35. Two synthesis strategies for D-ring-modified blebbistatin analogs 204. A. Introduction of ring D 
at the start of the sequence, as applied in chapter 1. B. Late-stage incorporation of ring D, as reported by 
Lawson et al.
82
 and discussed in the Literature overview. 
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For example, the formation of the amidine intermediate 203 of derivatives bearing electron-
withdrawing groups or amino groups (which form an electron-withdrawing ammonium group 
upon protonation under the acidic reaction conditions) on ring D, proceeded in low yields (0–
42%). Hence, there is an unmet need for a strategy enabling the late-stage incorporation of 
ring D. In this context, Lawson et al.82 have developed a method, which was discussed in the 
Literature overview. Yet, this procedure was not applied during the synthesis efforts 
described in chapter 1, because of its length and low overall yield (2–9%, Scheme 35B). A 
need for an efficient alternative thus remains.  
This would require a number of adaptations to the method of Lawson et al. (Scheme 36).82 
First, a protecting group other than para-methoxyphenyl needs to be selected. During the 
research described in this PhD thesis, the allyl group has proven to be a protecting group 
that can ultimately be cleaved off without affecting the (S)-blebbistatin scaffold. Second, the 
isolation of the quinolinone intermediate can be omitted by application of the two-step one-
pot procedure for the conversion of amidines to α-hydroxy ketones developed in this work. 
Third, the protection and deprotection of the hydroxyl group can possibly be eliminated, 
considering the low reactivity of the tertiary alcohol toward CuI-catalyzed arylations.107  
  
Scheme 36. A proposed third synthesis strategy for D-ring-modified (S)-blebbistatin analogs (S)-204. 
Combining these three alterations, the number of reaction steps for the late-stage 
incorporation of ring D could be reduced from 9 to 5. This would provide easy access to 
(S)-blebbistatin analogs (S)-204 with electron-withdrawing (e.g. NO2) or amino substituents 
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(e.g. N(Allyl)2, NH2), which were difficult or impossible to obtain via the original pathway 
(Scheme 35A). Furthermore, 18F- or C(18F)3-labelled derivatives (and the non-radioactive 
reference compounds) could present interesting research tool compounds for tracer studies 
using Positron Emission Tomography (PET) imaging. 
Light sensitivity and phototoxicity 
In chapter 1, the blue-light sensitivity of (S)-blebbistatin (S)-4 was quantified and it has 
become clear that research applications requiring blue-light irradiation are best conducted 
with (S)-4’-nitroblebbistatin (S)-130. However, the underlying mechanisms of light sensitivity 
still need clarification. Furthermore, Képiró et al. suggest that light sensitivity and 
phototoxicity are not correlated based on the observation that (S)-4’-chloroblebbistatin (S)-57 
is photostable but phototoxic.52 Yet, in chapter 1, we have found that their photostability 
experiments might be insufficient for a correct assessment of light sensitivity. It would thus 
also be interesting to study the correlation between light sensitivity and phototoxicity in more 
depth.  
Potency 
In order to evaluate the potential of (S)-blebbistatin derivatives as a starting point for the 
development of non-muscle myosin II-targeted therapeutic tools, the possibilities for 
myosin II inhibitory potency enhancement were investigated in chapters 1–3. In these 
studies, rabbit skeletal-muscle myosin II was used as a model for non-muscle myosin II, 
since purified or recombinantly expressed non-muscle myosin II is not easily accessible and 
its production costs are exceptionally high. Although we do not expect the produced 
blebbistatin analogs to display a substantially different relative potency as compared to (S)-
blebbistatin (S)-4 for non-muscle myosin II ATPase inhibition, it would still be interesting to 
evaluate the compounds against the latter isoform. If similar results (i.e. IC50 values in the 
micromolar range) would be obtained, this would confirm that the blebbistatin scaffold is not 



















1.1. General methods 
Reactions were performed in non-flame-dried glassware and open to the air unless otherwise 
noted. Yields refer to chromatographically and spectroscopically (1H-NMR) homogeneous 
material, unless otherwise stated. 
1.1.1. Solvents and reagents 
Dry dichloromethane was freshly distilled over CaH2 under a nitrogen atmosphere, or 
obtained using an MBraun SPS-800 system. Dry tetrahydrofuran was freshly distilled from 
sodium/benzophenone under a nitrogen atmosphere, or obtained using an MBraun SPS-800 
system. Dry 1,4-dioxane was purchased from Sigma-Aldrich. Dry acetonitrile, dry methanol 
and dry N,N-dimethylformamide were purchased from Acros Organics. Reagents were 
purchased at the highest commercial quality and were used as received without further 
purification.  
1.1.2. High-performance liquid chromatography 
HPLC and HPLC-MS analyses were performed on an Agilent 1200 series HPLC system 
fitted with an Ascentis® Express C18 column (particle size 2.7 µm, length 30 mm, internal 
diameter 4.6 mm) and connected to a UV-VIS detector and an Agilent 1100 series LC/MSD-
type SL mass spectrometer (ESI, 70 eV) using a mass-selective single-quadrupole detector. 
A mixture of acetonitrile/water (5 mM NH4OAc) was used as eluent. 
The enantiomeric excess (ee) of chiral compounds was determined via chiral-HPLC analysis 
using a Daicel Chiralpak IA column (particle size 5 µm, length 150 mm, internal diameter 
2.1 mm). The detection wavelength was set at 234 nm, 268 nm or 296 nm. Analyses under 
reversed-phase and normal-phase conditions were performed at 25 °C and 35 °C, 
respectively. 
1.1.3. Thin-layer chromatography 
Thin-layer chromatography (TLC) was carried out on 0.25-mm Merck silica plates (60 F254). 




1.1.4. Column chromatography 
Flash column chromatography was performed on an automated Reveleris® X1 flash 
chromatography system, using Reveleris® C18 or Reveleris® silica cartridges. 
1.1.5. Melting points 
Melting points were determined using a Wagner & Munz WME Heizbank Kofler bench. 
1.1.6. Optical rotation 
Optical rotations were obtained on a Jasco P-2000 polarimeter and are reported in 
deg mL g-1 dm-1; concentrations are reported in grams per 100 mL. 
1.1.7. NMR spectroscopy 
NMR spectra were recorded on a Bruker Avance III Nanobay 400-MHz spectrometer at room 
temperature. Peaks were assigned with the aid of COSY, HSQC, HMBC and NOESY 
experiments. Samples were dissolved in CDCl3, DMSO-d6 or CD3OD.
 1H-NMR (400 MHz) 
chemical shifts are reported in ppm and measured relative to tetramethylsilane or the 
residual undeuterated solvent as the internal reference. 13C-NMR (100.6 MHz) chemical 
shifts are reported in ppm and were measured relative to the residual solvent as the internal 
reference. The following abbreviations were used to explain peak multiplicities: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet, br. = broad. 
1.1.8. Infrared spectroscopy 
Infrared spectroscopy was performed on a Shimadzu IRAFFINITY-1S WL spectrophotometer 
with an ATR (Attenuated Total Reflectance) accessory. Samples were analyzed in neat form 
and selected peaks are reported.  
1.1.9. Mass spectrometry 
Low-resolution mass spectra were recorded on an Agilent 1100 series LC/MSD-type SL 
mass spectrometer (ESI, 70 eV) using a mass-selective single-quadrupole detector. High-
resolution mass spectra (HRMS) were recorded using an Agilent Technologies 6210 time-of-
flight (TOF) or Thermo Scientific MAT95XP-Trap mass spectrometer (ESI).  
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1.1.10. X-ray analysis 
All X-ray diffraction analyses were performed by Prof. dr. Kristof Van Hecke, XStruct, 
Department of Inorganic and Physical Chemistry, Ghent University, Belgium.   
X-ray intensity data were collected, at 100 K, on a Agilent Supernova Dual Source (Cu at 
zero) diffractometer equipped with an Atlas CCD detector using CuKα radiation 
(λ = 1.54178 Å) and ω scans. The images were interpreted and integrated with the program 
CrysAlisPro (Agilent Technologies). Using Olex2, the structures were solved by direct 
methods using the ShelXL program package. Non-hydrogen atoms were anisotropically 
refined and the hydrogen atoms in the riding mode and isotropic temperature factors fixed at 
1.2 times U (eq) of the parent atoms (1.5 times U (eq) for methyl and hydroxyl groups).  
CCDC 1485738 and 1485739 contain the supplementary crystallographic data for this work 
and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from 
the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: 
+44-1223-336033; or deposit@ccdc.cam.ac.uk). 
1.2. Synthesis procedures and compound characterization 
1.2.1. General procedure for the allyl protection of iodophenols 
The allylation of iodophenols was based on a publication of Brown Ripin and Vetelino.86 
In a bulb of 500 mL, containing 225 mL of 2-methyltetrahydrofuran, 39.0 g of iodophenol 
(177 mmol, 1 equiv), 340 mL of 25% (m/v) aqueous NaOH, 0.857 g of tetra-
n-butylammonium bromide (2.66 mmol, 0.015 equiv) and 16.2 mL of allyl bromide 
(186 mmol, 1.05 equiv) were brought together. The resulting mixture was stirred under reflux 
for 0.5–2 hours, cooled down to room temperature and diluted with 350 mL of diethyl ether 
and 175 mL of water. The two layers were separated and the aqueous layer was extracted 
with 350 mL of diethyl ether. The combined organic layers were washed with 350 mL of 
brine, dried over magnesium sulfate and evaporated in vacuo.  
1.2.1.1. Synthesis of aryl iodide 100 
Aryl iodide 100 was synthesized from 3-iodophenol (98) (39.0 g, 177 mmol, 1 equiv). 
Evaporation in vacuo afforded aryl iodide 100 (46.1 g, quant.) as a yellow-orange oil. 
1-(Allyloxy)-3-iodobenzene (100)108,109 
Yield = quant. Yellow-orange oil. Rf = 0.66 (hexane/ethyl acetate, 9:1). 
1H-NMR (400 MHz, CDCl3): δ = 4.50 (2H, dt, J1 = 5.2 Hz, J2 = 1.3 Hz, 
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OCH2), 5.26–5.33 (1H, m, OCH2CHCH
aHb), 5.36–5.45 (1H, m, OCH2CHCH
aHb), 6.02 (1H, 
ddt, J1 = 17.3 Hz, J2 = 10.5 Hz, J3 = 5.2 Hz, OCH2CH), 6.85–6.90 (1H, m, H
6), 6.99 (1H, t, 
J = 8.0 Hz, H5), 7.26–7.28 (1H, m, H2), 7.26–7.30 (1H, m, H4). MW = 260.07. 
1.2.1.2. Synthesis of aryl iodide 159 
Aryl iodide 159 was synthesized from 4-iodophenol (157) (13.5 g, 61.5 mmol, 1 equiv). 
Evaporation in vacuo afforded aryl iodide 159 (17.6 g, quant) as a yellow oil. 
1-(Allyloxy)-4-iodobenzene (159)110,111 
Yield = quant. Yellow oil. Rf = 0.72 (hexane/ethyl acetate, 1:1). 
1H-NMR 
(400 MHz, CDCl3): δ = 4.50 (2H, ddd, J1 = 5.3 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, OCH2), 
5.29 (1H, dq, J1 = 10.5 Hz, J2 = 1.4 Hz, OCH2CHCH
aHb), 5.40 (1H, dtd, 
J1 = 17.2 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, OCH2CHCH
aHb), 6.02 (1H, ddt, 
J1 = 17.2 Hz, J2 = 10.5 Hz, J3 = 5.3 Hz, OCH2CH), 6.67–6.72 (2H, m, H
2, H6), 
7.52–7.57 (2H, m, H3, H5). MW = 260.07. 
1.2.2. General procedure for the allyl protection of iodoanilines 
The allylation of iodoanilines was based on a publication of Vandekerckhove et al.87 
A bulb of 500 mL, equipped with an oven-dried reflux condenser and kept under a nitrogen 
atmosphere, was loaded with 100 mL of dry tetrahydrofuran and iodoaniline (95.6 mmol, 
1 equiv). Then, the solution was cooled to 0 °C and 120 mL of lithiumbis(trimethylsilyl)amide 
(1-M solution in tetrahydrofuran, 120 mmol, 1.25 equiv) and 33.1 mL of allyl bromide 
(382 mmol, 4 equiv) were added. The reaction was stirred for 1–2 hours at reflux 
temperature. Next, the solution was cooled to 0 °C, a second portion of 
lithiumbis(trimethylsilyl)amide (1-M solution in tetrahydrofuran, 120 mL, 120 mmol, 
1.25 equiv) was added and the reaction mixture was refluxed for 0.5–1 hour. If conversion 
was not complete, the solution was again cooled to 0 °C, a third portion of 
lithiumbis(trimethylsilyl)amide (1-M solution in tetrahydrofuran, 47.8 mL, 47.8 mmol, 
0.5 equiv) was added and the solution was stirred for another hour at reflux temperature. 
Subsequently, the mixture was cooled down to room temperature, quenched with 800 mL of 
saturated aqueous NH4Cl and evaporated under reduced pressure. The residual aqueous 
layer was extracted with an equal volume of ethyl acetate (3×). The combined organic layers 
were concentrated in vacuo to a volume of 600 mL and washed with an equal volume of 
saturated aqueous NaHCO3 and brine. Drying with magnesium sulfate and evaporation in 
vacuo resulted in a red oil. The side product N,N-bis(trimethylsilyl)allylamine (102) was 
distilled off (20 mbar, 56‒63 °C). 
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1.2.2.1. Synthesis of aryl iodide 101 
Aryl iodide 101 was synthesized from 3-iodoaniline (99) (11.5 mL, 95.6 mmol, 1 equiv). The 
residue (28.8 g) obtained upon distillation was dissolved in 17 mL of hexane and half of the 
total volume was manually injected on a Reveleris® 120-g silica cartridge (12% (m/m) 
sample loading) for purification via automated flash chromatography (flow rate: 80 mL min-1; 
eluent: 7 column volumes (CV) of 100% (v/v) hexane, followed by 4 CV of 100% (v/v) ethyl 
acetate; detection wavelength: 254 nm). The same conditions were applied to purify the 
other half of the crude mixture. Evaporation resulted in aryl iodide 101 (21.4 g, 75%) as a 
yellow oil.  
N,N-Diallyl-3-iodoaniline (101) 
Yield = 75%. Yellow oil. Rf = 0.24 (hexane). 
1H-NMR (400 MHz, CDCl3): 
δ = 3.85–3.91 (4H, m, N(CH2CHCH
aHb)2), 5.12–5.20 (2H, m, 
N(CH2CHCH
aHb)2), 5.14–5.20 (2H, m, N(CH2CHCH
aHb)2), 5.76–5.88 (2H, m, 
N(CH2CHCH
aHb)2), 6.60–6.66 (1H, m, H
6), 6.88 (1H, t, J = 7.9 Hz, H5), 6.97–
7.01 (1H, m, H4), 6.99–7.01 (1H, m, H2). 13C-NMR (100.6 MHz, CDCl3): 
δ = 52.6 (N(CH2CHCH2)2), 95.4 (C
3), 111.5 (C6), 116.3 (N(CH2CHCH2)2), 120.9 (C
2), 125.1 
(C4), 130.4 (C5), 133.2 (N(CH2CHCH2)2), 149.8 (C
1). IR (ATR, cm-1): νmax = 980, 1233, 1489, 
1551, 1587. MS (ESI): m/z (%) = 299.6 ([M+H]+, 100). HRMS (ESI): calculated for C12H15IN 
([M+H]+) 300.0244; found 300.0254. MW = 299.16. 
1.2.2.2. Synthesis of aryl iodide 160 
Aryl iodide 160 was synthesized from 4-iodoaniline (158) (11.0 g, 50 mmol, 1 equiv). The 
residue (17.2 g) obtained upon distillation was dissolved in ethyl acetate and coated under 
reduced pressure onto silica. Subsequently, purification was performed via automated flash 
chromatography with hexane/ethyl acetate as eluent on a Reveleris® 120-g silica cartridge 
(14% (m/m) sample loading; flow rate: 80 mL min-1; eluent: 7 CV of 100% (v/v) hexane, 
followed by 5 CV of 100% (v/v) ethyl acetate; detection wavelength: 254 nm). Evaporation 
resulted in aryl iodide 160 (15.1 g, quant) as a yellow oil.  
N,N-Diallyl-4-iodoaniline (160) 
Yield = quant. Yellow oil. Rf = 0.43 (hexane/ethyl acetate, 99:1). 
1H-NMR 
(400 MHz, CDCl3): δ = 3.86–3.91 (4H, m, N(CH2CHCH2)2), 5.11–5.18 (2H, m, 
N(CH2CHCH
aHb)2), 5.13–5.18 (2H, m, N(CH2CHCH
aHb)2), 5.76–5.87 (2H, m, 
N(CH2CHCH2)2), 6.43–6.49 (2H, m, H
2, H6), 7.38–7.44 (2H, m, H3, H5). 13C-NMR 
(100.6 MHz, CDCl3): δ = 52.7 (N(CH2CHCH2)2), 77.0 (C
4), 114.6 (C2, C6), 116.2 
(N(CH2CHCH2)2), 133.3 (N(CH2CHCH2)2), 137.6 (C
3, C5), 148.2 (C1). IR (ATR, 
cm-1): νmax = 802, 918, 1233, 1491, 1585. MS (ESI): m/z (%) = 300.1 ([M+H]
+, 31). 
MW = 299.16. 
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1.2.3. General procedure for the N-arylation of pyrrolidin-2-one (39) with aryl iodides 
The preparation of amides 19,104,106,161 was adopted from Haldón et al.84 
In a flame-dried bulb of 250 mL, containing 100 mL of dry 1,4-dioxane, 0.952 g of CuI 
(5.00 mmol, 0.05 equiv) and 1.49 g of tris(3,5-dimethyl-1H-pyrazol-1-yl)methane (5.00 mmol, 
0.05 equiv) were brought together under a nitrogen atmosphere. Then, aryl iodide 
(100 mmol, 1 equiv), 9.12 mL of pyrrolidin-2-one (39) (120 mmol, 1.2 equiv) and 42.4 g of 
K3PO4 (200 mmol, 2 equiv) were added and the reaction mixture was stirred at reflux 
temperature for 19–24 hours. A beige suspension was formed during this step. Next, the 
suspension was cooled down to room temperature and the solids were filtered off on a 
sintered-glass Büchner funnel. The filter cake was rinsed with ethyl acetate until the filtrate 
turned colorless. The filtrate was washed with an equal volume of 3-M aqueous HCl (3×) and 
brine, after which the organic layer was dried over magnesium sulfate and evaporated in 
vacuo. 
1.2.3.1. Synthesis of amide 19 
Amide 19 was synthesized from iodobenzene (92) (11.2 mL, 100 mmol, 1 equiv) and 
pyrrolidin-2-one (39) (9.12 mL, 120 mmol, 1.2 equiv). Evaporation in vacuo afforded 
amide 19 (14.3 g, 89%) as beige fibers.  
1-Phenylpyrrolidin-2-one (19)112,113 
Yield = 89%. Beige fibers. 1H-NMR (400 MHz, CDCl3): δ = 2.11–2.21 (2H, m, H
4), 
2.61 (2H, t, J = 8.1 Hz, H3), 3.87 (2H, t, J = 7.0 Hz, H5), 7.11–7.17 (1H, m, H4’), 
7.33–7.40 (2H, m, H3’, H5’), 7.58–7.64 (2H, m, H2’, H6’). MW = 161.20.  
 
1.2.3.2. Synthesis of amide 104 
Amide 104 was synthesized from aryl iodide 100 (45.0 g, 173 mmol, 1 equiv) and pyrrolidin-
2-one (39) (15.8 mL, 208 mmol, 1.2 equiv). Evaporation in vacuo afforded a red oil (38.9 g) 
which was further purified via automated flash chromatography with hexane/ethyl acetate as 
eluent. Half of the crude mixture was manually injected on a Reveleris® 120-g silica cartridge 
(16% (m/m) sample loading) and the injection valve was subsequently rinsed twice with 5 mL 
of the initial mobile phase (flow rate: 80 mL min-1; eluent: 2 CV of 12% (v/v) ethyl acetate, 
followed by a gradient from 12% (v/v) to 100% (v/v) ethyl acetate over 10 CV; detection 
wavelengths: 254 nm and 268 nm). Next, the same conditions were applied to purify the 
other half of the crude mixture. Evaporation yielded amide 104 (28.2 g, 75%) as a yellow-




Yield = 75%. Yellow-orange oil. Rf = 0.51 (ethyl acetate). 
1H-NMR 
(400 MHz, CDCl3): δ = 2.10–2.20 (2H, m, H
4), 2.61 (2H, t, J = 8.1 Hz, H3), 
3.84 (2H, t, J = 7.0 Hz, H5), 4.55 (2H, ddd, J1 = 5.3 Hz, J2 = 1.5 Hz, 
J3 = 1.4 Hz, OCH2), 5.29 (1H, dq, J1 = 10.6 Hz, J2 = 1.4 Hz, 
OCH2CHCH
aHb), 5.42 (1H, dtd, J1 = 17.3 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, 
OCH2CHCH
aHb), 6.06 (1H, ddt, J1 = 17.3 Hz, J2 = 10.6 Hz, J3 = 5.3 Hz, 
OCH2CH), 6.71 (1H, ddd, J1 = 8.2 Hz, J2 = 2.3 Hz, J3 = 0.7 Hz, H
4’), 7.13 (1H, ddd, 
J1 = 8.2 Hz, J2 = 2.1 Hz, J3 = 0.7 Hz, H
6’), 7.25 (1H, t, J = 8.2 Hz, H5’), 7.37 (1H, dd, 
J1 = 2.3 Hz, J2 = 2.1 Hz, H
2’). 13C-NMR (100.6 MHz, CDCl3): δ = 18.0 (C
4), 32.9 (C3), 48.9 
(C5), 68.9 (OCH2), 106.8 (C
2’), 110.8 (C4’), 112.1 (C6’), 117.8 (OCH2CHCH2), 129.5 (C
5’), 
133.2 (OCH2CH), 140.6 (C
1’), 158.9 (C3’), 174.3 (C2). MS (ESI): m/z (%) = 218.1 ([M+H]+, 
100). HRMS (ESI): calculated for C13H16NO2 ([M+H]
+) 218.1176; found 218.1178. 
MW = 217.26. 
1.2.3.3. Synthesis of amide 106 
Amide 106 was synthesized from aryl iodide 103 (28.5 g, 124 mmol, 1 equiv) and pyrrolidin-
2-one (39) (11.3 mL, 149 mmol, 1.2 equiv). Evaporation in vacuo afforded amide 106 (20.4 g, 
88%) as beige crystals.  
3-(2-Oxopyrrolidin-1-yl)benzonitrile (106)114 
Yield = 88%. Beige crystals (m.p. 83 °C). 1H-NMR (400 MHz, CDCl3): 
δ = 2.16–2.26 (2H, m, H4’), 2.64 (2H, t, J = 8.1 Hz, H3’), 3.87 (2H, t, J = 7.0 Hz, 
H5’), 7.40 (1H, dt, J1 = 7.7 Hz, J2 = 1.3 Hz, H
6), 7.44–7.49 (1H, m, H5), 7.91 (1H, 
ddd, J1 = 8.3 Hz, J2 = 2.3 Hz, J3 = 1.3 Hz, H
4), 7.96–7.99 (1H, m, H2). 13C-NMR 
(100.6 MHz, CDCl3): δ = 17.8 (C
4’), 32.6 (C3’), 48.3 (C5’), 112.9 (C1), 118.6 
(CN), 122.5 (C2), 123.5 (C4), 127.6 (C6), 129.7 (C5), 140.2 (C3), 175.6 (C2’). IR 
(ATR, cm-1): νmax = 1227, 1335, 1391, 1487, 1692 (C=O), 2230 (CN). MS (ESI): 
m/z (%) = 186.9 ([M+H]+, 100). HRMS (ESI): calculated for C11H11N2O ([M+H]
+) 187.0866; 
found 187.0860. MW = 186.21.  
1.2.3.4. Synthesis of amide 161 
Amide 161 was synthesized from aryl iodide 159 (16.2 g, 62.3 mmol, 1 equiv) and pyrrolidin-
2-one (39) (5.69 mL, 74.8 mmol, 1.2 equiv). Evaporation in vacuo afforded an orange solid 
(24.2 g) of which 12.1 g was dissolved in dichloromethane and coated under reduced 
pressure onto silica. Subsequently, purification was performed via automated flash 
chromatography with hexane/ethyl acetate as eluent on a Reveleris® 120-g cartridge (10% 
(m/m) sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 20% (v/v) ethyl acetate, 
followed by a gradient from 20% (v/v) to 100% (v/v) ethyl acetate over 20 CV; detection 
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wavelengths: 234 nm and 250 nm). The same conditions were applied to purify the other half 
of the crude mixture. Evaporation resulted in amide 161 (10.2 g, 75%) as a white powder. 
1-(4-Allyloxyphenyl)pyrrolidin-2-one (161) 
Yield = 75%. White powder (m.p. 104 °C). Rf = 0.16 (hexane/ethyl acetate, 1:1). 
1H-NMR (400 MHz, CDCl3): δ = 2.10–2.20 (2H, m, H
4), 2.59 (2H, t, J = 8.1 Hz, 
H3), 3.83 (2H, t, J = 7.0 Hz, H5), 4.53 (2H, ddd, J1 = 5.3 Hz, J2 = 1.5 Hz, 
J3 = 1.4 Hz, OCH2), 5.28 (1H, ddt, J1 = 10.5 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, 
OCH2CHCH
aHb), 5.41 (1H, dq, J1 = 17.3 Hz, J2 = 1.5 Hz, OCH2CHCH
aHb), 6.05 
(1H, ddt, J1 = 17.3 Hz, J2 = 10.5 Hz, J3 = 5.3 Hz, OCH2CH), 6.89–6.94 (2H, m, 
H3’, H5’), 7.46–7.52 (2H, m, H2’, H6’). 13C-NMR (100.6 MHz, CDCl3): δ = 18.1 (C
4), 
32.5 (C3), 49.2 (C5), 69.1 (OCH2), 115.0 (C
3’, C5’), 117.7 (OCH2CHCH2), 121.7 (C
2’, C6’), 
132.8 (C1’), 133.2 (OCH2CH), 155.6 (C
4’), 173.9 (C2). IR (ATR, cm-1): νmax = 827, 1018, 1225, 
1508, 1680 (C=O). MS (ESI): m/z (%) = 218.2 ([M+H]+, 100). HRMS (ESI): calculated for 
C13H16NO2 ([M+H]
+) 218.1176; found 218.1178. MW = 217.26. 
1.2.4. Synthesis of amide 105 and amide 162 
For the synthesis of amide 105 and amide 162, the general procedure for the N-arylation of 
pyrrolidin-2-one (39) with aryl iodides (procedure 1.2.3.) was slightly modified. 
In a flame-dried bulb of 250 mL, containing 96 mL of dry 1,4-dioxane, 0.909 g of CuI 
(4.76 mmol, 0.05 equiv) and 1.42 g of tris(3,5-dimethyl-1H-pyrazol-1-yl)methane (4.76 mmol, 
0.05 equiv) were brought together under a nitrogen atmosphere. Then, 28.5 g of aryl iodide 
(95.3 mmol, 1 equiv), 8.68 mL of pyrrolidin-2-one (39) (114 mmol, 1.2 equiv) and 40.5 g of 
K3PO4 (191 mmol, 2 equiv) were added under a nitrogen atmosphere and the reaction 
mixture was stirred under reflux for 24 hours. Next, a second portion of CuI (0.909 g, 
4.76 mmol, 0.05 equiv) and tris(3,5-dimethyl-1H-pyrazol-1-yl)methane (1.42 g, 4.76 mmol, 
0.05 equiv) were added and the reaction mixture was refluxed for 24 hours. Afterwards, a 
third portion of CuI (0.909 g, 4.76 mmol, 0.05 equiv) and of tris(3,5-dimethyl-1H-pyrazol-1-yl)-
methane (1.42 g, 4.76 mmol, 0.05 equiv) were added and the mixture was stirred for another 
24 hours at reflux temperature. A beige suspension was formed during this reaction. After 
cooling to room temperature, the solids were filtered off on a sintered-glass Büchner funnel 
and the filter cake was rinsed with ethyl acetate until the filtrate turned colorless. The filtrate 
was washed with an equal volume of saturated aqueous NH4Cl (3×) and brine, after which 
the organic layer was isolated, dried with magnesium sulfate and evaporated in vacuo. 
1.2.4.1. Synthesis of amide 105 
Amide 105 was synthesized from aryl iodide 101 (28.5 g, 95.3 mmol, 1 equiv) and pyrrolidin-
2-one (39) (8.68 mL, 114 mmol, 1.2 equiv). Evaporation in vacuo afforded an orange-red oil 
EXPERIMENTAL PROCEDURES 
121 
(32.5 g) of which 5.41 g was dissolved in acetonitrile and coated under reduced pressure 
onto 10.8 g of Davisil® C18 silica. Subsequently, purification was performed via automated 
flash chromatography with water/acetonitrile as eluent on a Reveleris® 120-g C18 cartridge 
(5% (m/m) sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 20% (v/v) acetonitrile, 
followed by a gradient from 20% (v/v) to 40% (v/v) acetonitrile over 30 CV and finally a 
gradient from 40% (v/v) to 100% (v/v) acetonitrile over 20 CV; detection wavelengths: 
222 nm and 262 nm). Next, the same conditions were repeated another 5 times to purify the 
remaining parts of the crude mixture. Evaporation resulted in amide 105 (19.3 g, 79%) as a 
yellow oil. 
1-(3-(Diallylamino)phenyl)pyrrolidin-2-one (105) 
Yield = 79%. Yellow oil. Rf = 0.27 (hexane/ethyl acetate, 3:2). 
1H-NMR 
(400 MHz, CDCl3): δ = 2.07–2.17 (2H, m, H
4), 2.58 (2H, t, J = 8.1 Hz, H3), 
3.83 (2H, t, J = 7.0 Hz, H5), 3.93 (4H, dt, J1 = 4.9 Hz, J2 = 1.7 Hz, 
N(CH2CHCH
aHb)2), 5.16 (2H, dtd, J1 = 9.3 Hz, J2 = 1.7 Hz, J3 = 1.6 Hz, 
N(CH2CHCH
aHb)2), 5.19 (2H, dtd, J1 = 16.3 Hz, J2 = 1.7 Hz, J3 = 1.6 Hz, 
N(CH2CHCH
aHb)2), 5.85 (2H, ddt, J1 = 16.3 Hz, J2 = 9.3 Hz, J3 = 4.9 Hz, 
N(CH2CHCH
aHb)2), 6.47–6.52 (1H, m, H
4’), 6.75 (1H, ddd, J1 = 8.1 Hz, 
J2 = 2.1 Hz, J3 = 0.6 Hz, H
6’), 7.16 (1H, dd, J1 = 8.2 Hz, J2 = 8.1 Hz, H
5’), 7.16 (1H, dd, 
J1 = 2.2 Hz, J2 = 2.1 Hz, H
2’). 13C-NMR (100.6 MHz, CDCl3): δ = 18.1 (C
4), 32.9 (C3), 49.1 
(C5), 52.9 (N(CH2CHCH2)2), 104.7 (C
2’), 108.0 (C6’), 108.9 (C4’), 116.1 (N(CH2CHCH2)2), 
129.2 (C5’), 133.9 (N(CH2CHCH2)2), 140.3 (C
1’), 149.2 (C3’), 174.1 (C2). IR (ATR, cm-1): 
νmax = 1400, 1504, 1578, 1603, 1697 (C=O). MS (ESI): m/z (%) = 256.8 ([M+H]
+, 100). HRMS 
(ESI): calculated for C16H21N2O ([M+H]
+) 257.1648; found 257.1647. MW = 256.35. 
1.2.4.2. Synthesis of amide 162 
Amide 162 was synthesized from aryl iodide 160 (14.1 g, 47.3 mmol, 1 equiv) and pyrrolidin-
2-one (39) (4.31 mL, 56.7 mmol, 1.2 equiv). Evaporation in vacuo afforded a red-brown oil 
(13.9 g) of which 6.95 g was dissolved in acetonitrile and coated under reduced pressure 
onto 13.9 g of Davisil® C18 silica. Subsequently, purification was performed via automated 
flash chromatography with water/acetonitrile as eluent on a Reveleris® 120-g C18 cartridge 
(6% (m/m) sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 20% (v/v) acetonitrile, 
followed by a gradient from 20% (v/v) to 40% (v/v) acetonitrile over 30 CV and finally a 
gradient from 40% (v/v) to 100% (v/v) acetonitrile over 20 CV; detection wavelengths: 
222 nm and 262 nm). Next, the same conditions were repeated to purify the other half of the 
crude mixture. Evaporation of the combined fractions resulted in amide 162 (9.13 g, 75%) as 




Yield = 75%. Orange-brown solid (m.p. 73 °C). Rf = 0.29 (hexane/ethyl acetate, 
2:3). 1H-NMR (400 MHz, CDCl3): δ = 2.07–2.17 (2H, m, H
4), 2.57 (2H, t, 
J = 8.1 Hz, H3), 3.79 (2H, t, J = 7.0 Hz, H5), 3.90 (4H, dt, J1 = 4.8 Hz, J2 = 1.8 Hz, 
N(CH2CHCH2)2), 5.12–5.17 (2H, m, N(CH2CHCH
aHb)2), 5.12–5.20 (2H, m, 
N(CH2CHCH
aHb)2), 5.84 (2H, ddt, J1 = 17.1 Hz, J2 = 10.0 Hz, J3 = 4.8 Hz, 
N(CH2CHCH2)2), 6.65–6.71 (2H, m, H
3’, H5’), 7.33–7.38 (2H, m, H2’, H6’). 
13C-NMR (100.6 MHz, CDCl3): δ = 18.1 (C
4), 32.4 (C3), 49.4 (C5), 52.9 
(N(CH2CHCH2)2), 112.5 (C
3’, C5’), 116.1 (N(CH2CHCH2)2), 122.1 (C
2’, C6’), 128.8 (C1’), 133.9 
(N(CH2CHCH2)2), 146.1 (C
4’), 173.7 (C2). IR (ATR, cm-1): νmax = 814, 920, 1184, 1227, 1678 
(C=O). MS (ESI): m/z (%) = 257.1 ([M+H]+, 100). MW = 256.35. 
1.2.5. Synthesis of thioamide 107 
In a flame-dried bulb of 100 mL, containing 50 mL of dry tetrahydrofuran, 1.86 g of 
amide 106 (10.0 mmol, 1 equiv) and 2.00 g of Lawesson’s reagent 110 (5.00 mmol, 
0.5 equiv) were brought together under a nitrogen atmosphere and stirred for 30 minutes at 
reflux temperature. Then, the reaction mixture was cooled to 0 °C, diluted with 50 mL of 
diethyl ether and the resulting slurry was filtered off over celite. Evaporation of the filtrate in 
vacuo afforded a yellow solid (3.70 g) which was dissolved in toluene and coated under 
reduced pressure onto silica. Subsequently, purification was performed via automated flash 
chromatography with hexane/ethyl acetate as eluent on a Reveleris® 80-g silica cartridge 
(5% (m/m) sample loading; flow rate: 60 mL min-1; eluent: 2 CV of 0% (v/v) ethyl acetate, 
followed by a gradient from 0% (v/v) to 30% (v/v) ethyl acetate over 60 CV and finally 5 CV of 
100% (v/v) ethyl acetate; detection wavelength: 272 nm). This afforded thioamide 107 
(1.60 g, 79%) as off-white fibers. 
3-(2-Thioxopyrrolidin-1-yl)benzonitrile (107)  
Yield = 79%. Off-white fibers (m.p. 132 °C). 1H-NMR (400 MHz, CDCl3): 
δ = 2.22–2.32 (2H, m, H4’), 3.24 (2H, t, J = 7.8 Hz, H3’), 4.15 (2H, t, J = 7.2 Hz, 
H5’), 7.53–7.63 (2H, m, H5, H6), 7.87–7.92 (2H, m, H4, H2). 13C-NMR 
(100.6 MHz, CDCl3): δ = 20.7 (C
4’), 46.4 (C3’), 58.1 (C5’), 113.2 (C1), 117.9 
(CN), 128.3 (C2), 129.4 (C4), 130.0 (C5), 130.9 (C6), 141.2 (C3), 204.0 (C2’). IR 
(ATR, cm-1): νmax = 1134 (C=S), 1256, 1294, 1420, 1487, 2228 (CN). MS (ESI): 
m/z (%) = 203.2 ([M+H]+, 100). MW = 202.28.  
1.2.6. Synthesis of indole 151 
Indole 151 was synthesized via a procedure published by Myochin et al.115 
In a flame-dried bulb of 250 mL, 11.0 g of 6-bromoindole (150) (56.1 mmol, 1 equiv) was 
dissolved in 60 mL of dry N,N-dimethylformamide. The reaction mixture was cooled to 0 °C, 
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after which 1.41 g of NaH (58.9 mmol, 1.05 equiv) was added. The reaction mixture was 
stirred for 30 minutes at 0 °C under a nitrogen atmosphere. Then, 4.85 mL of allyl bromide 
(56.1 mmol, 1 equiv) was added and the mixture was stirred for 30 minutes at room 
temperature. Afterwards, the mixture was diluted with 900 mL of diethyl ether, washed with 
brine (3× 300 mL) and water (3× 300 mL), and the organic layer was dried over magnesium 
sulfate. Evaporation in vacuo afforded indole 151 (13.1 g, 99%) as an orange-red oil. 
1-Allyl-6-bromoindole (151)115 
Yield = 99%. Orange-red oil. Rf = 0.28 (hexane/ethyl acetate, 99:1). 
1H-NMR (400 MHz, CDCl3): δ = 4.68 (2H, dt, J1 = 5.3 Hz, J2 = 1.5 Hz, 
NCH2), 5.07 (1H, dtd, J1 = 17.1 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, 
NCH2CHCH
aHb), 5.22 (1H, dtd, J1 = 10.3 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, 
NCH2CHCH
aHb), 5.97 (1H, ddt, J1 = 17.1 Hz, J2 = 10.3 Hz, J3 = 5.3 Hz, 
NCH2CH), 6.48 (1H, dd, J1 = 3.2 Hz, J2 = 0.6 Hz, H
3), 7.06 (1H, d, J = 3.2 Hz, H2), 7.20 (1H, 
dd, J1 = 8.4 Hz, J2 = 1.8 Hz, H
5), 7.45–7.48 (1H, m, H7), 7.45–7.50 (1H, m, H4). MW = 236.11. 
1.2.7. Synthesis of aryl bromide 152 
Aryl bromide 152 was synthesized via a procedure published by Myochin et al.115  
In a bulb of 100 mL, 11.9 g of indole 151 (50.5 mmol, 1 equiv) was dissolved in 70 mL of 
glacial acetic acid. The reaction mixture was cooled to 0 °C after which 3.33 g of NaCNBH3 
(53.0 mmol, 1.05 equiv) was added and the mixture was stirred for 4.5 hours at room 
temperature. Afterwards, the mixture was quenched with 300 mL of 3-M aqueous NaOH and 
extracted with 700 mL of diethyl ether. The organic layer was washed with 3-M aqueous 
NaOH (3× 300 mL), brine (300 mL) and water (300 mL), and the organic layer was dried over 
magnesium sulfate. Evaporation in vacuo afforded a yellow oil (15.2 g) of which 7.62 g was 
dissolved in dichloromethane and coated under reduced pressure onto 12.0 g of Davisil® 
C18 silica. Subsequently, purification was performed via automated flash chromatography 
with water/acetonitrile as eluent on a Reveleris® 120-g C18 cartridge (6% (m/m) sample 
loading; flow rate: 80 mL min-1; eluent: 2 CV of 60% (v/v) acetonitrile, followed by a gradient 
from 60% (v/v) to 80% (v/v) acetonitrile over 20 CV; detection wavelength: 218 nm and 
266 nm). The same conditions were applied to purify the other half of the crude mixture. 
Evaporation of the combined fractions afforded aryl bromide 152 (9.57 g, 80%) as a light-
yellow oil. 
1-Allyl-6-bromoindoline (152)115 
Yield = 80%. Light-yellow oil. Rf = 0.25 (hexane/dichloromethane, 4:1). 
1H-NMR (400 MHz, CDCl3): δ = 2.90 (2H, t, J = 8.4 Hz, H
3), 3.38 (2H, t, 
J = 8.4 Hz, H2), 3.68 (2H, ddd, J1 = 5.9 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, 
NCH2CHCH




aHb), 5.27 (1H, dq, J1 = 10.3 Hz, J2 = 1.4 Hz, NCH2CHCH
aHb), 5.86 (1H, ddt, 
J1 = 17.1 Hz, J2 = 10.3 Hz, J3 = 5.9 Hz, NCH2CHCH
aHb), 6.57 (1H, d, J = 1.6 Hz, H7), 6.73 
(1H, dd, J1 = 7.6 Hz, J2 = 1.6 Hz, H
5), 6.89 (1H, d, J = 7.6 Hz, H4). MW = 238.13. 
1.2.8. General procedure for the N-arylation of pyrrolidin-2-one (39) with aryl bromides 
The N-arylation of pyrrolidin-2-one (39) with aryl bromides was based on a procedure of 
Klapars et al.97 
In a flame-dried bulb of 100 mL, containing 60 mL of dry 1,4-dioxane, 0.238 g of CuI 
(1.25 mmol, 0.05 equiv) and 269 µL of N,N’-dimethylethylenediamine (2.50 mmol, 0.1 equiv) 
were brought together under a nitrogen atmosphere. Then, aryl bromide (25.0 mmol, 
1 equiv), 2.28 mL of pyrrolidin-2-one (39) (30.0 mmol, 1.2 equiv) and 6.91 g of K2CO3 
(50.0 mmol, 2 equiv) were added and the reaction mixture was stirred at reflux temperature 
for 4–23 hours. Next, a second portion of CuI (0.238 g, 1.25 mmol, 0.05 equiv) and 
N,N’-dimethylethylenediamine (269 µL, 2.50 mmol, 0.1 equiv) were added and the mixture 
was stirred for 6–14 hours at reflux temperature. The resulting suspension was cooled to 
room temperature and the solids were filtered off on a sintered-glass Büchner funnel. The 
filter cake was rinsed with 150 mL of ethyl acetate. The filtrate was washed with saturated 
aqueous NH4Cl (3× 60 mL) and brine (60 mL), after which the organic layer was dried over 
magnesium sulfate and evaporated in vacuo. 
1.2.8.1. Synthesis of amide 145 
Amide 145 was synthesized from aryl bromide 144 (5.18 g, 25.0 mmol, 1 equiv) and 
pyrrolidin-2-one (39) (2.28 mL, 30.0 mmol, 1.2 equiv). Evaporation in vacuo afforded 
amide 145 (5.17 g, 98%) as an off-white powder. 
1-(Naphthalen-2-yl)pyrrolidin-2-one (145)116,117 
Yield = 98%. Off-white powder. Rf = 0.57 (hexane/ethyl acetate, 3:2). 
1H-NMR 
(400 MHz, CDCl3): δ = 2.17–2.27 (2H, m, H
4), 2.67 (2H, t, J = 8.1 Hz, H3), 3.99 
(2H, t, J = 7.0 Hz, H5), 7.39–7.45 (1H, m, H6’ or H7’), 7.43–7.49 (1H, m, H6’ or 
H7’), 7.78–7.83 (2H, m, H5’, H8’), 7.84 (1H, d, J = 9.0 Hz, H4’), 7.86 (1H, d, 
J = 2.2 Hz, H1’), 7.98 (1H, dd, J1 = 9.0 Hz, J2 = 2.2 Hz, H
3’). MW = 211.26. 
1.2.8.2. Synthesis of amide 148 
Amide 148 was synthesized from aryl bromide 147 (5.20 g, 25.0 mmol, 1 equiv) and 
pyrrolidin-2-one (39) (2.28 mL, 30.0 mmol, 1.2 equiv). Evaporation in vacuo afforded 




Yield = 90%. Off-white powder (m.p. 146 °C). 1H-NMR (400 MHz, CDCl3): 
δ = 2.20–2.30 (2H, m, H4), 2.70 (2H, t, J = 8.1 Hz, H3), 4.00 (2H, t, J = 7.0 Hz, 
H5), 7.61 (1H, d, J = 7.2 Hz, H4’), 7.87 (1H, d, J = 2.1 Hz, H
5’), 7.97 (1H, d, 
J = 9.0 Hz, H8’), 8.15 (1H, dd, J1 = 9.0 Hz, J2 = 2.1 Hz, H
7’), 8.49 (1H, d, 
J = 7.2 Hz, H3’), 9.19 (1H, br. s, H1’). 13C-NMR (100.6 MHz, CDCl3): δ = 18.0 
(C4), 32.9 (C3), 48.7 (C5), 114.2 (C5’), 120.3 (C4’), 120.7 (C7’), 125.7 (C8a’), 128.5 
(C8’), 136.3, 141.0 (C4a’, C6’), 143.5 (C3’), 151.9 (C1’), 174.8 (C2). IR (ATR, cm-1): 
νmax = 748, 822, 864, 1217, 1690 (C=O). MS (ESI): m/z (%) = 213.1 ([M+H]
+, 100). 
MW = 212.25. 
1.2.8.3. Synthesis of amide 153 
Amide 153 was synthesized from aryl bromide 152 (9.53 g, 40.0 mmol, 1 equiv) and 
pyrrolidin-2-one (39) (3.65 mL, 48.0 mmol, 1.2 equiv). Evaporation in vacuo afforded 
amide 153 (9.60 g, 99%) as a yellow-orange oil. 
1-(1-Allylindolin-6-yl)pyrrolidin-2-one (153) 
Yield = 99%. Yellow-orange oil. 1H-NMR (400 MHz, CDCl3): δ = 2.07–2.17 
(2H, m, H4), 2.58 (2H, t, J = 8.1 Hz, H3), 2.92 (2H, t, J = 8.3 Hz, H3’), 3.36 
(2H, t, J = 8.3 Hz, H2’), 3.72 (2H, ddd, J1 = 6.0 Hz, J2 = 1.4 Hz, J3 = 1.3 Hz, 
NCH2CHCH
aHb), 3.82 (2H, t, J = 7.0 Hz, H5), 5.19 (1H, ddt, J1 = 10.2 Hz, 
J2 = 1.5 Hz, J3 = 1.3 Hz, NCH2CHCH
aHb), 5.28 (1H, ddt, J1 = 17.1 Hz, 
J2 = 1.5 Hz, J3 = 1.4 Hz, NCH2CHCH
aHb), 5.90 (1H, ddt, J1 = 17.1 Hz, 
J2 = 10.2 Hz, J3 = 6.0 Hz, NCH2CH), 6.67 (1H, dd, J1 = 7.9 Hz, J2 = 1.9 Hz, H
5’), 6.92 (1H, d, 
J = 1.9 Hz, H7’), 7.02 (1H, d, J = 7.9 Hz, H4’). 13C-NMR (100.6 MHz, CDCl3): δ = 18.1 (C
4), 
28.0 (C3’), 32.8 (C3), 49.5 (C5), 51.8 (NCH2CH), 53.5 (C
2’), 100.5 (C7’), 109.4 (C5’), 117.4 
(NCH2CHCH2), 124.1 (C
4’), 126.9 (C3a’), 133.9 (NCH2CH), 139.0 (C
6’), 152.7 (C7a’), 174.0 
(C2). MS (ESI): m/z (%) = 243.1 ([M+H]+, 100). MW = 242.32. 
1.2.8.4. Synthesis of amide 127 
Amide 127 was synthesized from aryl bromide 167 (5.40 g, 26.7 mmol, 1 equiv) and 
pyrrolidin-2-one (39) (2.44 mL, 32.1 mmol, 1.2 equiv). Evaporation in vacuo afforded 
amide 127 (5.25 g, 95%) as yellow-orange fibers. 
1-(4-Nitrophenyl)pyrrolidin-2-one (127)118  
Yield = 95%. Yellow-orange fibers. 1H-NMR (400 MHz, CDCl3): δ = 2.18–2.29 
(2H, m, H4), 2.68 (2H, t, J = 8.1 Hz, H3), 3.93 (2H, t, J = 7.1 Hz, H5), 7.81–7.88 
(2H, m, H2’, H6’), 8.21–8.28 (2H, m, H3’, H5’). MW = 206.20. 
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1.2.9. Synthesis of amide 192 
In a flame-dried bulb of 50 mL, 1.29 g of (±)-pyroglutamic acid (191) (10.0 mmol, 1 equiv) 
was dissolved in 25 mL of allyl alcohol. The reaction mixture was cooled to 0 °C and 
0.871 mL of SOCl2 (12.0 mmol, 1.2 equiv) was added dropwise. The mixture was stirred for 
17 hours at room temperature under a nitrogen atmosphere, after which it was diluted with 
50 mL of ethyl acetate and stirred for 15 minutes in the presence of 10.0 g of K2CO3. Then, 
the solids were filtered off on a sintered-glass Büchner funnel and the filter cake was rinsed 
with ethyl acetate until the filtrate turned colorless. Evaporation of the filtrate in vacuo 
resulted in amide 192 (1.64 g, 97%) as an off-white powder. 
(±)-Allyl 5-oxopyrrolidine-2-carboxylate (192)119 
Yield = 97%. Off-white powder. 1H-NMR (400 MHz, CDCl3): δ = 2.20–
2.56 (4H, m, H3, H4), 4.25–4.31 (1H, m, H2), 4.66 (2H, ddd, J1 = 5.9 Hz, 
J2 = 1.4 Hz, J3 = 1.3 Hz, OCH2), 5.29 (1H, dq, J1 = 10.4 Hz, J2 = 1.3 Hz, 
OCH2CHCH
aHb), 5.35 (1H, dtd, J1 = 17.2 Hz, J2 = 1.4 Hz, J3 = 1.3 Hz, OCH2CHCH
aHb), 5.92 
(1H, ddt, J1 = 17.2 Hz, J2 = 10.4 Hz, J3 = 5.9 Hz, OCH2CH), 6.27 (1H, br. s, NH). 
MW = 169.18. 
1.2.10. Synthesis of amide 195 
In a bulb of 10 mL, containing 4 mL of dry acetonitrile, 0.258 g of (±)-pyroglutamic acid (191) 
(2.00 mmol, 1 equiv) and 0.598 mL of 1,8-diazabicyclo[5.4.0]-undec-7-ene (4.00 mmol, 
2 equiv) were brought together. After 10 minutes and 20 minutes, 0.139 g of di-μ-hydroxo-
bis[(N,N,N′,N′-tetramethylethylene-diamine)copper(II)] chloride (0.300 mmol, 0.15 equiv) and 
0.366 g of phenylboronic acid (194) (3.00 mmol, 1.5 equiv) were added, respectively, and the 
reaction mixture was stirred at room temperature for 48 hours. Afterwards, the solvent was 
evaporated in vacuo and the residue was dissolved in 30 mL of saturated aqueous NH4Cl 
and washed with ethyl acetate (3× 20 mL). The aqueous layer was acidified with 3-M 
aqueous HCl and extracted with ethyl acetate (3× 50 mL). The combined organic extracts 
were washed with brine (2× 25 mL) and dried over magnesium sulfate. Evaporation in vacuo 
afforded amide 195 (0.349 g, 85%) as an off-white powder. 
(±)-5-Oxo-1-phenylpyrrolidine-2-carboxylic acid (195)120  
Yield = 85%. Off-white powder (m.p. 170 °C). 1H-NMR (400 MHz, CDCl3): 
δ = 2.19–2.31 (1H, m, H3a), 2.47–2.65 (2H, m, H3b, H4a), 2.68–2.82 (1H, m, 
H4b), 4.70–4.77 (1H, m, H2), 7.17–7.23 (1H, m, H4’), 7.32–7.40 (2H, m, H3’, 
H5’), 7.43–7.48 (2H, m, H2’, H6’), 9.86 (1H, br. s, OH). 13C-NMR (100.6 MHz, 
CDCl3): δ = 23.3 (C
3), 30.7 (C4), 61.5 (C2), 122.0 (C2’, C6’), 125.9 (C4’), 129.1 
(C3’, C5’), 137.8 (C1’), 174.8, 175.9 (C5, C(O)OH). IR (ATR, cm-1): νmax = 756, 
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1231, 1499, 1587, 1630 (C=O), 1738 (C=O). MS (ESI): m/z (%) = 206.1 ([M+H]+, 100). 
HRMS (ESI): calculated for C11H12NO3 ([M+H]
+) 206.0812; found 206.0806. MW = 205.21. 
1.2.11. Synthesis of amide 193 
In a flame-dried bulb of 100 mL, 3.26 g of amide 195 (15.9 mmol, 1 equiv) was dissolved in 
40 mL of allyl alcohol. The reaction mixture was cooled to 0 °C and 1.38 mL of SOCl2 
(19.1 mmol, 1.2 equiv) was added dropwise. The mixture was stirred for 9 hours at room 
temperature under a nitrogen atmosphere. Next, a second portion of SOCl2 (1.38 mL, 
19.1 mmol, 1.2 equiv) was added and the mixture was stirred for another 15 hours at room 
temperature, after which the solvent was evaporated in vacuo. The residue was dissolved in 
170 mL of ethyl acetate, washed with saturated aqueous NaHCO3 (3× 80 mL) and water 
(80 mL), and dried over magnesium sulfate. Evaporation of the organic layer resulted in an 
orange oil (5.40 g) which was dissolved in dichloromethane and coated under reduced 
pressure onto silica. Subsequently, purification was performed via automated flash 
chromatography with hexane/ethyl acetate as eluent on a Reveleris® 40-g silica cartridge 
(10% (m/m) sample loading; flow rate: 40 mL min-1; eluent: 2 CV of 12% (v/v) ethyl acetate, 
followed by a gradient from 12% (v/v) to 60% (v/v) ethyl acetate over 14 CV; detection 
wavelengths: 238 nm and 292 nm). Evaporation afforded amide 193 (3.61 g, 93%) as an 
orange oil. 
(±)-Allyl 5-oxo-1-phenylpyrrolidine-2-carboxylate (193) 
Yield = 93%. Orange oil. Rf = 0.30 (hexane/ethyl acetate, 1:1). 
1H-NMR 
(400 MHz, CDCl3): δ = 2.14–2.27 (1H, m, H
3a), 2.45–2.65 (2H, m, H3b, 
H4a), 2.68–2.83 (1H, m, H4b), 4.56–4.66 (2H, m, OCH2), 4.72–4.81 (1H, 
m, H2), 5.19–5.25 (1H, m, OCH2CHCH
aHb), 5.19–5.28 (1H, m, 
OCH2CHCH
aHb), 5.82 (1H, ddt, J1 = 16.7 Hz, J2 = 11.0 Hz, J3 = 5.9 Hz, 
OCH2CH), 7.15–7.22 (1H, m, H
4’), 7.32–7.40 (2H, m, H3’, H5’), 7.43–7.50 
(2H, m, H2’, H6’). 13C-NMR (100.6 MHz, CDCl3): δ = 23.3 (C
3), 30.8 (C4), 61.8 (C2), 66.1 
(OCH2), 119.2 (OCH2CHCH2), 121.9 (C
2’, C6’), 125.7 (C4’), 129.1 (C3’, C5’), 131.1 (OCH2CH), 
138.1 (C1’), 171.5 (C(O)O), 174.2 (C5). IR (ATR, cm-1): νmax = 1186, 1387, 1501, 1707 (C=O), 
1744 (C=O). MS (ESI): m/z (%) = 245.8 ([M+H]+, 100). HRMS (ESI): calculated for 
C14H16NO3 ([M+H]
+) 246.1125; found 246.1117. MW = 245.27. 
1.2.12. Synthesis of amide 199 
In a bulb of 250 mL, 3.23 g of amide 193 (13.2 mmol, 1 equiv) was dissolved in ethanol. The 
reaction mixture was cooled to 0 °C and 0.598 g of NaBH4 (15.8 mmol, 1.2 equiv) was 
added, after which the mixture was stirred for 4 hours at room temperature. Next, a second 
and third portion of NaBH4 (0.598 g, 15.8 mmol, 1.2 equiv) were added after 4 hours and 
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8 hours, respectively. After a total reaction time of 10 hours, the reaction mixture was cooled 
to 0 °C, quenched with 50 mL of 2-M aqueous HCl and extracted with dichloromethane 
(150 mL, 150 mL and 50 mL). The combined organic layers were washed with 150 mL of 
brine and dried over magnesium sulfate. Evaporation in vacuo afforded amide 199 (2.35 g, 
93%) as an off-white powder. 
(±)-5-(Hydroxymethyl)-1-phenylpyrrolidin-2-one (199)121  
Yield = 93%. Off-white powder. 1H-NMR (400 MHz, CDCl3): δ = 1.71 (1H, dd, 
J1 = 5.9 Hz, J2 = 5.1 Hz, OH), 2.09–2.22 (1H, m, H
4a), 2.23–2.36 (1H, m, H4b), 
2.53 (1H, ddd, J1 = 17.2 Hz, J2 = 10.1 Hz, J3 = 5.7 Hz, H
3a), 2.71 (1H, ddd, 
J1 = 17.2 Hz, J2 = 10.0 Hz, J3 = 7.3 Hz, H
3b), 3.60 (1H, ddd, J1 = 11.4 Hz, 
J2 = 5.9 Hz, J3 = 2.7 Hz, CH
aHbOH), 3.70 (1H, ddd, J1 = 11.4 Hz, J2 = 5.1 Hz, 
J3 = 4.6 Hz, CH
aHbOH), 4.24–4.33 (1H, m, H5), 7.17–7.27 (1H, m, H4’), 7.35–
7.43 (4H, m, H2’, H3’, H5’, H6’). MW = 191.23. 
1.2.13. Synthesis of amide 198 
In a flame-dried bulb of 25 mL, 0.805 g of amide 199 (4.21 mmol, 1 equiv) was dissolved in 
12 mL of dry tetrahydrofuran/N,N-dimethylformamide (2:1). The reaction mixture was cooled 
to 0 °C, after which 0.152 g of NaH (6.32 mmol, 1.5 equiv) was added. The reaction mixture 
was stirred for 30 minutes at 0 °C under a nitrogen atmosphere. Then, 0.728 mL of allyl 
bromide (8.42 mmol, 2 equiv) was added and the mixture was stirred for 1 hour at room 
temperature. Afterwards, the mixture was diluted with 120 mL of ethyl acetate, washed with 
brine (3× 40 mL) and water (3× 40 mL), and the organic layer was dried over magnesium 
sulfate. Evaporation in vacuo afforded amide 198 (0.897 g, 92%) as a yellow oil. 
(±)-5-(Allyloxymethyl)-1-phenylpyrrolidin-2-one (198) 
Yield = 92%. Yellow oil. Rf = 0.19 (hexane/ethyl acetate, 1:1). 
1H-NMR 
(400 MHz, CDCl3): δ = 2.09–2.20 (1H, m, H
4a), 2.32 (1H, ddt, 
J1 = 12.8 Hz, J2 = 10.0 Hz, J3 = 8.3 Hz, H
4b), 2.51 (1H, ddd, J1 = 17.1 Hz, 
J2 = 10.0 Hz, J3 = 4.6 Hz, H
3a), 2.72 (1H, ddd, J1 = 17.1 Hz, J2 = 9.8 Hz, 
J3 = 8.3 Hz, H
3b), 3.40 (1H, dd, J1 = 9.8 Hz, J2 = 5.0 Hz, NCHCH
aHbO), 
3.46 (1H, dd, J1 = 9.8 Hz, J2 = 3.1 Hz, NCHCH
aHbO), 3.88 (2H, ddd, 
J1 = 5.4 Hz, J2 = 1.5 Hz, J3 = 1.3 Hz, NCHCH
aHbOCH2), 4.32 (1H, dddd, J1 = 8.3 Hz, 
J2 = 5.0 Hz, J3 = 3.3 Hz, J4 = 3.1 Hz, H
5), 5.13 (1H, ddt, J1 = 10.6 Hz, J2 = 1.5 Hz, J3 = 1.3 Hz, 
NCHCHaHbOCH2CHCH
aHb), 5.18 (1H, dq, J1 = 17.2 Hz, J2 = 1.5 Hz, 
NCHCHaHbOCH2CHCH
aHb), 5.79 (1H, ddt, J1 = 17.2 Hz, J2 = 10.6 Hz, J3 = 5.4 Hz, 
NCHCHaHbOCH2CH), 7.21 (1H, tt, J1 = 6.5 Hz, J2 = 2.1 Hz, H
4’), 7.35–7.44 (4H, m, H2’, H3’, 
H5’, H6’). 13C-NMR (100.6 MHz, CDCl3): δ = 22.0 (C
4), 31.4 (C3), 59.9 (C5), 70.0 (NCHCH2O), 
72.2 (NCHCH2OCH2), 117.1 (NCHCH2OCH2CHCH2), 124.3 (C
2’, C6’), 126.0 (C4’), 129.1 (C3’, 
C5’), 134.3 (NCHCH2OCH2CH), 137.7 (C
1’), 174.9 (C2). IR (ATR, cm-1): νmax = 1294, 1398, 
1499, 1597, 1697 (C=O). MS (ESI): m/z (%) = 232.0 ([M+H]+, 55). MW = 231.30. 
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1.2.14. Synthesis of amine 20 
The preparation of amine 20 was adopted from Lawson et al.82 
To a solution of 30.5 g of 2-amino-5-methylbenzoic acid (184 mmol, 1 equiv) in 500 mL of 
methanol, 30 mL of concentrated H2SO4 was added and the resulting mixture was stirred at 
reflux temperature for 3 days. After cooling to room temperature, the solvent was removed in 
vacuo. The yellow residue was taken up in 250 mL of ethyl acetate and washed 
subsequently with an equal volume of 1-M aqueous NaOH. The organic layer was dried over 
magnesium sulfate and evaporated in vacuo to afford amine 20 (31.0 g, quant.) as a beige-
orange powder. 
Methyl 2-amino-5-methylbenzoate (20)122,123 
Yield = quant. Beige-orange powder. 1H-NMR (400 MHz, CDCl3): δ = 2.22 
(3H, s, CH3), 3.85 (3H, s, OCH3), 5.53 (2H, br. s, NH2), 6.59 (1H, d, 
J = 8.3 Hz, H3), 7.09 (1H, dd, J1 = 8.3 Hz, J2 = 2.2 Hz, H
4), 7.66 (1H, d, 
J = 2.2 Hz, H6). MW = 165.19. 
1.2.15. Synthesis of amine 175 
To a solution of 1.98 g of 3-amino-2-naphthoic acid (174) (10.6 mmol, 1 equiv) in 30 mL of 
methanol, 1.73 mL of concentrated H2SO4 (31.8 mmol, 3 equiv) was added and the resulting 
mixture was stirred at reflux temperature for 24 hours. Next, a second portion of H2SO4 
(1.73 mL, 31.8 mmol, 3 equiv) was added and the mixture was stirred for another 24 hours. 
After cooling to room temperature, the solvent was removed in vacuo. The yellow residue 
was taken up in 80 mL of ethyl acetate and washed subsequently with 40 mL of 3-M 
aqueous NaOH. The organic layer was dried over magnesium sulfate and evaporated in 
vacuo to afford amine 175 (2.05 g, 96%) as a yellow powder. 
Methyl 3-amino-2-naphthoate (175)124,125  
Yield = 96%. Yellow powder. 1H-NMR (400 MHz, CDCl3): δ = 3.95 (3H, s, 
OCH3), 5.57 (2H, br. s, NH2), 6.97 (1H, s, H
4), 7.15–7.22 (1H, m, H7), 7.36–
7.43 (1H, m, H6), 7.53 (1H, d, J = 8.3 Hz, H5), 7.71 (1H, d, J = 8.2 Hz, H8), 
8.50 (1H, s, H1). MW = 201.23. 
1.2.16. Synthesis of methyl 5-methyl-2,4-dinitrobenzoate (178) 
The synthesis was based on a procedure of Wang et al.126  
A solution of 24.7 g of methyl 3-methyl-4-nitrobenzoate (177) (127 mmol, 1 equiv) in 117 mL 
of concentrated H2SO4 (2.15 mol, 17 equiv) was cooled to −15 °C and 23.5 mL of fuming 
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HNO3 (506 mmol, 4 equiv) was added dropwise over 2 hours. The resulting mixture was 
stirred at −20 °C for 20 hours and poured into 1500 mL of crushed ice. The suspension was 
extracted with ethyl acetate (3× 1000 mL) and the combined organic layers were washed 
with 530 mL of 1-M aqueous NaOH (until pH 7 was reached). The organic layer was dried 
over magnesium sulfate and evaporated in vacuo to afford yellow crystals (29.4 g, 97%) 
containing 85% (m/m) of methyl 5-methyl-2,4-dinitrobenzoate (178) and 15% (m/m) of methyl 
3-methyl-2,4-dinitrobenzoate. Portions of 9.80 g of the crystals were redissolved in 235 mL of 
boiling 2-propanol and left untouched for 75 minutes at room temperature. After 25 minutes 
needles had formed which were filtered off after an additional 50 minutes. This afforded off-
white crystals (20.1 g, 66%) containing 92% (m/m) of methyl 5-methyl-2,4-dinitrobenzoate 
178 and 8% (m/m) of methyl 3-methyl-2,4-dinitrobenzoate. Again, portions of 6.68 g of these 
crystals were redissolved in 220 mL of boiling 2-propanol and left untouched for 1.5 hours at 
room temperature. After 40 minutes needles had formed, which were filtered off after an 
additional 50 minutes. This afforded pure methyl 5-methyl-2,4-dinitrobenzoate (178) (16.7 g, 
55%) as off-white needles. 
Methyl 5-methyl-2,4-dinitrobenzoate (178)126,127 
Yield = 55%. Off-white needles (from isopropanol, m.p. 109 °C). 1H-NMR 
(400 MHz, CDCl3): δ = 2.74 (3H, s, CH3), 3.97 (3H, s, OCH3), 7.71 (1H, s, H
6), 
8.60 (1H, s, H3). 13C-NMR (100.6 MHz, CDCl3): δ = 20.5 (CH3), 53.8 (OCH3), 
120.9 (C3), 131.4 (C1), 134.2 (C6), 139.7 (C5), 145.6 (C2), 149.4 (C4), 164.5 
(C=O). IR (ATR, cm-1): νmax = 1277, 1356 (NO2), 1373 (NO2), 1533 (NO2), 
1721 (C=O). MW = 240.17. 
1.2.17. Synthesis of indole 181 
The preparation was based on a procedure of Showalter et al.101  
A flame-dried bulb of 500 mL, kept under a nitrogen atmosphere, was loaded with 150 mL of 
dry 1,4-dioxane and 8.64 g of methyl 5-methyl-2,4-dinitrobenzoate (178) (36.0 mmol, 
1 equiv). Next, 5.74 mL of 1,1-dimethoxy-N,N-dimethylmethylamine (179) (43.2 mmol, 
1.2 equiv) was added and the resulting mixture was stirred at reflux temperature for 4 hours. 
Then, a second portion of 1,1-dimethoxy-N,N-dimethylmethylamine (179) (1.43 mL, 
10.8 mmol, 0.3 equiv) was added and the reaction mixture was refluxed for another 16 hours. 
After cooling to room temperature, the dark-red solution, containing intermediate 180 as the 
only product, was transferred to a bulb of 1000 mL and diluted with 60 mL of methanol. 
Afterwards, 2.66 g of 10% (m/m) Pd/C was added and the mixture was hydrogenated at 
1 bar, using balloons filled with H2 gas, for 16 hours at room temperature. Next, the solids 
were filtered off over celite and the filter cake was rinsed with 275 mL of tetrahydrofuran. 
Evaporation of the filtrate in vacuo afforded a dark-red oil (7.45 g) which was dissolved in 
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tetrahydrofuran and coated under reduced pressure onto silica. Subsequently, purification 
was performed via automated flash chromatography with hexane/ethyl acetate as eluent on a 
Reveleris® 80-g silica cartridge (9% (m/m) sample loading; flow rate: 60 mL min-1; eluent: 
2 CV of 10% (v/v) ethyl acetate, followed by a gradient from 10% (v/v) to 70% (v/v) ethyl 
acetate over 20 CV; detection wavelength: 242 nm). Evaporation afforded compound 181 
(5.56 g, 81%) as a beige powder. 
Methyl 6-amino-1H-indole-5-carboxylate (181)126 
Yield = 81%. Beige powder (m.p. 171 °C). 1H-NMR (400 MHz, CDCl3): 
δ = 3.89 (3H, s, OCH3), 5.46 (2H, br. s, NH2), 6.40–6.46 (1H, m, H
3), 6.59 (1H, 
s, H7), 6.98–7.04 (1H, m, H2), 7.84 (1H, br. s, NH), 8.24 (1H, s, H4). 13C-NMR 
(100.6 MHz, CDCl3): δ = 51.4 (OCH3), 96.0 (C
7), 103.6 (C3), 107.6 (C5), 120.6 
(C3a), 123.9 (C2), 124.9 (C4), 140.6 (C7a), 146.5 (C6), 169.2 (C=O). IR (ATR, 
cm-1): νmax = 789, 1069, 1167, 1244, 1283, 1676 (C=O), 3339 (NH2), 3455 (NH2). MS (ESI): 
m/z (%) = 191.0 ([M+H]+, 100). MW = 190.20. 
1.2.18. Synthesis of indole 182 
Indole 182 was synthesized based on a procedure published by Myochin et al.115  
In a flame-dried bulb of 1000 mL, 13.6 g of compound 181 (71.7 mmol, 1 equiv) was 
dissolved in 375 mL of dry N,N-dimethylformamide. The reaction mixture was cooled to 0 °C, 
after which 1.81 g of NaH (75.3 mmol, 1.05 equiv) was added. The reaction mixture was 
stirred for 30 minutes at 0 °C under a nitrogen atmosphere. Then, 6.20 mL of allyl bromide 
(71.7 mmol, 1 equiv) was added and the mixture was stirred for 30 minutes at 0 °C. 
Afterwards, the mixture was diluted with 1700 mL of ethyl acetate, washed with brine (3× 
550 mL) and water (3× 550 mL), and the organic layer was dried over magnesium sulfate. 
Evaporation in vacuo afforded a dark-red oil (21.0 g) of which 5.25 g was dissolved in 
acetonitrile and coated under reduced pressure onto 10.5 g of Davisil® C18 silica. 
Subsequently, purification was performed via automated flash chromatography with 
water/acetonitrile as eluent on a Reveleris® 120-g C18 cartridge (4% (m/m) sample loading; 
flow rate: 80 mL min-1; eluent: 2 CV of 30% (v/v) acetonitrile, followed by a gradient from 30% 
(v/v) to 50% (v/v) acetonitrile over 30 CV; detection wavelength: 244 nm). The same 
conditions were repeated another 3 times to purify the remaining parts of the crude mixture. 
Evaporation afforded indole 182 (11.8 g, 71%) as a yellow powder. 
Methyl 1-allyl-6-amino-1H-indole-5-carboxylate (182) 
Yield = 71%. Yellow powder (m.p. 76 °C). 1H-NMR (400 MHz, CDCl3): 
δ = 3.89 (3H, s, OCH3), 4.57 (2H, dt, J1 = 5.2 Hz, J2 = 1.5 Hz, NCH2), 5.02–
5.11 (1H, m, NCH2CHCH
aHb), 5.17–5.23 (1H, m, NCH2CHCH
aHb), 5.55 (2H, 
br. s, NH2), 5.95 (1H, ddt, J1 = 17.0 Hz, J2 = 10.5 Hz, J3 = 5.2 Hz, NCH2CH), 
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6.40 (1H, d, J = 3.3 Hz, H3), 6.48 (1H, s, H7), 6.90 (1H, d, J = 3.3 Hz, H2), 8.22 (1H, s, H4). 
13C-NMR (100.6 MHz, CDCl3): δ = 48.7 (NCH2), 51.4 (OCH3), 94.6 (C
7), 102.6 (C3), 107.2 
(C5), 117.4 (NCH2CHCH2), 121.3 (C
3a), 125.1 (C4), 127.9 (C2), 133.0 (NCH2CH), 140.8 (C
7a), 
146.2 (C6), 169.3 (C=O). IR (ATR, cm-1): νmax = 1173, 1254, 1287, 1630, 1684 (C=O), 3370 
(NH2), 3474 (NH2). MS (ESI): m/z (%) = 231.0 ([M+H]
+, 100). MW = 230.27. 
1.2.19. Synthesis of amine 183 
Reduction of indole 182 to indoline 183 was based on a procedure of Myochin et al.115  
In a bulb of 250 mL, 11.8 g of indole 182 (51.0 mmol, 1 equiv) was dissolved in 70 mL of 
glacial acetic acid. The reaction mixture was cooled to 0 °C, after which 3.37 g of NaCNBH3 
(53.6 mmol, 1.05 equiv) was added and the mixture was stirred for 4 hours at room 
temperature. Afterwards, the mixture was quenched with 300 mL of 3-M aqueous NaOH 
(until pH 7 was reached) and extracted with diethyl ether (600 mL, 200 mL and 200 mL). The 
organic layer was washed with 1-M aqueous NaOH (3× 300 mL), brine (300 mL) and water 
(300 mL), and the organic layer was dried over magnesium sulfate. Evaporation in vacuo 
afforded amine 183 (10.9 g, 92%) as an off-white powder. 
Methyl 1-allyl-6-aminoindoline-5-carboxylate (183) 
Yield = 92%. Off-white powder (m.p. 74 °C). 1H-NMR (400 MHz, CDCl3): 
δ = 2.88 (2H, t, J = 8.2 Hz, H3), 3.45 (2H, t, J = 8.2 Hz, H2), 3.71–3.75 (2H, m, 
NCH2CHCH
aHb), 3.79 (3H, s, OCH3), 5.16–5.23 (1H, m, NCH2CHCH
aHb), 
5.19–5.27 (1H, m, NCH2CHCH
aHb), 5.61 (1H, s, H7), 5.70 (2H, br. s, NH2), 
5.76–5.88 (1H, m, NCH2CHCH
aHb), 7.49 (1H, s, H4). 13C-NMR (100.6 MHz, 
CDCl3): δ = 26.7 (C
3), 50.0 (NCH2), 50.8 (OCH3), 52.4 (C
2), 92.1 (C7), 99.7 
(C5), 117.4 (NCH2CHCH2), 119.5 (C
3a), 126.0 (C4), 132.9 (NCH2CH), 152.7 (C
6), 156.3 (C7a), 
168.6 (C=O). IR (ATR, cm-1): νmax = 1236, 1296, 1597, 1632, 1639 (C=O), 3348 (NH2), 3453 
(NH2). MS (ESI): m/z (%) = 233.0 ([M+H]
+, 100). MW = 232.28. 
1.2.20. General procedure for the synthesis of amidines from amides and amines 
A flame-dried bulb of 250 mL, kept under a nitrogen atmosphere, was loaded with 120 mL of 
dry dichloromethane and amide (43.9 mmol, 1 equiv). Next, 8.18 mL of POCl3 (87.7 mmol, 
2 equiv) was added and the resulting mixture was stirred at room temperature for 24 hours. 
Afterwards, a solution of amine (46.0 mmol, 1.05 equiv) in dry dichloromethane (45 mL) was 
added via cannula and the reaction mixture was heated to 35 °C for 1–4 days. Then, the 
reaction mixture was cooled to 0 °C, basified with 3-M aqueous NaOH until the pH equaled 
10 and subsequently extracted with ethyl acetate (450 mL and 150 mL). The combined 
organic layers were washed with 300 mL of brine, dried over magnesium sulfate and 
evaporated in vacuo. 
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1.2.20.1. Synthesis of amidine 21 
Amidine 21 was synthesized from amide 19 (2.42 g, 15.0 mmol, 1 equiv) and amine 20 
(2.60 g, 15.8 mmol, 1.05 equiv). Evaporation in vacuo afforded an orange-brown oil (5.71 g) 
which was dissolved in acetonitrile/dichloromethane (1:1) and coated under reduced 
pressure onto 11.4 g of Davisil® C18 silica. Subsequently, purification was performed via 
automated flash chromatography with water/acetonitrile as eluent on a Reveleris® 120-g C18 
cartridge (5% (m/m) sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 30% (v/v) 
acetonitrile, followed by a gradient from 30% (v/v) to 100% (v/v) acetonitrile over 20 CV and 
finally 2 CV of 100% (v/v) acetonitrile; detection wavelengths: 218 nm and 246 nm). 
Evaporation afforded amidine 21 (3.90 g, 78%) as an off-white powder.  
Methyl 5-methyl-2-((1-phenylpyrrolidin-2-ylidene)amino)benzoate (21)50 
Yield = 78%. Off-white powder. 1H-NMR (400 MHz, CDCl3): δ = 1.98–
2.09 (2H, m, H4’), 2.31 (3H, s, CH3), 2.46 (2H, t, J = 7.8 Hz, H
3’), 3.81 
(3H, s, OCH3), 3.87 (2H, t, J = 6.9 Hz, H
5’), 6.71 (1H, d, J = 8.1 Hz, H3), 
7.02–7.08 (1H, m, H4”), 7.15–7.21 (1H, m, H4), 7.31–7.38 (2H, m, H3”, 
H5”), 7.65 (1H, d, J = 1.8 Hz, H6), 7.79–7.84 (2H, m, H2”, H6”). 
MW = 308.37. 
1.2.20.2. Synthesis of amidine 109 
Amidine 109 was synthesized from amide 106 (20.8 g, 112 mmol, 1 equiv) and amine 20 
(19.4 g, 117 mmol, 1.05 equiv). Evaporation in vacuo afforded a red-brown oil (38.8 g) of 
which 6.47 g was dissolved in acetonitrile/dichloromethane (1:1) and coated under reduced 
pressure onto 12.9 g of Davisil® C18 silica. Subsequently, purification was performed via 
automated flash chromatography with water/acetonitrile as eluent on a Reveleris® 120-g C18 
cartridge (5% (m/m) sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 30% (v/v) 
acetonitrile, followed by a gradient from 30% (v/v) to 100% (v/v) acetonitrile over 20 CV and 
finally 2 CV of 100% (v/v) acetonitrile; detection wavelengths: 216 nm and 274 nm). Next, the 
same conditions were repeated another 5 times to purify the remaining parts of the crude 
mixture. Evaporation yielded amidine 109 (11.2 g, 30%) as an off-white powder.  
Methyl 2-((1-(3-cyanophenyl)pyrrolidin-2-ylidene)amino)-5-methylbenzoate (109) 
Yield = 30%. Off-white powder (m.p. 116 °C). Rf = 0.32 
(hexane/ethyl acetate/triethylamine, 7:3:0.5). 1H-NMR (400 MHz, 
CDCl3): δ = 2.03–2.13 (2H, m, H
4’), 2.33 (3H, s, CH3), 2.49 (2H, t, 
J = 7.8 Hz, H3’), 3.82 (3H, s, OCH3), 3.86 (2H, t, J = 6.9 Hz, H
5’), 6.69 
(1H, d, J = 8.1 Hz, H3), 7.21 (1H, dd, J1 = 8.1 Hz, J2 = 1.6 Hz, H
4), 
7.31 (1H, ddd, J1 = 7.8 Hz, J2 = 1.3 Hz, J3 = 1.1 Hz, H
4”), 7.42 (1H, 
dd, J1 = 8.0 Hz, J2 = 7.8 Hz, H
5”), 7.69 (1H, d, J = 1.6 Hz, H6), 8.08–8.17 (1H, m, H6”), 8.21 
(1H, dd, J1 = 1.6 Hz, J2 = 1.3 Hz, H





3’), 50.2 (C5’), 51.8 (OCH3), 112.4 (C
3”), 119.2 (CN), 121.2 (C1), 122.5 (C3), 
123.0 (C2”), 124.0 (C6”), 125.9 (C4”), 129.4 (C5”), 131.2 (C6), 131.6 (C5), 133.7 (C4), 142.2 
(C1”), 149.8 (C2), 159.8 (C2’), 167.4 (C=O). IR (ATR, cm-1): νmax = 1204, 1396, 1483, 1663 
(C=N), 1717 (C=O), 2228 (CN). MS (ESI): m/z (%) = 333.6 ([M+H]+, 100). HRMS (ESI): 
calculcated for C20H20N3O2 ([M+H]
+) 334.1550; found 334.1543. MW = 333.38.  
1.2.20.3. Synthesis of amidine 113 
Amidine 113 was synthesized from amide 104 (26.5 g, 122 mmol, 1 equiv) and amine 20 
(21.1 g, 128 mmol, 1.05 equiv). Evaporation in vacuo afforded an orange-brown oil (42.9 g) 
of which 14.3 g was dissolved in dichloromethane and coated under reduced pressure onto 
28.6 g of silica. Subsequently, purification was performed via automated flash 
chromatography with hexane/ethyl acetate/triethylamine as eluent on a Reveleris® 120-g 
silica cartridge (12% (m/m) sample loading; flow rate: 80 mL min-1; eluent: 2 CV of a 7% (v/v) 
ethyl acetate/triethylamine mixture (ethyl acetate + 16% (v/v) triethylamine), followed by a 
gradient from 7% (v/v) to 60% (v/v) ethyl acetate/triethylamine mixture over 10 CV; detection 
wavelengths: 246 nm and 298 nm). Next, the same conditions were repeated twice to purify 
the remaining parts of the crude mixture. Evaporation afforded amidine 113 (22.2 g, 50%) as 
a light-yellow powder.   
Methyl 2-((1-(3-allyloxyphenyl)pyrrolidin-2-ylidene)amino)-5-methylbenzoate (113) 
Yield = 50%. Light-yellow powder (m.p. 66 °C). Rf = 0.42 
(hexane/ethyl acetate/triethylamine, 7:3:0.5). 1H-NMR 
(400 MHz, CDCl3): δ = 1.98–2.07 (2H, m, H
4’), 2.32 (3H, s, CH3), 
2.46 (2H, t, J = 7.8 Hz, H3’), 3.83 (3H, s, OCH3), 3.85 (2H, t, 
J = 6.9 Hz, H5’), 4.53 (2H, ddd, J1 = 5.4 Hz, J2 = 1.5 Hz, 
J3 = 1.4 Hz, OCH2), 5.25 (1H, ddt, J1 = 10.6 Hz, J2 = 1.5 Hz, 
J3 = 1.4 Hz, OCH2CHCH
aHb), 5.39 (1H, dq, J1 = 17.2 Hz, J2 = 1.5 Hz, OCH2CHCH
aHb), 6.05 
(1H, ddt, J1 = 17.2 Hz, J2 = 10.6 Hz, J3 = 5.4 Hz, OCH2CH), 6.62 (1H, ddd, J1 = 8.1 Hz, 
J2 = 2.3 Hz, J3 = 0.8 Hz, H
4”), 6.70 (1H, d, J = 8.1 Hz, H3), 7.18 (1H, dd, J1 = 8.1 Hz, 
J2 = 1.8 Hz, H
4), 7.22 (1H, dd, J1 = 8.2 Hz, J2 = 8.1 Hz, H
5”), 7.30 (1H, ddd, J1 = 8.2 Hz, 
J2 = 2.0 Hz, J3 = 0.8 Hz, H
6”), 7.65 (1H, d, J = 1.8 Hz, H6), 7.67 (1H, dd, J1 = 2.3 Hz, 
J2 = 2.0 Hz, H
2”). 13C-NMR (100.6 MHz, CDCl3): δ = 19.7 (C
4’), 20.6 (CH3), 29.2 (C
3’), 50.7 
(C5’), 51.7 (OCH3), 68.8 (OCH2), 107.3 (C
2”), 109.4 (C4”), 112.6 (C6”), 117.7 (OCH2CHCH2), 
121.9 (C1), 122.9 (C3), 129.2 (C5”), 131.0 (C5, C6), 133.5 (OCH2CH), 133.5 (C
4), 142.7 (C1”), 
150.6 (C2), 158.8 (C3”), 159.7 (C2’), 167.8 (C=O). IR (ATR, cm-1): νmax = 1184, 1219, 1396, 
1593, 1649 (C=N), 1717 (C=O). MS (ESI): m/z (%) = 364.6 ([M+H]+, 100). HRMS (ESI): 
calculated for C22H25N2O3 ([M+H]
+) 365.1860; found 365.1848. MW = 364.44. 
1.2.20.4. Synthesis of amidine 146 
Amidine 146 was synthesized from amide 145 (3.80 g, 18.0 mmol, 1 equiv) and amine 20 
(3.12 g, 18.9 mmol, 1.05 equiv). Evaporation in vacuo afforded an orange-brown oil (8.54 g) 
EXPERIMENTAL PROCEDURES 
135 
which was dissolved in acetonitrile/dichloromethane (1:1) and coated under reduced 
pressure onto 17.1 g of Davisil® C18 silica. Subsequently, purification was performed via 
automated flash chromatography with water/acetonitrile as eluent on a Reveleris® 120-g C18 
cartridge (7% (m/m) sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 30% (v/v) 
acetonitrile, followed by a gradient from 30% (v/v) to 80% (v/v) acetonitrile over 20 CV and 
finally 2 CV of 80% (v/v) acetonitrile; detection wavelength: 216 nm and 244 nm). 
Evaporation afforded amidine 146 (3.12 g, 48%) as an off-white powder. 
Methyl 5-methyl-2-((1-(naphthalen-2-yl)pyrrolidin-2-ylidene)amino)benzoate (146) 
Yield = 48%. Off-white powder (m.p. 132 °C). 1H-NMR (400 MHz, 
CDCl3): δ = 2.04–2.15 (2H, m, H
4’), 2.33 (3H, s, CH3), 2.51 (2H, t, 
J = 7.8 Hz, H3’), 3.84 (3H, s, OCH3), 3.99 (2H, t, J = 6.9 Hz, H
5’), 
6.74 (1H, d, J = 8.1 Hz, H3), 7.19 (1H, dd, J1 = 8.1 Hz, J2 = 1.7 Hz, 
H4), 7.33–7.39 (1H, m, H6”), 7.39–7.45 (1H, m, H7”), 7.65–7.69 (1H, 
m, H6), 7.73–7.81 (2H, m, H5”, H8”), 7.80 (1H, d, J = 9.0 Hz, H4”), 
7.91 (1H, d, J = 1.8 Hz, H1”), 8.31 (1H, dd, J1 = 9.0 Hz, J2 = 1.8 Hz, 
H3”). 13C-NMR (100.6 MHz, CDCl3): δ = 19.8 (C
4’), 20.6 (CH3), 29.1 (C
3’), 50.9 (C5’), 51.8 
(OCH3), 116.4 (C
1”), 121.3 (C3”), 122.0 (C1), 123.1 (C3), 124.5 (C6”), 126.0 (C7”), 127.4, 127.5 
(C5”, C8”), 128.1 (C4”), 130.1 (C4a”), 131.1 (C5, C6), 133.5 (C4), 133.8 (C8a”), 139.4 (C2”), 150.6 
(C2), 159.9 (C2’), 167.8 (C=O). IR (ATR, cm-1): νmax = 1200, 1304, 1396, 1626, 1653 (C=N), 
1717 (C=O). MS (ESI): m/z (%) = 359.2 ([M+H]+, 100). MW = 358.44. 
1.2.20.5. Synthesis of amidine 154 
Amidine 154 was synthesized from amide 153 (9.59 g, 39.6 mmol, 1 equiv) and amine 20 
(6.54 g, 41.6 mmol, 1.05 equiv). Evaporation in vacuo afforded a dark-red oil (19.5 g) of 
which 6.50 g was dissolved in dichloromethane and coated under reduced pressure onto 
13.0 g of Davisil® C18 silica. Subsequently, purification was performed via automated flash 
chromatography with water/acetonitrile as eluent on a Reveleris® 120-g C18 cartridge (5% 
(m/m) sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 50% (v/v) acetonitrile, a 
gradient from 50% (v/v) to 60% (v/v) acetonitrile over 20 CV, a gradient from 60% (v/v) to 
100% (v/v) acetonitrile over 10 CV, and finally 2 CV of 100% (v/v) acetonitrile; detection 
wavelength: 218 nm and 314 nm). Next, the same conditions were repeated twice to purify 
the remaining parts of the crude mixture. Evaporation afforded amidine 154 (6.49 g, 42%) as 
an orange oil. 
Methyl 2-((1-(1-allylindolin-6-yl)pyrrolidin-2-ylidene)amino)-5-methylbenzoate (154) 
Yield = 42%. Orange oil. Rf = 0.22 (hexane/ethyl acetate, 1:1). 
1H-NMR (400 MHz, CDCl3): δ = 1.94–2.07 (2H, m, H
4’), 2.31 
(3H, s, CH3), 2.44 (2H, t, J = 7.8 Hz, H
3’), 2.89 (2H, t, J = 8.2 Hz, 
H3”), 3.32 (2H, t, J = 8.2 Hz, H2”), 3.70 (2H, ddd, J1 = 6.1 Hz, 
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J2 = 1.4 Hz, J3 = 1.3 Hz, NCH2CHCH
aHb), 3.81 (3H, s, OCH3), 3.82 (2H, t, J = 6.9 Hz, H
5’), 
5.15 (1H, ddt, J1 = 10.4 Hz, J2 = 1.5 Hz, J3 = 1.3 Hz, NCH2CHCH
aHb), 5.26 (1H, ddt, 
J1 = 17.0 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, NCH2CHCH
aHb), 5.90 (1H, ddt, J1 = 17.0 Hz, 
J2 = 10.4 Hz, J3 = 6.1 Hz, NCH2CHCH
aHb), 6.69 (1H, d, J = 8.1 Hz, H3), 6.88 (1H, dd, 
J1 = 7.9 Hz, J2 = 1.6 Hz, H
5”), 7.01 (1H, d, J = 7.9 Hz, H4”), 7.16 (1H, dd, J1 = 8.1 Hz, 
J2 = 2.0 Hz, H
4), 7.19 (1H, d, J = 1.6 Hz, H7”), 7.62 (1H, J = 2.0 Hz, H6). 13C-NMR 
(100.6 MHz, CDCl3): δ = 19.9 (C
4’), 20.6 (CH3), 28.1 (C
3”), 29.1 (C3’), 51.4 (C5’), 51.7 (OCH3), 
52.1 (NCH2CH), 53.6 (C
2”), 101.6 (C7”), 110.3 (C5”), 117.2 (NCH2CHCH2), 122.1 (C
1), 123.2 
(C3), 124.0 (C4”), 125.5 (C3a”), 130.7 (C5), 130.9 (C6), 133.3 (C4), 134.4 (NCH2CH), 141.1 
(C6”), 151.0 (C2), 152.5 (C7a”), 159.7 (C2’), 168.0 (C=O). IR (ATR, cm-1): νmax = 1491, 1501, 
1611, 1659 (C=N), 1722 (C=O). MS (ESI): m/z (%) = 390.2 ([M+H]+, 100). MW = 389.50. 
1.2.20.6. Synthesis of amidine 163 
Amidine 163 was synthesized from amide 161 (9.53 g, 43.9 mmol, 1 equiv) and amine 20 
(7.61 g, 46.0 mmol, 1.05 equiv). Evaporation in vacuo afforded an orange-brown oil (15.5 g) 
of which 7.75 g was dissolved in acetonitrile/dichloromethane (1:1) and coated under 
reduced pressure onto 15.5 g of Davisil® C18 silica. Subsequently, purification was 
performed via automated flash chromatography with water/acetonitrile as eluent on a 
Reveleris® 120-g C18 cartridge (6% (m/m) sample loading; flow rate: 80 mL min-1; eluent: 
2 CV of 30% (v/v) acetonitrile, followed by a gradient from 30% (v/v) to 100% (v/v) 
acetonitrile over 20 CV and finally 2 CV of 100% (v/v) acetonitrile; detection wavelength: 
214 nm). The same conditions were applied to purify the other half of the crude mixture. 
Evaporation afforded amidine 163 (12.5 g, 78%) as an orange oil. 
Methyl 2-((1-(4-allyloxyphenyl)pyrrolidin-2-ylidene)amino)-5-methylbenzoate (163) 
Yield = 78%. Orange oil. Rf = 0.38 (hexane/ethyl 
acetate/triethylamine, 7:3:0.5). 1H-NMR (400 MHz, CDCl3): δ = 1.98–
2.07 (2H, m, H4’), 2.31 (3H, s, CH3), 2.43 (2H, t, J = 7.8 Hz, H
3’), 3.82 
(3H, s, OCH3), 3.82 (2H, t, J = 6.9 Hz, H
5’), 4.51 (2H, ddd, 
J1 = 5.3 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, OCH2), 5.26 (1H, ddt, 
J1 = 10.5 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, OCH2CHCH
aHb), 5.39 (1H, dq, 
J1 = 17.2 Hz, J2 = 1.5 Hz, OCH2CHCH
aHb), 6.04 (1H, ddt, 
J1 = 17.2 Hz, J2 = 10.5 Hz, J3 = 5.3 Hz, OCH2CH), 6.70 (1H, d, 
J = 8.1 Hz, H3), 6.88–6.94 (2H, m, H3”, H5”), 7.16 (1H, dd, J1 = 8.1 Hz, J2 = 1.8 Hz, H
4), 7.63 
(1H, d, J = 1.8 Hz, H6), 7.66–7.72 (2H, m, H2”, H6”). 13C-NMR (100.6 MHz, CDCl3): δ = 19.8 
(C4’), 20.6 (CH3), 29.0 (C
3’), 51.0 (C5’), 51.7 (OCH3), 69.1 (OCH2), 114.9 (C
3”, C5”), 117.5 
(OCH2CHCH2), 122.1 (C
1), 122.2 (C2”, C6”), 123.3 (C3), 130.8 (C5), 131.0 (C6), 133.4 (C4), 
133.5 (OCH2CH), 135.0 (C
1”), 150.9 (C2), 154.6 (C4”), 159.8 (C2’), 167.9 (C=O). IR (ATR, 
cm-1): νmax = 1244, 1404, 1512, 1659 (C=N), 1722 (C=O). MS (ESI): m/z (%) = 365.3 ([M+H]
+, 
100). HRMS (ESI): calculated for C22H25N2O3 ([M+H]
+) 365.1860; found 365.1868. 
MW = 364.44. 
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1.2.20.7. Synthesis of amidine 128 
Amidine 128 was synthesized from amide 127 (3.76 g, 18.2 mmol, 1 equiv) and amine 20 
(3.01 g, 19.1 mmol, 1.05 equiv). Evaporation in vacuo afforded a dark-yellow powder (6.50 g) 
which was dissolved in dichloromethane and coated under reduced pressure onto 13.0 g of 
Davisil® C18 silica. Subsequently, purification was performed via automated flash 
chromatography with water/acetonitrile as eluent on a Reveleris® 120-g C18 cartridge (5% 
(m/m) sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 30% (v/v) acetonitrile, a 
gradient from 30% (v/v) to 80% (v/v) acetonitrile over 20 CV; detection wavelength: 214 nm 
and 324 nm). Evaporation afforded amidine 128 (1.28 g, 20%) as a yellow powder. 
Methyl 5-methyl-2-((1-(4-nitrophenyl)pyrrolidin-2-ylidene)amino)benzoate (128)52 
Yield = 20%. Yellow powder. 1H-NMR (400 MHz, CDCl3): δ = 2.06–
2.15 (2H, m, H4’), 2.34 (3H, s, CH3), 2.52 (2H, t, J = 7.9 Hz, H
3’), 3.81 
(3H, s, OCH3), 3.93 (2H, t, J = 6.9 Hz, H
5’), 6.70 (1H, d, J = 8.1 Hz, H3), 
7.24 (1H, dd, J1 = 8.1 Hz, J2 = 1.8 Hz, H
4), 7.71 (1H, d, J = 1.8 Hz, H6), 
8.03–8.08 (2H, m, H2”, H6”), 8.19–8.25 (2H, m, H3”, H5”). MW = 353.38. 
1.2.20.8. Synthesis of amidine 176 
Amidine 176 was synthesized from amide 19 (1.13 g, 7.00 mmol, 1 equiv) and amine 175 
(1.48 g, 7.35 mmol, 1.05 equiv). Evaporation in vacuo afforded an orange-brown oil (2.21 g) 
which was dissolved in dichloromethane and coated under reduced pressure onto 4.42 g of 
Davisil® C18 silica. Subsequently, purification was performed via automated flash 
chromatography with water/acetonitrile as eluent on a Reveleris® 80-g C18 cartridge (3% 
(m/m) sample loading; flow rate: 60 mL min-1; eluent: 2 CV of 40% (v/v) acetonitrile, followed 
by a gradient from 40% (v/v) to 100% (v/v) acetonitrile over 20 CV; detection wavelength: 
242 nm). Evaporation afforded amidine 176 (1.57 g, 65%) as a yellow-orange waxy oil. 
Methyl 3-((1-phenylpyrrolidin-2-ylidene)amino)-2-naphthoate (176) 
Yield = 65%. Yellow-orange waxy oil. 1H-NMR (400 MHz, CDCl3): 
δ = 2.00–2.13 (2H, m, H4’), 2.55 (2H, t, J = 7.6 Hz, H3’), 3.89 (3H, s, 
OCH3), 3.91 (2H, t, J = 7.5 Hz, H
5’), 7.07 (1H, t, J = 7.3 Hz, H4”), 7.19 
(1H, s, H4), 7.31–7.41 (3H, m, H3”, H5”, H7), 7.43–7.50 (1H, m, H6), 7.67 
(1H, d, J = 8.3 Hz, H5), 7.82 (1H, d, J = 8.3 Hz, H8), 7.85 (2H, d, 
J = 8.2 Hz, H2”, H6”), 8.38 (1H, s, H1). 13C-NMR (100.6 MHz, CDCl3): 
δ = 19.9 (C4’), 29.5 (C3’), 50.7 (C5’), 52.0 (OCH3), 118.6 (C
4), 120.4 
(C2”, C6”), 123.1 (C4”), 124.1 (C2), 124.4 (C7), 126.6 (C5), 127.9 (C6), 128.6 (C3”, C5”), 128.7 
(C8), 128.8 (C8a), 131.8 (C1), 135.9 (C4a), 141.5 (C1”), 149.0 (C3), 160.3 (C2’), 167.8 (C=O). IR 
(ATR, cm-1): νmax = 752, 1200, 1306, 1396, 1653 (C=N), 1721 (C=O). MS (ESI): m/z 
(%) = 345.0 ([M+H]+, 100). MW = 344.41. 
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1.2.20.9. Synthesis of amidine 184 
Amidine 184 was synthesized from amide 19 (6.45 g, 40.0 mmol, 1 equiv) and amine 183 
(9.76 g, 42.0 mmol, 1.05 equiv). Evaporation in vacuo afforded a dark-red oil (14.2 g) of 
which 4.74 g was dissolved in dichloromethane and coated under reduced pressure onto 
9.48 g of Davisil® C18 silica. Subsequently, purification was performed via automated flash 
chromatography with water/acetonitrile as eluent on a Reveleris® 120-g C18 cartridge (4% 
(m/m) sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 50% (v/v) acetonitrile, followed 
by a gradient from 50% (v/v) to 60% (v/v) acetonitrile over 20 CV and finally a gradient from 
60% (v/v) to 100% (v/v) acetonitrile over 10 CV; detection wavelengths: 280 nm and 
336 nm). The same conditions were repeated twice to purify the remaining parts of the crude 
mixture. Evaporation afforded amidine 184 (7.26 g, 48%) as an orange waxy oil. 
Methyl 1-allyl-6-((1-phenylpyrrolidin-2-ylidene)amino)indoline-5-carboxylate (184) 
Yield = 48%. Orange waxy oil. 1H-NMR (400 MHz, CDCl3): δ = 1.95–
2.10 (2H, m, H4’), 2.48 (2H, t, J = 7.7 Hz, H3’), 2.95 (2H, t, J = 8.3 Hz, 
H3), 3.46 (2H, t, J = 8.3 Hz, H2), 3.66–3.79 (2H, m, NCH2CHCH2), 3.75 
(3H, s, OCH3), 3.86 (2H, t, J = 6.8 Hz, H
5’), 5.11–5.22 (1H, m, 
NCH2CHCH
aHb), 5.14–5.28 (1H, m, NCH2CHCH
aHb), 5.73–5.89 (1H, 
m, NCH2CHCH2), 5.82 (1H, br. s, H
7), 7.03 (1H, t, J = 7.5 Hz, H4”), 7.34 
(2H, dd, J1 = 7.8 Hz, J2 = 7.5 Hz, H
3”, H5”), 7.63 (1H, br. s, H4), 7.83 
(2H, d, J = 7.8 Hz, H2”, H6”). 13C-NMR (100.6 MHz, CDCl3): δ = 19.7 (C
4’), 27.2 (C3), 28.8 
(C3’), 50.3 (NCH2CHCH2), 50.5 (C
5’), 51.1 (OCH3), 52.6 (C
2), 100.1 (C7), 109.3 (C5), 117.5 
(NCH2CHCH2), 120.2 (C
2”, C6”), 122.7 (C4”), 123.6 (C3a), 127.0 (C4), 128.6 (C3”, C5”), 133.1 
(NCH2CHCH2), 141.6 (C
1”), 155.6, 155.7 (C6, C7a), 159.1 (C2’), 167.4 (C=O). IR (ATR, cm-1): 
νmax = 1234, 1393, 1497, 1597, 1614, 1655 (C=N), 1703 (C=O). MS (ESI): m/z (%) = 376 
([M+H]+, 100). MW = 375.47. 
1.2.20.10. Synthesis of amidine 196 
Amidine 196 was synthesized from amide 193 (0.245 g, 1.00 mmol, 1 equiv) and amine 20 
(0.165 g, 1.05 mmol, 1.05 equiv). Evaporation in vacuo afforded an orange-brown oil 
(0.355 g) which was dissolved in acetonitrile/dichloromethane (1:1) and coated under 
reduced pressure onto 0.710 g of Davisil® C18 silica. Subsequently, purification was 
performed via automated flash chromatography with water/acetonitrile as eluent on a 
Reveleris® 12-g C18 cartridge (3% (m/m) sample loading; flow rate: 30 mL min-1; eluent: 
2 CV of 30% (v/v) acetonitrile, followed by a gradient from 30% (v/v) to 100% (v/v) 
acetonitrile over 20 CV; detection wavelength: 214 nm and 250 nm). Evaporation afforded 





Yield = 21%. Yellow oil. Rf = 0.64 (hexane/ethyl acetate, 1:1). 
1H-NMR (400 MHz, CDCl3): δ = 2.05–2.17 (1H, m, H
3a), 2.31 
(3H, s, CH3), 2.33–2.63 (3H, m, H
3b, H4), 3.84 (3H, s, OCH3), 
4.59–4.68 (2H, m, OCH2), 4.71–4.78 (1H, m, H
2), 5.20–5.27 
(1H, m, OCH2CHCH
aHb), 5.23–5.32 (1H, m, OCH2CHCH
aHb), 
5.80–5.92 (1H, m, OCH2CH), 6.73 (1H, d, J = 8.0 Hz, H
6’), 7.09 
(1H, t, J = 7.6 Hz, H4”), 7.14–7.22 (1H, m, H5’), 7.34 (2H, dd, J1 = 8.0 Hz, J2 = 7.6 Hz, H
3”, 
H5”), 7.65 (1H, br. s, H3’), 7.68 (2H, d, J = 8.0 Hz, H2”, H6”). 13C-NMR (100.6 MHz, CDCl3): 
δ = 20.6 (CH3), 25.1 (C
3), 27.3 (C4), 51.8 (OCH3), 63.6 (C
2), 65.9 (OCH2), 118.9 
(OCH2CHCH2), 121.9 (C
2’), 122.1 (C2”, C6”), 123.0 (C6’), 124.3 (C4”), 128.9 (C3”, C5”), 131.1 
(C4’), 131.3 (C3’), 131.5 (OCH2CH), 133.5 (C
5’), 140.3 (C1”), 150.1 (C1’), 160.0 (C5), 168.0 
(C(O)OMe), 172.3 (COOAllyl). MS (ESI): m/z (%) = 393.1 ([M+H]+, 100). MW = 392.46. 
1.2.20.11. Synthesis of amidine 200 
Amidine 200 was synthesized from amide 198 (0.942 g, 4.07 mmol, 1 equiv) and amine 20 
(0.673 g, 4.28 mmol, 1.05 equiv). Evaporation in vacuo afforded an orange oil (1.96 g) which 
was dissolved in dichloromethane and coated under reduced pressure onto 3.92 g of 
Davisil® C18 silica. Subsequently, purification was performed via automated flash 
chromatography with water/acetonitrile as eluent on a Reveleris® 40-g C18 cartridge (4% 
(m/m) sample loading; flow rate: 40 mL min-1; eluent: 2 CV of 40% (v/v) acetonitrile, followed 
by a gradient from 40% (v/v) to 100% (v/v) acetonitrile over 20 CV; detection wavelength: 
218 nm and 236 nm). Evaporation afforded amidine 201 (0.803 g, 52%) as a yellow oil. 
(±)-Methyl 2-((5-(allyloxymethyl)-1-phenylpyrrolidin-2-ylidene)amino)-5-methylbenzo-
ate (200) 
Yield = 52%. Yellow oil. Rf = 0.52 (hexane/ethyl acetate, 1:1). 
1H-NMR (400 MHz, CDCl3): δ = 1.99–2.11 (1H, m, H
4a’), 2.12–
2.27 (1H, m, H4b’), 2.30 (3H, s, CH3), 2.38 (1H, ddd, 
J1 = 16.4 Hz, J2 = 9.3 Hz, J3 = 4.1 Hz, H
3a’), 2.49 (1H, dt, 
J1 = 16.4 Hz, J2 = 9.0 Hz, H
3b’), 3.43 (1H, dd, J1 = 9.6 Hz, 
J2 = 6.5 Hz, NCHCH
aHbO), 3.52 (1H, dd, J1 = 9.6 Hz, 
J2 = 3.2 Hz, NCHCH
aHbO), 3.82 (3H, s, OCH3), 3.90–3.94 (2H, m, NCHCH
aHbOCH2), 4.37 
(1H, ddt, J1 = 7.8 Hz, J2 = 6.5 Hz, J3 = 3.2 Hz, H
5’), 5.14 (1H, dq, J1 = 10.6 Hz, J2 = 1.5 Hz, 
NCHCHaHbOCH2CHCH
aHb), 5.21 (1H, dq, J1 = 17.2 Hz, J2 = 1.5 Hz, 
NCHCHaHbOCH2CHCH
aHb), 5.84 (1H, ddd, J1 = 17.2 Hz, J2 = 10.6 Hz, J3 = 5.4 Hz, 
NCHCHaHbOCH2CH), 6.70 (1H, d, J = 8.1 Hz, H
3), 7.07–7.16 (1H, m, H4”), 7.15 (1H, dd, 
J1 = 8.1 Hz, J2 = 1.4 Hz, H
4), 7.36 (2H, t, J = 7.9 Hz, H3”, H5”), 7.62 (1H, d, J = 1.4 Hz, H6), 
7.66 (2H, d, J = 7.9 Hz, H2”, H6”). 13C-NMR (100.6 MHz, CDCl3): δ = 20.6 (CH3), 23.6 (C
4’), 
27.4 (C3’), 51.7 (OCH3), 61.2 (C
5’), 70.2 (NCHCH2O), 72.3 (NCHCH2OCH2), 117.0 
(NCHCH2OCH2CHCH2), 122.1 (C
1), 123.4 (C3), 124.2 (C2”, C6”), 124.6 (C4”), 128.9 (C3”, C5”), 
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130.9, 131.0 (C5, C6), 133.4 (C4), 134.5 (NCHCH2OCH2CH), 139.9 (C
1”), 150.7 (C2), 161.0 
(C2’), 167.9 (C=O). IR (ATR, cm-1): νmax = 1396, 1489, 1499, 1663 (C=N), 1722 (C=O). MS 
(ESI): m/z (%) = 379.0 ([M+H]+, 100). MW = 378.47. 
1.2.21. General procedure for the synthesis of quinolinones from amidines 
The synthesis of quinolinones 23,117,118 from amidines 21,109,113 was performed via a 
modified procedure of Lawson et al.82 
A flame-dried bulb of 100 mL, kept under a nitrogen atmosphere, was loaded with 15 mL of 
dry tetrahydrofuran and amidine (14.7 mmol, 1 equiv). Then, the solution was cooled to 
−78 °C and 36.8 mL of lithiumbis(trimethylsilyl)amide (1-M solution in tetrahydrofuran, 
36.8 mmol, 2.5 equiv) was added. Subsequently, the mixture was stirred at 0 °C for 1 hour 
before being quenched by the addition of 60 mL of saturated aqueous NH4Cl. The layers 
were separated and the organic layer was washed with an equal volume of saturated 
aqueous NH4Cl (2×) and concentrated in vacuo to approximately 10 mL. Next, the residue 
was diluted with 75 mL of ethyl acetate, dried over magnesium sulfate and evaporated in 
vacuo.  
1.2.21.1. Synthesis of quinolinone 23 
Quinolinone 23 was synthesized from amidine 21 (4.54 g, 14.7 mmol, 1 equiv). Evaporation 
in vacuo gave a yellow-orange powder which was washed on a sintered-glass Büchner 
funnel with ice-cold ethyl acetate until the filtrate turned colorless. This afforded 
quinolinone 23 (3.98 g, 98%) as a beige powder. 
6-Methyl-1-phenyl-2,3,4,9-tetrahydro-1H-pyrrolo[2,3-b]quinolin-4-one (23)50 
Yield = 98%. Beige powder. 1H-NMR (400 MHz, DMSO-d6): δ = 2.41 
(3H, s, CH3), 3.17 (2H, t, J = 7.9 Hz, H
3), 4.07 (2H, t, J = 7.9 Hz, H2), 
7.01 (1H, t, J = 7.2 Hz, H4’), 7.32 (1H, dd, J1 = 8.4 Hz, J2 = 1.8 Hz, H
7), 
7.39 (2H, dd, J1 = 7.9 Hz, J2 = 7.2 Hz, H
3’, H5’), 7.51 (1H, d, J = 8.4 Hz, 
H8), 7.77 (1H, br. s, H5), 8.05 (2H, br. s, H2’, H6’), 10.46 (1H, br. s, NH). 
MW = 276.33. 
1.2.21.2. Synthesis of quinolinone 117 
Quinolinone 117 was obtained from amidine 109 (10.8 g, 30.9 mmol, 1 equiv). Evaporation in 
vacuo resulted in an ochreous powder (12.3 g) which was washed on a sintered-glass 
Büchner funnel with ice-cold ethyl acetate until the filtrate turned colorless. This afforded 




Yield = 86%. Beige powder (m.p. 252 °C). 1H-NMR (400 MHz, 
DMSO-d6): δ = 2.43 (3H, s, CH3), 3.20 (2H, t, J = 7.6 Hz, H
3’), 4.10 
(2H, t, J = 7.6 Hz, H2’), 7.36 (1H, d, J = 8.2 Hz, H7’), 7.41 (1H, d, 
J = 7.7 Hz, H6), 7.57 (1H, d, J = 8.2 Hz, H8’), 7.58 (1H, dd, 
J1 = 8.2 Hz, J2 = 7.7 Hz, H
5), 7.80 (1H, br. s, H5’), 8.39 (1H, d, 
J = 8.2 Hz, H4), 8.62 (1H, br. s, H2), 10.63 (1H, br. s, NH). 13C-NMR 
(100.6 MHz, DMSO-d6): δ = 21.5 (CH3), 22.3 (C
3’), 48.4 (C2’), 106.8 (C3a’), 111.8 (C1), 119.2 
(C4a’), 119.8 (CN), 120.1 (C2), 121.0 (C5’), 121.8 (C4), 124.1 (C6), 126.8 (C8’), 130.3 (C5), 
131.1 (C7’), 131.8 (C6’), 143.2 (C3), 146.5 (C8a’), 154.7 (C4’), 159.4 (C9a’). IR (ATR, cm-1): 
νmax = 1308, 1321, 1429, 1483, 1568, 1638 (C=O), 2241 (CN). MS (ESI): m/z (%) = 301.7 
([M+H]+, 100). HRMS (ESI): calculated for C19H16N3O ([M+H]
+) 302.1288; found 302.1296. 
MW = 301.34. 
1.2.21.3. Synthesis of quinolinone 118 
Quinolinone 118 was prepared from amidine 113 (19.9 g, 54.6 mmol, 1 equiv). Evaporation 
in vacuo resulted in an orange powder (18.7 g) which was washed on a sintered-glass 
Büchner funnel with ice-cold ethyl acetate until the filtrate turned colorless. This afforded 
quinolinone 118 (15.0 g, 82%) as an off-white powder. 
1-(3-Allyloxyphenyl)-6-methyl-2,3,4,9-tetrahydro-1H-pyrrolo[2,3-b]quinolin-4-one (118) 
Yield = 82%. Off-white powder (m.p. 203 °C). Rf = 0.13 (ethyl 
acetate). 1H-NMR (400 MHz, DMSO-d6): δ = 2.42 (3H, s, CH3), 
3.17 (2H, t, J = 7.9 Hz, H3), 4.06 (2H, t, J = 7.9 Hz, H2), 4.63 (2H, 
ddd, J1 = 5.2 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, OCH2), 5.29 (1H, ddt, 
J1 = 10.6 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, OCH2CHCH
aHb), 5.46 
(1H, dq, J1 = 17.2 Hz, J2 = 1.5 Hz, OCH2CHCH
aHb), 6.11 (1H, 
ddt, J1 = 17.2 Hz, J2 = 10.6 Hz, J3 = 5.2 Hz, OCH2CH), 6.60 (1H, d, J = 7.8 Hz, H
4’), 7.26 (1H, 
t, J = 7.8 Hz, H5’), 7.32 (1H, dd, J1 = 8.4 Hz, J2 = 1.5 Hz, H
7), 7.45 (1H, d, J = 7.8 Hz, H
6’), 
7.52 (1H, d, J = 8.4 Hz, H8), 7.77 (1H, br. s, H5), 8.04 (1H, br. s, H2’), 10.46 (1H, br. s, NH). 
13C-NMR (100.6 MHz, DMSO-d6): δ = 21.5 (CH3), 22.3 (C
3), 48.6 (C2), 68.6 (OCH2), 104.5 
(C6’), 106.9 (C3a), 107.5 (C4’), 110.0 (C2’), 117.9 (OCH2CHCH2), 119.1 (C
4a), 121.0 (C5), 126.7 
(C8), 129.6 (C5’), 130.8 (C7), 131.2 (C6), 134.4 (OCH2CH), 143.8 (C
1’), 146.8 (C8a), 154.2 (C4), 
158.9 (C3’), 159.8 (C9a). IR (ATR, cm-1): νmax = 1209, 1383, 1412, 1553, 1570, 1612 (C=O). 
MS (ESI): m/z (%) = 332.7 ([M+H]+, 100). HRMS (ESI): calculated for C21H21N2O2 ([M+H]
+) 
333.1598; found 333.1604. MW = 332.40. 
1.2.22. General procedure for the asymmetric α-hydroxylation of quinolinones 




An oven-dried bulb of 50 mL, evacuated and back-filled with argon (5×), was loaded with 
5 mL of dry tetrahydrofuran and quinolinone (1.00 mmol, 1 equiv). Then, the solution was 
cooled to −78 °C and 1.20 mL of lithiumbis(trimethylsilyl)amide (1-M solution in 
tetrahydrofuran, 1.20 mmol, 1.2 equiv) was added. The reaction was stirred for 30 minutes at 
−78 °C and a solution of oxaziridine 14 or 15 (0.716 g, 2.40 mmol, 2.4 equiv) in dry 
tetrahydrofuran (10 mL) was added via syringe. Subsequently, the mixture was stirred at 
−15 °C for 16 hours before being quenched by the addition of 35 mL of saturated aqueous 
NH4Cl. Saturated aqueous Na2S2O3 (100 mL) was then added and the reaction mixture was 
extracted with diethyl ether (3× 150 mL). The combined organic extracts were concentrated 
in vacuo. The residue was dissolved in 40 mL of dichloromethane and subsequently washed 
with 0.3-M aqueous HCl (3× 60 mL). The combined aqueous layers were washed with 60 mL 
of diethyl ether, basified with 3-M aqueous NaOH until pH 10 was reached and extracted with 
ethyl acetate (2× 250 mL). The combined organic extracts were dried over magnesium 
sulfate and evaporated in vacuo. 
1.2.22.1. Synthesis of (S)-blebbistatin (S)-4 
(S)-Blebbistatin (S)-4 was synthesized from quinolinone 23 (0.276 g, 1.00 mmol, 1 equiv) 
using oxaziridine 14 (0.716 g, 2.40 mmol, 2.4 equiv). Evaporation in vacuo gave (S)-4 
(0.250 g, 85%) as a bright-yellow powder. The enantiomeric excess was 75% as determined 
by chiral-HPLC analysis. This powder was redissolved in 10 mL of boiling acetonitrile and left 
untouched overnight at room temperature which afforded (S)-blebbistatin (S)-4 (0.108 g, 
37%) as bright-yellow crystals with an enantiomeric excess of >99%. 
(S)-3a-Hydroxy-6-methyl-1-phenyl-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-4-one 
((S)-4)50 
Yield = 37%. Bright-yellow crystals (from acetonitrile). Ee >99%, chiral 
HPLC: tR ((S)-4) = 7.32 min, tR ((R)-4) = 9.77 min (Daicel Chiralpak IA 
column, acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). 1H-NMR 
(400 MHz, DMSO-d6): δ = 2.23–2.30 (2H, m, H3), 2.31 (3H, br. s, CH3), 
3.90–4.02 (1H, m, H2a), 4.02–4.12 (1H, m, H2b), 6.84 (1H, s, OH), 7.13 
(1H, d, J = 8.1 Hz, H8), 7.15 (1H, t, J = 7.3 Hz, H4’), 7.38 (1H, dd, 
J1 = 8.1 Hz, J2 = 1.8 Hz, H
7), 7.40–7.47 (2H, m, H3’, H5’), 7.54 (1H, d, J = 1.8 Hz, H5), 8.09 
(2H, d, J = 7.9 Hz, H2’, H6’). MW = 292.33. 
1.2.22.2. Synthesis of (R)-blebbistatin (R)-4 
(R)-Blebbistatin (R)-4 was synthesized from quinolinone 23 (0.138 g, 0.500 mmol, 1 equiv) 
using oxaziridine 15 (0.358 g, 1.20 mmol, 2.4 equiv). Evaporation in vacuo resulted in (R)-4 
(0.0918 g, 63%) as a yellow powder. The enantiomeric excess was 75% as determined by 
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chiral-HPLC analysis. The powder was redissolved in 5 mL of boiling acetonitrile and left 
untouched overnight at room temperature which resulted in (R)-blebbistatin (R)-4 (0.0299 g, 
20%) as bright-yellow crystals with an enantiomeric excess of 99%. 
(R)-3a-Hydroxy-6-methyl-1-phenyl-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-4-one 
((R)-4) 
Yield = 20%. Bright-yellow crystals (from acetonitrile). Ee 99%, chiral 
HPLC: tR ((R)-4) = 9.77 min, tR ((S)-4) = 7.31 min (Daicel Chiralpak IA 
column, acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). 1H-NMR 
(400 MHz, DMSO-d6): δ = 2.23–2.30 (2H, m, H3), 2.31 (3H, br. s, CH3), 
3.90–4.02 (1H, m, H2a), 4.02–4.12 (1H, m, H2b), 6.84 (1H, s, OH), 7.13 
(1H, d, J = 8.1 Hz, H8), 7.15 (1H, t, J = 7.3 Hz, H4’), 7.38 (1H, dd, 
J1 = 8.1 Hz, J2 = 1.8 Hz, H
7), 7.40–7.47 (2H, m, H3’, H5’), 7.54 (1H, d, J = 1.8 Hz, H5), 8.09 
(2H, d, J = 7.9 Hz, H2’, H6’). MW = 292.33. 
1.2.22.3. Synthesis of (S)-3’-cyanoblebbistatin (S)-93 
(S)-3’-Cyanoblebbistatin (S)-93 was synthesized from quinolinone 117 (1.51 g, 5.00 mmol, 
1 equiv) using oxaziridine 14 (3.58 g, 12.0 mmol, 2.4 equiv). Evaporation in vacuo resulted in 
(S)-93 (1.54 g, 97%) as a yellow powder. The enantiomeric excess was 83% as determined 
by chiral-HPLC analysis. 
(S)-3-(3a-Hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-yl)-
benzonitrile ((S)-93) 
Yield = 97%. Yellow powder (m.p. 235 °C). Ee 83%, chiral HPLC: 
tR ((S)-93) = 7.68 min, tR ((R)-93) = 10.1 min (Daicel Chiralpak IA 
column, acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). [α]
D
25
 = −248 
(c = 0.11 in tetrahydrofuran). 1H-NMR (400 MHz, DMSO-d6): 
δ = 2.25–2.36 (5H, m, H3’, CH3), 3.97–4.12 (2H, m, H
2’), 6.92 (1H, s, 
OH), 7.19 (1H, d, J = 8.2 Hz, H8’), 7.42 (1H, dd, 
J1 = 8.2 Hz, J2 = 2.0 Hz, H
7’), 7.57 (1H, d, J = 2.0 Hz, H5’), 7.59 (1H, ddd, J1 = 7.8 Hz, 
J2 = 1.5 Hz, J3 = 1.1 Hz, H
6), 7.65 (1H, dd, J1 = 8.1 Hz, J2 = 7.8 Hz, H
5), 8.45 (1H, ddd, 
J1 = 8.1 Hz, J2 = 2.0 Hz, J3 = 1.1 Hz, H
4), 8.61 (1H, dd, J1 = 2.0 Hz, J2 = 1.5 Hz, H
2). 13C-NMR 
(100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.6 (C
3’), 47.8 (C2’), 73.2 (C3a’), 112.1 (C1), 119.3 
(CN), 121.6 (C4a’), 122.6 (C2), 124.2 (C4), 126.6 (C8’), 126.9 (C5’), 127.1 (C6), 130.6 (C5), 
133.6 (C6’), 137.0 (C7’), 141.7 (C3), 148.7 (C8a’), 165.9 (C9a’), 194.7 (C4’). IR (ATR, cm-1): 
νmax = 783, 1265, 1300, 1562, 1587 (C=N), 1695 (C=O), 2232 (CN), 3401 (OH). MS (ESI): 
m/z (%) = 317.6 ([M+H]+, 100). HRMS (ESI): calculated for C19H16N3O2 ([M+H]
+) 318.1237; 
found 318.1247. MW = 317.35. 
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1.2.22.4. Synthesis of (R)-3’-cyanoblebbistatin (R)-93 
(R)-3’-Cyanoblebbistatin (R)-93 was synthesized from quinolinone 117 (1.51 g, 5.00 mmol, 
1 equiv) using oxaziridine 15 (3.58 g, 12.0 mmol, 2.4 equiv). Evaporation in vacuo resulted in 
(R)-93 (1.50 g, 95%) as a yellow powder. The enantiomeric excess was 84% as determined 
by chiral-HPLC analysis. 
(R)-3-(3a-Hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-yl)-
benzonitrile ((R)-93) 
Yield = 95%. Yellow powder (from acetonitrile, m.p. 232 °C). 
Ee 84%, chiral HPLC: tR ((R)-93) = 9.88 min, tR ((S)-93) = 7.67 min 




 = +251 (c = 0.14 in tetrahydrofuran). 1H-NMR 
(400 MHz, DMSO-d6): δ = 2.25–2.36 (5H, m, H3’, CH3), 3.97–4.12 
(2H, m, H2’), 6.92 (1H, s, OH), 7.19 (1H, d, J = 8.2 Hz, H8’), 7.42 (1H, 
dd, J1 = 8.2 Hz, J2 = 2.0 Hz, H
7’), 7.57 (1H, d, J = 2.0 Hz, H5’), 7.59 (1H, ddd, J1 = 7.8 Hz, 
J2 = 1.5 Hz, J3 = 1.1 Hz, H
6), 7.65 (1H, dd, J1 = 8.1 Hz, J2 = 7.8 Hz, H
5), 8.45 (1H, ddd, 
J1 = 8.1 Hz, J2 = 2.0 Hz, J3 = 1.1 Hz, H
4), 8.61 (1H, dd, J1 = 2.0 Hz, J2 = 1.5 Hz, H
2). 13C-NMR 
(100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.6 (C
3’), 47.8 (C2’), 73.2 (C3a’), 112.1 (C1), 119.3 
(CN), 121.6 (C4a’), 122.6 (C2), 124.2 (C4), 126.6 (C8’), 126.9 (C5’), 127.1 (C6), 130.6 (C5), 
133.6 (C6’), 137.0 (C7’), 141.7 (C3), 148.7 (C8a’), 165.9 (C9a’), 194.7 (C4’). IR (ATR, cm-1): 
νmax = 783, 1265, 1300, 1562, 1587 (C=N), 1695 (C=O), 2232 (CN), 3401 (OH). MS (ESI): 
m/z (%) = 317.6 ([M+H]+, 100). HRMS (ESI): calculated for C19H16N3O2 ([M+H]
+) 318.1237; 
found 318.1236. MW = 317.35. 
1.2.22.5. Synthesis of (S)-3’-allyloxyblebbistatin (S)-120 
(S)-3’-Allyloxyblebbistatin (S)-120 was synthesized from quinolinone 118 (11.5 g, 34.6 mmol, 
1 equiv) using oxaziridine 14 (24.8 g, 83.0 mmol, 2.4 equiv). Evaporation in vacuo resulted in 
(S)-120 (8.19 g, 68 %) as an orange powder. The enantiomeric excess was 78% as 
determined by chiral-HPLC analysis. The powder was redissolved in 80 mL of boiling 
acetonitrile and left untouched for 30 minutes at room temperature. After 20 minutes, crystals 
had formed. After an additional 10 minutes, the obtained crystals were filtered off. This 
resulted in (S)-3’-allyloxyblebbistatin (S)-120 (2.29 g, 19%) as bright, gold leaf-like crystals 
with an enantiomeric excess of >99%. 
(S)-1-(3-Allyloxyphenyl)-3a-hydroxy-6-methyl-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]-
quinolin-4-one ((S)-120) 
Yield = 19%. Bright gold leaf-like crystals (from acetonitrile, 
m.p. 176 °C). Ee >99%, chiral HPLC: tR ((S)-120) = 11.2 min, 
tR ((R)-120) = 14.2 min (Daicel Chiralpak IA column, 
acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). [α]
D
25
 = −327 
(c = 0.11 in tetrahydrofuran). 1H-NMR (400 MHz, DMSO-d6): 
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δ = 2.22–2.29 (2H, m, H3), 2.31 (3H, s, CH3), 3.92–4.00 (1H, m, H
2a), 4.00–4.09 (1H, m, H2b), 
4.62 (2H, ddd, J1 = 5.2 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, OCH2), 5.29 (1H, ddt, J1 = 10.6 Hz, 
J2 = 1.5 Hz, J3 = 1.4 Hz, OCH2CHCH
aHb), 5.44 (1H, dq, J1 = 17.3 Hz, J2 = 1.5 Hz, 
OCH2CHCH
aHb), 6.09 (1H, ddt, J1 = 17.3 Hz, J2 = 10.6 Hz, J3 = 5.2 Hz, OCH2CH), 6.75 (1H, 
dd, J1 = 8.2 Hz, J2 = 2.2 Hz, H
4’), 6.83 (1H, s, OH), 7.14 (1H, d, J = 8.1 Hz, H8), 7.32 (1H, t, 
J = 8.2 Hz, H5’), 7.39 (1H, dd, J1 = 8.1 Hz, J2 = 1.8 Hz, H
7), 7.50 (1H, dd, J1 = 8.2 Hz, 
J2 = 1.9 Hz, H
6’), 7.54 (1H, d, J = 1.8 Hz, H5), 7.99 (1H, dd, J1 = 2.2 Hz, J2 = 1.9 Hz, H
2’). 
13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.7 (C
3), 48.0 (C2), 68.7 (OCH2), 73.4 
(C3a), 106.9 (C2’), 110.3 (C4’), 112.2 (C6’), 118.0 (OCH2CHCH2), 121.5 (C
4a), 126.4 (C8), 126.8 
(C5), 129.9 (C5’), 132.9 (C6), 134.2 (OCH2CH), 137.0 (C
7), 142.2 (C1’), 149.4 (C8a), 158.8 
(C3’), 165.8 (C9a), 195.0 (C4). IR (ATR, cm-1): νmax = 770, 937, 1175, 1298, 1589 (C=N), 1695 
(C=O). MS (ESI): m/z (%) = 348.6 ([M+H]+, 100). HRMS (ESI): calculated for C21H21N2O3 
([M+H]+) 349.1547; found 349.1544. MW = 348.40. 
1.2.22.6. Synthesis of (R)-3’-allyloxyblebbistatin (R)-120 
(R)-3’-Allyloxyblebbistatin (R)-120 was synthesized from quinolinone 118 (2.66 g, 8.00 mmol, 
1 equiv) using oxaziridine 15 (5.73 g, 19.2 mmol, 2.4 equiv). Evaporation in vacuo resulted in 
(R)-120 (2.15 g, 77%) as an orange powder. The enantiomeric excess was 79% as 
determined by chiral-HPLC analysis. The powder was redissolved in 20 mL of boiling 
acetonitrile and left untouched for 30 minutes at room temperature. After 20 minutes, crystals 
had formed which were filtered off after an additional 10 minutes. This resulted in 
(R)-3’-allyloxyblebbistatin (R)-120 (1.00 g, 36%) as bright, gold leaf-like crystals with an 
enantiomeric excess of >99%. 
(R)-1-(3-Allyloxyphenyl)-3a-hydroxy-6-methyl-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]-
quinolin-4-one ((R)-120) 
Yield = 36%. Bright gold leaf-like crystals (from acetonitrile, 
m.p. 170 °C). Ee >99%, chiral HPLC: tR ((R)-120) = 14.2 min, 
tR ((S)-120) = 11.2 min (Daicel Chiralpak IA column, 
acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). [α]
D
25
 = +313 
(c = 0.12 in tetrahydrofuran). 1H-NMR (400 MHz, DMSO-d6): 
δ = 2.22–2.29 (2H, m, H3), 2.31 (3H, s, CH3), 3.92–4.00 (1H, m, 
H2a), 4.00–4.09 (1H, m, H2b), 4.62 (2H, ddd, J1 = 5.2 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, OCH2), 5.29 
(1H, ddt, J1 = 10.6 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, OCH2CHCH
aHb), 5.44 (1H, dq, J1 = 17.3 Hz, 
J2 = 1.5 Hz, OCH2CHCH
aHb), 6.09 (1H, ddt, J1 = 17.3 Hz, J2 = 10.6 Hz, J3 = 5.2 Hz, 
OCH2CH), 6.75 (1H, dd, J1 = 8.2 Hz, J2 = 2.2 Hz, H
4’), 6.83 (1H, s, OH), 7.14 (1H, d, 
J = 8.1 Hz, H8), 7.32 (1H, t, J = 8.2 Hz, H5’), 7.39 (1H, dd, J1 = 8.1 Hz, J2 = 1.8 Hz, H
7), 7.50 
(1H, dd, J1 = 8.2 Hz, J2 = 1.9 Hz, H
6’), 7.54 (1H, d, J = 1.8 Hz, H5), 7.99 (1H, dd, J1 = 2.2 Hz, 
J2 = 1.9 Hz, H
2’). 13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.7 (C
3), 48.0 (C2), 68.7 
(OCH2), 73.4 (C
3a), 106.9 (C2’), 110.3 (C4’), 112.2 (C6’), 118.0 (OCH2CHCH2), 121.5 (C
4a), 
126.4 (C8), 126.8 (C5), 129.9 (C5’), 132.9 (C6), 134.2 (OCH2CH), 137.0 (C
7), 142.2 (C1’), 
149.4 (C8a), 158.8 (C3’), 165.8 (C9a), 195.0 (C4). IR (ATR, cm-1): νmax = 770, 937, 1175, 1298, 
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1589 (C=N), 1695 (C=O). MS (ESI): m/z (%) = 348.6 ([M+H]+, 100). HRMS (ESI): calculated 
for C21H21N2O3 ([M+H]
+) 349.1547; found 349.1551. MW = 348.40. 
1.2.23. Synthesis of (S)-3’-(diallylamino)blebbistatin (S)-121 and (R)-3’-(diallylamino)-
blebbistatin (R)-121 
Amidine 114 was obtained from amide 105 (24.6 g, 96.0 mmol, 1 equiv) and amine 20 
(16.7 g, 101 mmol, 1.05 equiv) via the general procedure for the synthesis of amidines from 
amides and amines (procedure 1.2.20.). During aqueous work-up, part of the amidine 114 
was converted into side product 115 due to hydrolysis of the amidine functionality. 
Evaporation in vacuo afforded a red-brown oil (39.0 g) of which 6.50 g was dissolved in 
acetonitrile/dichloromethane (1:1) and coated under reduced pressure onto 13.0 g of 
Davisil® C18 silica. Subsequently, purification was performed via automated flash 
chromatography with water/acetonitrile as eluent on a Reveleris® 120-g C18 cartridge (5% 
(m/m) sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 40% (v/v) acetonitrile, a 
gradient from 40% (v/v) to 80% (v/v) acetonitrile over 20 CV, 4 CV of 80% (v/v) acetonitrile 
and finally 3 CV of 100% (v/v) acetonitrile; detection wavelengths: 256 nm and 330 nm). 
Next, the same conditions were repeated another 5 times to purify the remaining parts of the 
crude mixture. Evaporation resulted in crude amidine 114 (11.9 g) as a red-brown oil that still 
contained 14% (m/m) of side product 115 as impurity. 
Quinolinone 119 was synthesized from 8.69 g of the crude amidine 114 (18.5 mmol of 114, 
1 equiv) via the general procedure for the synthesis of quinolinones from amidines 
(procedure 1.2.21.). Evaporation in vacuo resulted in a red oil (8.83 g) which was dissolved 
in tetrahydrofuran and coated under reduced pressure onto 26.5 g of silica. Subsequently, 
purification was performed via automated flash chromatography with hexane/ethyl 
acetate/methanol as eluent on a Reveleris® 80-g silica cartridge (11% (m/m) sample loading; 
flow rate: 60 mL min-1; eluent: 2 CV of 50% (v/v) ethyl acetate, a gradient from 50% (v/v) to 
100% (v/v) ethyl acetate over 10 CV, 5 CV of 100% (v/v) ethyl acetate and finally 25 CV of a 
10% (v/v) methanol/90% (v/v) ethyl acetate mixture; detection wavelengths: 256 nm and 
334 nm). Evaporation resulted in crude quinolinone 119 (4.97 g) as an orange oil that still 
contained 9% (m/m) of side product 116 (formed out of side product 115 during reaction) as 
impurity. 
1.2.23.1. Synthesis of (S)-3’-(diallylamino)blebbistatin (S)-121 
(S)-3’-(Diallylamino)blebbistatin (S)-121 was synthesized from 3.96 g of the crude 
quinolinone 119 (9.71 mmol of 119, 1 equiv) via the general procedure for the asymmetric 
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α-hydroxylation of quinolinones (procedure 1.2.22.) and using oxaziridine 14 (6.95 g, 
23.3 mmol, 2.4 equiv). Evaporation in vacuo resulted in (S)-121 (3.05 g, 81%) as an orange 
powder. The enantiomeric excess was 76% as determined by chiral-HPLC analysis. The 
powder was redissolved in 60 mL of boiling absolute ethanol and left untouched for 1 hour at 
room temperature. After 40 minutes fibers had formed which were filtered off after an 
additional 20 minutes. This resulted in (S)-3’-(diallylamino)blebbistatin (S)-121 (0.762 g, 
20%) as bright-orange cotton-like fibers with an enantiomeric excess of >99%. 
(S)-1-(3-(Diallylamino)phenyl)-3a-hydroxy-6-methyl-2,3,3a,4-tetrahydro-1H-pyrrolo-
[2,3-b]quinolin-4-one ((S)-121) 
Yield = 20%. Bright-orange cotton-like fibers (from absolute 
ethanol, m.p. 167 °C). Ee >99%, chiral HPLC: 
tR ((S)-121) = 27.1 min, tR ((R)-121) = 31.1 min (Daicel Chiralpak 




 = −342 (c = 0.12 in tetrahydrofuran). 1H-NMR (400 MHz, 
DMSO-d6): δ = 2.19–2.27 (2H, m, H3), 2.30 (3H, s, CH3), 3.87–
3.95 (1H, m, H2a), 3.94‒4.07 (5H, m, N(CH2CHCH
aHb)2, H
2b), 
5.12–5.20 (2H, m, N(CH2CHCH
aHb)2), 5.14–5.24 (2H, m, N(CH2CHCH
aHb)2), 5.92 (2H, ddt, 
J1 = 17.1 Hz, J2 = 10.2 Hz, J3 = 5.1 Hz, N(CH2CHCH
aHb)2), 6.47 (1H, dd, J1 = 8.2 Hz, 
J2 = 2.0 Hz, H
4’), 6.79 (1H, s, OH), 6.98 (1H, dd, J1 = 8.1 Hz, J2 = 2.0 Hz, H
6’), 7.07 (1H, d, 
J = 8.1 Hz, H8), 7.15 (1H, dd, J1 = 8.2 Hz, J2 = 8.1 Hz, H
5’), 7.38 (1H, dd, J1 = 8.1 Hz, 
J2 = 1.8 Hz, H
7), 7.52 (1H, d, J = 1.8 Hz, H5), 7.94 (1H, t, J = 2.0 Hz, H2’). 13C-NMR 
(100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.8 (C
3), 47.9 (C2), 53.0 (N(CH2CHCH2)2), 73.5 
(C3a), 104.8 (C2’), 107.4 (C6’), 108.3 (C4’), 116.4 (N(CH2CHCH2)2), 121.4 (C
4a), 126.2 (C8), 
126.8 (C5), 129.4 (C5’), 132.5 (C6), 134.8 (N(CH2CHCH2)2), 137.0 (C
7), 141.9 (C1’), 148.9 
(C3’), 149.8 (C8a), 165.7 (C9a), 195.1 (C4). IR (ATR, cm-1): νmax = 752, 1231, 1474, 1582, 1611 
(C=N), 1670 (C=O), 3323 (OH). MS (ESI): m/z (%) = 387.5 ([M+H]+, 100). HRMS (ESI): 
calculated for C24H26N3O2 ([M+H]
+) 388.2020; found 388.2035. MW = 387.47. 
1.2.23.2. Synthesis of (R)-3’-(diallylamino)blebbistatin (R)-121 
(R)-3’-(Diallylamino)blebbistatin (R)-121 was synthesized from 0.903 g of the crude 
quinolinone 119 (2.21 mmol of 119, 1 equiv) via the general procedure for the asymmetric 
α-hydroxylation of quinolinones (procedure 1.2.22.) and using oxaziridine 15 (1.58 g, 
5.31 mmol, 2.4 equiv). Evaporation in vacuo resulted in (R)-3’-(diallylamino)blebbistatin 
(R)-121 (0.686 g, 80%) as an orange powder. The enantiomeric excess was 74% as 
determined by chiral-HPLC analysis. The powder was redissolved in 15 mL of boiling 
absolute ethanol and left untouched for 50 minutes at room temperature. After 30 minutes 
fibers had formed which were filtered off after an additional 20 minutes. This resulted in 
(R)-3’-(diallylamino)blebbistatin (R)-121 (0.160 g, 19%) as bright-orange cotton-like fibers 




[2,3-b]quinolin-4 one ((R)-121) 
Yield = 19%. Bright-orange cotton-like fibers (from absolute 
ethanol, m.p. 167 °C). Ee 98%, chiral HPLC: 
tR ((R)-121) = 31.1 min, tR ((S)-121) = 27.7 min (Daicel Chiralpak 




 = +327 (c = 0.18 in tetrahydrofuran). 1H-NMR (400 MHz, 
DMSO-d6): δ = 2.19–2.27 (2H, m, H3), 2.30 (3H, s, CH3), 3.87–
3.95 (1H, m, H2a), 3.94‒4.07 (5H, m, N(CH2CHCH
aHb)2, H
2b), 
5.12–5.20 (2H, m, N(CH2CHCH
aHb)2), 5.14–5.24 (2H, m, N(CH2CHCH
aHb)2), 5.92 (2H, ddt, 
J1 = 17.1 Hz, J2 = 10.2 Hz, J3 = 5.1 Hz, N(CH2CHCH
aHb)2), 6.47 (1H, dd, J1 = 8.2 Hz, 
J2 = 2.0 Hz, H
4’), 6.79 (1H, s, OH), 6.98 (1H, dd, J1 = 8.1 Hz, J2 = 2.0 Hz, H
6’), 7.07 (1H, d, 
J = 8.1 Hz, H8), 7.15 (1H, dd, J1 = 8.2 Hz, J2 = 8.1 Hz, H
5’), 7.38 (1H, dd, J1 = 8.1 Hz, 
J2 = 1.8 Hz, H
7), 7.52 (1H, d, J = 1.8 Hz, H5), 7.94 (1H, t, J = 2.0 Hz, H2’). 13C-NMR 
(100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.8 (C
3), 47.9 (C2), 53.0 (N(CH2CHCH2)2), 73.5 
(C3a), 104.8 (C2’), 107.4 (C6’), 108.3 (C4’), 116.4 (N(CH2CHCH2)2), 121.4 (C
4a), 126.2 (C8), 
126.8 (C5), 129.4 (C5’), 132.5 (C6), 134.8 (N(CH2CHCH2)2), 137.0 (C
7), 141.9 (C1’), 148.9 
(C3’), 149.8 (C8a), 165.7 (C9a), 195.1 (C4). IR (ATR, cm-1): νmax = 752, 1231, 1474, 1582, 1611 
(C=N), 1670 (C=O), 3323 (OH). MS (ESI): m/z (%) = 387.5 ([M+H]+, 100). HRMS (ESI): 
calculated for C24H26N3O2 ([M+H]
+) 388.2020; found 388.2023. MW = 387.47. 
1.2.24. General procedure for the one-pot synthesis of α-hydroxy ketones from 
amidines 
An oven-dried bulb of 100 mL, degassed and back-filled with argon (5×), was loaded with 
30 mL of dry tetrahydrofuran and 2.15 g of amidine (6.00 mmol, 1 equiv). Then, the solution 
was cooled to −78 °C and 12.6 mL of lithiumbis(trimethylsilyl)amide (1-M solution in 
tetrahydrofuran, 12.6 mmol, 2.1 equiv) was added, after which the mixture was stirred at 0 °C 
for 1–2 hours. Afterwards, the reaction was cooled to −78 °C and a solution of oxaziridine 14 
and/or oxaziridine 15 (4.29 g, 14.4 mmol, 2.4 equiv) in dry tetrahydrofuran (34 mL) was 
added via cannula. Subsequently, the mixture was stirred at −15 °C for 15–16 hours before 
being quenched by the addition of 350 mL of saturated aqueous NH4Cl. The reaction mixture 
was extracted with diethyl ether (3× 440 mL) and the combined organic extracts were 
concentrated to a volume of 220 mL and subsequently washed with 0.3-M aqueous HCl (3× 
240 mL). The combined aqueous layers were washed with 180 mL of hexane, basified with 
3-M aqueous NaOH until pH 10 was reached and extracted with ethyl acetate (2× 1000 mL). 
The combined organic extracts were dried over magnesium sulfate and evaporated in vacuo. 
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1.2.24.1. Synthesis of (S)-blebbistatin (S)-4 
(S)-Blebbistatin (S)-4 was synthesized from amidine 21 (0.167 g, 0.500 mmol, 1 equiv) using 
oxaziridine 14 (0.358 g, 1.20 mmol, 2.4 equiv). Evaporation in vacuo afforded (S)-4 (0.146 g, 
quant) as an ochreous powder. The enantiomeric excess was 86% as determined by chiral-
HPLC analysis (Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). 
1.2.24.2. Synthesis of (S)-benzo[c’]blebbistatin (S)-136 
(S)-Benzo[c’]blebbistatin (S)-136 was synthesized from amidine 146 (2.15 g, 6.00 mmol, 
1 equiv) using oxaziridine 14 (4.29 g, 14.4 mmol, 2.4 equiv). Evaporation in vacuo afforded 
(S)-136 (1.03 g, 50%) as a yellow powder. The enantiomeric excess was 72% as determined 
by chiral-HPLC analysis. The powder was redissolved in 175 mL of boiling acetonitrile and 
left untouched for 30 minutes at room temperature. This resulted in (S)-benzo[c’]blebbistatin 
(S)-136 (0.546 g, 26%) as bright-yellow crystals with an enantiomeric excess of >99%. 
(S)-3a-Hydroxy-6-methyl-1-(naphthalen-2-yl)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]-
quinolin-4-one ((S)-136) 
Yield = 26%. Bright-yellow crystals (from acetonitrile, m.p. 246 °C). 
Ee >99%, chiral HPLC: tR ((S)-136) = 16.6 min, 
tR ((R)-136) = 22.1 min (Daicel Chiralpak IA column, 
acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). [α]
D
25
 = −486 
(c = 0.10 in tetrahydrofuran). 1H-NMR (400 MHz, DMSO-d6): 
δ = 2.27–2.40 (2H, m, H3), 2.33 (3H, s, CH3), 4.08–4.24 (2H, m, H
2), 
6.90 (1H, s, OH), 7.20 (1H, d, J = 8.1 Hz, H8), 7.41 (1H, dd, 
J1 = 8.1 Hz, J2 = 1.8 Hz, H
7), 7.43–7.49 (1H, m, H6’), 7.50–7.56 (1H, m, H7’), 7.56 (1H, d, 
J = 1.8 Hz, H5), 7.88–7.95 (2H, m, H5’, H8’), 7.97 (1H, d, J = 9.0 Hz, H4’), 8.42 (1H, d, 
J = 2.1 Hz, H1’), 8.51 (1H, dd, J1 = 9.0 Hz, J2 = 2.1 Hz, H
3’). 13C-NMR (100.6 MHz, DMSO-d6): 
δ = 20.7 (CH3), 28.8 (C
3), 48.2 (C2), 73.4 (C3a), 116.6 (C1’), 120.4 (C3’), 121.5 (C4a), 125.5 
(C6’), 126.5 (C8), 126.8 (C5), 127.0 (C7’), 127.9, 128.1 (C5’, C8’), 128.6 (C4’), 130.2 (C4a’), 132.9 
(C6), 133.7 (C8a’), 137.0 (C7), 138.9 (C2’), 149.5 (C8a), 165.8 (C9a), 195.0 (C4). IR (ATR, cm-1): 
νmax = 737, 800, 1587, 1605 (C=N), 1695 (C=O). MS (ESI): m/z (%) = 343.1 ([M+H]
+, 100). 
HRMS (ESI): calculated for C22H19N2O2 ([M+H]
+) 343.1441; found 343.1451. MW = 342.40. 
1.2.24.3. Synthesis of (S)-4’-allyloxyblebbistatin (S)-141 
(S)-4’-Allyloxyblebbistatin (S)-141 was synthesized from amidine 163 (2.50 g, 6.86 mmol, 
1 equiv) using oxaziridine 14 (4.90 g, 16.5 mmol, 2.4 equiv). Evaporation in vacuo afforded 
(S)-141 (1.03 g, 43%) as a bright-yellow powder. The enantiomeric excess was 82% as 
determined by chiral-HPLC analysis. The powder was redissolved in 9 mL of boiling 
acetonitrile and left untouched for 7 minutes at room temperature. After 2 minutes crystals 
had formed which were filtered off after an additional 5 minutes. This resulted in (S)-4’-
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allyloxyblebbistatin (S)-141 (0.474 g, 20%) as bright-yellow crystals with an enantiomeric 
excess of >99%. 
(S)-1-(4-Allyloxyphenyl)-3a-hydroxy-6-methyl-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]-
quinolin-4-one ((S)-141) 
Yield = 20%. Bright-yellow crystals (from acetonitrile, m.p. 192 °C). 
Ee >99%, chiral HPLC: tR ((S)-141) = 13.7 min, 
tR ((R)-141) = 22.5 min (Daicel Chiralpak IA column, 
acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). [α]
D
25
 = −452 
(c = 0.18 in tetrahydrofuran). 1H-NMR (400 MHz, DMSO-d6): 
δ = 2.22–2.28 (2H, m, H3), 2.30 (3H, s, CH3), 3.88–3.95 (1H, m, 
H2a), 4.00–4.09 (1H, m, H2b), 4.59 (2H, ddd, J1 = 5.2 Hz, J2 = 1.6 Hz, 
J3 = 1.5 Hz, OCH2), 5.28 (1H, ddt, J1 = 10.5 Hz, J2 = 1.6 Hz, J3 = 1.5 Hz, OCH2CHCH
aHb), 
5.42 (1H, dq, J1 = 17.3 Hz, J2 = 1.6 Hz, OCH2CHCH
aHb), 6.06 (1H, ddt, J1 = 17.3 Hz, 
J2 = 10.5 Hz, J3 = 5.2 Hz, OCH2CH), 6.79 (1H, s, OH), 6.99–7.05 (2H, m, H
3’, H5’), 7.07 (1H, 
d, J = 8.1 Hz, H8), 7.35 (1H, dd, J1 = 8.1 Hz, J2 = 2.1 Hz, H
7), 7.52 (1H, d, J = 2.1 Hz, H5), 
7.94–8.00 (2H, m, H2’, H6’). 13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 29.0 (C
3), 48.2 
(C2), 68.8 (OCH2), 73.4 (C
3a), 115.1 (C3’, C5’), 117.9 (OCH2CHCH2), 121.4 (C
4a), 121.7 (C2’, 
C6’), 126.1 (C8), 126.8 (C5), 132.2 (C6), 134.3 (OCH2CH), 134.4 (C
1’), 136.9 (C7), 150.0 (C8a), 
154.9 (C4’), 165.3 (C9a), 195.1 (C4). IR (ATR, cm-1): νmax = 800, 827, 937, 995, 1107, 1595 
(C=N), 1688 (C=O). MS (ESI): m/z (%) = 349.3 ([M+H]+, 100). HRMS (ESI): calculated for 
C21H21N2O3 ([M+H]
+) 349.1547; found 349.1549. MW = 348.40. 
1.2.24.4. Synthesis of (S)-4’-nitroblebbistatin (S)-130 
(S)-4’-Nitroblebbistatin (S)-130 was synthesized from amidine 128 (1.15 g, 3.25 mmol, 
1 equiv) using oxaziridine 14 (2.32 g, 7.8 mmol, 2.4 equiv). Evaporation in vacuo afforded an 
orange oil (1.09 g), containing 40% (m/m) of (S)-4’-nitroblebbistatin (S)-130 and 60% (m/m) 
of dimer 168, which was dissolved in tetrahydrofuran and coated under reduced pressure 
onto silica. Subsequently, purification was performed via automated flash chromatography 
with hexane/ethyl acetate as eluent on a Reveleris® 120-g silica cartridge (1% (m/m) sample 
loading; flow rate: 80 mL min-1; eluent: 2 CV of 0% (v/v) ethyl acetate, followed by a gradient 
from 0% (v/v) to 40% (v/v) ethyl acetate over 30 CV; detection wavelengths: 260 nm and 
368 nm). This resulted in (S)-4’-nitroblebbistatin (S)-130 (0.416 g, 38%) as an orange 
powder. The enantiomeric excess was 82% as determined by chiral-HPLC analysis analysis. 
The powder was redissolved in 25 mL of boiling acetonitrile and left untouched for 19 hours 
at room temperature. This resulted in (S)-4’-nitroblebbistatin (S)-130 (0.248 g, 23%) as 





Yield = 23%. Orange crystals. Rf = 0.32 (hexane/ethyl acetate, 1:1). 
Ee >99%, chiral HPLC: tR ((S)-130) = 16.6 min, tR ((R)-130) = 32.1 min 
(Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min-1, 
25 °C). 1H-NMR (400 MHz, DMSO-d6): δ = 2.25–2.40 (2H, m, H3), 2.34 
(3H, s, CH3), 4.03–4.15 (2H, m, H
2), 6.97 (1H, s, OH), 7.24 (1H, d, 
J = 8.1 Hz, H8), 7.45 (1H, dd, J1 = 8.1 Hz, J2 = 1.8 Hz, H
7), 7.59 (1H, d, 
J = 1.8 Hz, H5), 8.28–8.34 (2H, m, H2’, H6’), 8.36–8.42 (2H, m, H3’, H5’). 
MW = 337.34. 
1.2.24.5. Synthesis of (S)-benzo[h]blebbistatin (S)-170 
(S)-Benzo[h]blebbistatin (S)-170 was synthesized from amidine 176 (2.07 g, 6.00 mmol, 
1 equiv) using oxaziridine 14 (4.29 g, 14.4 mmol, 2.4 equiv). Evaporation in vacuo afforded 
(S)-170 (1.50 g, 76%) as a dark-yellow-orange powder. The enantiomeric excess was 72% 
as determined by chiral-HPLC analysis. The powder was redissolved in 270 mL of boiling 
acetonitrile and left untouched for 2 hours at room temperature. After 35 minutes crystals had 
formed which were filtered off after an additional 75 minutes. This resulted in 
(S)-benzo[h]blebbistatin (S)-170 (0.285 g, 14%) as dark-orange crystals with an enantiomeric 
excess of >99%. 
(S)-3a-Hydroxy-1-phenyl-2,3,3a,4-tetrahydro-1H-benzo[g]pyrrolo[2,3-b]quinolin-4-one 
((S)-170) 
Yield = 14%. Dark-orange crystals (from acetonitrile, m.p. 245 °C). 
Ee >99%, chiral HPLC: tR ((S)-170) = 9.12 min, 
tR ((R)-170) = 12.7 min (Daicel Chiralpak IA column, 
acetonitrile/water (60:40), 1.0 mL min-1, 25 °C). 1H-NMR (400 MHz, 
DMSO-d6): δ = 2.29 (1H, dd, J1 = 13.3 Hz, J2 = 5.9 Hz, H
3a), 2.33–
2.45 (1H, m, H3b), 3.99 (1H, dd, J1 = 9.4 Hz, J2 = 9.0 Hz, H
2a), 4.10 
(1H, ddd, J1 = 9.8 Hz, J2 = 9.4 Hz, J3 = 5.9 Hz, H
2b), 6.92 (1H, s, OH), 7.17 (1H, t, J = 7.3 Hz, 
H4’), 7.38–7.45 (1H, m, H7), 7.42–7.49 (2H, m, H3’, H5’), 7.53–7.60 (1H, m, H8), 7.66 (1H, br. 
s, H10), 7.88 (1H, d, J = 8.2 Hz, H9), 8.04 (1H, d, J = 8.1 Hz, H6), 8.14 (2H, d, J = 7.9 Hz, H2’, 
H6’), 8.41 (1H, s, H5). 13C-NMR (100.6 MHz, DMSO-d6): δ = 28.6 (C3), 47.8 (C2), 73.8 (C3a), 
120.1 (C2’, C6’), 122.1 (C10), 122.9 (C4a), 123.9 (C4’), 125.5 (C7), 127.7 (C9), 128.9 (C5), 129.1 
(C3’, C5’), 129.4 (C8), 129.9 (C5a), 130.2 (C6), 137.9 (C9a), 141.1 (C1’), 147.0 (C10a), 164.6 
(C11a), 194.7 (C4). IR (ATR, cm-1): νmax = 748, 891, 1308, 1578, 1587 (C=N), 1707 (C=O). MS 
(ESI): m/z (%) = 329.1 ([M+H]+, 100). HRMS (ESI): calculated for C21H17N2O2 ([M+H]
+) 





1.2.24.6. Synthesis of (S)-(N-allyl-2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-173 
(S)-(N-Allyl-2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-173 was synthesized from amidine 
184 (5.22 g, 13.9 mmol, 1 equiv) using oxaziridine 14 (9.94 g, 33.4 mmol, 2.4 equiv). 
Evaporation in vacuo afforded (S)-173 (3.64 g, 73%) as a dark-yellow powder. The 
enantiomeric excess was 92% as determined by chiral-HPLC analysis. The powder was 
redissolved in 330 mL of boiling acetonitrile and left untouched for 45 minutes at room 
temperature. After 10 minutes crystals had formed which were filtered off after an additional 
35 minutes. This resulted in (S)-(N-allyl-2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-173 
(1.19 g, 24%) as dark-yellow fibers with an enantiomeric excess of 96%. 
(S)-1-Allyl-5a-hydroxy-8-phenyl-2,3,5,5a,6,7-hexahydro-1H,8H-dipyrrolo[2,3-b:3',2'-g]-
quinolin-5-one ((S)-173) 
Yield = 24%. Dark-yellow fibers (from acetonitrile, m.p. 245 °C). 
Ee 96%, chiral HPLC: tR ((S)-173) = 12.3 min, tR ((R)-173) = 
14.4 min (Daicel Chiralpak IA column, acetonitrile/water (50:50), 
1.0 mL min-1, 25 °C). 1H-NMR (400 MHz, DMSO-d6): δ = 2.05–2.17 
(1H, m, H6a), 2.24 (1H, dd, J1 = 13.3 Hz, J2 = 5.6 Hz, H
6b), 2.95 (2H, 
t, J = 8.4 Hz, H3), 3.56 (2H, t, J = 8.4 Hz, H2), 3.87–4.00 (3H, m, H7a, 
NCH2CHCH
aHb), 4.03 (1H, td, J1 = 9.8 Hz, J2 = 5.6 Hz, H
7b), 5.17–5.25 (1H, m, 
NCH2CHCH
aHb), 5.20–5.29 (1H, m, NCH2CHCH
aHb), 5.80–5.93 (1H, m, NCH2CHCH
aHb), 
6.21 (1H, s, H10), 6.54 (1H, s, OH), 7.13 (1H, t, J = 7.3 Hz, H4’), 7.36 (1H, br. s, H4), 7.38–
7.46 (2H, m, H3’, H5’), 8.08 (2H, d, J = 8.0 Hz, H2’, H6’). 13C-NMR (100.6 MHz, DMSO-d6): 
δ = 26.7 (C3), 29.5 (C6), 48.0 (C7), 49.2 (NCH2CHCH2), 52.2 (C
2), 72.8 (C5a), 102.3 (C10), 
110.7 (C4a), 117.7 (NCH2CHCH2), 120.0 (C
2’, C6’), 122.5 (C4), 123.8 (C4’), 125.7 (C3a), 129.1 
(C3’, C5’), 133.4 (NCH2CHCH2), 141.2 (C
1’), 154.5 (C9a), 158.5 (C10a), 167.1 (C8a), 191.5 (C5). 
IR (ATR, cm-1): νmax = 1281, 1288, 1468, 1549, 1585 (C=N), 1649 (C=O), 3343 (OH). MS 
(ESI): m/z (%) = 360.0 ([M+H]+, 100). HRMS (ESI): calculated for C22H22N3O2 ([M+H]
+) 
360.1707; found 360.1711. MW = 359.43. 
1.2.24.7. Synthesis of (±)-2-(allyloxymethyl)blebbistatin (±)-188 
(±)-2-(Allyloxymethyl)blebbistatin (±)-188 was synthesized from amidine 200 (0.621 g, 
1.64 mmol, 1 equiv) using oxaziridine 14 (0.586 g, 1.97 mmol, 1.2 equiv) and oxaziridine 15 
(0.586 g, 1.97 mmol, 1.2 equiv). Evaporation in vacuo afforded an orange powder (0.534 g, 







 Yield = 90%. Orange powder. 1H-NMR (400 MHz, DMSO-d6): 
δ = 2.15–2.26 (1H, m, H3a (major), H3a (minor)), 2.28 (3H, s, CH3 
(major), CH3 (minor)), 2.31–2.40 (1H, m, H
3b (major), H3b (minor)), 
3.43–3.49 (1.68H, m, NCHCH2OCH2 (major)), 3.59–3.96 (2.32H, 
m, NCHCH2O (major), NCHCH2OCH2 (minor)), 4.64–4.74 (1H, m, 
H2 (major), H2 (minor)), 4.98–5.04 (0.84H, m, 
NCHCH2OCH2CHCH
aHb (major)), 5.00–5.08 (0.84H, m, NCHCH2OCH2CHCH
aHb (major)), 
5.07–5.13 (0.16H, m, NCHCH2OCH2CHCH
aHb (minor)), 5.11–5.19 (0.16H, m, 
NCHCH2OCH2CHCH
aHb (minor)), 5.65 (0.84H, ddd, J1 = 17.2 Hz, J2 = 10.6 Hz, J3 = 5.3 Hz, 
NCHCH2OCH2CH (major)), 5.74–5.86 (0.16H, m, NCHCH2OCH2CH (minor), 6.84 (0.16H, s, 
OH (minor)), 6.89 (0.84H, s, OH (major)), 6.93 (0.84H, d, J = 8.1 Hz, H8 (major)), 6.99 
(0.16H, d, J = 8.1 Hz, H8 (minor)), 7.16–7.22 (0.16H, m, H4’ (minor)), 7.23–7.31 (0.84H, m, 
H4’ (major)), 7.27–7.34 (1H, m, H7 (major), H7 (minor)), 7.39–7.49 (2H, m, H3’ (major), H5’ 
(major), H3’ (minor), H5’ (minor)), 7.50 (1H, d, J = 1.8 Hz, H5 (major), H5 (minor)), 7.55–7.62 
(1.68H, m, H2’ (major), H6’ (major)), 7.77–7.83 (0.32H, m, H2’ (minor), H6’ (minor)). 13C-NMR 
(100.6 MHz, DMSO-d6): δ = 20.6 (CH3 (major), CH3 (minor)), 32.4 (C
3 (major), C3 (minor)), 
58.7 (C2 (major), C2 (minor)), 68.2 (NCHCH2OCH2 (major), NCHCH2OCH2 (minor)), 71.6 
(NCHCH2O (major)), 71.7 (NCHCH2O (minor)), 72.4 (C
3a (major), C3a (minor)), 117.0 
(NCHCH2OCH2CHCH2 (major)), 117.1 (NCHCH2OCH2CHCH2 (minor)), 121.8 (C
4a (major), 
C4a (minor)), 123.4 (C2’ (minor), C6’ (minor)), 125.6 (C2’ (major), C6’ (major)), 125.8 (C8 
(major), C8 (minor)), 126.2 (C4’ (major), C4’ (minor)), 126.9 (C5 (major), C5 (minor)), 129.0 (C3’ 
(major), C5’ (major)), 129.2 (C3’ (minor), C5’ (minor)), 132.1 (C6 (major)), 132.5 (C6 (minor)), 
135.2 (NCHCH2OCH2CH (major), NCHCH2OCH2CH (minor)), 136.9 (C
7 (major), C7 (minor)), 
138.4 (C1’ (major), C1’ (minor)), 150.2 (C8a (major), C8a (minor)), 166.6 (C9a (major), C9a 
(minor)), 195.3 (C4 (major), C4 (minor)). IR (ATR, cm-1): νmax = 737, 1287, 1477, 1589, 1609 
(C=N), 1686 (C=O). MS (ESI): m/z (%) = 363.0 ([M+H]+, 100). HRMS (ESI): calculated for 
C22H23N2O3 ([M+H]
+) 363.1703; found 363.1710. MW = 362.43. 
1.2.25. General procedure for the allyl deprotection of allyl phenyl ethers 
The allyl deprotection of allyl phenyl ethers was adopted from a publication of Vutukuri et 
al.92 
In a flame-dried bulb of 250 mL, containing 200 mL of dry methanol, allyl phenyl ether 
(4.21 mmol, 1 equiv) and 0.243 g of tetrakis(triphenylphosphine)palladium(0) (0.211 mmol, 
0.05 equiv) were brought together under a nitrogen atmosphere and stirred for 5 minutes at 
room temperature. Then, 3.49 g of K2CO3 (25.3 mmol, 6 equiv) was added and the reaction 
mixture was stirred for 1–1.5 hours at 50 °C. Afterwards, the mixture was concentrated to a 
volume of 25 mL, diluted with 400 mL of ethyl acetate and washed with saturated aqueous 




1.2.25.1. Synthesis of (S)-3’-hydroxyblebbistatin (S)-94 
(S)-3’-Hydroxyblebbistatin (S)-94 was synthesized from (S)-3’-allyloxyblebbistatin (S)-120 
(1.47 g, 4.21 mmol, 1 equiv). Evaporation in vacuo afforded a bright-red powder (1.53 g) 
which was dissolved in tetrahydrofuran and coated under reduced pressure onto silica. 
Subsequently, purification was performed via automated flash chromatography with 
hexane/ethyl acetate as eluent on a Reveleris® 80-g silica cartridge (2% (m/m) sample 
loading; flow rate: 60 mL min-1; eluent: 2 CV of 15% (v/v) ethyl acetate, followed by a 
gradient from 15% (v/v) to 100% (v/v) ethyl acetate over 15 CV; detection wavelengths: 
220 nm and 264 nm). This resulted in (S)-3’-hydroxyblebbistatin (S)-94 (1.03 g, 79%) as a 




Yield = 79%. Bright-orange powder (m.p. 179 °C). Rf = 0.40 
(hexane/ethyl acetate, 2:3). Ee 99%, chiral HPLC: 
tR ((S)-94) = 3.87 min, tR ((R)-94) = 5.18 min (Daicel Chiralpak IA 
column, acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). [α]
D
25
 = −332 
(c = 0.11 in tetrahydrofuran). 1H-NMR (400 MHz, DMSO-d6): 
δ = 2.20–2.27 (2H, m, H3), 2.31 (3H, s, CH3), 3.87–3.95 (1H, m, H
2a), 
3.96–4.06 (1H, m, H2b), 6.56 (1H, dd, J1 = 8.1 Hz, J2 = 2.1 Hz, H
4’), 6.81 (1H, s, OH), 7.12 
(1H, d, J = 8.1 Hz, H8), 7.19 (1H, dd, J1 = 8.2 Hz, J2 = 8.1 Hz, H
5’), 7.35–7.41 (2H, m, H6’, H7), 
7.53 (1H, d, J = 1.6 Hz, H5), 7.71 (1H, t, J = 2.1 Hz, H2’), 9.50 (1H, s, ArOH). 13C-NMR 
(100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.7 (C
3), 48.0 (C2), 73.4 (C3a), 107.6 (C2’), 110.8 
(C6’), 111.2 (C4’), 121.4 (C4a), 126.3 (C8), 126.8 (C5), 129.8 (C5’), 132.7 (C6), 136.9 (C7), 142.1 
(C1’), 149.7 (C8a), 158.0 (C3’), 165.7 (C9a), 195.1 (C4). IR (ATR, cm-1): νmax = 826, 1236, 1589, 
1605 (C=N), 1663 (C=O), 3219 (OH), 3360 (OH). MS (ESI): m/z (%) = 308.7 ([M+H]+, 100). 
HRMS (ESI): calculated for C18H17N2O3 ([M+H]
+) 309.1234; found 309.1233. MW = 308.33. 
1.2.25.2. Synthesis of (R)-3’-hydroxyblebbistatin (R)-94 
(R)-3’-Hydroxyblebbistatin (R)-94 was synthesized from (R)-3’-allyloxyblebbistatin (R)-120 
(0.182 g, 0.521 mmol, 1 equiv). Evaporation in vacuo afforded an orange oil (0.200 g) which 
was dissolved in tetrahydrofuran and coated under reduced pressure onto silica. 
Subsequently, purification was performed via automated flash chromatography with 
hexane/ethyl acetate as eluent on a Reveleris® 12-g silica cartridge (2% (m/m) sample 
loading; flow rate: 36 mL min-1; eluent: 2 CV of 15% (v/v) ethyl acetate, followed by a 
gradient from 15% (v/v) to 100% (v/v) ethyl acetate over 15 CV; detection wavelengths: 
220 nm and 264 nm). This resulted in (R)-3’-hydroxyblebbistatin (R)-94 (0.120 g, 75%) as a 
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Yield = 75%. Bright-orange powder (m.p. 202 °C). Rf = 0.40 
(hexane/ethyl acetate, 2:3). Ee 98%, chiral HPLC: 
tR ((R)-94) = 5.11 min, tR ((S)-94) = 3.91 min (Daicel Chiralpak IA 
column, acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). [α]
D
25
 = +320 
(c = 0.12 in tetrahydrofuran). 1H-NMR (400 MHz, DMSO-d6): 
δ = 2.20–2.27 (2H, m, H3), 2.31 (3H, s, CH3), 3.87–3.95 (1H, m, H
2a), 
3.96–4.06 (1H, m, H2b), 6.56 (1H, dd, J1 = 8.1 Hz, J2 = 2.1 Hz, H
4’), 6.81 (1H, s, OH), 7.12 
(1H, d, J = 8.1 Hz, H8), 7.19 (1H, dd, J1 = 8.2 Hz, J2 = 8.1 Hz, H
5’), 7.35–7.41 (2H, m, H6’, H7), 
7.53 (1H, d, J = 1.6 Hz, H5), 7.71 (1H, t, J = 2.1 Hz, H2’), 9.50 (1H, s, ArOH). 13C-NMR 
(100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.7 (C
3), 48.0 (C2), 73.4 (C3a), 107.6 (C2’), 110.8 
(C6’), 111.2 (C4’), 121.4 (C4a), 126.3 (C8), 126.8 (C5), 129.8 (C5’), 132.7 (C6), 136.9 (C7), 142.1 
(C1’), 149.7 (C8a), 158.0 (C3’), 165.7 (C9a), 195.1 (C4). IR (ATR, cm-1): νmax = 826, 1236, 1589, 
1605 (C=N), 1663 (C=O), 3219 (OH), 3360 (OH). MS (ESI): m/z (%) = 308.6 ([M+H]+, 100). 
HRMS (ESI): calculated for C18H17N2O3 ([M+H]
+) 309.1234; found 309.1239. MW = 308.33. 
1.2.25.3. Synthesis of (S)-4’-hydroxyblebbistatin (S)-139 
(S)-4’-Hydroxyblebbistatin (S)-139 was synthesized from (S)-4’-allyloxyblebbistatin (S)-141 
(0.294 g, 0.842 mmol, 1 equiv). Evaporation in vacuo afforded bright-orange fibers (0.372 g) 
which were dissolved in tetrahydrofuran and coated under reduced pressure onto silica. 
Subsequently, purification was performed via automated flash chromatography with 
hexane/ethyl acetate as eluent on a Reveleris® 40-g silica cartridge (1% (m/m) sample 
loading; flow rate: 40 mL min-1; eluent: 2 CV of 16% (v/v) ethyl acetate, followed by a 
gradient from 16% (v/v) to 70% (v/v) ethyl acetate over 25 CV; detection wavelengths: 
220 nm and 262 nm). This resulted in (S)-4’-hydroxyblebbistatin (S)-139 (0.201 g, 77%) as a 
bright-orange powder. The enantiomeric excess was >99% as determined by chiral-HPLC 
analysis of (S)-4’-benzyloxyblebbistatin (S)-142 (see procedure 1.2.34.). 
(S)-3a-Hydroxy-1-(4-hydroxyphenyl)-6-methyl-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]-
quinolin-4-one ((S)-139) 
Yield = 77%. Bright-orange powder (m.p. 224 °C). Rf = 0.30 
(hexane/ethyl acetate, 7:13). Ee >99%. [α]
D
25
 = −473 (c = 0.13 in 
tetrahydrofuran). 1H-NMR (400 MHz, CD3OD): δ = 2.31–2.39 (2H, m, 
H3), 2.33 (3H, s, CH3), 3.87–3.95 (1H, m, H
2a), 4.09–4.17 (1H, m, H2b), 
6.84–6.90 (2H, m, H3’, H5’), 7.08 (1H, d, J = 8.2 Hz, H8), 7.33 (1H, dd, 
J1 = 8.2 Hz, J2 = 2.2 Hz, H
7), 7.54–7.60 (2H, m, H2’, H6’), 7.62 (1H, d, 
J = 2.2 Hz, H5). 13C-NMR (100.6 MHz, CD3OD): δ = 19.2 (CH3), 29.0 (C
3), 49.5 (C2), 73.4 
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(C3a), 115.2 (C3’, C5’), 120.8 (C4a), 124.0 (C2’, C6’), 124.9 (C8), 126.5 (C5), 131.7 (C1’), 132.2 
(C6), 136.5 (C7), 149.7 (C8a), 155.2 (C4’), 166.0 (C9a), 195.2 (C4). IR (ATR, cm-1): νmax = 804, 
1209, 1476, 1584, 1597 (C=N), 1665 (C=O), 3210 (OH), 3591 (OH). MS (ESI): 
m/z (%) = 309.2 ([M+H]+, 100). HRMS (ESI): calculated for C18H17N2O3 ([M+H]
+) 309.1234; 
found 309.1234. MW = 308.33. 
1.2.26. General procedure for the allyl deprotection of allyl phenyl amines 
The allyl deprotection of allyl phenyl amines was based on a publication of Belardi and 
Micalizio.128 
In a flame-dried bulb of 25 mL, containing 20 mL of dry dichloromethane, 0.358 g of allyl 
phenyl amine (0.924 mmol, 1 equiv), 0.865 g of N,N’-dimethylbarbituric acid (126) 
(5.55 mmol, 6 equiv) and 0.106 g of tetrakis(triphenylphosphine)palladium(0) (0.0924 mmol, 
0.1 equiv) were brought together under a nitrogen atmosphere and stirred for 1 hour at reflux 
temperature. Afterwards, the reaction mixture was cooled to room temperature, diluted with 
150 mL of ethyl acetate and washed with saturated aqueous NaHCO3 (2× 50 mL). The 
organic layer was dried over magnesium sulfate and evaporated in vacuo. 
1.2.26.1. Synthesis of (S)-3’-aminoblebbistatin (S)-95 
(S)-3’-Aminoblebbistatin (S)-95 was synthesized from (S)-3’-(diallylamino)blebbistatin 
(S)-121 (0.358 g, 0.924 mmol, 1 equiv). Evaporation in vacuo afforded a brown oil (0.496 g) 
which was taken up in tetrahydrofuran and coated under reduced pressure onto silica. 
Subsequently, purification was performed via automated flash chromatography with 
hexane/ethyl acetate as eluent on a Reveleris® 40-g silica cartridge (1% (m/m) sample 
loading; flow rate: 40 mL min-1; eluent: 2 CV of 20% (v/v) ethyl acetate, followed by a 
gradient from 20% (v/v) to 100% (v/v) ethyl acetate over 20 CV; detection wavelengths: 
220 nm and 264 nm). This resulted in (S)-3’-aminoblebbistatin (S)-95 (0.215 g, 76%) as a 




Yield = 76%. Dark-yellow-orange powder (m.p. 207 °C). Rf = 0.33 
(hexane/ethyl acetate, 1:4). Ee >99%, chiral HPLC: 
tR ((S)-95) = 4.41 min, tR ((R)-95) = 6.35 min (Daicel Chiralpak IA 




 = −383 (c = 0.10 in tetrahydrofuran). 1H-NMR (400 MHz, 
DMSO-d6): δ = 2.18–2.26 (2H, m, H3), 2.30 (3H, s, CH3), 3.82–3.91 
(1H, m, H2a), 3.93–4.05 (1H, m, H2b), 5.14 (2H, br. s, NH2), 6.37 (1H, dd, J1 = 7.9 Hz, 
J2 = 1.7 Hz, H
4’), 6.78 (1H, s, OH), 7.04 (1H, dd, J1 = 8.0 Hz, J2 = 7.9 Hz, H
5’), 7.11 (1H, d, 
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J = 8.1 Hz, H8), 7.17 (1H, dd, J1 = 8.0 Hz, J2 = 1.9 Hz, H
6’), 7.34 (1H, dd, J1 = 1.9 Hz, 
J2 = 1.7 Hz, H
2’), 7.37 (1H, dd, J1 = 8.1 Hz, J2 = 1.9 Hz, H
7), 7.51 (1H, d, J = 1.9 Hz, H5). 
13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.3 (C
3), 48.0 (C2), 73.4 (C3a), 106.1 (C2’), 
108.2 (C6’), 110.3 (C4’), 121.4 (C4a), 126.3 (C8), 126.7 (C5), 129.4 (C5’), 132.4 (C6), 136.9 (C7), 
141.7 (C1’), 149.4 (C3’), 150.0 (C8a), 165.6 (C9a), 195.2 (C4). IR (ATR, cm-1): νmax = 1233, 
1476, 1578, 1599, 1692, 3360, 3443 (NH2, OH). MS (ESI): m/z (%) = 307.7 ([M+H]
+, 100). 
HRMS (ESI): calculated for C18H18N3O2 ([M+H]
+) 308.1394; found 308.1387. MW = 307.35. 
1.2.26.2. Synthesis of (R)-3’-aminoblebbistatin (R)-95 
(R)-3’-Aminoblebbistatin (R)-95 was synthesized from (R)-3’-(diallylamino)blebbistatin 
(R)-121 (0.0530 g, 0.137 mmol, 1 equiv). Evaporation in vacuo afforded a brown oil 
(0.0731 g) which was taken up in tetrahydrofuran and coated under reduced pressure onto 
silica. Subsequently, purification was performed via automated flash chromatography with 
hexane/ethyl acetate as eluent on a Reveleris® 12-g silica cartridge (1% (m/m) sample 
loading; flow rate: 36 mL min-1; eluent: 2 CV of 20% (v/v) ethyl acetate, followed by a 
gradient from 20% (v/v) to 100% (v/v) ethyl acetate over 20 CV; detection wavelengths: 
220 nm and 264 nm). This resulted in (R)-3’-aminoblebbistatin (R)-95 (0.0301 g, 72%) as a 




Yield = 72%. Dark yellow-orange powder (m.p. 174 °C). Rf = 0.33 
(hexane/ethyl acetate, 1:4). Ee 95%, chiral HPLC: 
tR ((R)-95) = 6.35 min, tR ((S)-95) = 4.44 min (Daicel Chiralpak IA 




 = +358 (c = 0.11 in tetrahydrofuran). 1H-NMR (400 MHz, 
DMSO-d6): δ = 2.18–2.26 (2H, m, H3), 2.30 (3H, s, CH3), 3.82–3.91 
(1H, m, H2a), 3.93–4.05 (1H, m, H2b), 5.14 (2H, br. s, NH2), 6.37 (1H, dd, J1 = 7.9 Hz, 
J2 = 1.7 Hz, H
4’), 6.78 (1H, s, OH), 7.04 (1H, dd, J1 = 8.0 Hz, J2 = 7.9 Hz, H
5’), 7.11 (1H, d, 
J = 8.1 Hz, H8), 7.17 (1H, dd, J1 = 8.0 Hz, J2 = 1.9 Hz, H
6’), 7.34 (1H, dd, J1 = 1.9 Hz, 
J2 = 1.7 Hz, H
2’), 7.37 (1H, dd, J1 = 8.1 Hz, J2 = 1.9 Hz, H
7), 7.51 (1H, d, J = 1.9 Hz, H5). 
13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.3 (C
3), 48.0 (C2), 73.4 (C3a), 106.1 (C2’), 
108.2 (C6’), 110.3 (C4’), 121.4 (C4a), 126.3 (C8), 126.7 (C5), 129.4 (C5’), 132.4 (C6), 136.9 (C7), 
141.7 (C1’), 149.4 (C3’), 150.0 (C8a), 165.6 (C9a), 195.2 (C4). IR (ATR, cm-1): νmax = 1233, 
1476, 1578, 1599, 1692, 3360, 3443 (NH2, OH). MS (ESI): m/z (%) = 307.7 ([M+H]
+, 100). 
HRMS (ESI): calculated for C18H18N3O2 ([M+H]
+) 308.1394; found 308.1403. MW = 307.35. 
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1.2.27. General procedure for the selective hydrolysis of aromatic nitriles to amides 
The selective hydrolysis of aromatic nitriles to amides was performed via an adopted 
procedure from Fowler et al.93  
In a flame-dried bulb of 250 mL, containing 150 mL of dry dichloromethane, nitrile 
(3.18 mmol, 1 equiv) and 1.31 mL of N,N-diethylhydroxylamine (12.7 mmol, 4 equiv) were 
brought together under a nitrogen atmosphere and the reaction mixture was stirred at reflux 
temperature for 24 hours. Next, a second portion of N,N-diethylhydroxylamine (1.31 mL, 
12.7 mmol, 4 equiv) was added and the reaction mixture was refluxed for another 24 hours. 
During the reaction, the product had precipitated. After cooling to room temperature, the 
solids were filtered off on a sintered-glass Büchner funnel and rinsed with ice-cold 
dichloromethane until the filtrate turned colorless. The residue was dried under reduced 
pressure. 
1.2.27.1. Synthesis of (S)-3’-carbamoylblebbistatin (S)-96 
(S)-3’-Carbamoylblebbistatin (S)-96 was synthesized from (S)-3’-cyanoblebbistatin (S)-93 
(1.01 g, 3.18 mmol, 1 equiv). Drying of the residue under reduced pressure afforded (S)-96 
(0.969 g, 91%) as an ochreous powder. The enantiomeric excess was 86% as determined by 
chiral-HPLC analysis. Portions of 190 mg of the powder were redissolved in 80 mL of boiling 
absolute ethanol. The cooling solution was left untouched for 24 hours at room temperature, 
during which yellow fibers had formed. In one case, evaporation in vacuo of the mother liquor 
resulted in (S)-3’-carbamoylblebbistatin (S)-96 (0.152 g, 73%) as a yellow powder with an 
enantiomeric excess of 98%. In one other case, the crop afforded (S)-3’-carbamoyl-
blebbistatin (S)-96 (0.0422 g, 20%) as bright-yellow fibers with an enantiomeric excess of 
98%. The three other recrystallizations resulted in scalemic mixtures in both the crops and 
the mother liquors. In those cases the crop and the mother liquor were recombined and the 
recrystallization protocol was repeated. 
(S)-3-(3a-Hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-yl)-
benzamide ((S)-96) 
Yield = 20–73%. Bright-yellow fibers or yellow powder (from 
absolute ethanol, m.p. 267 °C). Ee 98%, chiral HPLC: 
tR ((S)-96) = 20.9 min, tR ((R)-96) = 17.6 min (Daicel Chiralpak IA 
column, hexane/dichloromethane/absolute ethanol (10:90:3), 
0.5 mL min-1, 35 °C). [α]
D
25
 = −288 (c = 0.07 in tetrahydrofuran). 
1H-NMR (400 MHz, DMSO-d6): δ = 2.25–2.36 (5H, m, H3’, CH3), 
3.97–4.06 (1H, m, H2a’), 4.05–4.16 (1H, m, H2b’), 6.87 (1H, s, OH), 7.13 (1H, d, J = 8.1 Hz, 
H8’), 7.39 (1H, dd, J1 = 8.1 Hz, J2 = 1.7 Hz, H
7’), 7.42 (1H, br. s, NHaHb), 7.51 (1H, dd, 
J1 = 8.1 Hz, J2 = 7.8 Hz, H
5), 7.55 (1H, d, J = 1.7 Hz, H5’), 7.64 (1H, d, J = 7.8 Hz, H6), 8.02 




(100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.8 (C
3’), 48.0 (C2’), 73.3 (C3a’), 118.9 (C2), 121.5 
(C4a’), 122.9 (C6), 123.2 (C4), 126.4 (C8’), 126.8 (C5’), 129.0 (C5), 132.9 (C6’), 135.4 (C1), 
136.9 (C7’), 141.0 (C3), 149.4 (C8a’), 165.8 (C9a’), 168.2 (CONH2), 195.0 (C
4’). IR (ATR, cm-1): 
νmax = 764, 1288, 1477, 1574, 1599 (C=N), 1667 (C=O), 1697 (C=O), 3321, 3491 (NH2, OH). 
MS (ESI): m/z (%) = 335.6 ([M+H]+, 100). HRMS (ESI): calculated for C19H18N3O3 ([M+H]
+) 
336.1343; found 336.1346. MW = 335.36. 
1.2.27.2. Synthesis of (R)-3’-carbamoylblebbistatin (R)-96 
(R)-3’-Carbamoylblebbistatin (R)-96 was synthesized from (R)-3’-cyanoblebbistatin (R)-93 
(1.01 g, 3.18 mmol, 1 equiv). Drying under reduced pressure afforded (R)-96 (0.955 g, 90%) 
as an ochreous powder. The enantiomeric excess was 86% as determined by chiral-HPLC 
analysis. Portions of 190 mg of the powder were redissolved in 80 mL of boiling absolute 
ethanol. The solutions were left untouched for 24 hours at room temperature, during which 
time yellow fibers had formed. In one case, evaporation in vacuo of the mother liquor 
resulted in (R)-3’-carbamoylblebbistatin (R)-96 (0.103 g, 49%) as a yellow powder with an 
enantiomeric excess of 97%. The four other recrystallizations resulted in scalemic mixtures in 
both the crops and the mother liquors. In those cases the crop and the mother liquor were 
recombined and the crystallization protocol was repeated. 
(R)-3-(3a-Hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-yl)-
benzamide ((R)-96) 
Yield = 49%. Yellow powder (from absolute ethanol, m.p. 267 °C). 
Ee 97%, chiral HPLC: tR ((R)-96) = 17.3 min, tR ((S)-96) = 21.4 min 
(Daicel Chiralpak IA column, hexane/dichloromethane/absolute 
ethanol (10:90:3), 0.5 mL min-1, 35 °C). [α]
D
25
 = +269 (c = 0.07 in 
tetrahydrofuran). 1H-NMR (400 MHz, DMSO-d6): δ = 2.25–2.36 
(5H, m, H3’, CH3), 3.97–4.06 (1H, m, H
2a’), 4.05–4.16 (1H, m, H2b’), 
6.87 (1H, s, OH), 7.13 (1H, d, J = 8.1 Hz, H8’), 7.39 (1H, dd, J1 = 8.1 Hz, J2 = 1.7 Hz, H
7’), 
7.42 (1H, br. s, NHaHb), 7.51 (1H, dd, J1 = 8.1 Hz, J2 = 7.8 Hz, H
5), 7.55 (1H, d, J = 1.7 Hz, 
H5’), 7.64 (1H, d, J = 7.8 Hz, H6), 8.02 (1H, br. s, NHaHb), 8.24 (1H, br. s, H2), 8.52 (1H, dd, 
J1 = 8.1 Hz, J2 = 1.6 Hz, H
4). 13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.8 (C
3’), 
48.0 (C2’), 73.3 (C3a’), 118.9 (C2), 121.5 (C4a’), 122.9 (C6), 123.2 (C4), 126.4 (C8’), 126.8 (C5’), 
129.0 (C5), 132.9 (C6’), 135.4 (C1), 136.9 (C7’), 141.0 (C3), 149.4 (C8a’), 165.8 (C9a’), 168.2 
(CONH2), 195.0 (C
4’). IR (ATR, cm-1): νmax = 764, 1288, 1477, 1574, 1599 (C=N), 1667 
(C=O), 1697 (C=O), 3321, 3491 (NH2, OH). MS (ESI): m/z (%) = 335.6 ([M+H]
+, 100). HRMS 
(ESI): calculated for C19H18N3O3 ([M+H]
+) 336.1343; found 336.1340. MW = 335.36. 
1.2.28. General procedure for the hydrolysis of amides to carboxylic acids 
A bulb of 10 mL was loaded with 4.6 mL of demineralized water, 0.74 mL of concentrated 
H2SO4 (13.6 mmol, 30 equiv) and amide (0.457 mmol, 1 equiv), after which the reaction 
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mixture was stirred at 70 °C for 14 hours. The resulting black slurry was filtered off over celite 
and the filter cake was rinsed with demineralized water until the filtrate turned colorless. 
Afterwards, the pH of the yellow filtrate was adjusted to 4–5 with 3-M aqueous NaOH and the 
water was lyophilized for 21 hours (0.31 mbar, 21 °C). This resulted in a light-yellow powder 
containing the product together with salts, such as Na2SO4. Isolation of the product from this 
mixture was conducted by stirring the powder in 90 mL of absolute ethanol for 30 minutes. 
Next, the solids were filtered off on a sintered-glass Büchner funnel. The filter cake was 
rinsed with absolute ethanol until the filtrate turned colorless, upon which the filtrate was 
evaporated in vacuo. 
To overcome the separation difficulties associated with chiral-HPLC analysis of carboxylic 
acids (S)-97 and (R)-97, an analytical sample was converted into the corresponding methyl 
esters by means of diazomethane. A vial, equipped with a stirring bar, was loaded with a 
pinch of carboxylic acid, 0.3 mL of methanol and 20 drops of freshly prepared diazomethane. 
For the preparation of diazomethane, see procedure 1.2.29. CAUTION! Due to the dangers 
associated with diazomethane handling, sharp-edged glassware was avoided and 
diazomethane was added using a Pasteur pipette which was fire polished prior to use. 
When dealing with diazomethane, the experimenter should first thoroughly study the 
literature on the properties and safe handling of this hazardous reagent.129,130 The 
reaction mixture was stirred at room temperature for 45 minutes, during which the carboxylic 
acid functionality was almost completely converted into the corresponding methyl ester 
without affecting the alcohol moiety. Excess diazomethane and the solvent were evaporated 
under a flow of nitrogen gas. The yellow residue was redissolved in 1 mL of acetonitrile and 
analyzed as such. 
1.2.28.1. Synthesis of (S)-3’-carboxyblebbistatin (S)-97 
(S)-3’-Carboxyblebbistatin (S)-97 was synthesized from (S)-3’-carbamoylblebbistatin (S)-96 
(0.153 g, 0.457 mmol, 1 equiv). Evaporation in vacuo of the filtrate afforded a yellow powder 
(0.108 g) which was dissolved in 2.5 mL of absolute ethanol and further purified via 
preparative TLC with dichloromethane/methanol (9:1) as eluent. This resulted in 
(S)-3’-carboxyblebbistatin (S)-97 (0.0332 g, 22%) as a bright-orange powder. The 
enantiomeric excess of the corresponding (S)-methyl ester (see general procedure above) 




benzoic acid ((S)-97) 
Yield = 22%. Bright-orange powder (m.p. 250 °C). Rf = 0.14 
(dichloromethane/methanol, 9:1). Ee ≥96%, chiral HPLC methyl 
ester: tR ((S)-methyl ester) = 61.6 min, tR ((R)-methyl 
ester) = 73.6 min (Daicel Chiralpak IA column, acetonitrile/water 
(30:70), 1.0 mL min-1, 25 °C). [α]
D
25
 = −217 (c = 0.11 in absolute 
ethanol). 1H-NMR (400 MHz, 0.18 M NaHCO3 in D2O): δ = 2.22 
(3H, s, CH3), 2.30–2.38 (2H, m, H
3’), 3.91–4.00 (1H, m, H2a’), 4.05–4.16 (1H, m, H2b’), 6.96 
(1H, d, J = 8.4 Hz, H8’), 7.34 (1H, d, J = 8.4 Hz, H7’), 7.46 (1H, dd, J1 = 8.0 Hz, J2 = 7.9 Hz, 
H5), 7.55 (1H, br. s, H5’), 7.68 (1H, d, J = 7.9 Hz, H6), 7.75 (1H, d, J = 8.0 Hz, H4), 7.94 (1H, 
br. s, H2). 13C-NMR (100.6 MHz, 0.18 M NaHCO3 in D2O): δ = 19.6 (CH3), 28.2 (C
3’), 49.4 
(C2’), 73.8 (C3a’), 120.1 (C4a’), 123.1 (C2), 124.8 (C8’), 125.7 (C4), 126.5 (C6), 127.2 (C5’), 129.2 
(C5), 133.9 (C6’), 137.5 (C1 or C3), 138.3 (C7’), 138.8 (C1 or C3), 148.8 (C8a’), 160.4 (NaHCO3), 
166.0 (C9a’), 174.8 (COO-), 196.5 (C4’). IR (ATR, cm-1): νmax = 758, 1209, 1298, 1381, 1555, 
1585 (C=N), 1678 (C=O). MS (ESI): m/z (%) = 336.6 ([M+H]+, 100). HRMS (ESI): calculated 
for C19H17N2O4 ([M+H]
+) 337.1183; found 337.1181. MW = 336.35. 
1.2.28.2. Synthesis of (R)-3’-carboxyblebbistatin (R)-97 
(R)-3’-Carboxyblebbistatin (R)-97 was synthesized from (R)-3’-carbamoylblebbistatin (R)-96 
(0.0500 g, 0.149 mmol, 1 equiv). Evaporation in vacuo of the filtrate afforded (R)-3’-carboxy-
blebbistatin (R)-97 (0.0378 g, 75%) as a bright-yellow powder. The enantiomeric excess of 
the corresponding (R)-methyl ester (see general procedure above) was 91% as determined 
by chiral-HPLC analysis. 
(R)-3-(3a-Hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-yl)-
benzoic acid ((R)-97) 
Yield = 75%. Bright-yellow powder (m.p. 250 °C). Ee ≥91%, chiral 
HPLC methyl ester: tR ((R)-methyl ester) = 73.3 min, tR ((S)-methyl 
ester) = 62.7 min (Daicel Chiralpak IA column, acetonitrile/water 
(30:70), 1.0 mL min-1, 25 °C). [α]
D
25
 = +172 (c = 0.11 in absolute 
ethanol). 1H-NMR (400 MHz, 0.18 M NaHCO3 in D2O): δ = 2.22 
(3H, s, CH3), 2.30–2.38 (2H, m, H
3’), 3.91–4.00 (1H, m, H2a’), 4.05–
4.16 (1H, m, H2b’), 6.96 (1H, d, J = 8.4 Hz, H8’), 7.34 (1H, d, J = 8.4 Hz, H7’), 7.46 (1H, dd, 
J1 = 8.0 Hz, J2 = 7.9 Hz, H
5), 7.55 (1H, br. s, H5’), 7.68 (1H, d, J = 7.9 Hz, H6), 7.75 (1H, d, 
J = 8.0 Hz, H4), 7.94 (1H, br. s, H2). 13C-NMR (100.6 MHz, 0.18 M NaHCO3 in D2O): δ = 19.6 
(CH3), 28.2 (C
3’), 49.4 (C2’), 73.8 (C3a’), 120.1 (C4a’), 123.1 (C2), 124.8 (C8’), 125.7 (C4), 126.5 
(C6), 127.2 (C5’), 129.2 (C5), 133.9 (C6’), 137.5 (C1 or C3), 138.3 (C7’), 138.8 (C1 or C3), 148.8 
(C8a’), 160.4 (NaHCO3), 166.0 (C
9a’), 174.8 (COO-), 196.5 (C4’). IR (ATR, cm-1): νmax = 758, 
1209, 1298, 1381, 1555, 1585 (C=N), 1678 (C=O). MS (ESI): m/z (%) = 336.6 ([M+H]+, 100). 
HRMS (ESI): calculated for C19H17N2O4 ([M+H]
+) 337.1183; found 337.1188. MW = 336.35. 
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1.2.29. Synthesis of diazomethane 
CAUTION! Diazomethane is a toxic and explosive compound! When dealing with 
diazomethane, the experimenter should first thoroughly study the literature on the 
properties and safe generation and handling of this hazardous reagent!129,130 The 
synthesis must be carried out in a properly working hood using dedicated and 
thoroughly inspected equipment! Do not use sharp-edged glassware or ground joints!  
A 250-mL distilling flask was fitted with a condenser set for distillation and with a dropping 
funnel by means of special cork stoppers. The condenser was connected to an L-shaped 
glass tube which in its turn was connected to an ice-cooled 250-mL Büchner flask by means 
of special cork stoppers. Pressure build-up has to be avoided by means of an opening to the 
environment. 
A solution of 2.14 g of N-methyl-N-nitroso-para-toluenesulfonamide (10.0 mmol, 1 equiv) in 
25 mL of diethyl ether was added to the distilling flask which was cooled to 0 °C. A solution of 
0.561 g of KOH (10.0 mmol, 1 equiv) in 60 mL of absolute ethanol was added dropwise by 
means of an addition funnel (without mechanical stirring!). After complete addition, a solution 
of diazomethane in diethyl ether was distilled off by heating the reaction mixture to 60 °C for 
about 30 minutes, using a warm (but CERTAINLY BELOW 70 °C) water bath. CAUTION! At 
no time the water should boil! Never use other means of heating! Diazomethane may 
explode at 100 °C! During distillation, diethyl ether was added via the dropping funnel until 
the distillate turned colorless. The yellow distillate, a dilute solution of diazomethane in 
diethyl ether, was collected in a Büchner flask cooled to 0 °C. CAUTION! Explosion hazard! 
The solution should be dilute! 
1.2.30. General procedure for the esterification of phenols using acid chlorides 
In a flame-dried bulb of 50 mL, phenol (0.489 mmol, 1 equiv) was dissolved in 25 mL of dry 
acetonitrile. The reaction mixture was cooled to 0 °C, after which 0.167 g of Cs2CO3 
(0.511 mmol, 1.05 equiv), 0.0119 g of 4-(dimethylamino)pyridine (0.0973 mmol, 0.2 equiv) 
and acid chloride (0.632 mmol, 1.3 equiv) were added sequentially. Then, the reaction 
mixture was stirred for 30 minutes at room temperature under a nitrogen atmosphere. 
Afterwards, the mixture was evaporated in vacuo, diluted with 150 mL of ethyl acetate and 
washed with saturated aqueous NH4Cl (2× 50 mL). The organic layer was dried over 
magnesium sulfate and evaporated in vacuo.  
EXPERIMENTAL PROCEDURES 
163 
1.2.30.1. Synthesis of (S)-3’-acryloxyblebbistatin (S)-131 
(S)-3’-Acryloxyblebbistatin (S)-131 was synthesized from (S)-3’-hydroxyblebbistatin (S)-94 
(0.150 g, 0.487 mmol, 1 equiv) and acryloyl chloride (51.5 µL, 0.633 mmol, 1.3 equiv). 
Evaporation in vacuo afforded an orange oil (0.161 g) which was dissolved in 
dichloromethane and coated onto silica under reduced pressure. Subsequently, purification 
was performed via automated flash chromatography with hexane/ethyl acetate as eluent on a 
Reveleris® 12-g silica cartridge (1% (m/m) sample loading; flow rate: 36 mL min-1; eluent: 
2 CV of 6% (v/v) ethyl acetate, followed by a gradient from 6% (v/v) to 60% (v/v) ethyl 
acetate over 30 CV; detection wavelengths: 220 nm and 270 nm). This resulted in (S)-3’-
acryloxyblebbistatin (S)-131 (0.107 g, 61%) as a yellow powder. The enantiomeric excess 
was >99% as determined by chiral-HPLC analysis. 
(S)-3-(3a-Hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-yl)-
phenyl acrylate ((S)-131) 
Yield = 61%. Yellow powder (m.p. 178 °C). Rf = 0.51 
(hexane/ethyl acetate, 1:1). Ee >99%, chiral HPLC: 
tR ((S)-131) = 7.63 min, tR ((R)-131) = 8.85 min (Daicel Chiralpak 




 = −295 (c = 0.16 in tetrahydrofuran). 1H-NMR (400 MHz, 
DMSO-d6): δ = 2.21–2.36 (5H, m, H3’, CH3), 3.93–4.10 (2H, m, 
H2’), 6.19 (1H, dd, J1 = 10.2 Hz, J2 = 1.1 Hz, C(O)CHCH
aHb), 6.46 (1H, dd, J1 = 17.4 Hz, 
J2 = 10.2 Hz, C(O)CH), 6.58 (1H, dd, J1 = 17.4 Hz, J2 = 1.1 Hz, C(O)CHCH
aHb), 6.89 (1H, s, 
OH), 6.97 (1H, dd, J1 = 8.1 Hz, J2 = 2.1 Hz, H
6), 7.13 (1H, d, J = 8.2 Hz, H8’), 7.39 (1H, dd, 
J1 = 8.2 Hz, J2 = 1.6 Hz, H
7’), 7.48 (1H, dd, J1 = 8.3 Hz, J2 = 8.1 Hz, H
5), 7.55 (1H, d, 
J = 1.6 Hz, H5’), 7.94 (1H, dd, J1 = 8.3 Hz, J2 = 2.0 Hz, H
4), 8.10 (1H, dd, J1 = 2.1 Hz, 
J2 = 2.0 Hz, H
2). 13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.6 (C
3’), 48.0 (C2’), 73.3 
(C3a’), 113.3 (C2), 117.1 (C4, C6), 121.5 (C4a’), 126.5 (C8’), 126.8 (C5’), 128.2 (C(O)CH), 130.0 
(C5), 133.1 (C6’), 134.2 (C(O)CHCH2), 136.9 (C
7’), 142.0 (C3), 149.1 (C8a’), 150.8 (C1), 164.6 
(C(O)CH), 165.8 (C9a’), 194.9 (C4’). IR (ATR, cm-1): νmax = 802, 1022, 1146, 1221, 1589 
(C=N), 1692 (C=O), 1734 (C=O). MS (ESI): m/z (%) = 362.5 ([M+H]+, 100). HRMS (ESI): 
calculated for C21H19N2O4 ([M+H]
+) 363.1339; found 363.1345. MW = 362.39. 
1.2.30.2. Synthesis of (S)-3’-propionyloxyblebbistatin (S)-132 
(S)-3’-Propionyloxyblebbistatin (S)-132 was synthesized from (S)-3’-hydroxyblebbistatin 
(S)-94 (0.150 g, 0.487 mmol, 1 equiv) and propionyl chloride (59.5 µL, 0.682 mmol, 
1.4 equiv). Evaporation in vacuo afforded (S)-3’-propionyloxyblebbistatin (S)-132 as a bright-





phenyl propionate ((S)-132) 
Yield = 99%. Bright-yellow powder (m.p. 176 °C). Rf = 0.53 
(hexane/ethyl acetate, 1:1). Ee 99%, chiral HPLC: tR ((S)-132) = 
16.4 min, tR ((R)-132) = 20.8 min (Daicel Chiralpak IA column, 
acetonitrile/water (40:60), 1.0 mL min-1, 25 °C). [α]
D
25
 = −290 
(c = 0.13 in tetrahydrofuran). 1H-NMR (400 MHz, DMSO-d6): 
δ = 1.16 (3H, t, J = 7.5 Hz, C(O)CH2CH3), 2.21–2.36 (5H, m, H
3’, 
CH3), 2.65 (2H, q, J = 7.5 Hz, C(O)CH2), 3.92–4.10 (2H, m, H
2’), 6.88 (1H, s, OH), 6.91 (1H, 
dd, J1 = 8.1 Hz, J2 = 2.0 Hz, H
6), 7.14 (1H, d, J = 8.0 Hz, H8’), 7.40 (1H, dd, J1 = 8.0 Hz, 
J2 = 1.6 Hz, H
7’), 7.45 (1H, dd, J1 = 8.3 Hz, J2 = 8.1 Hz, H
5), 7.55 (1H, d, J = 1.6 Hz, H5’), 7.90 
(1H, dd, J1 = 8.3 Hz, J2 = 1.9 Hz, H
4), 8.05 (1H, dd, J1 = 2.0 Hz, J2 = 1.9 Hz, H
2). 13C-NMR 
(100.6 MHz, DMSO-d6): δ = 9.4 (C(O)CH2CH3), 20.7 (CH3), 27.4 (C(O)CH2), 28.6 (C
3’), 48.0 
(C2’), 73.3 (C3a’), 113.5 (C2), 116.9 (C4), 117.3 (C6), 121.5 (C4a’), 126.5 (C8’), 126.8 (C5’), 129.9 
(C5), 133.1 (C6’), 136.9 (C7’), 142.0 (C3), 149.2 (C8a’), 151.1 (C1), 165.8 (C9a’), 173.1 
(C(O)CH2), 194.9 (C
4’). IR (ATR, cm-1): νmax = 791, 1096, 1134, 1593 (C=N), 1684 (C=O), 
1755 (C=O), 3420 (OH). MS (ESI): m/z (%) = 364.6 ([M+H]+, 100). HRMS (ESI): calculated 
for C21H21N2O4 ([M+H]
+) 365.1496; found 365.1502. MW = 364.40. 
1.2.31. General procedure for the amidation of anilines using acid anhydrides 
The selective monoamidation of anilines was adopted from a publication of Jahani et al.95  
In a bulb of 10 mL, containing 3 mL of absolute ethanol, 0.0028 g of guanidine hydrochloride 
(0.0293 mmol, 0.15 equiv), acid anhydride (0.197 mmol, 1.01 equiv) and aniline 
(0.195 mmol, 1 equiv) were brought together under a nitrogen atmosphere. The reaction 
mixture was heated to 40 °C and stirred for 30 minutes. Next, the mixture was diluted with 
75 mL of ethyl acetate and washed with saturated aqueous NaHCO3 (2× 40 mL) and brine 
(30 mL). The organic layer was dried over magnesium sulfate and evaporated in vacuo. 
1.2.31.1. Synthesis of (S)-3’-acrylamidoblebbistatin (S)-133 
(S)-3’-Acrylamidoblebbistatin (S)-133 was synthesized from (S)-3’-aminoblebbistatin (S)-95 
(0.0600 g, 0.195 mmol, 1 equiv) and acrylic anhydride (22.7 µL, 0.197 mmol, 1.01 equiv). 
Evaporation in vacuo afforded a yellow powder (0.0670 g) which was dissolved in acetone 
and further purified via preparative TLC with hexane/ethyl acetate (2:3) as eluent. This 
resulted in (S)-3’-acrylamidoblebbistatin (S)-133 (0.0515 g, 73%) as an orange powder. The 






Yield = 73%. Orange powder (m.p. 236 °C). Rf = 0.21 
(hexane/ethyl acetate, 2:3). Ee 99%, chiral HPLC: tR ((S)-133) = 
24.2 min, tR ((R)-133) = 11.1 min (Daicel Chiralpak IA column, 
hexane/dichloromethane/absolute ethanol (10:90:3), 
0.5 mL min-1, 35 °C). 1H-NMR (400 MHz, DMSO-d6): δ = 2.22–
2.37 (5H, m, H3’, CH3), 3.89–3.99 (1H, m, H
2a’), 3.99–4.10 (1H, 
m, H2b’), 5.78 (1H, dd, J1 = 10.0 Hz, J2 = 1.9 Hz, C(O)CHCH
aHb), 6.29 (1H, dd, J1 = 17.0 Hz, 
J2 = 1.9 Hz, C(O)CHCH
aHb), 6.49 (1H, dd, J1 = 17.0 Hz, J2 = 10.0 Hz, C(O)CH), 6.85 (1H, s, 
OH), 7.17 (1H, d, J = 7.9 Hz, H8’), 7.37 (1H, dd, J1 = 8.2 Hz, J2 = 8.1 Hz, H
5), 7.40 (1H, dd, 
J1 = 7.9 Hz, J2 = 1.7 Hz, H
7’), 7.48–7.56 (1H, m, H6), 7.54 (1H, d, J = 1.7 Hz, H5’), 7.80 (1H, 
dd, J1 = 8.2 Hz, J2 = 1.8 Hz, H
4), 8.43 (1H, dd, J1 = 2.0 Hz, J2 = 1.8 Hz, H
2), 10.22 (1H, br. s, 
NH). 13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.8 (C
3’), 48.0 (C2’), 73.3 (C3a’), 
111.3 (C2), 115.2 (C6), 115.4 (C4), 121.5 (C4a’), 126.5 (C8’), 126.8 (C5’), 127.4 (C(O)CHCH2), 
129.4 (C5), 132.4 (C(O)CHCH2), 132.8 (C
6’), 136.9 (C7’), 139.8 (C1), 141.3 (C3), 149.5 (C8a’), 
163.7 (C(O)CH), 165.7 (C9a’), 195.0 (C4’). IR (ATR, cm-1): νmax = 781, 797, 1238, 1476, 1589 
(C=N), 1667 (C=O), 1684 (C=O). MS (ESI): m/z (%) = 361.5 ([M+H]+, 100). HRMS (ESI): 
calculated for C21H20N3O3 ([M+H]
+) 362.1499; found 362.1497. MW = 361.39. 
1.2.31.2. Synthesis of (S)-3’-propionylamidoblebbistatin (S)-134 
(S)-3’-Propionylamidoblebbistatin (S)-134 was synthesized from (S)-3’-aminoblebbistatin 
(S)-95 (0.0600 g, 0.195 mmol, 1 equiv) and propionic anhydride (25.3 µL, 0.197 mmol, 
1.01 equiv). Evaporation in vacuo afforded (S)-3’-propionylamidoblebbistatin (S)-134 
(0.0648 g, 91%) as an orange powder. The enantiomeric excess was >99% as determined 
by chiral-HPLC analysis. 
(S)-N-(3-(3a-Hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-
1-yl)phenyl)propionamide ((S)-134) 
Yield = 91%. Orange powder (m.p. 220 °C). Ee >99%, chiral 
HPLC: tR ((S)-134) = 17.4 min, tR ((R)-134) = 9.37 min (Daicel 
Chiralpak IA column, hexane/dichloromethane/absolute ethanol 
(10:90:3), 0.5 mL min-1, 35 °C). [α]
D
25
 = −306 (c = 0.21 in 
tetrahydrofuran). 1H-NMR (400 MHz, DMSO-d6): δ = 1.11 (3H, t, 
J = 7.5 Hz, C(O)CH2CH3), 2.22–2.30 (2H, m, H
3’), 2.31 (3H, s, 
CH3), 2.36 (2H, q, J = 7.5 Hz, C(O)CH2), 3.88–3.96 (1H, m, H
2a’), 3.97–4.08 (1H, m, H2b’), 
6.84 (1H, s, OH), 7.16 (1H, d, J = 8.1 Hz, H8’), 7.32 (1H, t, J = 8.1 Hz, H5), 7.39 (1H, dd, 
J1 = 8.1 Hz, J2 = 1.9 Hz, H
7’), 7.41–7.47 (1H, m, H6), 7.54 (1H, d, J = 1.9 Hz, H5’), 7.74–7.80 
(1H, m, H4), 8.33 (1H, t, J = 1.9 Hz, H2), 9.93 (1H, br. s, NH). 13C-NMR (100.6 MHz, 
DMSO-d6): δ = 10.1 (C(O)CH2CH3), 20.7 (CH3), 28.8 (C
3’), 30.0 (C(O)CH2), 48.0 (C
2’), 73.3 
(C3a’), 110.9 (C2), 114.9 (C6), 114.9 (C4), 121.5 (C4a’), 126.4 (C8’), 126.8 (C5’), 129.2 (C5), 
132.7 (C6’), 136.9 (C7’), 140.2 (C1), 141.2 (C3), 149.6 (C8a’), 165.7 (C9a’), 172.5 (C(O)CH2), 
195.1 (C4’). IR (ATR, cm-1): νmax = 775, 1107, 1238, 1458, 1595 (C=N), 1622 (C=O), 1668 
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(C=O), 3260, 3441 (NH, OH). MS (ESI): m/z (%) = 363.5 ([M+H]+, 100). HRMS (ESI): 
calculated for C21H22N3O3 ([M+H]
+) 364.1656; found 364.1661. MW = 363.41. 
1.2.32. Synthesis of (S)-(2,3-dihydro-1H)-pyrrolo[2,3-c’]blebbistatin (S)-135 
Amidine 154 (2.64 g, 6.77 mmol, 1 equiv) was converted via the general procedure for the 
one-pot synthesis of α-hydroxy ketones from amidines (see procedure 1.2.24.). Evaporation 
in vacuo afforded an orange-brown powder (1.29 g) containing 86% (m/m) of compound 
(S)-155 and 14% (m/m) of molecule (S)-156. The enantiomeric excess of (S)-155 in this 
mixture was 80% as determined by chiral-HPLC analysis (Daicel Chiralpak IA column, 
acetonitrile/water (60:40), 1.0 mL min-1, 25 °C). The powder was redissolved in 50 mL of 
boiling acetonitrile and left untouched for 19 hours at room temperature. This afforded dark-
yellow-brown fibers (0.212 g), containing 91% (m/m) of (S)-155 and 9% (m/m) of (S)-156, 
with an enantiomeric excess of >99%.  
(S)-(2,3-Dihydro-1H)-pyrrolo[2,3-c’]blebbistatin (S)-135 was synthesized from 0.210 g of the 
crude (S)-155/(S)-156 (91:9) mixture (0.512 mmol of (S)-155, 1 equiv) via the general 
procedure for the allyl deprotection of allyl phenyl amines (see procedure 1.2.26.). 
Evaporation in vacuo afforded an orange-brown powder (0.354 g) which was dissolved in 
tetrahydrofuran and coated under reduced pressure onto silica. Subsequently, purification 
was performed via automated flash chromatography with hexane/ethyl acetate as eluent on a 
Reveleris® 40-g silica cartridge (1% (m/m) sample loading; flow rate: 40 mL min-1; eluent: 
2 CV of 20% (v/v) ethyl acetate, followed by a gradient from 20% (v/v) to 100% (v/v) ethyl 
acetate over 20 CV; detection wavelengths: 220 nm and 250 nm). This resulted in 
(S)-(2,3-dihydro-1H)-pyrrolo[2,3-c’]blebbistatin (S)-135 (0.125 g, 73%) as an orange powder. 
The enantiomeric excess was >99% as determined by chiral-HPLC analysis analysis. 
(S)-3a-Hydroxy-1-(indolin-6-yl)-6-methyl-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-
4-one ((S)-135) 
Yield = 73%. Orange powder. Rf = 0.22 (hexane/ethyl acetate, 1:1). 
Ee >99%, chiral HPLC: tR ((S)-135) = 4.93 min, tR ((R)-135) = 
8.19 min (Daicel Chiralpak IA column, acetonitrile/water (60:40), 
1.0 mL min-1, 25 °C). 1H-NMR (400 MHz, DMSO-d6): δ = 2.18–2.25 
(2H, m, H3), 2.29 (3H, s, CH3), 2.90 (2H, t, J = 8.4 Hz, H
3’), 3.44 (2H, 
t, J = 8.4 Hz, H2’), 3.82–3.89 (1H, m, H2a), 3.95–4.04 (1H, m, H2b), 
5.64 (1H, br. s, NH), 6.78 (1H, s, OH), 7.00–7.06 (1H, m, H4’), 7.03–
7.07 (2H, m, H5’, H8), 7.33–7.38 (1H, m, H7), 7.36–7.38 (1H, m, H7’), 7.51 (1H, d, J = 1.8 Hz, 
H5). 13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 28.9 (C
3), 29.2 (C3’), 47.2 (C2’), 48.5 
(C2), 73.5 (C3a), 101.5 (C7’), 109.2 (C5’), 121.3 (C4a), 124.3 (C4’), 125.1 (C3a’), 126.1 (C8), 
126.7 (C5), 132.2 (C6), 136.9 (C7), 140.3 (C6’), 150.1 (C8a), 153.4 (C7a’), 165.5 (C9a), 195.2 
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(C4). IR (ATR, cm-1): νmax = 1229, 1479, 1582, 1599 (C=N), 1692 (C=O). MS (ESI): m/z 
(%) = 334.1 ([M+H]+, 100). HRMS (ESI): calculated for C20H20N3O2 ([M+H]
+) 334.1550; found 
334.1554. MW = 333.39. 
1.2.33. Synthesis of (S)-(1H)-pyrrolo[2,3-c’]blebbistatin (S)-138 
Oxidation of (S)-(2,3-dihydro-1H)-pyrrolo[2,3-c’]blebbistatin (S)-135 to (S)-(1H)-pyrrolo-
[2,3-c’]blebbistatin (S)-138 was based on a procedure reported by Reggelin et al.131 
In a bulb of 50 mL, 0.105 g of (S)-135 (0.316 mmol, 1 equiv) was dissolved in 40 mL of 
chloroform, after which 0.312 g of MnO2 (88%(m/m)) (3.16 mmol, 10 equiv) was added, and 
the mixture was stirred for 3 hours at room temperature. Next, the solids were filtered off over 
celite and the filter cake was rinsed with 120 mL of tetrahydrofuran. Evaporation of the filtrate 
in vacuo afforded (S)-(1H)-pyrrolo[2,3-c’]blebbistatin (S)-138 (0.0729 g, 70%) as an orange 




Yield = 70%. Orange powder (m.p. 233 °C). Ee >99%, chiral HPLC: 
tR ((S)-138) = 4.52 min, tR ((R)-138) = 5.94 min (Daicel Chiralpak IA 
column, acetonitrile/water (60:40), 1.0 mL min-1, 25 °C). [α]
D
25
 = −578 
(c = 0.10 in tetrahydrofuran). 1H-NMR (400 MHz, DMSO-d6): 
δ = 2.23–2.34 (2H, m, H3), 2.30 (3H, s, CH3), 3.94–4.04 (1H, m, H
2a), 
4.10–4.21 (1H, m, H2b), 6.40–6.45 (1H, m, H3’), 6.81 (1H, s, OH), 
7.07 (1H, d, J = 8.1 Hz, H8), 7.32–7.37 (1H, m, H2’), 7.33–7.40 (1H, 
m, H7), 7.50–7.55 (1H, m, H5), 7.50–7.55 (2H, m, H4’, H5’), 8.23 (1H, br. s, H7’), 11.14 (1H, br. 
s, NH). 13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 29.2 (C
3), 49.0 (C2), 73.6 (C3a), 
101.4 (C3’), 104.6 (C7’), 113.2 (C5’), 120.2 (C4’), 121.4 (C4a), 125.0 (C3a’), 126.0 (C8), 126.3 
(C2’), 126.8 (C5), 131.9 (C6), 135.1, 136.2 (C6’, C7a’), 136.9 (C7), 150.4 (C8a), 165.6 (C9a), 
195.3 (C4). IR (ATR, cm-1): νmax = 799, 833, 1476, 1595 (C=N), 1678 (C=O), 3244, 3402 (NH, 
OH). MS (ESI): m/z (%) = 332.1 ([M+H]+, 100). HRMS (ESI): calculated for C20H18N3O2 
([M+H]+) 332.1394; found 332.1396. MW = 331.38. 
1.2.34. Synthesis of (S)-4’-benzyloxyblebbistatin (S)-142 
In a flame-dried bulb of 10 mL, 0.0300 g of (S)-4’-hydroxyblebbistatin (S)-139 (0.0973 mmol, 
1 equiv) was dissolved in 5 mL of dry acetonitrile. The reaction mixture was cooled to 0 °C, 
after which 0.0015 g of NaI (0.0097 mmol, 0.1 equiv), 0.0333 g of Cs2CO3 (0.102 mmol, 
1.05 equiv) and 12.1 µL of benzyl bromide (0.102 mmol, 1.05 equiv) were added 
sequentially. Then, the reaction mixture was stirred for 1 hour at 50 °C under a nitrogen 
atmosphere. Afterwards, the mixture was diluted with 30 mL of ethyl acetate and washed 
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with saturated aqueous NH4Cl (2× 10 mL). The organic layer was dried over magnesium 
sulfate and evaporated in vacuo. This resulted in a yellow-orange powder (0.0475 g) which 
was dissolved in tetrahydrofuran and coated under reduced pressure onto silica. 
Subsequently, purification was performed via automated flash chromatography with 
hexane/ethyl acetate as eluent on a Reveleris® 12-g silica cartridge (1% (m/m) sample 
loading; flow rate: 30 mL min-1; eluent: 2 CV of 10% (v/v) ethyl acetate, followed by a 
gradient from 10% (v/v) to 70% (v/v) ethyl acetate over 30 CV; detection wavelengths: 
228 nm and 268 nm). This resulted in (S)-4’-benzyloxyblebbistatin (S)-142 (0.0242 g, 62%) 




Yield = 62%. Yellow powder. Rf = 0.32 (hexane/ethyl acetate, 
3:2). Ee >99%, chiral HPLC: tR ((S)-142) = 6.80 min, tR ((R)-142) = 
9.55 min (Daicel Chiralpak IA column, acetonitrile/water (70:30), 
1.0 mL min-1, 25 °C). 1H-NMR (400 MHz, DMSO-d6): δ = 2.21–
2.28 (2H, m, H3), 2.30 (3H, s, CH3), 3.87–3.95 (1H, m, H
2a), 4.00–
4.09 (1H, m, H2b), 5.13 (2H, s, OCH2), 6.79 (1H, s, OH), 7.05–7.11 
(3H, m, H8, H3’, H5’), 7.31–7.38 (2H, m, H4”, H7), 7.38–7.44 (2H, m, 
H3”, H5”), 7.45–7.49 (2H, m, H2”, H6”), 7.52 (1H, d, J = 1.6 Hz, H5), 
7.94–8.00 (2H, m, H2’, H6’). 13C-NMR (100.6 MHz, DMSO-d6): 
δ = 20.7 (CH3), 29.0 (C
3), 48.2 (C2), 69.8 (OCH2), 73.4 (C
3a), 115.3 (C3’, C5’), 121.4 (C4a), 
121.7 (C2’, C6’), 126.1 (C8), 126.8 (C5), 128.2 (C2”, C6”), 128.3 (C4”), 128.9 (C3”, C5”), 132.2 
(C6), 134.5 (C1’), 136.9 (C7), 137.6 (C1”), 150.0 (C8a), 155.0 (C4’), 165.3 (C9a), 195.1 (C4). IR 
(ATR, cm-1): νmax = 733, 1236, 1481, 1510, 1597 (C=N), 1692 (C=O). MS (ESI): 
m/z (%) = 399.2 ([M+H]+, 100). HRMS (ESI): calculated for C25H23N2O3 ([M+H]
+) 399.1703; 
found 399.1713. MW = 398.45. 
1.2.35. Synthesis of (S)-4’-aminoblebbistatin (S)-140 
In each of seven vials of 3 mL, 5.0 mg of (S)-4’-nitroblebbistatin (S)-130 (0.015 mmol, 
1 equiv) was dissolved in 2 mL of methanol, after which 9.4 mg of ammonium formate 
(0.148 mmol, 10 equiv) and 5.0 mg of 10% (m/m) Pd/C were added. The mixture was stirred 
for 15 minutes at room temperature. Next, the contents of all seven vials were filtered off 
over celite and the filter cake was rinsed with 20 mL of methanol. Afterwards, the filtrate was 
concentrated to a volume of 5 mL, diluted with 70 mL of ethyl acetate, washed with saturated 
aqueous NH4Cl (2× 30 mL) and dried over magnesium sulfate. Evaporation in vacuo afforded 
a dark-orange powder (0.039 g) which was dissolved in tetrahydrofuran and coated under 
reduced pressure onto silica. Subsequently, purification was performed via automated flash 
chromatography with hexane/ethyl acetate as eluent on a Reveleris® 12-g silica cartridge 
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(0.3% (m/m) sample loading; flow rate: 36 mL min-1; eluent: 2 CV of 20% (v/v) ethyl acetate, 
followed by a gradient from 20% (v/v) to 100% (v/v) ethyl acetate over 20 CV; detection 
wavelengths: 246 nm and 260 nm). This resulted in (S)-4’-aminoblebbistatin (S)-140 (9.8 mg, 
31%) as a bright-red powder. 
(S)-1-(4-Aminophenyl)-3a-hydroxy-6-methyl-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]-
quinolin-4-one ((S)-140)54 
Yield = 31%. Bright-red powder. Rf = 0.25 (hexane/ethyl acetate, 1:4). 
1H-NMR (400 MHz, DMSO-d6): δ = 2.17–2.24 (2H, m, H3), 2.28 (3H, s, 
CH3), 3.77–3.89 (1H, m, H
2a), 3.94–4.04 (1H, m, H2b), 5.06 (2H, br. s, 
NH2), 6.71 (1H, s, OH), 6.57–6.64 (2H, m, H
3’, H5’), 7.01 (1H, d, 
J = 8.2 Hz, H8), 7.31 (1H, dd, J1 = 8.1 Hz, J2 = 1.7 Hz, H
7), 7.48 (1H, d, 
J = 1.7 Hz, H5), 7.62–7.67 (2H, m, H2’, H6’). 13C-NMR (100.6 MHz, 
DMSO-d6): δ = 20.6 (CH3), 29.1 (C
3), 48.4 (C2), 73.5 (C3a), 114.1 (C3’, 
C5’), 121.2 (C4a), 122.1 (C2’, C6’), 126.0 (C8), 126.7 (C5), 130.2 (C1’), 131.5 (C6), 136.9 (C7), 
146.0 (C4’), 150.7 (C8a), 165.0 (C9a), 195.3 (C4). IR (ATR, cm-1): νmax = 833, 1263, 1477, 
1508, 1593 (C=N), 1674 (C=O), 3347 (NH2), 3445 (OH), 3499 (NH2). MS (ESI): 
m/z (%) = 308.0 ([M+H]+, 100). HRMS (ESI): calculated for C18H18N3O2 ([M+H]
+) 308.1394; 
found 308.1390. MW = 307.35. 
1.2.36. Synthesis of (S)-(2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-172 
For the synthesis of (S)-(2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-172, the general 
procedure for the allyl deprotection of allyl phenyl amines (see procedure 1.2.26.) was 
modified.  
In a flame-dried bulb of 250 mL, containing 70 mL of dry dichloromethane, 0.867 g of 
(S)-(N-allyl-2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-173 (2.41 mmol, 1 equiv), 2.25 g of 
N,N’-dimethylbarbituric acid (126) (14.4 mmol, 6 equiv) and 0.277 g of tetrakis(triphenyl-
phosphine)palladium(0) (0.241 mmol, 0.1 equiv) were brought together under a nitrogen 
atmosphere and stirred at reflux temperature. A second, third and fourth portion of 
tetrakis(triphenylphosphine)palladium(0) (0.277 g, 0.241 mmol, 0.1 equiv) were added after 
1.5, 3 and 4.5 hours, respectively. During the reaction, the product had precipitated. After a 
total reaction time of 6 hours, the reaction mixture was cooled to room temperature and the 
solids were filtered off on a sintered-glass Büchner funnel and rinsed with dichloromethane 
until the filtrate turned colorless. The residue was dried under reduced pressure to afford 
(S)-(2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-172 (0.730 g, 95%) as a yellow powder. 





Yield = 95%. Yellow powder (m.p. >250 °C). Ee 98%, chiral HPLC: 
tR ((S)-172) = 13.5 min, tR ((R)-172) = 18.8 min (Daicel Chiralpak IA 
column, acetonitrile/water (30:70), 1.0 mL min-1, 25 °C). 1H-NMR 
(400 MHz, DMSO-d6): δ = 2.02–2.16 (1H, m, H6a), 2.23 (1H, dd, 
J1 = 13.3 Hz, J2 = 4.8 Hz, H
6b), 2.92 (2H, t, J = 8.0 Hz, H3), 3.58 (2H, 
t, J = 8.0 Hz, H2), 3.91 (1H, t, J = 8.8 Hz, H7a), 3.96–4.09 (1H, m, 
H7b), 6.19 (1H, s, H10), 6.51 (1H, s, OH), 6.74 (1H, br. s, NH), 7.12 (1H, t, J = 7.2 Hz, H4’), 
7.37 (1H, br. s, H4), 7.41 (2H, dd, J1 = 7.7 Hz, J2 = 7.2 Hz, H
3’, H5’), 8.07 (2H, d, J = 7.7 Hz, 
H2’, H6’). 13C-NMR (100.6 MHz, DMSO-d6): δ = 27.7 (C3), 29.6 (C6), 46.8 (C2), 47.9 (C7), 72.7 
(C5a), 103.3 (C10), 110.8 (C4a), 119.8 (C2’, C6’), 122.8 (C4), 123.7 (C4’), 124.9 (C3a), 129.1 (C3’, 
C5’), 141.2 (C1’), 154.2 (C9a), 160.0 (C10a), 166.9 (C8a), 191.4 (C5). IR (ATR, cm-1): 
νmax = 1285, 1310, 1406, 1472, 1555 (C=N), 1657 (C=O), 3314 (NH, OH). MS (ESI): m/z 
(%) = 320.0 ([M+H]+, 100). HRMS (ESI): calculated for C19H18N3O2 ([M+H]
+) 320.1394; found 
320.1401. MW = 319.36. 
1.2.37. Synthesis of (S)-(1H)-pyrrolo[3,2-h]blebbistatin (S)-171 
In a bulb of 100 mL, 0.400 g of (S)-(2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-172 
(1.25 mmol, 1 equiv) was dissolved in 50 mL of N,N-dimethylformamide, after which 1.24 g of 
MnO2 (88% (m/m)) (12.5 mmol, 10 equiv) was added. A second, third, fourth and fifth portion 
of MnO2 (88% (m/m)) (1.24 g, 12.5 mmol, 10 equiv) were added after 5, 10, 15 and 
20 minutes, respectively. After a total reaction time of 25 minutes, the solids were filtered off 
over celite and the filter cake was rinsed with 300 mL of tetrahydrofuran. The filtrate was 
evaporated to remove tetrahydrofuran. The residue was diluted with 800 mL of ethyl acetate 
and washed with brine (3× 250 mL) and water (3× 250 mL). Next, the organic layer was dried 
over magnesium sulfate and evaporation in vacuo afforded (S)-(1H)-pyrrolo[3,2-h]blebbistatin 
(S)-171 (0.381 g, 96%) as a brown powder. 
(S)-5a-Hydroxy-8-phenyl-5,5a,6,7-tetrahydro-1H,8H-dipyrrolo[2,3-b:3',2'-g]quinolin-
5-one (S)-171 
Yield = 96%. Brown powder (m.p. >250 °C). 1H-NMR (400 MHz, 
DMSO-d6): δ = 2.16–2.31 (2H, m, H6), 3.94 (1H, t, J = 8.2 Hz, H7a), 
3.98–4.09 (1H, m, H7b), 6.51 (1H, br. s, H3), 6.69 (1H, s, OH), 7.08–
7.16 (1H, m, H4’), 7.12 (1H, s, H10), 7.33 (1H, t, J = 2.4 Hz, H2), 7.43 
(2H, dd, J1 = 8.0 Hz, J2 = 7.9 Hz, H
3’, H5’), 8.02 (1H, s, H4), 8.12 (2H, 
d, J = 8.0 Hz, H2’, H6’), 11.27 (1H, br. s, NH). 13C-NMR (100.6 MHz, 
DMSO-d6): δ = 29.1 (C6), 47.5 (C7), 73.2 (C5a), 103.7 (C3), 107.5 (C10), 116.0 (C4a), 119.6 
(C2’, C6’), 120.5 (C4), 123.3 (C4’), 125.1 (C3a), 127.4 (C2), 129.1 (C3’, C5’), 141.5 (C10a, C1’), 
146.0 (C9a), 164.0 (C8a), 194.9 (C5). IR (ATR, cm-1): νmax = 760, 1308, 1562, 1591, 1603 
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(C=N), 1676 (C=O), 3258 (NH, OH). MS (ESI): m/z (%) = 317.9 ([M+H]+, 100). HRMS (ESI): 
calculated for C19H16N3O2 ([M+H]
+) 318.1237; found 318.1251. MW = 317.35. 
1.2.38. Synthesis of (±)-trans-2-(hydroxymethyl)blebbistatin (±)-trans-185 and (±)-cis-
2-(hydroxymethyl)blebbistatin (±)-cis-185 
In a flame-dried bulb of 100 mL, containing 50 mL of dry methanol, 0.534 g of (±)-2-(allyloxy-
methyl)blebbistatin (±)-188 (1.24 mmol of (±)-trans-188 and 0.236 mmol of (±)-cis-188, 
1 equiv) and 0.0848 g of tetrakis(triphenylphosphine)palladium(0) (0.0737 mmol, 0.05 equiv) 
were brought together under a nitrogen atmosphere and stirred for 5 minutes at room 
temperature. Then, 1.22 g of K2CO3 (8.84 mmol, 6 equiv) was added and the reaction 
mixture was stirred for 10 hours at reflux temperature. Afterwards, the mixture was 
concentrated to a volume of 5 mL, diluted with 140 mL of ethyl acetate, washed with 
saturated aqueous NH4Cl (2× 30 mL) and dried over magnesium sulfate. Evaporation in 
vacuo afforded an orange-brown oil (0.640 g) which was diluted with 50 mL of 
tetrahydrofuran. This resulted in precipitation of (±)-cis-(2-hydroxymethyl)blebbistatin 
(±)-cis-185 (0.0270 g, 36%) as a yellow powder which was filtered off on a sintered-glass 
Büchner funnel. Next, the filtrate was coated under reduced pressure onto silica. 
Subsequently, purification was performed via automated flash chromatography with 
hexane/ethyl acetate as eluent on a Reveleris® 40-g silica cartridge (2% (m/m) sample 
loading; flow rate: 40 mL min-1; eluent: 2 CV of 20% (v/v) ethyl acetate, followed by a 
gradient from 20% (v/v) to 100% (v/v) ethyl acetate over 25 CV; detection wavelengths: 
220 nm and 258 nm). Evaporation afforded (±)-trans-2-(hydroxymethyl)blebbistatin (±)-trans-
185 (0.120 g, 30%) as an orange powder. 
(±)-Trans-3a-hydroxy-2-(hydroxymethyl)-6-methyl-1-phenyl-2,3,3a,4-tetrahydro-
1H-pyrrolo[2,3-b]quinolin-4-one ((±)-trans-185) 
Yield = 30%. Orange powder. 1H-NMR (400 MHz, DMSO-d6): 
δ = 2.18–2.36 (2H, m, H3), 2.28 (3H, s, CH3), 3.46 (1H, ddd, 
J1 = 11.6 Hz, J2 = 5.1 Hz, J3 = 2.4 Hz, CH
aHbOH), 3.52 (1H, ddd, 
J1 = 11.6 Hz, J2 = 4.9 Hz, J3 = 4.7 Hz, CH
aHbOH), 4.52–4.62 (1H, m, 
H2), 4.76 (1H, dd, J1 = 5.1 Hz, J2 = 4.9 Hz, CH
aHbOH), 6.86 (1H, s, 
OH), 6.93 (1H, d, J = 8.1 Hz, H8), 7.22–7.29 (1H, m, H4’), 7.28–7.34 
(1H, m, H7), 7.41–7.49 (2H, m, H3’, H5’), 7.50 (1H, d, J = 1.9 Hz, H5), 7.58–7.66 (2H, m, H2’, 
H6’). 13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 31.6 (C
3), 59.6 (CH2OH), 60.1 (C
2), 
72.6 (C3a), 121.8 (C4a), 125.4 (C2’, C6’), 125.8, 125.9 (C8, C4’), 126.8 (C5), 129.0 (C3’, C5’), 
132.0 (C6), 136.9 (C7), 138.6 (C1’), 150.3 (C8a), 166.9 (C9a), 195.4 (C4). MS (ESI): m/z 
(%) = 323.0 ([M+H]+, 100). HRMS (ESI): calculated for C19H19N2O3 ([M+H]
+) 323.1390; found 





Yield = 36%. Yellow powder (m.p. >250 °C). 1H-NMR (400 MHz, 
DMSO-d6): δ = 2.17–2.35 (2H, m, H3), 2.28 (3H, s, CH3), 3.54–3.72 
(2H, m, CH2OH), 4.51–4.64 (1H, m, H
2), 5.51 (1H, t, J = 4.5 Hz, 
CH2OH), 6.91 (1H, s, OH), 7.00 (1H, d, J = 8.1 Hz, H
8), 7.19 (1H, t, 
J = 7.6 Hz, H4’), 7.28–7.37 (1H, m, H7), 7.44 (2H, dd, J1 = 7.9 Hz, 
J2 = 7.6 Hz, H
3’, H5’), 7.49 (1H, br. s, H5), 7.85 (2H, d, J = 7.9 Hz, H2’, 
H6’). 13C-NMR (100.6 MHz, DMSO-d6): δ = 20.7 (CH3), 31.6 (C
3), 61.1 (C2), 61.4 (CH2OH), 
72.9 (C3a), 121.7 (C4a), 123.3 (C2’, C6’), 125.1 (C4’), 126.1 (C8), 126.8 (C5), 129.3 (C3’, C5’), 
132.4 (C6), 136.9 (C7), 139.2 (C1’), 149.8 (C8a), 166.8 (C9a), 195.2 (C4). IR (ATR, cm-1): 
νmax = 1022, 1292, 1477, 1574, 1589 (C=N), 1703 (C=O). MS (ESI): m/z (%) = 323.0 ([M+H]
+, 
100). HRMS (ESI): calculated for C19H19N2O3 ([M+H]
+) 323.1390; found 323.1397. 
MW = 322.36. 
2. ATPase assay 
2.1. Preparation of F-actin filaments stock solution 
Pre-formed rabbit skeletal-muscle F-actin filaments (cat. # AKF99) were purchased from 
Cytoskeleton, Inc. in lyophilized form (1 mg). The protein was dissolved in 2.4 mL of Milli-Q 
water and gently mixed to a concentration of 0.4 mg mL-1. To allow the filaments to 
dissociate from each other, this solution was incubated at room temperature for 10 minutes. 
Then, the filaments were aliquoted into 100 µL samples, snap frozen in liquid nitrogen and 
stored at −80 °C. For compounds (S)-93–97,120,121,131–134, 
(S)-135,136,138,139,141,142, (S)-130,140,170–173 and (±)-185,188, different batches of 
pre-formed rabbit skeletal-muscle F-actin filaments were used. As a reference, compound 
(S)-4 was evaluated with all batches of pre-formed rabbit skeletal-muscle F-actin filaments. 
2.2. Preparation of myosin stock solution 
Full-length rabbit skeletal-muscle myosin II protein (cat. # MY02) was purchased from 
Cytoskeleton, Inc. in lyophilized form (1 mg). The protein was dissolved in 100 µL of Milli-Q 
water containing 1 mM DTT and incubated on ice for 5 minutes to completely solubilize it to a 
concentration of 10 mg mL-1. Care should be taken not to vortex the solution, in order to 
avoid protein denaturation caused by shear stress. Then, the myosin solution was further 
aliquoted into 10 µL samples, snap frozen in liquid nitrogen and stored at −80 °C. For 
compounds (S)-93–97,120,121,131–134, (S)-135,136,138,139,141,142, (S)-130,140,170–
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173 and (±)-185,188, different batches of full-length rabbit skeletal-muscle myosin II protein 
were used. As a reference, compound (S)-4 was evaluated with all batches of full-length 
rabbit skeletal-muscle myosin II protein. 
2.3. Preparation of ATP stock solution 
Adenosine 5’-triphosphate disodium salt (ATP, cat. # BSA04) was purchased from 
Cytoskeleton, Inc. in lyophilized form (1 mg). The ATP was reconstituted to 100 mM with 
1 mL of ice-cold 100 mM Tris-HCl pH 7.5 and then aliquoted into 10 µL samples, snap frozen 
in liquid nitrogen and stored at −20 °C. For compounds (S)-93–97,120,121,130–134, 
(S)-135,136,138,139,141,142, (S)-130,140,170–173 and (±)-185,188, different batches of 
adenosine 5’-triphosphate disodium salt were used. As a reference, compound (S)-4 was 
evaluated with all batches of adenosine 5’-triphosphate disodium salt. 
2.4. ATPase assay 
Screening for inhibitors of rabbit skeletal-muscle myosin II ATPase activity was performed in 
an ATPase end-point assay adapted from the method of Kodama et al.132 Incubation times 
and relative amounts of F-actin, myosin and ATP were determined based on a publication of 
Cheung et al.67 As the linear range for inorganic phosphate detection of the assay extends 
from approximately 0.1 nmol to 1.5 nmol of inorganic phosphate, a total amount of 1.6 nmol 
ATP was used.** 
Prior to each assay, aliquoted samples of F-actin, myosin and ATP were defrosted rapidly in 
a 37-°C water bath and further dilutions were made: myosin was diluted to 33 µg mL-1 with 
ice-cold reaction buffer (15 mM Tris-HCl pH 7.5, 25 mM KCl, 10 mM MgCl2, 0.1 mM EGTA) 
and stored on ice, ATP was diluted to 0.04 mM with ice-cold 15 mM Tris-HCl pH 7.5 and 
stored on ice, F-actin was diluted to 133 µg mL-1 with reaction buffer and stored at room 
temperature.  
Chemical compounds dissolved in DMSO (1 µL) were transferred into each well of a 96-well 
plate. Then, 15 µL of reaction buffer, 15 µL of 133 µg mL-1 F-actin and 15 µL of 33 µg mL-1 
myosin were subsequently distributed in each well using a multichannel pipette. Afterwards, 
the ATP hydrolysis reaction was initiated by adding 15 µL of 0.04 mM ATP per well using a 
multichannel pipette and was then incubated for 1 hour at 37 °C. To measure the amount of 
                                               
**
 The 0.4 mg mL
-1
 solution of pre-formed rabbit skeletal-muscle F-actin filaments (cat. # AKF99) from 
Cytoskeleton, Inc. already contains 0.2 mM ATP.  
EXPERIMENTAL PROCEDURES 
174 
inorganic phosphate (Pi) generated during the enzymatic hydrolysis of ATP, 139 µL of 
development solution (CytoPhos™ reagent, cat. # BK054 from Cytoskeleton) was added to 
each well using a multichannel pipette. After 20 minutes, the absorbance at 650 nm was 
measured in each assay well using a SpectraMax® Paradigm® Multi-Mode Microplate 
Reader. On each assay plate, two concentrations of (S)-4 (2.25 µM or 1 µM for 93–
97,120,121,131–134 and 130,135,136,138–142,170–173,185,188, respectively, and 
32.5 µM) were included as a positive control and the resulting amount of inhibition was 
comparable over the different assay plates. All screenings were carried out twice (N = 2).  
2.5. IC50 determination 
Data points representing the mean ± s.d. of at least three samples, were plotted on semi-log 
axes and a 4-parameter logistic curve, based on the following equation, was fitted to the 
means. 







                                                                
Here, y represents the ATPase activity of rabbit skeletal-muscle myosin II (%) and x 
corresponds to the compound concentration (µM). A is the ATPase activity corresponding to 
the asymptote at high compound concentrations (%), B is the ATPase activity corresponding 
to the asymptote at low compound concentrations (%), C represents the compound 
concentration corresponding to the midpoint between A and B (µM) (i.e. IC50 value) and D 
describes how rapidly the curve makes its transition from the asymptotes in the center of the 
curve.  
3. Determination of steady-state aqueous solubility 
The steady-state aqueous solubility was determined by Eurofins Panlabs. 
Compounds were added to a PBS pH 7.4 buffer as a 10-mM DMSO solution and were 
incubated at room temperature while agitating the suspension. DMSO and compound 
concentrations were 2% (v/v) and 200 µM, respectively. After 24 hours, the suspension was 
centrifuged and filtered through a 0.2-µM filter membrane. Compound concentrations in the 
buffer sample were determined by HPLC. Absorption spectra (230 nm) were recorded and 
the concentration of the dissolved compound was determined by comparing the peak area of 
the principal peak in the buffer sample with the peak area of the corresponding peak in a 
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calibration standard (200 µM) containing organic solvent (methanol/water (60:40)). The 
experiments were performed in duplicate. 
4. Microscopic imaging of fluorescence 
This experiment was performed by Glenn Wagemans, Laboratory of Experimental Cancer 
Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent 
University, Belgium. 
Different concentrations of test compounds, or DMSO as a solvent control, were added to 
DMEM/Ham’s F-12 (1:1) medium supplemented with 100 IU mL-1 penicillin (Gibco, 
Merelbeke, Belgium), 100 µg mL-1 streptomycin (Gibco, Merelbeke, Belgium) and 10% (v/v) 
fetal bovine serum (in threefold, final concentrations were 5 µM or 50 µM, 0.1% (v/v) DMSO). 
After 24 h of incubation at 37 °C, fluorescence images (488 nm excitation, GFP) were 
acquired on a Zeiss Axiovert 200M fluorescence microscope using a 20× objective.  
5. Fluorescence measurements 
Fluorescence measurements were performed using an Edinburgh Instruments F900 
Fluorescence Spectrometer equipped with a 450-W Xenon Lamp (Department of Inorganic 
and Physical Chemistry, Ghent University, Belgium). Compounds were dissolved in methanol 
and further diluted with PBS to obtain a final concentration of 20 µM. The amount of 
methanol was maintained at a constant concentration of 2.67% (v/v) in all samples. For all 
compounds, the emission spectrum was recorded after excitation at a wavelength of 488 nm 
(excitation slit width = 5 nm, emission slit width = 1 nm, dwell time = 0.5 sec). All compound 
emission spectra were corrected for the Raman lines of the solvent mixture by subtracting 
the emission spectrum of the solvent blank. 
6. In silico studies 
All in silico studies were performed by Dr. ing. Bart Roman using Molecular Operating 
Environment (MOE) 2015.10 (Chemical Computing Group) as molecular modelling 
software.94 Analyses were conducted based on the co-crystal structure of Dictyostelium 
discoideum myosin II heavy chain and (S)-blebbistatin (PDB: 1YV3).73 Automated structure 
preparation was performed using standard parameters. Partial charges were automatically 
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calculated. Minimizations were performed using an RMSD gradient of 0.001 kcal mol-1 Å-1 
and the AMBER99 force field. 
7. Determination of photostability 
7.1. 450-W Xenon Lamp light source 
(S)-Blebbistatin (S)-4 was dissolved in methanol and further diluted with PBS to obtain a final 
concentration of 20 µM. The amount of methanol was maintained at a constant concentration 
of 2.67% (v/v) in all samples. A different sample was used for each irradiation time. 
Irradiation at 488 nm (excitation slit width = 10 nm) was performed using an Edingburgh 
Instruments F900 Fluorescence Spectrometer equipped with a 450-W Xenon Lamp. 
Afterwards, the UV-VIS absorption spectrum was recorded for all samples using a Varian 
Cary-50 spectrophotometer. All absorption spectra were corrected for the solvent mixture by 
subtracting the absorption spectrum of the solvent blank. 
7.2. TL 140W/03 light source 
Stock solutions of chemical compounds were prepared in DMSO, DMSO/H2O (1:1) or a 1:1 
mixture of DMSO and DMEM supplemented with 20% (v/v) fetal calf serum. Then, 200 µL of 
each stock solution was transferred into the wells of 96-well plates. Separate wells were 
used for different irradiation times, so each well corresponded to one compound and one 
irradiation time. The solutions were irradiated for 0–90 min by placing the 96-well plates 
(covered with an evaporation lid) on top of two parallel tube lamps (TL 140W/03, Philips, 
Special Lighting, Belgium) emitting 390–470 nm with a maximum at 420 nm, using holders of 
6-cm height (Figure 23). On each 96-well plate, two columns could be irradiated with one 
tube lamp. After the appropriate illumination time, 200 µL (i.e. the total content) of each well 
was analyzed by HPLC as such: the absolute peak area of the compound under study was 
quantified and compared with that at the start of the experiment. The residual compound (%) 
was plotted in function of irradiation time (min) on semi-log axes and a 4-parameter logistic 
curve, based on the following equation, was fitted to the data points. 







                                                                
Here, y represents the relative amount of compound (%) and x corresponds to the irradiation 
time (min). A is the relative amount of compound corresponding to the asymptote at high 
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irradiation times (%), B is the relative amount of compound corresponding to the asymptote 
at low irradiation times (%), C represents the irradiation time corresponding to the midpoint 
between A and B (min) (i.e. DT50 value) and D describes how rapidly the curve makes its 
transition from the asymptotes in the center of the curve.  
8. Determination of Caco-2 cell permeability 
Caco-2 cell permeability was determined by Eurofins Panlabs. 
In short, Caco-2 cells were cultured on 96-well polycarbonate membrane filters and the 
apparent permeability (Papp) of test compounds was determined in the apical-to-basolateral 
(A-B) and basolateral-to-apical (B-A) directions across the Caco-2 cell monolayer. 
Compounds were prepared at 10 µM in HBSS-HEPES buffer, pH 7.4 (with a final DMSO 
concentration of 1% (v/v)) and added to the apical side (for A-B permeability) or basolateral 
side (for B-A permeability). The same buffer without compound was added to the basolateral 
side (for A-B permeability) or apical side (for B-A permeability). The assay plates were 
incubated at 37 °C with gentle shaking for 60 minutes (for A-B permeability) or 40 minutes 
(for B-A permeability). Samples were taken from the donor side at the start and from the 
donor and receiver sides at the end of the incubation and analyzed by HPLC-MS/MS. The 
apparent permeability (Papp) was calculated based on the appearance rate of compound in 
the receiver side. In addition, recovery of the test compound was determined as the relative 
amount of compound detected in both the receiver and the donor sides at the end of the 














Non-muscle myosin II is an actin-based motor of the cell that converts the energy released 
by ATP hydrolysis into force and movement in an ATPase cycle. As such, it plays an 
important role in embryonic development and in the normal functioning of the adult organism. 
Interest in the role of non-muscle myosin II in aberrant cellular function has strongly grown in 
recent years. Overactivity of non-muscle myosin II’s ATPase is associated with a range of 
human diseases, such as viral infections, liver fibrosis and portal hypertension, arthrofibrosis, 
glaucoma, methamphetamine use relapse and cancer metastasis. Inhibitors of non-muscle 
myosin II ATPase activity are therefore valuable tools for (i) dissecting the exact role of non-
muscle myosin II in normal and aberrant physiological functions (i.e. research tools) or (ii) 
developing targeted treatments against diseases involving non-muscle myosin II ATPase 
overactivity (i.e. therapeutic tools). 
The best-known inhibitor of non-muscle myosin II ATPase activity is (S)-blebbistatin (S)-i 
(Figure I). This molecule was discovered in 2001 during a high-throughput screening for 
inhibitors of non-muscle myosin IIA ATPase activity. It is a micromolar, uncompetitive 
inhibitor that stabilizes the myosin·ADP·Pi complex of the ATPase cycle and its chiral 
hydroxyl group is crucial for the selective activity of the (S)-enantiomer. Its cell membrane 
permeability, rapid inhibition and reversibility have established (S)-blebbistatin (S)-i as an 
important research tool to study cellular processes and diseases involving non-muscle 
myosin II function. Unfortunately, the affinity of (S)-blebbistatin (S)-i is not limited to non-
muscle myosin II, but also covers other myosin II isoforms (i.e. cardiac-, skeletal- and 
smooth-muscle myosin II). This feature and its low potency (IC50 values in the micromolar 
range) prohibit its use as a starting point for the development of non-muscle myosin II-
targeted therapeutic tools. (S)-Blebbistatin (S)-i also possesses several physicochemical 
liabilities that encumber its application as a research tool: it is sensitive to blue light, is 
(photo)toxic, has low water solubility and its (fluorescent) precipitates interfere in 
(fluorescence) read-outs. In order to eliminate some of the deficiencies related to its 
applications as a therapeutic tool and/or research tool, the development of novel blebbistatin 
derivatives was pursued in this PhD thesis. 
 
Figure I. Structure of (S)-blebbistatin (S)-i with designation of rings A–D and numbering within the scaffold. 
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Chapter 1 focused on the search for (S)-blebbistatin analogs (S)-xi–xiii and (S)-xiv,xvi,xvii 
with enhanced potency and/or improved research tool characteristics through modification of 
ring D. The tolerance of several modifications was investigated: (i) substituents of increasing 
size in the 3’-position, (ii) ring fusion at the 3’,4’-positions and (iii) functional groups of 
increasing size in the 4’-position. The synthesis of (S)-blebbistatin derivatives (S)-xi–xiii and 
(S)-xiv,xvi,xvii commenced with the coupling of rings D and C via aryl halides ii,vi and 
pyrrolidin-2-one, respectively (Scheme I). Ring A was introduced by condensation of 
amine iv and amides iii,vii. The presence of electron-withdrawing groups or amino groups 
(which form an electron-withdrawing ammonium group upon protonation under the acidic 
reaction conditions) on ring D hampered this step. Next, ring B was created via 
intramolecular ring closure of amidines v,viii through deprotonation with LiHMDS 
(Scheme II). Asymmetric α-hydroxylation of the (isolated) intermediate quinolinones ix was 
achieved via oxaziridine x and enantiopure compounds were obtained after recrystallization. 
Yet, the actual key step in the synthesis of (S)-blebbistatin derivatives (S)-xii,xvi was 
situated at the start of the sequence and involved the selection of a suitable protecting group 
which (i) would withstand the acidic conditions generated during synthesis of amidines v,viii, 
(ii) would be stable under the alkaline conditions of quinolinones ix formation and (iii) could 
be cleaved off without affecting the blebbistatin scaffold. The allyl group and cyano function 
proved appropriate protecting groups. Finally, analogs (S)-xii,xvi were also used as 
precursors for compounds (S)-xiii,xvii. 
 




Scheme II. Synthesis of D-ring-modified (S)-blebbistatin analogs (S)-xi–xiii and (S)-xiv,xvi,xvii described 
in chapter 1. 
In total 19 D-ring-modified (S)-blebbistatin analogs were synthesized and subsequently 
evaluated for their myosin II ATPase inhibitory potency. To this end, an in vitro steady-state 
ATPase assay against rabbit skeletal-muscle myosin II was developed. The latter myosin II 
isoform was used as a model for non-muscle myosin II, since purified or recombinantly 
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expressed non-muscle myosin II is not easily accessible and its production costs are 
exceptionally high. As the binding pocket of (S)-blebbistatin (S)-i is conserved over species 
and isoforms, the relative potency (as compared to (S)-blebbistatin (S)-i) observed for rabbit 
skeletal-muscle myosin II ATPase inhibition was expected to account for non-muscle 
myosin II as well. The thus obtained SAR information has highlighted that the 
(S)-configuration is essential for activity in all derivatives and has revealed that D-ring 
substitution does not lead to significant potency enhancement. 
Although this part of the (S)-blebbistatin scaffold is not suited to pursue an enhanced 
potency, we have shown that it can be used to fine-tune the research tool characteristics of 
the parent compound. For example, research applications requiring blue-light irradiation are 
best conducted with (S)-4’-nitroblebbistatin, since the latter analog is 10 times less blue-light 
sensitive than (S)-blebbistatin (S)-i. On the other hand, when solubility issues of 
(S)-blebbistatin (S)-i pose a problem for read-outs in cell-based experiments, (S)-3’-
hydroxyblebbistatin, (S)-3’-aminoblebbistatin or (S)-4’-aminoblebbistatin should be used as 
alternatives. These compounds combine a 30-fold higher aqueous solubility with 
conservation of cell permeability. From an economical point of view, 
(S)-3’-hydroxyblebbistatin is the best choice for these applications, since it is the most readily 
accessible.  
In chapter 2, the quest for enhanced myosin II ATPase inhibitory potency centered on the 
synthesis of a new series of (S)-blebbistatin analogs with a modified A-ring. Cyclic 
substituents fused at positions C6 and C7 were incorporated in compounds (S)-xxii and 
(S)-xxvi–xxviii. They were prepared in a similar fashion as D-ring-modified derivatives 
(S)-xi–xiii and (S)-xiv,xvi,xvii (Scheme III). Subsequently, the myosin II ATPase inhibitory 
potency was evaluated in an in vitro steady-state ATPase assay. Unfortunately, extension of 
ring A did not result in an enhanced binding affinity. These exploratory investigations, 
combined with literature results, strongly suggest that potency enhancement via A-ring 
substitution is unattainable.  
In chapter 3, potency enhancement was pursued via C-ring modification. Therefore, 
blebbistatin analogs (±)-xxxiii–xxxiv were decorated with cis- and trans-oriented 
functionalities. The synthesis proceeded via amidine xxxi (Scheme IV). α-Hydroxylation of 
this racemic intermediate with racemic mixtures of oxaziridines x and xxxii was 
diastereoselective, producing an 84:16 mixture of the trans- and cis-diastereoisomer. Finally, 
evaluation of the myosin II ATPase inhibitory potency of blebbistatin analogs (±)-xxxiii–xxxiv 
showed that a small modification on ring C already induced a large negative impact on 
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Scheme IV. Synthesis of C-ring-modified (±)-blebbistatin analogs (±)-xxxiii, (±)-trans-xxxiv and 
(±)-cis-xxxiv described in chapter 3. 
In conclusion, novel blebbistatin analogs with modified A-, C- or D-rings were developed with 
the aim of improving the therapeutic tool and/or research tool characteristics of the parent 
compound. These modifications did not result in an enhanced myosin II ATPase inhibitory 
potency and it is now clear that (S)-blebbistatin analogs are not applicable as a starting point 
for the development of non-muscle myosin II-targeted therapeutic tools. However, the 
research tool properties of (S)-blebbistatin (S)-i were improved through D-ring modification. 
These analogs therefore hold great potential for research applications in which cellular 










Niet-musculair myosine II is een motorproteïne dat (met behulp van actine) de energie die na 
ATP-hydrolyse vrijkomt, in kracht en beweging omzet tijdens een ATP-asecyclus. Op die manier 
speelt het een voorname rol tijdens de embryonale ontwikkeling en het normaal functioneren van 
het organisme. De laatste jaren is de interesse in de rol van niet-musculair myosine II in 
abnormale celfuncties sterk toegenomen. Zo wordt een overactiviteit van de ATP-asefunctie van 
niet-musculair myosine II met een reeks ziektes, zoals virale infecties, leverfibrose en een te 
hoge bloeddruk in de leverpoortader, arthrofibrose, glaucoom, herval bij methamfetaminegebruik 
en kankermetastasering, geassocieerd. Inhibitoren van de ATP-aseactiviteit van niet-musculair 
myosine II vormen dan ook waardevolle middelen om (i) de exacte rol van de ATP-aseactiviteit 
van niet-musculair myosine II in normale en abnormale fysiologische functies te ontrafelen (i.e. 
onderzoekshulpmiddelen) of (ii) doelgerichte behandelingen tegen ziektes, waarbij een 
overactiviteit van de ATP-asefunctie van niet-musculair myosine II betrokken is (i.e. 
therapeutische hulpmiddelen), te ontwikkelen. 
De bestgekende inhibitor van de ATP-aseactiviteit van niet-musculair myosine II is 
(S)-blebbistatine (S)-i (Figuur I). Deze molecule werd in 2001 ontdekt tijdens een high-throughput 
screening voor inhibitoren van de ATP-aseactiviteit van niet-musculair myosine IIA. Het is een 
micromolaire, anticompetitieve inhibitor die het myosine·ADP·Pi-complex van de ATP-asecyclus 
stabiliseert. Verder bepaalt de chirale hydroxylgroep de selectieve activiteit van het 
(S)-enantiomeer. De celmembraanpermeabiliteit, snelle werking en reversibiliteit hebben van 
(S)-blebbistatine (S)-i een belangrijk onderzoekshulpmiddel gemaakt. Het wordt dan ook intensief 
gebruikt om celprocessen en ziektes waarbij niet-musculair myosine II betrokken is, te 
onderzoeken. Een belangrijk nadeel hierbij is dat de affiniteit van (S)-blebbistatine (S)-i niet tot 
niet-musculair myosine II beperkt is, maar ook de andere isovormen van myosine II omvat (i.e. 
myosine II van het hartspierweefsel, skeletspierweefsel en glad spierweefsel). Deze 
eigenschappen en de lage werkzaamheid (micromolaire IC50-waarden) verhinderen het gebruik 
als startpunt voor de ontwikkeling van therapeutische hulpmiddelen gericht tegen niet-musculair 
myosine II. Daarnaast bezit (S)-blebbistatine (S)-i ook enkele fysicochemische beperkingen die 
de toepassing als onderzoekshulpmiddel bemoeilijken: het is gevoelig voor blauw licht, is 
(foto)toxisch, heeft een lage wateroplosbaarheid en de (fluorescente) kristallen interfereren bij 
(fluorescentie)-uitlezingen. Om enkele nadelen die gerelateerd zijn aan de toepassingen als een 
therapeutisch hulpmiddel en/of onderzoekshulpmiddel, te verhelpen, werd tijdens dit 
doctoraatsonderzoek dan ook getracht om nieuwe blebbistatineanalogen te ontwikkelen. 
 




Hoofdstuk 1 behandelde de zoektocht naar (S)-blebbistatineanalogen met een verhoogde 
werkzaamheid en/of verbeterde eigenschappen als onderzoekshulpmiddel door modificatie van 
ring D. Hierbij werd de mogelijkheid van verschillende wijzigingen onderzocht: (i) substituenten 
van toenemende grootte in de 3’-positie, (ii) ringfusie ter hoogte van de 3’,4’-posities en (iii) 
functionele groepen van toenemende grootte in de 4’-positie. De synthese van (S)-blebbistatine-
analogen (S)-xi–xiii en (S)-xiv,xvi,xvii begon met de koppeling van ringen D en C via 
respectievelijk arylhalides ii,vi en pyrrolidin-2-on (Schema I). Ring A werd geïntroduceerd door 
condensatie van amine iv en amides iii,vii. Hierbij bemoeilijkte de aanwezigheid van 
elektronzuigende groepen of aminogroepen (die een elektronzuigende ammoniumgroep vormen 
na protonering onder de zure omstandigheden) op ring D deze stap. Vervolgens werd ring B via 
een intramoleculaire ringsluiting van amidines v,viii (door deprotonering met LiHMDS) gevormd 
(Schema II). Een asymmetrische α-hydroxylering van de (geïsoleerde) intermediaire chinolinonen 
werd via oxaziridine x bewerkstelligd en enantiomeerzuivere moleculen werden na 
omkristallisering bekomen. De belangrijkste stap in de synthese van (S)-blebbistatinederivaten 
(S)-xii,xvi bevond zich echter aan het begin van de sequentie. Dit betrof de selectie van een 
geschikte beschermgroep die (i) de zure omstandigheden tijdens de synthese van amidines v,viii 
zou weerstaan, (ii) stabiel zou zijn onder de alkalische condities van de vorming van chinolinonen 
ix en (iii) verwijderd kon worden zonder het blebbistatinebasisskelet aan te tasten. Zo waren de 
allylgroep en cyaanfunctie geschikte beschermgroepen. Ten slotte werden analogen (S)-xii,xvi 
ook als precursoren voor moleculen (S)-xiii,xvii gebruikt. 
 




Schema II. Synthese van D-ringgemodificeerde (S)-blebbistatineanalogen (S)-xi–xiii en (S)-xiv,xvi,xvii 
beschreven in hoofdstuk 1. 
In totaal werden er 19 D-ringgemodificeerde (S)-blebbistatineanalogen gesynthetiseerd. Hun 
inhiberende werking op de ATP-aseactiviteit van myosine II werd vervolgens geëvalueerd. Om dit 
mogelijk te maken werd een in vitro, steady-state ATP-aseassay ontwikkeld tegen myosine II dat 
zich in het skeletspierweefsel van konijnen bevindt. Deze isovorm van myosine II werd als model 
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voor niet-musculair myosine II gebruikt, omdat opgezuiverd of recombinant niet-musculair 
myosine II niet eenvoudig te bekomen is en de productiekosten extreem hoog zijn. Aangezien de 
bindingsplaats van (S)-blebbistatine (S)-i over verschillende species en isovormen 
geconserveerd is, werd er verwacht dat de gemeten, relatieve werkzaamheid van de gemaakte 
verbindingen (vergeleken met (S)-blebbistatine (S)-i) ook voor niet-musculair myosine II van 
toepassing zou zijn. De aldus bekomen SAR-informatie heeft bevestigd dat de (S)-configuratie 
ook in deze nieuwe derivaten essentieel is voor de activiteit en heeft aangetoond dat substitutie 
van ring D geen significante werkzaamheidsverhoging tot gevolg heeft.  
Alhoewel dit deel van het (S)-blebbistatinebasisskelet niet geschikt is om een verhoogde 
werkzaamheid te bewerkstelligen, kan het wel toegepast worden om de eigenschappen van 
(S)-blebbistatine (S)-i inzake het gebruik als onderzoekshulpmiddel aan te passen. 
Onderzoekstoepassingen die bestraling met blauw licht vereisen, worden bijvoorbeeld best 
uitgevoerd met (S)-4’-nitroblebbistatine, aangezien dit analoog 10 keer minder lichtgevoelig dan 
(S)-blebbistatine (S)-i is. Wanneer de oplosbaarheidsproblemen van (S)-blebbistatine (S)-i 
daarentegen een probleem vormen voor uitlezingen in celgebaseerde experimenten, zouden 
(S)-3’-hydroxyblebbistatine, (S)-3’-aminoblebbistatine of (S)-4’-aminoblebbistatine als 
alternatieven gebruikt moeten worden. Deze moleculen bezitten namelijk een 30-maal hogere 
wateroplosbaarheid terwijl de celpermeabiliteit behouden blijft. Vanuit een economisch standpunt 
is het gebruik van (S)-3’-hydroxyblebbistatine de beste keuze in deze toepassingen, aangezien 
het het vlotst te bekomen is. 
In hoofdstuk 2 draaide de zoektocht naar een verhoogde werkzaamheid rond de synthese van 
een nieuwe reeks (S)-blebbistatineanalogen met een gewijzigde A-ring. Cyclische substituenten 




 gefuseerd zijn, werden in moleculen (S)-xxii en (S)-xxvi–
xxviii ingebouwd. Ze werden op een gelijkaardige manier als de D-ringgemodificeerde derivaten 
(S)-xi–xiii en (S)-xiv,xvi,xvii gemaakt (Schema III). Vervolgens werd de inhiberende werking op 
de ATP-aseactiviteit van myosine II in een in vitro, steady-state ATP-aseassay geëvalueerd. 
Jammer genoeg resulteerde de uitbreiding van ring A niet in een verhoogde bindingsaffiniteit. 
Een verhoging van de werkzaamheid lijkt dan ook onmogelijk via A-ringsubstitutie. 
In hoofdstuk 3 werd een verhoogde werkzaamheid via C-ringmodificatie nagestreefd. Daarom 
werden cis- en trans-georiënteerde functionaliteiten toegevoegd bij blebbistatineanalogen 
(±)-xxxiii–xxxiv. De synthese verliep via amidine xxxi (Schema IV). De α-hydroxylering van dit 
racemisch intermediair met racemische mengsels van oxaziridines x en xxxii was 
diastereoselectief, zodat een 84:16 mengsel van het trans- en cis-diastereomeer gevormd werd. 
Ten slotte toonde evaluatie van blebbistatineanalogen (±)-xxxiii–xxxiv inzake inhiberende 
werking op de ATP-aseactiviteit van myosine II aan dat een kleine wijziging ter hoogte van ring C 
reeds een grote negatieve impact op de werkzaamheid had. C-ringmodificatie kan dus niet 




Schema III. Synthese van A-ringgemodificeerde (S)-blebbistatineanalogen (S)-xxii en (S)-xxvi–xxviii 
beschreven in hoofdstuk 2. 
0~ 
1) 1 equiv. Óxx 
NH2 MaOH,IJ., 2x 24 h I // NH2 2) 1,05 aquiv. xix (omgekaarde toev.) I // Nn 
2x 3 aquiv. H2S04 ~~  ~:~~:~~.3 kt., 24 h ~~  
droge CH2CI2, 35 "C, 48 h b 
HOO MaOO MeOO 1 
~ 






(76%, e.o. 72%) ~ 
(14%, e.o. >99% na 
omkristallisaring) 
1) 2,1 equiv. LiHMDS 
droge THF, o ·c, 1,5 h 
Nr--f' 
1
) ~ :~:~: ~Cia ~r--f' 
droge CH2CI2, kt., 24 h I : D 
NH2 2) 1,05 equiv. xxiv (omgekeerde toev.) N ON 
droge CH2CI2, 35 •c, 3 dagen ;/ 
~ o ~ o 1 
XXIV (29%) XXV (48%) ~ 
2) 2,4 equiv. x j 
1) 2,1 equiv. LiHMDS 
droge THF, o •c, 1,5 h 
o droge THF, -15 •c, 16 h 
6 equiv. Me,NJlN. Me 
o o AA o 
~ 5x10equiv.Mn02 ~ 4x0,1eq~v.P;PPh~4 \JlA.,)_N) \JlA.,)_N) \JlA.,)_N) 
H N bDMF, kt., 5x 5 min H N h droge CH2CI2, IJ., 4x 1,5 h \ N b 
~ Î u 17 ~ Î 
(S)-xxviii (96%) (S)-xxvii (95%, e.o. 98%) (S)-xxvi 
(73%, e.o. 92%) 





Schema IV. Synthese van C-ringgemodificeerde (±)-blebbistatineanalogen (±)-xxxiii, (±)-trans-xxxiv en 
(±)-cis-xxxiv beschreven in hoofdstuk 3. 
Samenvattend kan er gesteld worden dat nieuwe blebbistatineanalogen met een gewijzigde A-, 
C- of D-ring ontwikkeld werden met als doel de eigenschappen van (S)-blebbistatine (S)-i inzake 
het gebruik als therapeutisch hulpmiddel en/of onderzoekshulpmiddel te verbeteren. Deze 
modificaties resulteerden niet in een verhoogde inhibirende werking op de ATP-aseactiviteit van 
myosine II. Het is dan ook duidelijk dat (S)-blebbistatineanalogen niet toegepast kunnen worden 
als startpunt voor de ontwikkeling van therapeutische hulpmiddelen gericht tegen niet-musculair 
myosine II. De eigenschappen van (S)-blebbistatine (S)-i die een impact op het gebruik als 
onderzoekshulpmiddel hebben, werden daarentegen wel verbeterd door D-ringmodificatie. Deze 
analogen hebben een zeer groot potentieel voor onderzoekstoepassingen waarin celprocessen 
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